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A b s t r a c t
Adenosine deaminase (ADA) severe combined immunodeficiency (SCED) is a life- 
threatening condition resulting from lack of the ADA enzyme. Consequences include 
immunodeficiency and non-immunological symptoms such as neurological 
abnormalities. Bone marrow transplantation (BMT) from a haploidentical donor usually 
results in complete restoration of immune function. However, the majority of patients 
do not have a matched donor and are therefore treated with enzyme replacement therapy 
(PEG-ADA). This treatment is not always fully effective, it is expensive and needs to be 
administered throughout life. Gene therapy is an alternative treatment, and previous 
trials for ADA deficiency have shown that it can significantly improve immunological 
function.
Immune recovery was assessed in three ADA-SCID patients treated with PEG-ADA by 
analysis of lymphocyte counts and emergence of naive T cells. One patient was not 
responding well to PEG-ADA and was enrolled in a Phase I clinical gene therapy trial. 
A gammaretroviral vector encoding ADA was constructed and tested extensively on cell 
lines and patient cells and a CD34+ cell transduction protocol was optimised. The gene 
therapy procedure was based on previous successful trials, and involved withdrawal of 
PEG-ADA prior to treatment to provide selective growth advantage for transduced cells, 
and mild conditioning to encourage engraftment. Assessments of immune function were 
then performed in a similar manner to patients treated with PEG-ADA.
Recent evidence from studies of ADA deficiency indicates that it is a multi-organ 
disease. However, gene therapy using CD34+ cells may only correct the 
immunodeficiency without ameliorating non-immunological symptoms. Hence, studies 
were performed to develop systemic gene therapy for ADA-SCID, involving the use of 
CD34+ cells and mesenchymal stem cells (MSCs). MSCs were isolated from bone 
marrow, and their multipotential nature was assessed prior to and following gene 
transfer using a cloned ADA lentiviral vector. Transduced MSCs maintained their 
ability to undergo differentiation and transgene expression was not affected by this.
These clinical and preclinical in vitro studies demonstrate that gene therapy holds 
therapeutic potential for treatment of ADA-SCID.
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C h a p t e r  1
1.1 A d e n o s in e  D e a m in a s e  D e f ic ie n c y
1.1.1 Severe Combined Immunodeficiency
Severe Combined Immunodeficiency (SCID) is a rare heterogeneous disorder that 
results in profound defects of both cellular and humoral immunity. Almost 100 
different primary immunodeficiencies have been documented (Primary 
immunodeficiency diseases, Report of an IUIS Scientific Committee, 1999), of 
which SCID is the most severe. Symptoms include failure to thrive, lymphopenia, 
fungal, viral and bacterial infections, and is lethal at an early age unless treated. 
Several genetic defects leading to the clinical and immunological phenotype of SCID 
have been identified, the most common being the X-linked disorder, accounting for 
40-50% of all SCID cases (Noguchi et al., 1993). Adenosine deaminase (ADA) 
deficiency is an autosomal recessive disease, which accounts for approximately 20% 
of all cases of SCID, based on studies reviewed by Hirschhom (1990a & b), although 
recent European data suggests that the incidence may be 11% of the SCID cases 
(Figure 1.1). ADA deficiency was first identified in the early 1970s (Giblett et al., 
1972), and is caused by a mutation in the gene for the ADA metabolic enzyme. It is a 
rare disease, affecting only between 1 in a million to 1 in 100,000 children. The child 
often presents in the first few months of life with failure to thrive, and suffers from a 
variety of infections. Other less common causes of SCID include deficiencies in the 
enzyme purine nucleoside phosphorylase (PNP), involved in the same metabolic 
pathway as ADA, and deficiencies in the recombination activating genes (RAG) 1 
and 2 important in the generation of antigen specific B and T cell receptors.
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4% -
□ Gamma chain
□ ADA
□  PNP
□  JAK3
■ Reticular dysgenesis
□  Cartilage hair hypoplasia
■  RAG-1 and -2
□  Others/unidentified
Figure 1.1. Prevalence of different forms of SCID.
1.1.2 Clinical Aspects of ADA Deficient SCID
The first and most severe clinical manifestation of ADA deficiency is 
immunodeficiency, which leaves the patient susceptible to infections. ADA-SCID 
patients have an absence of B, T and NK cells (Buckley et al., 1997), resulting in a 
complete absence in cellular and humoral immunity. ADA deficient patients often 
present with persistent diarrhoea, failure to thrive and candidiasis (Morgan et al., 
1987) as well as other opportunistic infections (viral, fungal, bacterial and 
protozoan). Patients with ADA deficiency are among the SCID patients which are 
most seriously ill, and often present in the first few months of life. The average age 
of presentation has been calculated to be 4.4 months (Arredondo-Vega et al., 1998), 
which includes the average delay in diagnosis of about 2 months after initial infective 
problems. This delay in diagnosis is often contributed to by the presence of some 
immunoglobulins at birth due to the maternal IgGs. However, 1-2 months after the 
birth, hypogammaglobulinaemia becomes apparent.
2 0
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Lymphopenia and elevation of toxic substrates such as dATP (discussed below) have 
been found to be present pre-natally (Linch et al., 1984). Moreover, ADA deficient 
patients do not have isoagglutinins and the immunoglobulins, especially IgA and 
IgM, are low or absent. As a result, the antibody responses to T-dependent antigens 
are severely impaired.
ADA deficiency not only results in immunodeficiency, but has been found to be a 
multi-organ disease, which may be as a result of ADA being a ubiquitous 
housekeeping enzyme (reviewed by Hirschhom et al., 1999). The systemic 
abnormalities include autoimmunity, skeletal abnormalities (Cederbaum et al., 
1976), cupping and flaring of costochondral junctions, renal mesangial sclerosis 
(Ratech et al., 1985) and hepatic abnormalities (Bollinger et al., 1996). Autopsies of 
early onset disease patients have revealed abnormalities in the spleen, lymph nodes, 
gut and thymus, (reviewed by Hirschhom et al., 1979d; Borzy et al., 1979; Ratech et 
al., 1985, 1989). Similarly to other cases of SCID, thymic biopsies and autopsies 
have revealed absent or small dysplastic organs, and no or low numbers of 
lymphocytes are found in thymus, spleen or lymph nodes (Ratech et al., 1989). 
Similar non-immunological symptoms are also found in ADA deficient mice 
including pulmonary and intestinal defects as well as hepatocyte degeneration 
(Migchielsen et al., 1995 & 1996; Wakamiya et al., 1995; Blackburn et al., 1998 and 
2000a & b; Aldrich et al., 2003) (discussed in more detail in section 1.1.6). However, 
due to often overwhelming infections in ADA deficient patients, it is difficult to 
determine whether these non-immunological abnormalities are primarily due to ADA 
deficiency. With improved survival as a result of bone marrow transplantations 
(BMT) and enzyme replacement therapy, it is likely that more symptoms will be 
discovered that were not previously apparent in the young children.
ADA patients have also been found to have significant neurological abnormalities 
including spasticity, head lag, movement disorders and sensori-neuronal deafness 
(Hirschhom et al., 1980; Tanaka et al., 1996; Albuquerque & Gaspar, 2004). A 
neuropsychological study also observed behavioural difficulties including 
hyperactivity, attention deficit and aggressive tendencies in transplant patients 
(Rogers et al., 2001). It has been found that high levels of ADA are expressed in the 
brain (Hirschhom et al., 1978), and that there is a significant correlation between
21
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dATP levels at diagnosis and total IQ (Rogers et al., 2001). The neurological 
abnormalities may also be due to increased interactions between adenosine and 
adenosine Ai receptors in nervous tissue, as there was found to be an improvement in 
neurological abnormalities concomitant with the lowering of toxic levels of 
metabolites as a result of therapeutic measures (Hirschhom et al., 1980).
Disease Type Phenotype
Neonatal/Infantile Onset 85-90%. Indistinguishable from other forms of SCID, except 
bony abnormalities in some patients.
Delayed/Late Onset Diagnosis after 2nd year of life. Antibodies present, weaken 
later. May have recurrent bacterial sinopulmonary infections, 
lymphopenia & autoimmunity.
Adult Onset Very rare. Late onset symptoms and persistent viral warts, 
lymphopenia.
Partial ADA Deficiency Often lack erythrocyte ADA -  retain normal immune function.
Table 1.1. Clinical phenotypes in ADA deficient SCID. A wide range of phenotypes have 
been observed, from early onset to adult onset.
The genotype in ADA deficiency results in a spectrum of clinical phenotypes, where 
the age at onset of disease differs (Table 1.1). As some of this variation occurred 
within families, it is thought that environmental differences such as early infections 
or early treatments may also influence the severity of the disease. The most common 
phenotype of ADA deficiency is the early onset “classical” SCID. These patients 
present with failure to thrive, lymphopenia, and absence of cellular and humoral 
immune system as a result of the lack of B, T, and NK cells. Unless treated, this form 
of ADA deficiency is fatal at an early age, usually due to overwhelming infections. 
Some of the early onset ADA deficient patients, unlike other SCID patients, also 
display non-immunological symptoms such as skeletal abnormalities of the 
costochondral junction (Wolfson & Cross, 1975; Cederbaum et al., 1976). 
Approximately 10-15% of ADA deficient patients have a delayed onset disease, 
diagnosed beyond the first year of life, and show an initially milder disease
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progression (Hirschhom, 1979a, b & c; Cohen et al., 1979; Geffner et al., 1986; 
Levy et al., 1988; Santisteban et al., 1993; Umetsu et al., 1994). These patients 
produce some immunoglobulins, however these are essentially non-specific 
antibodies (reviewed by Hirschhom, 1999). In some of these patients serious 
infections start at 2 to 3 years of age, but in others sinus and upper respiratory 
infections, including bacterial pneumonia, are observed in slightly younger patients.
Late onset ADA deficiency is diagnosed from around 3 to 15 years of age or even 
later in life (Geffner et al., 1986; Morgan et al., 1987; Levy et al., 1988; Shovlin et 
al., 1993; Ozsahin et al., 1997). These patients have numerous clinical 
manifestations, including lymphopenia (in particular T cell lymphopenia) and 
recurrent sinopulmonary bacterial infections, usually pneumonia caused by 
Streptococcus pneumoniae. They may lack IgG2 but have hyper-IgE and may have 
eosinophilia and autoimmunity. This group of patients may be under-diagnosed, but 
would show a gradual immunologic and clinical deterioration over time.
A very rare form of adult onset disease was reported in two siblings by Shovlin et al. 
in 1993. These two patients started to display a variety of symptoms in late 
adolescence, including persistent viral warts and immune-mediated 
thrombocytopenic purpura as well as all the symptoms displayed in the late onset 
disease.
Partial ADA deficiency has been identified as a result of a screening programme, and 
has been found to be due to the lack of ADA in erythrocytes. The majority of these 
individuals have a normal immune function as they display 5-80% of the normal 
ADA activity in non-erythroid cells (Cohen et al., 1978; reviewed by Hirschhom, 
1979b; Perignon et al., 1980; Borkowsky et al., 1980; Schmalstieg et al., 1983; 
Daddona et al., 1983; Hirschhom & Ellenbogen, 1986; Hart et al., 1986; reviewed by 
Hirschhom, 1990a & b). The lack of ADA in only erythrocytes is thought to be due 
to an unstable enzyme in cells which cannot synthesise new protein. Partial ADA 
deficiency has also been diagnosed as a result of somatic mosaicism of the mutations 
in the ADA gene (Hirschhom et al., 1994 & 1996; Arredondo-Vega et al., 2002). In 
one of these cases described by Hirschhom et al., it resulted from a very rare 
spontaneous reversion mutation to normal. The patient described by Arredondo-Vega
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et al., showed a second mutation which resulted in the normalisation of the splicing 
pattern.
Overproduction of ADA in erythrocytes has been identified in some patients with an 
inherited form of haemolytic anaemia (Valentine et al., 1977; Miwa et al., 1978; 
Perignon et al., 1982). Their ADA levels in lymphocytes were found to be normal, 
hence their immune system was functional. The anaemia was thought to be caused 
by low levels of erythroid ATP, due to increased adenosine monophosphate 
metabolism and decreased adenine nucleotide synthesis from adenosine (Perignon et 
al., 1982). Although the molecular basis for this condition is not known, it is thought 
that the enhanced ADA expression seen in red blood cells (RBCs) is due to a 
mutation in an ADA gene regulatory element.
1.1.3 Molecular Pathology of ADA Deficiency
ADA (EC3.5.4.4) is a metabolic enzyme of the purine salvage pathway, catalysing 
the irreversible, hydrolytic deamination of adenosine and 2’-deoxyadenosine (dAdo) 
to inosine and 2’-deoxyinosine respectively as depicted in Figure 1.2. It is a 
ubiquitous enzyme expressed at varying levels in different tissues, and is particularly 
abundant in tissues where there is a high turnover of cells and where a large amount 
of DNA needs to be salvaged. Although ADA is a general housekeeping enzyme, the 
main effect of its absence is on the immune system, which may be due to high levels 
of ADA being expressed in the thymus and in other lymphoid tissues, signifying its 
importance in these cell types. It is, however, believed that due to the ubiquitous 
nature of this enzyme, a lack of ADA also leads to non-immunological symptoms not 
usually seen in other SCID patients, such as hepatic (Bollinger et al., 1996) and 
neurological abnormalities (Hirschhom et al., 1980; Rogers et al., 2001).
Deficiencies in metabolic enzymes usually lead to disease either as a result of a toxic 
build-up of enzyme substrates, or as a result of the lack of enzyme products. In the 
case of ADA deficiency, it is the former which appears to be true because there are 
alternative pathways which can compensate for the lack of ADA products (reviewed 
by Hirschhom, 1999). It has been observed that the extent of the metabolic
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Figure 1.2. Reactions catalysed by ADA and purine nucleoside phosphorylase.
ADA converts adenosine and 2-deoxyadenosine to inosine and deoxyinosine 
respectively in a deamination reaction. These products are then further converted to 
hypoxanthine by the enzyme purine nucleoside phosphorylase as part of the purine 
salvage pathway. (Adapted from Hershfield and Mitchell, 2001).
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abnormalities is significantly related to the severity of the disease (Morgan et al., 
1987). ADA deficiency results in elevated toxic levels of the ADA substrates 
adenosine and deoxyadenosine (dAdo) in the plasma and elevated dAdo levels in the 
urine. Levels of dATP are also increased as this is produced from the 
phosphorylation of the increased levels of d-adenosine by the enzyme d-cytidine 
kinase or adenosine kinase in a usually minor pathway (Figure 1.3). Increased dATP 
is trapped in cells and is no longer in equilibrium with the extracellular fluid. It is this 
accumulation of dATP which appears to be the main cause of cellular toxicity, based 
on in vitro experiments. dATP inhibits the enzyme ribonucleotide reductase which is 
important in DNA replication. Ribonucleotide reductase catalyses the reduction of 
ADP, GDP, CDP and UDP to form dNTPs, in a rigorously controlled reaction, which 
maintains the dNTP pools at levels sufficient for only a few minutes of DNA 
replication. Hence, the inactivation of this enzyme by dATP leads to the inhibition of 
DNA replication, and consequently cellular toxicity. This effect is mainly apparent in 
cells of high turnover, such as thymocytes and lymphocytes, which may explain the 
selective toxicity to these cells in ADA deficient patients (Henderson et al., 1980; 
Ullman et al., 1980; Waddell & Ullman, 1983; Kubota et al., 1984; Albert et al., 
1984; Mann & Fox, 1986). Moreover, dATP tends to accumulate in erythrocytes and 
lymphocytes as a result of a higher rate of phosphorylation of dAdenosine compared 
with the rate of dephosphorylation and the subsequent trapping of dATP. A further 
way in which dATP may cause toxicity is by activating the caspase cascade in 
thymocytes and peripheral blood cells, which results in apoptosis in both dividing 
and non-dividing cells and could therefore explain the lack of thymocytes in ADA 
deficiency (Liu et al., 1996; Li et al., 1997). The substrate dAdenosine is derived 
mainly from the breakdown of DNA, hence it is expected to be highly expressed in 
areas of cell death such as the thymus where the T cells undergo apoptosis as a part 
of the selection procedure. On the basis of in vitro experiments, it has been proposed 
that high levels of dAdo result in DNA strand breaks (Brox et al., 1984). Elevated 
levels of dAdo, as well as adenosine, can also result in the inactivation of S-adenosyl 
homocysteine hydrolase (SAHH), with less than 5% normal activity usually being 
observed (Hershfield et al., 1979a & b; Hirschhom et al., 1981; Hershfield et al., 
1985; Hershfield et al., 1987; Santisteban et al., 1993; Hershfield et al., 1993). This 
leads to an increased level of adenosyl homocystein which inhibits methylation 
dependent reactions such as gene expression, RNA splicing and protein synthesis
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shown in this schematic diagram. AdoHcy, adenosyl homocystein. (Adapted from Hershfield and Mitchell, 2001).
C h a p t e r  1
(Kredich & Martin, 1977; Abeles et al., 1982). However, dAdo is thought to be less 
of a cause of cell toxicity than dATP, because elevated SAH has not been 
demonstrated in vivo in patients, and inhibition of SAHH is still observed in bone 
marrow transplanted patients who have normal immune functions.
Adenosine is a component of RNA and the energy storing compound ATP. It is, like 
dAdo, derived from the breakdown of ATP in dying cells. Adenosine is thought to 
exhibit its main effects through the G-protein associated adenosine Al and A2 
receptors leading to abnormal signal transduction, although these effects have not 
been shown to be clinically significant (Kizaki et al., 1988; Kizaki et al., 1990; 
Apasov et al., 1997). Adenosine may be the ADA substrate with the least effect on 
cell toxicity.
It is therefore apparent that the accumulation of the ADA substrates leads to cell 
toxicity, and the concentrations of these metabolites correlate with the severity of the 
disease. However, the reasons behind the selective toxicity to lymphocytes have not 
yet been fully elucidated. It has been proposed that the destruction of mainly the 
immune system can be attributed to the fact that ADA activity levels vary over 100- 
fold in the different tissues of the body. Because the immune cells display high levels 
of ADA activity, it appears logical that this is the system which is mainly affected. 
However, this theory fails to explain why other tissues that show high ADA activity 
levels are not affected, such as the gastrointestinal system. Hence, it is clear that 
more research needs to be performed to determine why ADA deficiency mainly 
affects the immune system.
1.1.4 ADA -  Gene, Protein and Enzyme Activity
The ADA gene is located on the long arm of chromosome 20 (20ql2-ql3.1) 
(Tischfield et al., 1974; Mohandas et al., 1980; Mohandas et al., 1984; Jhanwar et 
al., 1989). The human ADA gene has been cloned (Valerio et al., 1983; Valerio et 
al., 1985; Wiginton et al., 1983) and sequenced (Wiginton et al., 1986). The total 
length of the gene is 32,040 base pairs, made up of 12 exons and 11 introns (Figure 
1.4). The cDNA is approximately 1.5kb long, containing a coding region of 1089 
nucleotides.
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Figure 1.4. Schematic diagram of the human ADA gene (not to scale). The human gene 
for ADA is made up of 32,040 nucleotides. It is composed of 12 exons which give rise to a 
1.5kb cDNA, containing a 1089bp open reading frame. (Adapted from Hershfield and 
Mitchell, 2001).
The 40 kDa human protein is a monomer consisting of 363 amino acids (Daddona & 
Kelley, 1977; Schrader et al., 1976; Schrader & Stacy, 1977; Wiginton et al., 1981). 
The three-dimensional structure has been solved for the murine ADA (which is 83% 
identical to the human protein) by X-ray crystallography, and shows a parallel a/p 
barrel structure with a central zinc atom in the active site (Wilson et al., 1991; Sharff 
etal., 1992).
Adenosine deaminase is found mainly in the cytoplasm of the cells, however a small 
proportion can also be found in some cell types in a complex with two molecules of 
CD26 (Nishihara et al., 1973; Van der Weyden & Kelley, 1976; Daddona & Kelley, 
1978; Schrader et al., 1979; Daddona & Kelley, 1980). It is thought that the ADA 
expressed on the cell surface of cells may regulate local concentrations of adenosine 
which affect the stimulatory and inhibitory adenosine receptors.
The ADA protein is found in all tissues, although its levels of expression vary greatly 
over a 103-104 fold range (Brady & O’Donnovan, 1965; Van der Weyden & Kelley, 
1976). In addition, ADA is also developmentally regulated, where in humans a 
decrease in ADA expression is seen from immature cortical thymocytes to medullary 
thymocytes and mature T-lymphocytes, as well as in the maturation of B cells
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(Chechik et al., 1981; Chechik et al., 1984). ADA activity is thought to be important 
in all cell types, and the highest activity levels are detected in the thymus and in other 
lymphoid tissues, particularly immature T cells, in the brain and in the 
gastrointestinal tract. The lowest ADA activity levels are found in erythrocytes 
(Edwards et al., 1971; Van der Weyden & Kelley, 1976; Adams & Harkness, 1976; 
Carson et al., 1977; Hirschhom et al., 1978; Witte et al., 1991). Enzyme activity in 
many ADA-SCID patients is effectively undetectable, and if any activity is observed, 
this is usually due to the minor activity of a non-relevant isozyme that exhibits ADA 
activity and is not affected in ADA deficiency. Later onset patients have generally 
retained 2-5% of the enzyme activity (Shovlin et al., 1993). In most ADA deficient 
patients analysed it has been determined that the mutation in the ADA enzyme has 
resulted in an unstable protein, hence explaining the complete lack of ADA activity. 
Approximately half of the mutations identified in ADA deficient patients do not 
express enzyme activity. Of the remainder, one group of mutations result in 0.5-2% 
normal activity, a second group results in 3-6% and a third group results in ADA 
activity of 10-80% of normal. The reasons for these ranges in ADA activity may be 
due to the instability of the mutant protein, disruption of the central zinc-interacting 
amino acids or changes of amino acids in the active site (reviewed by Hirschhom, 
1993).
There appears to be a good correlation between levels of ADA activity and severity 
of disease. A lower enzyme activity is usually associated with a more severe disease 
progress. As carriers of the mutated ADA gene appear to have normal immune 
function, the amount of ADA activity levels needed to maintain a functional immune 
system are thought to be quite low, possibly as low as 5% of normal (Hirschhom, 
1999). Some children who present with late onset ADA-SCID have been found to 
have trace amounts of ADA activity, in the region of 1-2% of normal activity levels.
1.1.5 Mutational Analysis of ADA
More than 70 different mutations have been identified by Hirschhom (Hirschhom et 
al., 1992) and many others (reviewed by Hershfield and Mitchell, 2001) that result in 
ADA deficiency. A large proportion of these are point mutations (single base pair 
changes), although there are also some deletions (ranging from single nucleotide to
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large deletions), insertions (insertion of one or more nucleotides), splice mutations 
(often single nucleotide changes which result in abnormal splicing), as well as a few 
nonsense mutations (point mutations which introduce a pre-mature stop codon and 
therefore shorten the protein). From the mutations analysed in ADA deficiency, it 
appears that a small number of mutations may be responsible for the disease in 
several patients. This could be due to one of two reasons, either due to founder effect 
or due to mutational hot spots especially at CpG dinucleotides. Several missense 
mutations (point mutations resulting in an amino acid change) at mutational hot spots 
have been reported in ADA-SCID individuals, which would lead to either unstable or 
inactive protein. The gene is also rich in Alu sequences within the introns, which 
have been shown to be involved in causing deletions in the ADA gene.
Genotype/phenotype correlations have been studied to a large extent, however it has 
been made difficult mainly by the fact that ADA deficiency is such a rare disease and 
that most patients are compound heterozygotes, carrying two different mutations. 
These studies are also complicated because environment and linked or unlinked 
modifying genes can affect the genotype/phenotype relationship. One difficulty was 
how to define the clinical phenotype. This could be done by the age of onset or the 
extent of immunological abnormalities; however the cellular immune dysfunctions 
can be greatly modified by the time and nature of infectious agents the patient 
encounters. Phenotype could therefore also be defined by the amount of residual 
ADA activity, by the extent of accumulation of ADA substrates or by the response to 
different medications. Despite these difficulties, some correlations can still be 
defined. A patient homozygous for the Arg261Gly mutation and a patient with a 
mutation in the downstream codon were both found to have very severe phenotypes. 
These codons were discovered to be in the region of the substrate binding site which 
has been found to be conserved through evolution. It is therefore thought that these 
two mutations are candidates for markers of severe disease (Hirschhom et al., 1993). 
Other mutations have been found to confer a milder disease progress. Some patients 
who responded better than others to a crude form of enzyme replacement therapy, 
partial exchange transfusions, were found to carry certain mutations. Ala329Val is 
one mutation which may be associated with a milder phenotype and has been found 
to code for 0.5-2% of normal ADA activity. Similarly, Arg21 lHis was found in two 
patients to encode for some ADA activity, and two mutations at codon 101 were also
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identified in two other patients (Hirschhom et al., 1993). One of the mutations at 
codon 101 is thought to code for some ADA activity in T cells, hence it is likely to 
be a less severe mutation. Certain other mutations (e.g. Ala215Thr, Argl56His) were 
also found in several ADA deficient patients with a delayed onset but not in patients 
with early onset disease (Hirschhom et al., 1990c; Santisteban et al., 1993; Ozsahin 
et al., 1997). One of the delayed onset patients was found to have a mutation that 
allowed for the expression of 1% of normal ADA levels (Hirschhom et al., 1993). 
Analysis by Hershfield in 2003, revealed that 90% of the patients with an early onset 
disease had alleles expressing less than 0.05% of normal ADA activity. He also 
showed that only one of the early onset disease patients had one allele which resulted 
in slightly higher ADA activity. Moreover, the vast majority of the alleles known to 
confer 0.1-11% of normal ADA activity, were associated with delayed, adult onset or 
partial phenotypes. Hence it is clear that despite the difficulties in discerning 
genotype/phenotype relationships, some mutations have been identified which result 
in a more or less severe phenotype of ADA deficiency.
1.1.6 Mouse Models of ADA Deficiency
There are no naturally occurring animal models of ADA deficiency, however two 
groups initially reported the generation of ADA deficient mice, which had severe 
metabolic abnormalities and died perinatally due to liver damage (Migchielsen et al., 
1995 & 1996; Wakamiya et al., 1995). It was demonstrated that it was the lack of 
ADA which resulted in the perinatal death of these mice.
However, as a result of the perinatal death, the consequences of ADA deficiency on 
post-natal animals could not be assessed. Blackburn et al., (1998 and 2000a & b) 
managed to rescue the ADA deficient mice by expressing the ADA transgene 
selectively in the placenta. Once bom, these mice therefore lacked ADA expression, 
and were found to retain many features seen in ADA deficient humans, including 
immunodeficiency with combined T and B cell lymphopenia. They had smaller than 
usual spleens and thymuses, resulting in reduced lymphoid cell counts in these 
organs. The serum antibody levels decreased and B cell development was impaired 
(Aldrich et al., 2003). The mice, like ADA deficient individuals, also had severe 
metabolic abnormalities and appeared to exhibit many non-lymphoid abnormalities.
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They displayed bone and cartilage abnormalities of the ribs as well as renal 
abnormalities, attributed to the high levels of adenosine (Blackburn et al., 2000b). 
These mice survived for 3 weeks before succumbing to respiratory failure. 
Respiratory problems have also been found in ADA deficient individuals; however 
they were usually thought to be as a result of bacterial or viral pneumonia. In most of 
these cases though, an infectious agent could not be isolated. The observations made 
in the ADA deficient mice may therefore suggest that the metabolic abnormalities 
may also be responsible for respiratory problems in ADA deficient patients. 
Blackburn et al. also showed that treating the mice with a low dose of enzyme 
replacement therapy rescued the mice and improved pulmonary deficiencies although 
the immune status did not appear to improve (Blackburn et al., 2000b). It was found 
that a high-dose enzyme replacement therapy was required to decrease the 
metabolites in the spleen and thymus, increase the numbers of lymphocytes and thus 
improve immune function (Blackburn et al., 2000a). It therefore appears that the 
pulmonary and immunological abnormalities are related to the severity of the 
metabolic disturbances, and these findings may be significant to the treatment of 
ADA deficient individuals.
Therefore, the generation of these ADA deficient mice is very significant as the 
molecular defects leading to the immunological and non-immunological symptoms 
can be studied in more detail and treatments can be assessed. However, one also 
needs to consider the fact that there are important differences in the requirement for 
ADA during development of the foetus in mice and humans, so any conclusions from 
these experiments need to be carefully assessed.
1.2 D ia g n o s is  a n d  T r e a t m e n t s  f o r  A d e n o s in e  
D e a m in a s e  D e f ic ie n c y
1.2.1 Diagnosis of ADA Deficiency
A common method of diagnosing ADA deficiency is by the measurement of ADA 
enzyme activity in erythrocytes, lymphocytes or fibroblasts. ADA deficiency is often 
diagnosed once the patient has been admitted to hospital due to severe persistent
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infections, and has been found to have a B', T', NK' SCID phenotype. In pedigrees 
with a family history, diagnosis can also be carried out pre-natally by measuring the 
enzyme activity in amniotic cells (Hirschhom et al., 1975; Hirschhom, 1979b; 
Aitken et al., 1980; Ziegler et al., 1981) or chorionic villi (Aitken et al., 1980; 
Dooley et al., 1987). ADA deficient patients show very low or absent levels of ADA 
activity, whereas ADA carriers, who are generally healthy, have 5-80% of the normal 
ADA activity. ADA deficiency can also be diagnosed by measuring the amount of 
dATP in erythrocytes, which will be greatly increased in ADA deficient patients. 
Once ADA-SCID has been diagnosed by enzyme activity or dATP levels, it can be 
confirmed by DNA sequencing to reveal the mutation within the ADA gene, 
although this is not routinely undertaken in most centres.
1.2.2. Management of ADA Deficiency
At diagnosis, any infections must be specifically treated and the patient is given 
intravenous immunoglobulins (IVIG). The child should also be appropriately isolated 
(hence “the boy in the bubble” -  Klug & Cummings, 1999) to avoid exposure to 
common childhood vimses, and live vims vaccines should be avoided. However, 
without restoration of immune function, ADA deficiency is fatal in the first 2 years 
of life usually due to infectious complications.
1.2.3 Bone Marrow Transplantation
There are few treatment options available for ADA-SCID. The preferred treatment is 
bone marrow transplantation if a fully matched donor is available, although this is 
the case only for approximately one-third of the patients. A matched transplant is 
usually successful, resulting in complete or partial immune reconstitution and a 
survival rate of greater than 90% is observed (Fischer et al., 1990). This is thought to 
be due to the fact that no myeloablative conditioning is required prior to the 
transplant, as ADA deficient patients fail to produce B, T and NK cells. T cell 
engraftment usually occurs within a month, but humoral immunity recovers more 
slowly and is often not complete. Following BMT, metabolites in erythrocytes, 
plasma and urine are dramatically decreased (Chen et al., 1978; reviewed by 
Hirschhom, 1999). However, metabolites are still elevated, especially in plasma, 
when compared to normal, and SAH hydrolase activity remains low (Hirschhom et 
al., 1981 & reviewed by Hirschhom, 1999). It has been shown that even in patients
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who were immunologically normal 10 years following transplant, the 
deoxyadenosine and adenosine levels were still high in nonlymphoid tissues 
(Hirschhom et al., 1981), which may be important in regard to non-immunological 
symptoms of ADA deficient individuals.
If no matched donor is found, another option is to transplant mismatched marrow, 
which would be T cell depleted to minimise the risk of graft versus host disease 
(GVHD). However, as a result donor T cells do not return for 3 to 4 months and full 
T cell function may take longer to develop. It has also been found that B cell function 
remains abnormal, and consequently transplants from mismatched donors are less 
effective at restoring humoral immunity. Conditioning prior to a mismatched marrow 
transplant would usually need to be carried out to create ‘more space’ for the donor 
cells in the bone marrow. However, this leads to greater morbidity including 
complications such as renal and liver damage (Morgan et al., 1991) and long-term 
problems such as infertility (Morgan et al., 1991), dental defects (Cole et al., 2000), 
and cognitive abnormalities (Phipps et al., 1995). Transplantation without the use of 
conditioning would avoid the chemotherapy related complications, and has been 
found to increase survival rates. However, without the use of conditioning there is a 
greater risk of only partial immune reconstitution and a higher rate of rejection 
(Buckley et al., 1999). The survival rate beyond three years for this type of 
transplantation is only in the region of 28-67% (O’Reilly et al., 1989). It has also 
been noted that ADA deficient patients tend not to do as well as other SCID patients 
following this type of transplant. Therefore, due to greater morbidity and mortality 
associated with a mismatched transplant, this is normally not the treatment of choice.
1.2.4 Enzyme Replacement Therapy
An early form of enzyme replacement involved transfusions of irradiated red blood 
cells based on the observations that these cells have transport sites for both adenosine 
and deoxyadenosine and contain ADA (Polmar et al., 1976). Although ADA activity 
levels increased and metabolite concentrations decreased, this response was usually 
found to be transient and inadequate (Polmar et al., 1976; Cohen et al., 1978; 
Schmalstieg et al., 1978; Rubinstein et al., 1979; Dyminski et al., 1979; Hirschhom 
et al., 1980; Ziegler et al., 1980; Hutton et al., 1981; Davies et al., 1982). It did
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restore normal growth and development and prolonged survival in some of the 
patients, however any improvements in immunological function was short lived. This 
form of enzyme replacement therapy was therefore found to be ineffective and 
moreover carried the risk of transmitting infectious agents. As ADA has a half-life of 
only a few minutes, transfusions would need to be given constantly. This was not 
only impractical, but it also resulted in an increase in intracellular iron concentrations 
which lead to further toxic complications.
A more refined form of enzyme replacement therapy, polyethyleneglycol (PEG)- 
ADA therapy, was developed and patients who had survived with the RBC 
transfusions were quickly switched to this treatment. The covalent bonding of PEG 
to the ADA protein increased the half-life of the enzyme from minutes to days, 
making it more convenient to use. This treatment has been in use since 1987, it is 
thought to be safe and effective, and has seen good survival rates of nearly 80% 
(reviewed by Hershfield, 1995). One of the advantages of PEG-ADA is that unlike 
BMT it is not risky or invasive, and can therefore be offered even to seriously ill 
patients.
The treatment involves weekly or bi-weekly intra-muscular injections of PEG-ylated 
bovine ADA. It is an exogenous source of the enzyme, and relies on the fact that the 
metabolites are present in the plasma and body fluids and that the toxic metabolites 
such as dATP are in equilibrium with the precursor in the plasma so that when their 
concentrations are decreased in the plasma their intracellular concentrations are also 
decreased. When treating an ADA deficient patient, a rapid decrease in the toxic 
ADA metabolites dATP and dAdo is usually seen, resulting in levels that are lower 
than those seen following BMT, but are nevertheless slightly higher than normal 
(Hirschhom et al., 1980, 1981). As the metabolic defect is corrected by the 
exogenous ADA, SAHH activity increases to near normal, B cell numbers start to 
increase during the first month followed by T cells, and the lymphocyte counts then 
usually stabilise at levels slightly less than average. Although the lymphocyte 
numbers are near the lower end of the normal range, there is a good clinical 
protection from infection. PEG-ADA also results in restoration of normal growth and 
development and improves alertness. Several ADA-SCID patients have received 
PEG-ADA because they were considered too ill to undergo bone marrow
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transplantation. However, the mortality rate among those patients was still less than 
20%, which compares favourably to haploidentical BMT (Hershfield and Mitchell, 
2001).
No formal studies exist on the outcome of patients treated with PEG-ADA, and the 
data presented is taken from reports from Hershfield. Following the first year of 
treatment, most patients remain lymphopenic, although specific antibody responses 
have been observed in 50% of the patients who no longer receive regular 
gammaglobulin treatment. It appears that humoral immunity improves to a greater 
extent in patients who respond to PEG-ADA than patients treated with BMT (Ochs et 
al., 1992). Moreover, PEG-ADA unlike BMT is a systemic treatment, and in one 
study PEG-ADA administration resulted in complete normalisation of liver function 
tests in an ADA-SCID child who presented with persistent neonatal hepatitis for 
which no infectious cause could be found (reviewed by Hershfield & Mitchell, 
2001). It is therefore possible that PEG-ADA, being a systemic treatment leading to a 
greater reduction of metabolites, may result in a greater improvement of non- 
immunological symptoms as compared with BMT.
However, the degree of immune reconstitution can be varied even though the PEG- 
ADA treatment improves the metabolic abnormalities. Although there have been no 
toxic or allergic reactions to PEG-ADA, approximately 50% of the patients develop 
antibodies against bovine ADA. This may reduce the effectiveness of the treatment, 
although this has been proven in only a few patients (Reviewed by Hirschhom, 
1999). Immune dysregulation also sometimes occurs as it does in BMT. Hershfield et 
al. (1993) found that two patients treated with PEG-ADA developed refractory 
immune haemolytic anaemia. One of these patients required immune suppression and 
as a result developed Candida sepsis, leading to the death of the child. For the second 
patient, the PEG-ADA was withdrawn and a mismatched marrow transplant was 
attempted, though this was not successful as the patient died from complications 
related to the transplant. Another drawback with PEG-ADA is that it is not a curative 
treatment, and needs to be administered for the rest of the patient’s life. Therefore, 
with the high cost of approximately $100,000 per year per patient, the PEG-ADA 
treatment is not always available to the child. Furthermore, the effect of PEG-ADA
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administration long-term (>10 years) in terms of immune recovery and overall 
survival is not known.
1.2.5 Gene Therapy
For patients who do not have a matched donor, and for whom enzyme replacement is 
not effective or is not available, an attractive alternative is gene therapy. The first 
ever scientific article published mentioning the word “gene therapy” was in 1970, 
and speculated on the use of pseudoviruses containing therapeutic genes to transduce 
target cells (Osterman et al., 1970). Since then hundreds of gene therapy trials have 
been carried out for several different diseases. Gene therapy involves the transfer of 
DNA or RNA into cells in order to correct or modify their functions. Modification of 
cell function has been attempted by increasing the immunogenicity of tumour cells 
(Nabel et al., 1996), and correction of cell functions has also been attempted in 
diseases such as cystic fibrosis (Flotte et al., 1996) (CFTR gene) and familial 
hypercholesterolemia (Wilson et al., 1992) (LDL receptor).
1.2.5.1 Successful Gene Therapy for X-SCID
The first gene therapy trial to demonstrate therapeutic benefit was reported for X- 
SCID in the Paris trial in 2000 (Cavazzana-Calvo et al., 2000). X-SCID, as 
previously mentioned, is a condition characterised by a lack of T and NK cells. 
These deficiencies occur as a result of a lack of the common gamma-chain, a subunit 
of several interleukin receptors (IL-2, IL-4, IL-7, IL-9, IL-11, IL-15 and IL-21). 
Consequently, cytokine signalling transmitting survival and proliferative signals to T 
and NK cells is affected resulting in compromised immune cell development and 
function. The role of the gamma chain in the survival and proliferation of the 
lymphoid cells means that its expression through gene therapy should confer a major 
selective advantage to the transduced cells (Soudais et al., 2000). The Paris trial 
therefore utilised a gammaretroviral vector to introduce a functional gamma chain to 
autologous CD34+ cells. A recombinant fibronectin fragment was used to facilitate 
co-localisation of the virus particle and target cell, thus increasing the gene transfer 
efficiency. 11 boys were treated in this trial, and all but one have shown good 
immune reconstitution (Hacein-Bey-Abina et al., 2002). Immune reconstitution was 
rapid, with NK cells appearing at between 2 and 4 weeks post gene therapy, and the
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number and distribution of T cells increasing rapidly. Humoral immunity was also 
partially restored. However, as a direct result of the gene therapy three patients 
developed leukaemia, one of whom died. This is further discussed in the general 
discussion.
Eight patients have also been treated in Great Ormond Street Hospital, London, using 
a similar protocol to the Paris study. However, in the London study, no FCS was 
used for cell culture and the gammaretrovirus was pseudotyped with the GALV 
envelope rather than the amphotropic envelope. These differences may have been 
responsible for the higher gene transfer efficiencies observed in B cells and myeloid 
cells in the London study. No adverse events have been observed to date, and seven 
of the eight patients have showed good immune recovery similar to those in the Paris 
study and have cleared viral infections. Prophylactic medication was withdrawn in 
two patients (Gaspar et al., 2004). T cell responses to mitogenic and antigenic stimuli 
were normal and the T cell receptor repertoire was highly diverse following 
treatment. Where assessed, humoral activity, in terms of antibody production, was 
also restored. However one of the patients did not show immune reconstitution, 
possibly due to limited initiation of normal thymopoiesis as a result of older age at 
treatment, also observed in the Paris study (Howe et al., 2003; Thrasher et al., 2005). 
Therefore, therapeutic potential of gene therapy was first demonstrated for X-SCED.
1.2.5.2 Gene Therapy for ADA-SCID
The first inherited disease for which therapeutic gene therapy was undertaken was 
ADA deficiency in the early 1990’s (Blease, 1992; Bordignon et al., 1995; Blease et 
al., 1995; Kohn et al., 1995; Hoeben et al., 1992; Hoogerbrugge et al., 1992), and 
since then 24 ADA-SCID patients have been treated. ADA appeared to be a good 
candidate for gene therapy for several reasons, firstly because it is caused by a single 
gene defect. The gene was identified in 1983 (Valerio et al., 1983; Wiginton et al., 
1983; Orkin et al., 1983), which has allowed a great deal of research to be carried out 
on its function and regulation. Importantly, since ADA is a housekeeping enzyme, its 
expression does not need to be tightly regulated. In fact, individuals with as little as 
5% of and as much as 50 times more than normal ADA activity have been found to 
have functioning immune systems. Furthermore, murine models have shown that
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gene corrected lymphoid cells have a survival advantage over the non-transduced 
cells (Ferrari et al., 1991). Clinical observations have also been encouraging, as bone 
marrow transplantations have similarly shown that ADA containing cells have a 
selective advantage over ADA deficient cells (Parkman et al., 1975; Tjonnfjord et 
al., 1994). Another remarkable case saw an ADA deficient child improve clinically 
without any therapy. This was found to be due to a reversion of the mutation in a T 
lymphoid progenitor which then repopulated the entire T cell population, again 
showing evidence of selective advantage of ADA+ cells (Hirschhom et al., 1994; 
Hirschhom et al., 1996). Therefore, for these reasons, gene therapy for ADA 
deficiency was considered to have good chances of success, and clinical trials were 
therefore initiated following further encouraging results in preclinical studies.
Preclinical studies to ADA gene therapy were carried out in mice in the mid-1980’s, 
subsequent to reports that cultured human B and T cells transduced with an ADA 
retrovirus showed reduced sensitivity to 2-deoxyadenosine toxicity (Kantoff et al., 
1986). The murine study involved ex vivo gene transfer of the human ADA gene into 
haematopoietic stem cells (HSCs), which were reinfused into irradiated mice (Lim et 
al., 1987). Protein analysis showed that circulating haematopoietic cells that had 
been recovered were expressing the human ADA. Based on these preclinical 
observations, a similar protocol was suggested for use in ADA deficient patients. The 
proposed protocol involved the harvest of autologous bone marrow and transduction 
of the bone marrow cells ex vivo using a murine gammaretrovirus carrying the ADA 
cDNA prior to reinfusion of the transduced cells. This type of protocol was used in 
pre-clinical trials in rhesus monkeys (Van Beusechem et al., 1992), which showed 
that the retroviral transduced HSCs were capable of repopulating the haematopoietic 
compartment of irradiated recipients. Although the level of transgene expression was 
low, it was detectable in several haematopoietic cells at various times including at 
more than one year post gene therapy, and the therapy proved to be safe. Therefore, 
all preclinical trials supported the feasibility of gene therapy for ADA deficiency in 
humans.
Human gene therapy trials that have been carried out for ADA deficiency to date are 
listed in Table 1.2. Some of these trials have encountered difficulties, mainly relating 
to transduction of stem cells. This is partly due to the low numbers of stem cells in
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the bone marrow (less than 0.1% of bone marrow mononuclear cells (MNC)), and 
the mainly quiescent status of the cells resulting in low gene transfer efficiency. 
Cytokine inductions of these stem cells are therefore required to stimulate cell 
division and thus allow gammaretroviral transduction, however this usually also 
leads to stem cell differentiation, reducing their multipotential nature. These 
problems have been addressed in studies which have analysed vector design 
(Armentano et al., 1987; Hantzopoulos et al., 1989; Hock et al., 1989; Van 
Beusechem et al., 1990) and cytokine cocktails used to induce proliferation without 
differentiation (Bodine et al., 1989; Fletcher et al., 1991).
Study Gamma­
retroviral
Vector
Envelope Cell Type Number of 
Patients
Blease, NIH, 1990 LASN A PBL 2
Bordignon, Milan, 
1992
DC Am, DCA1 A BM CD34+ & 
PBL
2
Kohn, L.A., 1993 LASN A UCB CD34+ 3
Hoogerbrugge, 
Netherlands, 1993
LgAL A BM CD34+ 3
Onodera, Japan, 
1995
LASN A PBL 1
Aiuti, Milan, 2001 GIADA1 A BM CD34+ 6
NIH, 2001* N/A N/A N/A 4
Sakiyama, Japan, 
2005
GCsapM-ADA N/A BM CD34+ 2
Gaspar, London, 
2003
SFada/W G BM CD34+ 1
Table 1.2. Gene therapy trials carried out for ADA deficiency.
Abbreviations: A, amphotropic; PBL, peripheral blood lymphocytes; BM, bone marrow; 
UCB, umbilical cord blood; N/A, information not available; G, GALV.
* Details have not been published to date.
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1.2.5.3 ADA Gene Therapy -  Study by Blease et al.
As transduction conditions o f HSCs had not been fully determined at the time, the 
first human gene therapy trial for ADA deficiency carried out at the NIH (Blease, 
1992; Blease et al., 1995) utilised mature T cell lymphocytes. In this trial, two 
patients were treated, both of whom received monthly or bi-monthly injections of 
transduced T cells following stimulation using anti-CD3 antibody and IL-2. The 
vector used was the LASN (LTR-ADA-SV40-NeoR) gammaretroviral vector with an 
amphotropic envelope, and ADA expression was driven by the Moloney murine 
leukaemia virus (MoMLV) LTR. Crucially, this trial demonstrated that there was no 
toxicity related to the gene therapy. Follow-up studies also showed that although 
there was no great therapeutic effect, the transgene still persisted 10 years following 
the treatment of one of the patients. Approximately 30% of the T cells were 
transduced in that patient, whereas the second patient had less than 1% transduced T 
cells (Muul et al., 2003). This difference in transduced cells is possibly due to the 
great difference in original transduction efficiencies of the two patients’ cells (1-10% 
in the first patient and 0.1-1% in the second patient), or due to an immune response 
in the second patient to foetal calf serum (Tuschong et al., 2002) and a viral envelope 
protein (Muul et al., 2003). Both patients did have improved antibody titres and 
improved delayed hypersensitivity skin tests following gene therapy. However, 
reasons as to why gene therapy did not entirely correct the immune system are 
thought to be related to low transduction efficiency. Moreover, the patients were 
receiving PEG-ADA before the trial and at a reduced dose after the trial, and it is 
now believed that maintaining the patients on PEG-ADA removed or blunted the 
possible selective advantage of the ADA+ cells. Nevertheless, questions remained 
regarding the persistence of the transduced T cells without exogenous ADA and 
whether T cells alone would be sufficient for patient protection. Hence it was 
important to carry out further trials using stem cells that should provide the patient 
with a more varied repertoire of transduced immune cells. The possibility of 
discontinuing PEG-ADA treatments in gene-therapy candidates was also considered 
in order to enhance any selective advantage of transduced cells, thus allowing a 
better reconstitution of immune function.
42
C h a p t e r  1
1.2.5.4 ADA Gene Therapy -  Study by Bordignon et al.
The first gene therapy trial using HSCs was reported by Bordignon et al. in 1995. It 
involved the ex vivo transduction of both bone marrow derived HSCs and peripheral 
blood derived mature T lymphocytes using two different gammaretroviral vectors in 
order to facilitate the identification of the origin of recovered transduced cells. The 
patients received further injections of transduced T cells over time. Shortly after gene 
therapy circulating transduced T lymphocytes were detected originating from the 
peripheral blood derived T lymphocytes. However gradually more transduced cells 
could be identified originating from the transduced HSCs. Clinical improvement was 
observed as height and weight of both patients normalised, however, overall 
improvement could not be attributed to gene therapy because the patients were also 
receiving PEG-ADA. Importantly, analysis for recombinant virus was consistently 
negative.
1.2.5.5 ADA Gene Therapy -  Study by Kohn et al.
Kohn et al. carried out another gene therapy trial utilising HSCs. They transduced 
HSCs from umbilical cord blood of three pre-natally diagnosed ADA deficient 
patients using the NIH LASN vector (Kohn et al., 1995). These children received 
PEG-ADA from the first week of their lives. This study gave rise to several 
interesting observations regarding the possibilities for gene therapy, but also its 
limitations. It was found that even without cytoablative therapy, approximately 20% 
of granulocyte-macrophage colony-forming unit (CFU-GM) progenitor cells from 
UCB contained the transgene, although this decreased to 1% one year later in bone 
marrow cells. This treatment was announced a success as the children developed a 
functional immune system, and the immunoglobulin replacement therapy was 
removed. Two years following their gene therapy treatment, the PEG-ADA was 
gradually decreased. As the PEG-ADA was lowered, there was a marked decrease in 
circulating T cells but a 100-fold increase was seen in transduced T cells, suggesting 
a selective survival advantage of the transduced cells. Four years post gene therapy, 
PEG-ADA treatment was discontinued in one patient for two months as 10% of his T 
cells were transduced and it was hoped that the selective advantage introduced to 
these cells would result in an increase in their numbers. However, as the PEG-ADA 
was removed, the plasma ADA levels decreased, the dAdo increased to the high
43
C h a p t e r  1
levels seen prior to PEG-ADA therapy, and the S-adenosyl homocysteine hydrolase 
activity therefore decreased (Kohn et al., 1998). Moreover the absolute numbers of 
NK and B cells decreased to less than 25% compared with when he was receiving 
PEG-ADA. Although the number of T cells decreased, the frequency of transduced T 
cells increased to 30%, which is consistent with the selective advantage seen 
following bone marrow transplantations. However, the patient developed oral thrush, 
an upper respiratory infection and weight loss two months following discontinuation 
of PEG-ADA and was therefore reinstated on therapeutic doses of PEG-ADA. Upon 
reintroduction of exogenous ADA the patient immediately showed signs of 
immunological improvement with a decrease in dAdo, increase in B and NK cells 
and a reappearance of antigen-specific T lymphocytes. It therefore appeared that the 
transduced cells were not capable of sustaining the immune system without the 
presence of exogenous ADA.
1.2.5.6 ADA Gene Therapy -  Study by Hoogerbrugge et al.
Another trial using HSCs was carried out by Hoogerbrugge et al., who utilised bone 
marrow derived HSCs to treat three patients (Hoogerbrugge et al., 1992 & 1996). 
However, they did not achieve a good transduction efficiency, and as a result no 
transduced cells were detected long term. The lack of transduced cells long term was 
also attributed to the lack of myeloablation and the continuation of the PEG-ADA 
treatment removing the selective advantage of ADA+ cells. Therefore, no specific 
conclusions could be drawn from this study.
1.2.5.7 ADA Gene Therapy -  Study by Onodera et al.
Onodera et al. treated one ADA deficient patient, who has showed some immune 
reconstitution (Onodera et al., 1998). The NIH LASN vector was used to transduce T 
lymphocytes, and the patient was given ten infusions of the autologous cells over an 
18-month period. One year after the last infusion, circulating PBLs remained 10-20% 
transduced, resulting in ADA activity levels in T cells similar to ADA carriers. The 
T-lymphocyte counts increased and his immune function was improved. However, at 
the time of publication, there had only been a period of one year post gene therapy, 
hence follow-up data will be needed to determine the success of this trial. This group
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has since treated two more patients in the absence of PEG-ADA and no conditioning 
(Sakiyama et al., 2005).
1.2.5.8 ADA Gene Therapy -  Study by Bordignon & Aiuti
Aiuti et al. (2002b) showed that withdrawal of PEG-ADA can lead to improved 
immune reconstitution, contrary to the results of Kohn et al. in 1998. One of the 
patients in the study by Bordignon (Bordignon et al., 1995) had a frequency of 
transduced lymphocytes of 1-3% two years post gene therapy. The PEG-ADA, 
administered throughout the gene therapy study was found not to support T- 
lymphopoiesis, as the patient remained lymphopenic, had low response to antigens 
and reduced thymic function. It was therefore decided to discontinue PEG-ADA 
gradually to reintroduce the selective advantage of the transduced cells, along with 
further infusions of transduced PBLs. Following discontinuation of PEG-ADA, the 
proportion of transduced T cells increased, supporting the notion o f selective 
advantage of ADA+ cells. The absolute T cell counts also increased, along with an 
increase in PBL ADA activity, allowing for complete restoration of T cell functions. 
Following an infection, the PEG-ADA was reinstated briefly and once the infection 
was cleared, PEG-ADA was again discontinued. Following the second 
discontinuation, the levels of deoxyribonucleotides were found to decrease in the 
erythroid cells, suggesting that a certain number of transduced lymphocytes may be 
required for detoxification. Hence, these observations seem to imply that a selective 
advantage of transduced cells is important for the success of gene therapy for 
adenosine deaminase deficiency. Reasons as to why PEG-ADA withdrawal was 
successful in this study contrary to the findings of Kohn et al., may be related to the 
different target cells or the difference in number of transduced cells infused, or 
simply due to different responses to treatment seen in ADA deficient individuals.
1.2.5.9 ADA Gene Therapy -  Study by Aiuti et al.
A recent study using a modified protocol has had even more success. Aiuti et al. 
(2002a) used transduced autologous CD34+ cells to treat two patients, but unlike 
previous studies these patients did not commence on PEG-ADA due to socio­
economic reasons. The patients were also given a mild nonmyeloablative
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conditioning regimen, in order to create ‘more space’ for the transduced 
haematopoietic stem cells. Levels of engraftment of genetically corrected cells were 
therefore improved. The proportions of vector containing T cells were found to peak 
at 70% 11 months following gene therapy for Patient 1, and at 100% at day 240 for 
Patient 2. In Patient 1, 5-20% of granulocytes, monocytes, megakaryocytes and 
erythroid cells were found to contain the transgene a year following therapy. Gene 
therapy therefore resulted in increased lymphocyte counts, normalised serum 
immunoglobulin levels and improved immune systems concomitant with lower toxic 
ADA substrates and increased ADA activity levels. Both patients are now at home 
and are clinically well, showing normal growth and development. Interestingly, 
patient 1 has showed a better immune reconstitution than patient 2. There are three 
reasons thought to be important in this difference of response. Firstly, patient 1 
received a log higher in number of transduced CD34+ cells than patient 2. Secondly, 
patient 1 was only 7 months old whereas patient 2 was 2.5 years old, and this could 
be important for the level of HSC engraftment. Another important factor could be the 
degree of conditioning in each patient as a result of different routes of administration. 
It therefore appears that there are several factors in the gene therapy protocol crucial 
to its success, including the number of infused transduced cells, the level of 
conditioning achieved and the age of the patient at treatment. Following the 
successful treatment of these two patients, 3 further patients have been treated with 
similarly encouraging results (Aiuti et al., 2005).
1.2.6 Limitations of Current Treatments for ADA Deficiency
It has been demonstrated that ADA deficiency is a multi-organ disease, hence 
requiring a systemic treatment. Bone marrow transplantations have shown improved 
immunological function, however it is not a systemic treatment and the metabolites 
do remain above the normal range. PEG-ADA is a more systemic treatment, 
resulting in elimination of toxic metabolites. However, it is not a good long-term 
treatment as the effectiveness may decline with time, and the treatment becomes 
more expensive as the child grows and requires higher doses of enzyme. Therefore 
there is a need to develop a more long-term and systemic treatment for ADA 
deficiency.
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Correction of mature T cells or haematopoietic stem cells currently performed in 
gene therapy trials may not be sufficient in the case of ADA deficiency, as it has 
been shown to be a systemic disease. Hence the use of mesenchymal stem cells 
(MSCs) which are believed to be multipotential (discussed below) in combination 
with HSCs may be an alternative to the use of HSCs alone as it may offer a more 
systemic treatment. It was seen in the Italian study that gene therapy for ADA 
deficiency without the use of PEG-ADA results in a greater proportion of transduced 
circulating cells due to a selective advantage of these corrected cells. Hence patients 
already receiving PEG-ADA should probably have this discontinued prior to gene 
therapy. Mild conditioning also appears to increase the levels of engraftment of the 
transduced cells as it makes space in the bone marrow. Therefore gene therapy using 
lentiviral vectors to transduce HSCs and MSCs, the removal of PEG-ADA and the 
conditioning of the patient prior to gene therapy may offer a good treatment for ADA 
deficiency.
1.3 C o m p o n e n t s  R e q u ir e d  F o r  G e n e  T h e r a p y  o f  A D A  
D e f ic ie n c y
1.3.1 Gene Delivery Vehicles
As indicated in Table 1.2, all ADA-SCID gene therapy trials to date have utilised 
gammaretroviral vectors as gene delivery vehicles. Retroviral vectors have several 
advantages, including a large packaging capacity of up to 10 kilobases, efficient 
integration machinery, long-term expression of the transgene, and the absence of 
vector-induced cellular immune response as they do not encode viral specific 
proteins. Therefore it is thought that gammaretroviral or lentiviral vectors are the 
most appropriate gene delivery vehicles for diseases such as ADA deficiency where 
long-term gene expression and a lack of immune response are required.
Other viral vectors developed for gene therapy include lentiviruses, adenovirus, 
adeno-associated virus (AAV) and Herpes Simplex Virus (HSV). Lentiviruses are 
currently being developed and are further discussed in section 1.3.1.2. Adenoviral 
vectors are not appropriate to treat ADA deficiency as they show high
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immunogenicity and do not integrate, which would mean that the transgene would 
not be expressed long-term. Furthermore, cell specific targeting with adenovirus is 
difficult to achieve as it does not have an envelope to attach cell specific ligands 
(Gilgenkrantz et al., 1995; Yang & Wilson, 1995). AAV has been found to be 
inefficient at transducing primary cells, making it difficult to use for HSC transfer 
(Halbert et al., 1995). HSV has been evaluated for gene therapy for neuronal diseases 
such as Parkinson’s Disease, as it shows a long-lived asymptomatic stage in sensory 
neurons. However, its safety is of some concern as the wild-type virus has been 
shown to replicate lytically in human brain (reviewed by Latchman, 1994). Non-viral 
gene therapy is also under current development in order to try to improve the safety 
of the vector and to reduce the inflammatory response sometimes seen with viral 
vectors. However, non-viral vectors are still much less efficient than viral vectors, 
and the general goal of the development of non-viral vectors is to add features to 
DNA to mimic those functions that viruses already perform well. Therefore, non- 
viral vectors were not considered for gene therapy of ADA deficiency.
1.3.1.1 Gammaretroviral Vectors as Gene Delivery Vehicles
As a delivery tool, there are several important features of the viral vector. These 
include efficiency of transduction, the ability to target the cell types of interest, the 
expression of the transgene and the safety of the viral vector. A significant feature of 
gammaretroviral vectors for gene therapy is their ability to integrate into the genomic 
DNA of the host cell. Thus they can be used to introduce and permanently express 
genes in host cells, making them ideal delivery vectors to provide permanent 
correction of genetic diseases affecting the haematopoietic system (Karlsson, 1991).
The retroviral particle is composed of two single stranded RNA molecules, which are 
surrounded by a capsid and an envelope. The viral genome is composed of a 5’ and a 
3’ LTR which contain promoter and enhancer elements, where the U3 region of the 
5’ LTR drives pro viral transcription. Between the LTRs, the retrovirus contains the 
coding regions gag-pol-env in this order. Gag encodes structural proteins of the 
capsid, pol encodes the polymerase and integrase proteins, and env encodes the viral 
envelope. An important sequence element is the packaging sequence (v|/) which has 
been shown to play a role in assembling genomic RNA into virions. Attachment
48
C h a p t e r  1
(Att) sites within the LTRs have been found to be important as these are the sites 
where the integrase cleaves and binds the proviral ends to the host genomic DNA 
(reviewed by Luciw & Leung, 1992).
The viral life cycle has been extensively studied and involves the attachment to the 
host cell via receptors, internalisation, uncoating, reverse transcription, transportation 
to the nucleus and integration of the cDNA into the host cell genomic DNA to 
generate an integrated pro virus (Figure 1.5). The integrated pro virus is replicated 
during the cell cycle and passed on to daughter cells. The retroviral coding sequences 
are then expressed by the host cell transcriptional machinery. The newly synthesised 
viral proteins and RNAs are assembled to form new viral particles that bud out of the 
host cell, taking with them part of the cell membrane as a viral envelope (reviewed 
by Coffin, 1996). Reverse transcription is a complex mechanism by which the viral 
genomic RNA is transcribed into DNA and it is at this point that many mutations are 
introduced, especially important in HIV virulence. During reverse transcription a 
copy of the 3’ LTR is transferred onto the 5’ LTR. This strand-transfer step is 
exploited in the safety design feature of SIN vectors described in section 6.1.
Preferred sites of integration for gammaretroviral vectors have been particularly 
intensively studied following the leukaemia cases in three children in the Paris gene 
therapy trial. It was thought that integration was random, but it has now been 
revealed that gammaretroviruses have a strong preference for gene vicinity (Wu et 
al., 2003), which is discussed in more detail in section 8.2.1.
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Figure 1.5. Wild type retroviral lifecycle. Attachment of the virion is mediated by a 
receptor. The virus is then internalised, the RNA is reverse transcribed, and the DNA is 
integrated into the host cell’s genomic DNA where it becomes a pro virus. (Adapted from 
Luciw & Leung, 1992).
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The wild type viral vector has been extensively modified in order to increase its 
safety and comply with regulations for use in gene therapy trials. The 
gammaretroviral vector is designed so that it is replication defective, and the viral 
coding sequences present between the two long terminal repeats (LTRs) are replaced 
with the gene of interest. The plasmid also needs to incorporate signals for 
packaging, reverse transcription and integration. A packaging cell line is generally 
used to generate gammaretroviral particles (Figure 1.6). All of the proteins required 
for the production of virus particles (gag-pol and env) are stably maintained in the 
genome of the packaging cell line. This minimises the chance of recombination to 
produce replication competent retrovirus (RCR), and the virus particles themselves 
cannot produce further generations of virus particles as they do not encode the gag, 
pol or env genes. Replication competent MLV has been shown to cause lymphomas 
in primates used in gene therapy experiments (Donahue et al., 1992; Vanin et al., 
1994; Purcell et al., 1996). Thus, all clinical grade vectors produced are tested for 
RCRs, and the gammaretroviral vectors and packaging cell lines are carefully 
constructed to avoid overlapping sequences which could facilitate homologous 
recombination and generation of RCRs. The use of packaging cell lines therefore has 
several advantages including a minimal risk of recombination to generate infectious 
virus, a choice of viral envelope pseudotyping, a consistent titre of the virus 
generated and is amenability to industrial scale-up. However, due to the design of the 
replication defective vector, the multiplicity of infection (MOI) needs to be carefully 
selected. The separation of env from the viral vector expressing the transgene means 
that once the retrovirus has infected the target cell, a new generation virus cannot be 
generated as no gag, pol or env proteins are expressed. As no env protein is 
expressed in the transduced cell, there are no env proteins bound to the receptors of 
the host cell membrane, allowing for several viral particles to reinfect the same cell. 
Hence, if a high concentration of virus is used to transduce the target cell (i.e. a high 
MOI) several viral particles may integrate into the host cell genome and thus increase 
the risk of insertional mutagenesis. It is therefore important to balance the need for a 
high transduction efficiency, which usually results in a high transgene expression, 
and the risk of leukaemogenesis.
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Figure 1.6. Principles of a gammaretroviral packaging cell line. The packaging cell line 
provides the genes required for virus particle formation (gag, pol and env contained 
separately within the genome) which have been deleted from the vector. The packaging cell 
line is transfected with the plasmid vector DNA containing the gene of interest and the 
packaging signal i|/. Transcripts of the transfected plasmid are packaged into virions. These 
viral particles contain all functions required for one round of transduction and integration. 
(Adapted from Luciw & Leung, 1992).
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Although gammaretroviruses clearly have many advantages as gene delivery vehicles 
in ADA-SCID, the main limitation is their inability to infect non-dividing cells. It has 
been shown that preintegration complexes (PICs) of gammaretroviruses cannot cross 
an intact nuclear membrane (Roe et al., 1993). As a result gene transfer into slow 
dividing or non-dividing cells, such as HSCs and mesenchymal stem cells (Gothot et 
al., 1998; Conget & Minguell, 1999), is quite inefficient. As most of the HSCs are in 
the G0/G1 stage of the cell cycle, the cells need to be stimulated to divide by addition 
of specific cytokine combinations. This extended ex vivo culture of HSCs improves 
transduction efficiency but inevitably also results in differentiation of the HSCs, 
reducing their multipotential nature and engraftment potential (Bhatia et al., 1997; 
Gothot et al., 1998, Rebel et al., 1999; Demaison et al., 2000).
1.3.1.2 Lentiviral Vectors as Gene Delivery Vehicles
Lentiviruses are another family of retroviruses which have a more complex genome 
and replication cycle. Whereas the gammaretrovirus described in the previous section 
expresses only gag, pol and env, the lentivirus expresses additional accessory 
proteins including Tat, Rev, Nef, Vif, Vpr, and Vpu, whose functions are still to be 
fully elucidated. Tat is a transcriptional activator, Rev regulates transport of full- 
length or single-spliced viral RNA from the nucleus to the cytoplasm, Nef down- 
regulates the CD4 receptor and plays an important role in viral pathogenesis, Vif is 
important in viral infectivity, Vpu initiates CD4 degradation and enhances virion 
release, and Vpr is thought to be important in cell cycle arrest and fidelity of viral 
DNA synthesis (reviewed by Luciw, 1996; Mansky, 1996; reviewed by Frankel & 
Young, 1998; Mansky et al., 2000).
Vectors based on the HIV-1 lentivirus are currently being investigated as an 
improved gene delivery system. The main advantage of HIV-based vectors is that 
they can transduce and integrate into the cells’ genome without the need for cell 
division (Lewis et al., 1992; Bukrinsky et al., 1993; Lewis & Emerman, 1994; 
Naldini et al., 1996a). Whereas gammaretroviruses rely on the breakdown of the 
nuclear membrane during mitosis (Miller et al., 1990; Roe et al., 1993), lentiviruses 
have evolved properties relying on the use of a nuclear import pathway enabling the 
viral DNA to cross the nuclear membrane of the infected cell. Several different
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lentiviral proteins that control nuclear entry have been identified although none of 
them appear to be dominant (Gallay et al., 1995a & b, 1996, 1997). Three nuclear 
localisation motifs have been found in HIV integrase, however the exact localisation 
of these sequences are still uncertain (Gallay et al., 1997). One of the factors thought 
to be required for nuclear entry is the central flap sequence, the central polypurine 
tract (cPPT) (Follenzi et al., 2000). This DNA flap (so named because during reverse 
transcription, a central strand displacement following central initiation and 
termination of plus strand synthesis creates an stable plus strand overlap at the centre 
of the linear DNA molecule) has been shown to be involved in viral genome nuclear 
transport (Zennou et al., 2000), although the mechanism by which it enhances viral 
genome uptake into the nucleus has not yet been fully elucidated. It has been 
speculated that the central DNA flap may directly interact with components of the 
nuclear pore, or may be involved in the maturation of the HIV capsids into pre­
integration complexes. Zennou et al. found that the presence of the DNA flap 
increased transduction in HeLa cells by more than ten-fold. The inclusion of the 
cPPT element has also been shown to improve gene transfer into haematopoietic 
stem cells and the consequent gene expression (Sirven et al., 2000; Demaison et al., 
2002; Manganini et al., 2002). In fact, Sirven et al. showed that approximately 40% 
of CD34+ cells were transduced with lentivirus containing the cPPT element during 
the short culture period of 24 hours in the presence of cytokines. Two recent studies 
have shown that the lentivirus does not rely on the cPPT element for nuclear entry, 
however at a low MOI it appears that the flap gives the lentivirus an advantage for 
transduction of quiescent cells (Dvorin et al., 2002; Limon et al., 2002). Dvorin et al. 
also discovered that a valine residue at position 165 in the viral integrase was more 
important for nuclear translocation of viral nucleic acids than the cPPT element. This 
demonstrates that the process of nuclear translocation of lentiviral vectors is still not 
fully elucidated and that more studies are required to clarify this process.
As the lentiviral vector is based on the structure of HIV (usually HIV-1), the safety 
of the lentiviral vector has been of concern. In order to be considered for clinical 
applications, lentiviral vectors must comply with strict safety standards. This has 
been addressed by several groups and multiple alterations have been made to the 
vector in order to improve its safety. The modifications have occurred in a step-wise 
manner over time, and the different viral vectors are categorised into “generations”.
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In each of the different generations of lentiviral vectors, genes are deleted and split 
onto different vectors and sequence overlap is minimised to reduce the possibility of 
the generation of replication competent lentiviruses (RCL). The first generation 
design is generated from three plasmids: a gag-pol packaging plasmid, comprised of 
all of the HIV-1 proteins except the envelope, the transgene plasmid and a VSV-G 
envelope plasmid (Naldini et al., 1996b). This split genome system meant that 
multiple rearrangements and recombination events would be required to form a 
“wild-type” lentivirus. The second generation lentivirus is also generated from three 
separate plasmids (Figure 1.7). However, this vector has alterations in the gag-pol 
packaging construct, where the accessory genes vpr, vif, vpu and nef have been 
deleted, as these are not crucial for viral growth in vitro, but are vital for in vivo 
replication and pathogenesis. Thus only the two regulatory elements tat and rev are 
retained, and the 3’ LTR is replaced with a poly-A site. Hence five out of nine genes 
of the parental virus have been deleted, and this multiply attenuated lentivirus has 
been proven to retain the ability to transduce quiescent cells (Zufferey et al., 1997). 
Thus, there are three separate expression cassettes which have very little sequence 
overlap in order to minimise the chance of homologous recombination to generate a 
replication competent lentivirus. In the third generation vector, tat and rev have also 
been deleted from the gag-pol packaging plasmid (Dull et al., 1998). However, Rev 
positively affects the nuclear export of the unspliced gag-pol mRNA as well as the 
transfer vector genomic RNA. Therefore, as rev is still required, this is supplied by a 
fourth plasmid in order to minimise the chance of recombination events to generate a 
RCL. Tat, which binds to TAR in the transfer vector, is a crucial transactivator for 
lentiviral replication. However, it can be removed if a different promoter is used in 
the transfer vector. The deletion of Tat therefore improves the safety of the lentivirus 
as the infectivity is reduced. An additional safety feature utilised in most lentiviral 
vectors is the self-inactivating (SIN) system described in section 6.1.
Therapeutic efficacy of lentiviral vectors has been shown in murine and primate 
models for different diseases including mucopolysaccharidosis type VII (Bosch et 
al., 2000), metachromatic leukodystrophy (Consiglio et al., 2001) and Parkinson’s 
disease (Kordower et al., 2000). The first clinical trial in humans involving a 
lentiviral vector was recently initiated (MacGregor, 2001), which involved the 
expression of an anti-sense to the HIV envelope gene for the treatment of AIDS.
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Figure 1.7. Schematic diagram comparing the HIV provirus with the three plasmids used to generate the second generation lentiviral construct (not to 
scale). The elements of the HIV provirus required for one round of transduction have been placed on three separate plasmids in order to minimize the chance of 
recombination to produce a wild type virus. The lentivirus is pseudotyped with the VSV-G envelope which has a broad host range and results in a virus of high 
stability. The cPPT element has been included for efficient transduction. The internal promoter SFFV drives the expression of the ADA transgene, whose 
expression levels are increased by the WPRE. The U3 region of the 3’ LTR has been deleted to generate a safer SIN vector. (Adapted from Naldini et al., 
1996a).
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The long-term results of this and other lentiviral clinical trials will need to be 
thoroughly evaluated to determine the safety and efficacy of these viral vectors.
Some limitations with the use of lentiviruses still persist. Lentiviruses may be subject 
to the same silencing mechanisms as gamma-retroviruses, although this has not yet 
been confirmed. It has also been shown that, similarly to gammaretroviruses, 
lentiviral vectors preferentially integrate into transcriptionally active genes rather 
than non-coding regions of chromatin (Schroder et al., 2002). It was determined that 
most integrations (67%) were localised within genes.
1.3.1.3 Vector Safety Developments
Clearly, the safety of the viral vector is paramount, hence several safety 
improvements to vectors have been done and are currently ongoing. This includes 
minimising homology between vector and packaging constructs (Dull et al., 1998), 
developments of new and improved SIN vectors (Zufferey et al., 1998) and 
incorporation of flanking insulators (Emery et al., 2000; Ramezani et al., 2003; Li et 
al., 2005). Insulators operate only when located between the cis effectors and 
promoter (Udvardy et al., 1985; Prioleau et al., 1999), and the most studied insulator 
is the HS-4 chromatin insulator derived from the chicken P-globin locus control 
region. Insulators display two different activities both very useful for gene therapy: 
the ability to block enhancer activities and the ability to protect expression cassettes 
from silencing. Transgene expression thus remains high, and the frequency of vector 
mediated activation of host genes can be reduced, thus decreasing the rate of vector 
mediated genotoxicity (Emery et al., 2000; Ramezani et al., 2003; Li et al., 2005). 
Vectors targeted to specific cell types are also being designed, including the use of 
tissue specific promoters (Cannon et al., 1996; Certo et al., 1998) and natural or 
engineered envelope proteins to target specific cell types. The site specific 
integration machinery of bacteriophage <|)C31 has been utilised in non-viral vectors to 
achieve targeted integration in murine and human cells (Groth et al., 2000; Olivares 
et al., 2002, Ortiz-Urda et al., 2002). Incorporating the <|)C31 integrase system into 
viral vectors in order to avoid insertional mutagenesis is therefore a clear possibility.
57
C h a p t e r  1
1.3.2 Haematopoietic Stem Cells
Stem cells are characterised by their capacity for self-renewal and their 
multipotential nature. Examples of stem cells include haematopoietic, embryonic, 
neural, epithelial and mesenchymal stem cells. Stem cells were previously thought to 
be able to give rise only to cells that are in the tissues in which they reside, but are 
now thought to be able to generate cells of different tissues, referred to as 
“plasticity”. However, in order to differentiate into different cell types, they must 
first home to the appropriate microenvironment (Tavassoli & Minguell, 1991; Watt 
& Hogan, 2000). Hence, the stem cells have the ability to leave their tissue niche and 
circulate in the blood stream, known to occur with HSCs (Siena et al., 1989; Shields 
& Andrews, 1998) and MSCs (Fernandez et al., 1997; Erices et al., 2000; Reading et 
al., 2000). However, plasticity of stem cells is still under much debate, mainly due to 
limited techniques to assess the in vitro or in vivo differentiation potential.
Haematopoietic stem cells are perhaps the best characterised stem cells (Lemischka 
et al., 1986; Sachs, 1987; Spangrude et al., 1988). They usually reside within the 
bone marrow, but can be mobilised using cytokines (G-SCF) into the peripheral 
blood, known as mobilised peripheral blood derived stem cells. Another source of 
HSCs is umbilical cord blood, which has the highest frequency of cells capable of 
reconstituting the immune system of a NOD-SCID mouse (Wang et al., 1997). True 
HSCs can generate all the different cells in the blood (Figure 1.8), including immune 
cells such as B cells, T cells, NK cells, macrophages, dendritic cells, granulocytes 
and also erythrocytes (Hay, 1966). Their multipotential nature has been further 
evaluated, and some research groups believe that HSCs are also capable of
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Figurel.8. Schematic drawing to show the origin of mesenchymal and haematopoietic stem cells and examples of the daughter cells they generate.
Endoderm generates the epithelial cells of the digestive system, the mesoderm generates the supporting muscular and fibrous elements and the ectoderm gives 
rise to the epidermis and the entire nervous system.
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differentiating into other cells such as hepatocytes (Lagasse et al., 2000) and heart 
muscle cells (Orlic et al., 2001). However, these reports of transdifferentiation are 
still a point of debate, and are contradicted by observations of other research teams 
who have failed to reproduce these data (Wagers et al., 2002; Murry et al., 2004; 
Balsam et al., 2004). Nevertheless, the main interest in using HSCs in gene therapy 
is due to the well known ability of these cells to repopulate the haematopoietic 
system. Disadvantages of using HSCs include low rates of transduction as a result of 
their quiescent state and lack of cell surface receptors. This has resulted in a large 
amount of research into the use of cytokines to induce proliferation in order to 
facilitate gammaretroviral transduction. However, this activation also leads to 
differentiation into more committed haematopoietic progenitors which reduces the 
chances of targeting stem cells. Another drawback is that the most commonly used 
marker to isolate HSCs is CD34, and questions have been raised as to whether these 
cells are true stem cells as CD34' cells have also been found to possess properties of 
stem cells and CD34 is expressed reversibly on murine stem cells (Goodell et al., 
1996; Zanjani et al., 1998; Bhatia et al., 1998; Sato et al., 1999) (in this report, the 
term haematopoietic stem cells will be utilised although the cells used in experiments 
in this study have not been proven to be true stem cells and may sometimes represent 
more committed progenitor cells). The most widely accepted assay to test for the 
presence of HSCs is to analyse their ability to reconstitute the haematopoietic system 
of a myeloablated host, usually the NOD-SCID mouse (hence the cells are also 
termed SCID repopulating cells). This is because haematopoietic reconstitution 
requires both extensive self-renewal of the transplanted HSC as well as 
differentiation into all mature blood types.
The most successful gene therapy trial to date using HSCs has been for X-linked 
SCID in a Paris study of 11 boys (Cavazzana-Calvo et al., 2000; Hacein-Bey-Abina 
et al., 2002). This trial involved the gammaretroviral transfer of the common gamma 
chain gene into autologous bone marrow derived HSCs. 9 of the 11 boys showed 
good immunological reconstitution, with transduced B, T and NK cells persistently 
detected in the peripheral blood. This resulted in significant clinical improvement 
with resolution of infectious complications and other chronic symptoms from the 
SCID (discussed in section 1.2.5.1). However three of these boys later developed
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acute lymphocytic leukaemia as a direct result of the gene therapy procedure 
(discussed in more detail in section 8 .2 .1 ).
1.3.3 Mesenchymal Stem Cells
Mesenchymal stem cells are multipotential cells (Figure 1.8) capable of self-renewal. 
They are non-haematopoietic stem cells prevalent within the adult bone marrow 
where they form part of the connective tissue network, the bone marrow stroma. In 
this environment, MSCs secrete several haematopoietic and non-haematopoietic 
growth factors, and are therefore thought to be important for the formation and 
function of the stromal microenvironment. Mesenchymal stem cells were first 
discovered in 1976 by Friedenstein and colleagues, and are sometimes also referred 
to as fibroblast colony forming unit (CFU-F), marrow stromal cells or mesenchymal 
progenitor cells. MSCs were originally isolated by their adherence to tissue culture 
plastic, and have a spindle-shaped fibroblast like morphology. They have an average 
frequency of 1 cell per 104-105 bone marrow mononuclear cells (Friedenstein et al., 
1970; Gronthos & Simmons, 1996).
Some groups have published observations of a somewhat heterogeneous population 
of MSCs. Mets & Verdonk (1981) were the first to publish these observations and 
termed the different populations type I and type II cells (now called RSI and RS2 
respectively). RSI cells are described as spindle shaped, rapidly dividing cells, and 
RS2 cells as being broader, dividing slowly if at all. During subcultivation, the 
appearance of RS2 cells formed an increasing fraction of the total cell population. 
(Bruder et al., 1997). They noted that the spindle shaped cells have a higher 
replicative capacity, however the broad cells were not terminally differentiated cells, 
as they were still capable of differentiation. Since then, other groups have also 
demonstrated similar heterogeneity within the MSC population (Colter et al., 2000; 
Sekiya et al., 2002). It is also believed by some groups, that MSCs consist of a 
heterogeneous population of cells with different cells being uni-, bi- or multipotential 
cells. Owen and Friedenstein (1988) initially proposed this, and since then other 
research groups have also supported this theory (Kuznetsov et al., 1997; Pittenger et 
al., 1999). It is therefore clear that the properties of the MSCs have still not been 
fully elucidated, and different groups report contradicting observations regarding
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their functional potential. Thus, it is still a point of controversy as to whether MSCs 
are truly stem cells, as their self-renewal capacity has still not been demonstrated 
(hence the different names for these cells as some groups are reluctant to call them 
mesenchymal stem cells). In this report, the cells will be termed mesenchymal stem 
cells although it has not been proven that they are indeed true stem cells.
Some of the differences reported could be due to different isolation and culturing 
methods. Purification of MSCs using STRO-1 and VCAM (Gronthos et al., 2003) as 
well as D7-FIB positive selection followed by CD45low selection (Jones et al., 2002) 
has been attempted in order to try to obtain more pure populations. This sort of 
purification may be preferential for gene therapy purposes as it would reduce the 
time required for MSC isolation. However these methods are generally not as widely 
accepted as the plastic adherence method, as they could give rise to different types of 
cells.
Mesenchymal stem cells have also been isolated from sources other than the bone 
marrow. Cells that appear to be similar to MSCs have been reported to be derived 
from muscle (Williams et al., 1999), adipose (Loncar, 1992), bone (Nuttall et al., 
1998), and other organs. Particular interest has been paid to mesenchymal stem cells 
which have been derived from umbilical cord blood (Erices et al., 2000; Romanov et 
al., 2003; Lee, O.K. et al., 2004; Gang et al., 2004; Lee M.W. et al., 2004). These 
MSCs are thought to perhaps have a greater differentiation potential than bone 
marrow derived MSCs. This was demonstrated by Lee, O.K. et al., who 
differentiated MSCs into adipocytes, osteocytes, chondrocytes, hepatic cells and 
neuronal cells with a measurable action potential. Therefore, MSCs from an UCB 
source could be a promising therapeutic target. However, their presence and 
frequency in cord blood is still debated (Mareschi et al., 2001; Wexler et al., 2003; 
Yu et al., 2004).
Flow cytometric analyses have failed to identify specific markers for MSCs as they 
have been found to exhibit phenotypic markers of mesenchymal, endothelial, 
epithelial and muscle cells. MSCs do not express the common leukocyte marker 
CD45, the haematopoietic marker CD34, or the markers CD 14, CD33, CD117 or 
CD133. However, they do express the markers CD10, CD13, CD28, CD29, CD44,
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CD73 (SH3 & SH4), CD90, CD 105 (SH2 -  an epitope of endoglin), CD 166, LNGFR 
and STRO-1 (Haynesworth et al., 1992; Pittenger et al., 1999; Colter et al., 2000; 
Guo et al., 2001; Suva et al., 2004). Therefore, to confirm the identity of these cells, 
their potentials to differentiate into other tissues is generally demonstrated rather than 
the presence of specific markers.
Following the pioneering work by Friedenstein et al, it was shown by several groups 
that MSCs can differentiate into cells of the mesenchymal lineage, such as 
adipocytes, osteocytes and chondrocytes, as shown in Figure 1.8. (Piersma et al., 
1983; Piersma et al., 1985; Howlett et al., 1986; Friedenstein et al., 1987; Mardon et 
al., 1987; Owen & Friedenstein, 1988; Keating et al., 1990; Caplan, 1991; 
Haynesworth et al., 1992; Beresford et al., 1992; Cheng et al., 1994.; Rickard et al., 
1994; Clark & Keating, 1995; Prockop, 1997; Pittenger et al., 1999). Pittenger et al. 
importantly also showed that MSCs derived from individual stem cells retained the 
potential to differentiate along these lineages. MSCs have also been shown to 
differentiate into several other cell types including cardiomyocytes (Makino et al., 
1999; Toma et al., 2002; Shake et al., 2002; Mangi et al., 2003) and also into non- 
mesenchymal neuronal cells in vitro (Sanchez-Ramos et al., 2000; Kohyama et al., 
2001; Kim et al., 2002; Jiang et al., 2003) and in vivo (Azizi et al., 1998; Kopen et 
al., 1999).
In vivo MSC differentiation has been more difficult to demonstrate than the in vitro 
differentiation. However, Prockop et al., 1997, showed that MSCs can repopulate 
various tissues in mice following X-ray irradiation. MSCs, containing a mutated gene 
for type I collagen, were detected in bone, cartilage, marrow and spleen at a 
frequency of between 1 and 12%. Hence, MSCs can make important contributions to 
mesenchymal tissues in vivo.
Since their discovery, MSCs have been extensively studied because of their powerful 
ex vivo expansion and multilineage differentiation potentials, and have already been 
used extensively in different therapies. The first clinical trial using MSCs showed 
that it was feasible and safe to systemically infuse ex-vivo expanded autologous 
MSCs as they were well tolerated (Lazarus et al., 1995). Caplan and colleagues also 
demonstrated that MSCs can aid in the repair process when implanted into poorly
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healing bone. They injected MSCs locally, which were found to promote the repair 
of surgical incisions in the knee cartilage of rabbits (Caplan, 1990; Goldberg & 
Caplan, 1994; Bruder et al., 1994; Wakitani et al., 1994).
Mesenchymal stem cells have also been utilised in clinical trials for Osteogenesis 
Imperfecta (01). 01 is an inherited disorder caused by a defective type I collagen in 
osteoblasts. This leads to osteopenia, multiple fractures, severe bone abnormalities 
and a shortened stature. Pereira et al. (1998) demonstrated in a murine model, that 
transplantation of normal mesenchymal progenitor cells resulted in a greatly 
improved phenotype of the OI mouse. Based on these results, a human study was 
subsequently initiated by Horwitz and co-workers (Horwitz et al., 1999). Three 
patients were recruited for the study, where they transplanted unmanipulated marrow 
from sibling donors, following ablative conditioning of the patients. It was revealed 
that marrow derived osteoblasts precursors (presumed to be MSCs) migrated to the 
bones in all three children. Dense bone formation and a significant increase in total 
bone mineral content could be detected as early as three months following the 
transplant. An increase in growth rate and a reduction in the number of bone 
fractures were also observed. This study had important implications for future gene 
therapy trials using MSCs, as it was demonstrated for the first time in humans that 
MSCs were capable of engrafting, differentiating and normal functioning in vivo. 
Similarly, a clinical trial was carried out using purified MSCs (Horwitz et al., 2002), 
which also revealed modest engraftment levels.
In addition, MSCs have recently been considered to treat metachromatic 
leukodystrophy and Hurler’s Syndrome (Koc et al., 2002), myocardial infarction 
(Caparrelli et al., 2001; Shake et al., 2002; Mangi et al., 2003; Chen et al., 2004) and 
cancer (Studeny et al., 2002). Further potential uses of MSCs, which have only 
recently been discovered, are related to their apparent immunomodulatory functions. 
Mesenchymal stem cells have been described to induce a more tolerogenic 
phenotype on dendritic cells, naive and effector T cells and natural killer cells, which 
have come into contact with MSCs (Aggarwal & Pittenger, 2004). They have also 
been shown to inhibit T cell proliferation by arresting the cells at the G1 phase of the 
cell cycle (Glennie et al., 2005). Importantly, LeBlanc et al. (2003) also 
demonstrated in vitro that differentiated MSCs do not have an increased antigenicity.
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MSCs have also been shown to suppress lymphocyte proliferation in vitro 
(Bartholomew et al., 2002; Di Nicola et al., 2002) and prolong skin graft survival in 
vivo (Bartholomew et al., 2002), and have consequently been shown to suppress 
dendritic cell maturation and induce T-cell unresponsiveness (Zhang, W., et al., 
2004; Deng et al., 2004; Beyth et al., 2005, Aggarwal & Pittenger, 2005). Another 
interesting finding was that even xenogenic transplantation of MSCs was well 
tolerated, as demonstrated by Saito et al., 2002. They showed that murine MSCs 
were capable of engrafting into injured myocardium of rats. This may suggest that 
universal donors of MSCs could be utilised in clinical trials. These findings have 
prompted more research into the use of MSCs in the treatment of graft versus host 
disease (GVHD) (Ringden et al., 2002). Le Blanc et al. (2004) reported that a patient 
with severe treatment resistant grade IV acute GVHD of the gut and liver was 
transplanted with haploidentical MSCs and one year later appears to be clinically 
well. Hence, it has been suggested that MSCs may in the future be used not only to 
prevent graft versus host disease, but also to treat organ-transplant rejection and 
autoimmune disorders (Frank & Sayegh, 2004).
MSCs can also be used to introduce genes systemically, important for gene therapy 
of ADA-SCID. As ADA deficiency has been extensively studied, it has become 
apparent that it is a more systemic disease than other forms of SCID, most likely as a 
result of the ubiquitous nature of the ADA enzyme. It is therefore thought that the 
transduction and reinfusion of MSCs together with HSCs could offer a more 
systemic treatment than the use of HSCs alone as in current ADA gene therapy trials. 
Mesenchymal stem cells also have several other advantages over other stem cells 
currently used for gene therapy, such as haematopoietic and neural stem cells. MSCs 
can be easily expanded in culture without activation or differentiation, whereas both 
HSCs and neural progenitor cells have been found to be difficult to culture and 
expand ex vivo. MSCs also maintain their phenotype after expansion and maintain 
protein expression of the transgene for at least 6  months in vitro and for at least 3 
months in vivo (Lee et al., 2001). Moreover, large volumes of bone marrow are 
required to obtain adequate numbers of HSCs, and MSCs are clearly more easily 
accessible than neural stem cells (Glimm & Eaves, 1999; Carpenter et al., 1999). 
Importantly, mesenchymal stem cells do not only differentiate into cells of the 
mesenchymal lineage, but also into neural cells which may help correction of
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neurological abnormalities of ADA deficient patients (Hirschhom et al., 1980; 
Rogers et al., 2001).
MSCs may also have the ability to serve as a feeder layer for the growth of HSCs as 
reported for both human and murine MSCs in vitro (Dexter & Testa, 1976; Gartner 
& Kaplan, 1980; Quesenberry & Lowry, 1992; Sutherland et al., 1993; Deryugina & 
Muller-Sieburg, 1993; Haynesworth et al., 1996; Gordon et al., 1996; Majumdar et 
al., 1998; Dormady et al., 2001). Majumdar and colleagues (1998), for example, 
conducted a study analysing the ability of MSCs to maintain haematopoiesis in 
LTBMC (long term bone marrow culture) with CD34+ haematopoietic progenitors. 
In particular, they examined the expression of cell surface molecules, cytokines and 
growth factors by MSCs. They found that the MSCs expressed a wide array of 
cytokines some of which act on haematopoietic cells, and from methylcellulose 
haematopoietic colony assays they were able to determine that MSCs were capable 
of maintaining and supporting HSC differentiation of purified CD34+ cells. Murine 
studies have demonstrated that co-transplantation of human MSCs together with 
HSCs accelerates the haematopoietic recovery following bone marrow 
transplantation (Nolta et al., 1994 & 2002: Brouard et al., 1998; Noort et al., 2002; 
Bensidhoum et al., 2004). The haematopoietic support by the MSCs has been 
similarly demonstrated in humans (Koc et al., 1999, 2000, 2001), and it is a feature 
which would make the use of MSCs ideal for ADA gene therapy in combination with 
HSCs. However, the exact identity of the cells capable of supporting the HSCs is still 
being debated (Minguell et al., 2001). Therefore, if MSCs are to be used in the clinic, 
it is vital that the potentials of the cells in terms of engraftment and haematopoiesis 
support are well characterised, which may require a more precise study into the 
isolation procedure and culture conditions of these cells.
It is therefore clear that the use of mesenchymal stem cells in gene therapy for ADA 
deficiency may have several significant advantages, including their substantial 
expansion potential, differentiation potential and HSC support. However, it is crucial 
that the cells are extensively characterised, including their differentiation potential 
according to isolation procedure and cell culture conditions, to ensure that the most 
multipotential cells are utilised. This is particularly important for a multi-organ
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disease such as ADA-SCID, which is currently being treated with gene therapy 
protocols that may not offer systemic treatment.
1.4 Statement of Aims
The aims of this study are to:
1. Assess immune function of patients treated with PEG-ADA.
2. Construct a gammaretroviral vector expressing ADA and evaluate its efficiency in 
transduction of CD34+ cells for use in clinical gene therapy trial.
3. Assess immune recovery of ADA deficient gene therapy patient in comparison to 
ADA deficient patients treated with PEG-ADA.
4. Construct a lentiviral vector expressing ADA and evaluate its gene transfer 
efficiency in comparison to the gammaretroviral vector.
5. Generate mesenchymal stem cells and evaluate their differentiation potential.
6 . Investigate the possibility of a systemic treatment for ADA deficiency using ADA- 
lentiviral transduced CD34+ cells and MSCs.
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2.1. Reagent Suppliers
Chemicals were obtained from Sigma (Mo, USA), cell culture media from Invitrogen 
(Ca, USA), and restriction endonucleases and DNA modifying enzymes were 
obtained from Promega (Wi, USA) unless otherwise stated.
2.2 DNA Manipulations
2.2.1 Cloning
The human ADA gene was cloned by PCR amplification from the pOTB7 ADA 
vector (kind gift from Prof D. Valerio, Department of Gene Therapy, University of 
Leiden, Netherlands) using primers containing Xbal sites (forward primer: ATG TCT 
AGA ACC ATG GCC CAG ACG CCC, reverse primer: CGT CTA GAT CAG AGG 
TTC TGC CCT GCA G). These restriction sites were utilised to insert the gene into 
the gammaretroviral or lentiviral vector, using an intermediate pBluescript vector in 
order to facilitate the cloning procedure.
To create the pBlueScript-SFFV-ADA-WPRE, the SFFV-eGFP-WPRE fragment 
was replaced by SFFV-AD A-WPRE (The WPRE was a kind gift from Thomas 
Hope, University of Illinois, USA). The pBS-SEW plasmid was therefore digested 
with BamHI and Notl. These restriction sites were then blunted using Klenow large 
fragment DNA polymerase I (Invitrogen), and the vector religated using T4 DNA 
ligase. The pBS vector was cut using Xbal so that the hADA cDNA with Xbal 
linkers could then be inserted (refer to Figure 4.1).
For construction of the gammaretroviral-AD A vector, the gp91phox gene was 
removed from the gammaretroviral vector by digestion using EcoRI and Notl, and 
the vector was then blunted. The pBS-SAW vector was digested using Xbal and Xhol 
to release the ADA-WPRE fragment, which was then ligated into the 
gammaretroviral vector, already containing SFFV LTR to create the SFada/W vector 
(refer to Figure 4.1C).
The lentiviral-ADA vector was constructed by digesting pHR.Sin.cPPT.SEW with 
EcoRI and Kpnl to remove the SEW fragment. The pBS-SAW was also digested
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using EcoRI and Kpnl to release the SAW fragment, which was then directly ligated 
into the lentiviral backbone (refer to Figure 6.1 A).
2.2.2 Preparation of DH5a Cells
500mL Lennox L-Broth (LB) was inoculated using 5 mL of an overnight culture of 
the electro-competent E. coli strain DH5a (Promega). The cells were incubated at 
37°C in a shaking incubator for approximately four hours until the absorbance at 
600nm was approximately 0.8. To harvest, the flask was chilled on ice for 30 
minutes and the cells were centrifuged at 4,000xg for 15 minutes at 4°C. The 
bacterial pellet was resuspended in 500mL sterile 10% glycerol and centrifuged as 
previously. The pellet was then serially resuspended in 250mL, lOmL and 
approximately lmL of 10% glycerol so that the final cell concentration was 
approximately 3xl0 10 cells/mL. The bacterial suspension was aliquoted into 50pL 
samples and stored at -80°C.
2.2.3 Plasmid Preparations
DH5a cells were used to transform the gammaretroviral plasmid and the three 
lentiviral plasmids, all containing ampicillin resistance genes. Salts from the ligation 
buffer were removed from the plasmid preparation by dialysis on 0.25 pM 
nitrocellulose 10mm disc filters (Millipore, MA, USA) on distilled water for 20 
minutes. The plasmid solution was then added to 50pL of DH5a cells on ice in a 
2mm gap cuvette (Biorad, CA, USA), and was electroporated using the Gene Pulser 
Electroporator (Biorad) at 2.5kV, 200Q, 25pF. Approximately 950pL LB medium 
was added to the cells, which were incubated for 30-45 minutes at 37°C in a shaking 
incubator. The cells were plated on LB agar plates containing lOOpg/mL ampicillin 
and incubated overnight at 37°C, after which single colonies were used to inoculate 
5mL LB with lOOpg/mL ampicillin.
The plasmids were purified from the 5mL cultures using a Miniprep kit (Qiagen, KJ 
Venlo, The Netherlands) according to the manufacturers’ instructions, to screen for 
transformed colonies by restriction enzyme digests. Briefly, the bacterial cells were 
pelleted and the plasmid DNA was extracted by alkaline lysis in the presence of
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RNaseA. The lysates were neutralised and adjusted to high salt conditions prior to 
loading onto the silica-gel column. The column was washed and then eluted in low 
salt buffers. Once the plasmids had been analysed by restriction digests, 500pL of the 
transformed cultures was used to inoculate 500mL of LB-ampicillin for large scale 
plasmid preparations (Maxi Kit for the gammaretrovirus and Mega Kit for the 
lentiviral plasmids, both from Qiagen). Following overnight incubation at 37°C in a 
shaking incubator, the cells were pelleted by centrifugation at 4°C and resuspended 
in the presence of RNaseA. The plasmid DNA was purified by alkaline lysis of the 
bacteria, and the lysate was neutralised and filtered. The DNA was then bound to the 
anion-exchange resin column under low salt and pH conditions. The column was 
washed to remove unbound fractions and the plasmid was eluted using a high salt 
solution (1.6M NaCl) in 15% isopropanol, at pH7. The DNA was desalted by 
precipitation with isopropanol, and washed in 70% ethanol. The plasmid was 
resuspended in Tris-EDTA (TE) buffer and the DNA concentration was estimated by 
absorbance at 280nm using a GeneQuant machine (Pharmacia/Pfizer, NY, USA). 
The ratio of 280:260nm was then used to determine the purity of the DNA, with the 
absorbance ratio of 1 .8  indicating a pure sample with minimal protein contamination.
2.2.4 Sequencing of Plasmids
As the ADA gene was amplified by PCR, the sequence was verified by sequencing 
using DYEnamic ET dye terminator kit (Amersham, Little Chalfont, UK). The DNA 
to be sequenced was diluted to lpg / lOpL. The DNA was mixed with the primer (at 
5pM) and the DYEnamic ET terminator reagent premix. The samples were placed in 
a thermal cycler, and the following 25 cycle programme was initiated: 20 seconds at 
95°C, 15 seconds at 50°C and 1 minute at 60°C. Unincorporated dye-labelled 
terminators were removed by isopropanol precipitation, and the reaction products 
were resuspended in a formamide loading solution for separation and detection on 
the MegaBASE 1000 sequencing machine.
The gammaretroviral vector that was used for the clinical gene therapy trial 
(SFada/W) was sequenced by Lark Technologies from the 5’ LTR to the 3’ LTR 
inclusive.
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2.3 Cells and Cell Culture
All cells were incubated in humidified chambers at 37°C with 5% CO2. The cells 
utilised are listed in Table 2.1, and the media in which they were cultured in Table 
2.2. Table 2.3 displays the antibodies used for flow cytometry analysis and Western 
blotting. Flow cytometry was performed utilising a Becton Coulter Epics XL, with 
the aid of the Expo 32 (Becton Dickinson, NJ, USA) acquisition and analysis 
software.
Cells Origin Supplier Medium
Phoenix 293T Human Embryonic 
Kidney
Nolan Laboratories, 
Stanford, USA
DMEM
PG13 NIH 3T3 Mouse 
Fibroblast
M. Collins, UCL, 
London
DMEM
HeLa Human Cervical 
Carcinoma
ECAAC, Salisbury, UK DMEM
293T Human Embryonic Kidney ATCC, USA DMEM
Jurkats Human Leukaemic T cell Molecular Haematology, 
ICH, London
RPMI
Fibroblasts -  
Patient
Primary Skin Fibroblasts H. Gaspar, ICH, London DMEM
Fibroblasts -  
Normal
Primary Skin Fibroblasts M. Hubank, ICH, 
London
DMEM
Patient LCLs Peripheral Blood RPMI
CD34+s Mobilised Peripheral 
Blood or bone marrow
X-Vivo 10
MSCs Bone Marrow DMEM
Table 2.1. Cells and media used in this study.
Abbreviations: ECAAC; European Collection of Cell Cultures; LCL, Lymphoblastoid cell 
line; MSCs, mesenchymal stem cells.
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Media Name Medium Supplement Media Supplier
Complete DMEM DMEM with 
Glutamax
10% FCS, lOunits/mL 
Pen- lOpg/mL Strep
Invitrogen
Complete RPMI RPMI with 
Glutamax
10% FCS, lOunits/mL 
Pen- lOpg/mL Strep
Invitrogen
CD34
Gammaretroviral 
Activation Media
X-Vivo 10 1% HSA, 300ng/mL 
hSCF, 20ng/mL hIL-3, 
300ng/mL hFlt-3, 
lOOng/mL hTPO
Bio Whittaker, 
NJ, USA
CD34
Gammaretroviral 
Transduction Media
X-Vivo 10 1% HSA, 600ng/mL 
hSCF, 40ng/mL hIL-3, 
600ng/mL hFlt-3, 
200ng/mL hTPO
Bio Whittaker
CD34 Lentiviral 
Transduction Media
X-Vivo 10 1%HSA, lOOng/mL 
hSCF, lOOng/mL hFlt-3, 
20ng/mL hIL-6 , 20ng/mL 
hIL-3
Bio Whittaker
Table 2.2. Compositions of media used in this study.
Abbreviations: DMEM, Dulbeccos’ Modified Eagle Medium (Invitrogen); FCS, Foetal calf 
serum (Sigma); Pen-Strep, Penicillin-Streptomycin (Invitrogen); RPMI, Roswell Park 
Memorial Institute (Invitrogen); HSA, human serum albumin (Bio Products Laboratory); 
hSCF, human stem cell factor; hIL-3, human interleukin 3; hFlt-3 fms-like tyrosine kinase 3; 
hTPO, human thrombopoietin (all from R & D Systems).
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Name/
Specificity
Conjugate Application Species 
raised in
Concentration/
Dilution
Source
aADA - FC Mouse 5pg/100pL Hershfield
aMouse IgGl Biotin FC Rat 0.5pg/100pL Pharmingen
Streptavidin PE FC Mouse 1 :1 0 0 Pharmingen
aADA — Western Blot Goat 1 :1 0 0 Santa Cruz, 
CA, USA
agoat HRP Western Blot Donkey 1 :1 ,0 0 0 Serotec, 
Oxford, UK
Isotype IgGl FITC IP Mouse 1 :2 0 BD
Isotype IgGl PE IP Mouse 1 :2 0 BD
Isotype IgGl PerCP IP Mouse 1 :2 0 BD
aCD3 FITC IP Mouse 1 :2 0 BD
aCD3+16+56 FITC+PE IP Mouse 1 :2 0 BD
aCD4 PE IP Mouse 1 :2 0 BD
aCD4 PerCP IP Mouse 1 :2 0 BD
aCD8 PE IP Mouse 1 :2 0 BD
aCD8 CY IP Mouse 1 :2 0 BD
aCD19 PE IP Mouse 1 :2 0 BD
aCD27 FITC IP Mouse 1 :2 0 BD
aCD27 PE IP Mouse 1 :2 0 BD
aCD34 FITC IP Mouse 1 :2 0 BD
aCD45 PerCP IP Mouse 1 :2 0 BD
aCD45RO FITC IP Mouse 1 :2 0 BD
Isotype IgGl FITC MSC FC Mouse 1 :2 0 BD
Isotype IgGl PE MSC FC Mouse 1 :2 0 BD
Isotype IgGl PerCP MSC FC Mouse 1 :2 0 BD
Isotype IgG2a PE MSC FC Mouse 1 :2 0 eBioscience, 
CA, USA
Isotype IgG2b FITC MSC FC Rat 1 :2 0 eBioscience
aCD13 PE MSC FC Mouse 1 :2 0 BD
aCD14 FITC MSC FC Mouse 1 :2 0 BD
aCD29 PE MSC FC Mouse 1 :2 0 BD
aCD33 PE MSC FC Mouse 1 :2 0 BD
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aCD34 FITC MSC FC Mouse 1 :2 0 BD
aCD44 FITC MSC FC Rat 1 :1 0 0 eBioscience
Name/ Conjugate Application Species Concentration/ Source
Specificity raised in Dilution
aCD45 PerCP MSC FC Mouse 1 :2 0 BD
aCD73 (SH4) PE MSC FC Mouse 1 :2 0 BD
a  CD90 FITC MSC FC Mouse 1 :2 0 Serotec
aCD105 FITC MSC FC Mouse 1 :2 0 Serotec
aCD106 PE MSC FC Mouse 1 :2 0 BD
SH2 - MSC FC Mouse 1 :2 0 ATCC, VA, 
USA
aMouse FITC MSC FC Rat 1 :1 0 0 eBioscience
aGFAP - MSC Conf Mouse 1 :2 0 0 BD
aNSE - MSC Conf Mouse 1 :1 0 0 Santa Cruz
aTau-2 - MSC Conf Mouse 1 :2 0 0 BD
aNeuN - MSC Conf Mouse 1 :1 0 0 Chemicon, 
CA, USA
aMouse FITC MSC Conf Rat 1 :1 0 0 eBioscience
Phalloidin Alexa 488 MSC Conf 1 :2 0 Molecular
Probes,
Invitrogen
aCollagenll MSC IHC Mouse 1 :1 0 0 NeoMarkers/ 
Labvision, 
CA, USA
Table 2.3. Antibodies used in this study.
Abbreviations: FC, flow cytometry; PE, Phycoerythrin; HRP, Horseradish Peroxidase; FITC, 
Fluorescein isothiocyanate; IP, immunophenotyping; BD, Becton Dickinson; PerCP, 
Peridinin chlorophyll protein; Conf, Confocal; IHC, immunohistochemistry.
2.3.1 Generation of Epstein Barr Virus Immortalised Lympho- 
blastoid B Cell Line
Lymphoblastoid cell lines were generated from patient blood following informed 
consent. The patient blood sample (in EDTA) was mixed with an equal volume of 
RPMI 1640. The peripheral blood mononuclear cells (PBMCs) were isolated by
75
C h a p t e r  2
density gradient (1.077g/mL Ficoll-Paque from Pharmacia), by centrifugation at 
l,000xg for 20 minutes. The cells were washed twice in RPMI/20% FCS before 
resuspending approximately 3xl06 cells in 100 pL RPMI/20% FCS, mixed with 
concentrated Epstein Barr Virus (EBV) strain B95-8 (kind gift from Reza Sharifi). 
The cells were incubated with the virus at 37°C for 1 hour after which the volume 
was made up to lmL by adding complete RPMI and the cells were transferred to a 
24-well plate.
The LCLs were then maintained and expanded in complete RPMI. Once the LCL 
had been generated, three colour flow cytometry analysis was performed using the 
following lymphoid and leukocyte markers: CD3, CD 19, CD45 and CD27 (all from 
BD Biosciences) to confirm the homogeneity of B cells. The relevant antibodies 
were incubated with the cells for 30 minutes at 4°C, followed by washing in PBS and 
fixing in 1% paraformaldehyde (PFA) in PBS.
2.3.2 Production of Mesenchymal Stem Cells
Human mesenchymal stem cells were isolated (following informed consent) from 
patient or normal donor bone marrow samples using a Ficoll-Paque density gradient 
centrifugation followed by plastic adherence to the tissue culture flask. Following 
two passages by trypsinisation the cells appeared homogeneous. Morphology of the 
cells was analysed using the Olympus 1X70 inverted fluorescence microscope. The 
mesenchymal stem cells had a fibroblast-like morphology, and were characterised by 
their antigenic phenotype and their ability to differentiate into different mesenchymal 
lineages in vitro by controlled induction conditions.
2.3.3 MSC Antigenic Phenotyping
The mesenchymal stem cells were trypsinised and resuspended in 100 pL PBS. The 
appropriate antibodies (CD13, CD14, CD29, CD33, CD34, CD44, CD45, CD73 
(SH4), CD90, CD 105 (SH2), and CD 106) at appropriate dilutions (see Table 2.3) 
were added and incubated for 20 minutes at room temperature. Following the 
staining, the cells were washed twice in PBS prior to being fixed in PBS/1% PFA 
and analysed in the flow cytometer.
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Stain/Antibody/Assay Specificity Cell Type Identity
Oil Red O Lipid Vacuoles Adipocytes
Alizarin Red S Mineralisation of ECM Osteocytes
Calcium Deposition Assay Calcium Content Osteocytes
Toluidine Blue Proteoglycans within ECM Chondrocytes
Safranin O Sulfated proteoglycans Chondrocytes
Collagen II Cartilage Chondrocytes
GFAP Astrocyte marker Neural
Tau-2 Microtubule associated Neural
protein
NeuN Neuronal nuclei Neural
NSE Glycolytic enzyme specific Neural
to nervous tissue
Table 2.4. Stains and antibodies used to analyse MSC differentiation.
Abbreviations: ECM, extracellular matrix
2.3.4 Adipogenic Differentiation of Mesenchymal Stem Cells
Mesenchymal stem cells were seeded in a 12-well plate at a confluency of 3000 
cells/cm2. Adipogenic differentiation was induced by the addition of 0.5mmoles/L 1- 
methyl-3-isobutylxanthine (Sigma), lpmol/L dexamethasone, 5pg/mL insulin 
(Sigma), 60pmol/L indomethacine (Sigma), and 10% FCS to the media. The 
induction media was added to the cells every 2-3 days until the cells were confluent, 
usually after 2-3 weeks (Pittenger et al., 1999). Mesenchymal stem cells grown in the 
absence of induction media constituted the non-induced control cells.
Following differentiation, the cells were analysed by observation of morphology and 
by immunohistochemistry. The adipocytes were stained with Oil Red O (Sigma) 
which is specific for lipid deposits (Table 2.4). The media was removed and the cells 
were rinsed with PBS prior to fixing by incubation with 10% formalin (Sigma) for 60 
minutes at room temperature. The cells were then rinsed with sterile water followed 
by 60% isopropanol. The cells were incubated with 0.12% Oil Red O for 5 minutes 
at room temperature, after which they were washed with water. Hematoxylin
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counterstain (Sigma) was added for 1 minute and the cells were then washed with 
water prior to being viewed using the Olympus 1X70 inverted fluorescence 
microscope.
2.3.5 Osteogenic Differentiation of Mesenchymal Stem Cells
To induce osteogenic differentiation, mesenchymal stem cells were seeded as for 
adipogenic differentiation. For osteogenic differentiation, the MSCs were grown in 
media containing 0.1 pmoles/L dexamethasone (Sigma), lOmmoles/L p-glycerol 
phosphate (Sigma), 0.05mmoles/L ascorbic acid (Sigma) and 10% FCS. The 
induction media was similarly added to the cells every 2-3 days until the cells were 
confluent (Pittenger et al., 1999). Mesenchymal stem cells grown in the absence of 
induction media constituted the non-induced control cells.
Once the cells were differentiated, 2-3 weeks after the initiation of induction, the 
cells were analysed by observation of morphology and by immunohistochemistry. 
The osteocytes were also tested for calcium content by a dye-binding method. The 
calcium was extracted by incubating the cells in 0.5N HC1 for 4 hours at 4°C with 
shaking. The cells were then centrifuged at 500xg for 2 minutes and the calcium 
containing supernatant was collected. Calcium was then detected using the Sigma 
Calcium Detection Kit and the colour change was detected by measuring the 
absorbance at 575nm using a spectrophotometer. The calcium concentration was 
calculated by extrapolation from a calcium standard curve.
The differentiated cells were stained for deposits of calcium salts using Alizarin Red 
S stain as described by Bodine et al., 1996 (Table 2.4). For this, the osteocytes or 
non-differentiated control cells were washed in PBS and fixed in 10% formalin for 
ten minutes. Three washes with PBS were performed prior to staining with 2% 
Alizarin Red S for 2-5 minutes. The cells were then washed in PBS and visualised 
using the Olympus DC70 inverted fluorescence microscope.
2.3.6 Chondrogenic Differentiation of Mesenchymal Stem Cells
Mesenchymal stem cells were seeded at one million cells per well in a 96 well plate. 
Chondrogenic differentiation was induced by addition of lOng/mL TGFp3
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(Peprotech) and 1% bovine serum albumin (Sigma) to high glucose media. 
Mesenchymal stem cells grown in the absence of induction media constituted the 
non-induced control cells. However, as they were found to be non-viable, tumour 
sections (gift from S. Barker) were used as control in the staining procedures
The chondrogenic cell pellet was fixed in 10% formalin for one hour at room 
temperature. The pellet was carefully transferred to a 15 mL falcon tube, and was 
dehydrated in successive ethanol washes of 70%, 70%, 80%, 80%, 95%, and 95% for 
15 minutes in each concentration. The pellet was stained briefly in 1% eosin (in 
water) to aid visualisation of the small pellet which turns orange. Following the eosin 
stain, the pellet was washed 3x in 10% ethanol. The pellet was then transferred to a 5 
mL bijou tube and incubated twice in histoclear for 20 minutes each time. The pellet 
was transferred to three successive incubations in 58°C paraffin for 20 minutes each. 
The pellet was embedded in a paraffin block, and ribbons of 5 pm sections were cut. 
The sections were incubated in water at 40°C to straighten them, and they were then 
transferred to positively charged glass microscope slides. The slides with the sections 
were incubated at 60°C for one hour prior to being cooled for 10 minutes. The slides 
were stored at 4°C for future staining.
Chondrocyte sections were analysed by safranin-0 staining, which reveals the 
proteoglycans, toluidine blue which stains proteoglycans within ECM and by 
immunostaining for type II collagen (Table 2.4). The sections were deparaffinized by 
three successive 3 minute washes in histoclear, followed by two successive 3 minute 
washes in 100% ethanol, two successive 3 minute washes in 95% ethanol and one 
wash in 70% ethanol. For the Saffanin-O stain, the sections were incubated in 
Weigert’s ion hematoxylin for 4 minutes, followed by destaining in fresh acid 
alcohol (1% HC1 in 70% ethanol) and rinsing in water. The sections were stained 
with methyl green for 5 minutes and then with 0.1% aqueous Safranin O for 5 
minutes. Following staining, the sections were dehydrated by two successive 5 
minute washes in 95% ethanol, three successive 5 minute washes in 100% ethanol 
and three successive 5 minute washes in histoclear. Sections were mounted in DPX 
synthetic resin mounting medium for microscopy. For the Toluidine Blue staining, 
the sections were incubated in Toluidine Blue stain (1% Toluidine Blue in a 1%
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NaCl solution, pH2), followed by 3 washes in water. The sections were then 
dehydrated quickly through 95% ethanol and 2 incubations in 100% ethanol, 
followed by 3 washes in histoclear. The sections were then mounted in DPX 
synthetic resin mounting medium for microscopy. For the immunostaining for type II 
collagen, the sections were deparaffinized as previously described and incubated in 
water for 5 minutes. Endogenous peroxidase activity was quenched by incubating the 
pellet sections with DAKO peroxidase block for 5 minutes, followed by washed in 
deionised water and wash buffer (Tris buffered saline, 0.05% Tween). The sections 
were then treated with proteinase K for 5 minutes followed by washes in deionised 
water and wash buffer. The sections were incubated with the primary antibody to 
type II collagen for 30 minutes after pepsin (1 mg/ml) digest and then washed in wash 
buffer. The sections were incubated with peroxidase labelled secondary reagents and 
substrate chromogen (peroxidase-DAB) as per kit instructions (DAKO EnVision+ 
System HRP (DAB) kit) and counterstained with methyl green. The sections were 
then dehydrated in two successive 5 minute washes in 95% ethanol, three successive 
5 minute washes in 100% ethanol and three successive 5 minute washes in histoclear. 
The sections were then mounted in DPX synthetic resin mounting medium for 
microscope viewing using the Olympus 1X70 inverted fluorescence microscope.
2.3.7 Neuronal Differentiation of Mesenchymal Stem Cells
Mesenchymal stem cells were seeded in a 12-well plate at a confluency of 3000 
cells/cm2. Neuronal differentiation was induced by the addition of 20ng/mL hEGF 
and 20ng/mL hbFGF and 10% FCS to the media (Carpenter et al., 1999). The 
induction media was added to the cells every 2-3 days until the cells were confluent, 
usually after 2-3 weeks. Mesenchymal stem cells grown in the absence of induction 
media constituted the non-induced control cells.
The cells were analysed for neuronal differentiation by fluorescent immuno- 
histochemistry staining for the specific neuronal markers GFAP, Tau-2, NeuN and 
NSE (Table 2.4). The cells were washed in PBS and fixed using 10% formalin for 10 
minutes at 4°C. The cells were permeabilised in 0.5% v/v Triton X-100 for 5 minutes 
and washed three times in PBS. The cells were incubated for 20 minutes in 1% BSA 
prior to primary antibody staining (see Table 2.3) in block solution (1% BSA) for 
one hour. Following the staining, the cells were washed three times in PBS and
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incubated with the secondary antibody (see Table 2.3) for 45 minutes in block 
solution. Excess antibody was removed by three washes in PBS followed by a wash 
in water. The slides were mounted using DAKO fluorescence mounting medium and 
the coverslips were sealed with nail varnish. A laser-scanning confocal microscope 
(Leica, St Gallen, Switzerland) fitted with the appropriate filters was used to image 
slides. Images were processed using Leica TCS start and Adobe Photoshop software, 
with the help of Mike Blundell.
2.3.8 Mesenchymal Stem Cell Homing in a Murine Model
NOD/ LtSz -scid/scid (NOD-SCID) mice (original stocks kindly provided by John E 
Dick, Hospital for Sick Children, Toronto) were housed in sterile microisolator cages 
in a laminar flow caging system (Thoren, Hazleton, PA) and supplied with sterile 
food, water and bedding. All manipulations were conducted in a laminar flow hood.
Mesenchymal stem cells were marked with eGFP-lentivirus as described in section 
2.5.4. A proportion of cells were not transduced and served as negative controls. The 
transduced cells were analysed by flow cytometry to ensure that the cells had been 
successfully transduced. When this had been confirmed, the cells were trypsinised, 
washed in PBS and resuspended at a concentration of 0.5x106 cells/200pL. 
Transduced or untransduced MSCs (0.5x106 cells) were injected intravenously via 
the tail vein in 7 to 11 week old NOD-SCID mice that had been sublethally irradiated 
with 300cGy (137Cs source). Six weeks following the injection of the MSCs, the mice 
were sacrificed and analysed for the presence of human MSCs in different organs. 
The organs analysed were blood, bone marrow, spleen, thyroid gland, liver, kidney, 
brain, heart, lung, and muscle. They were analysed for eGFP expression by flow 
cytometry and for the human P-actin gene by real time PCR.
For the flow cytometric analysis, single cell suspensions were generated from the 
organs. Blood and bone marrow were processed by lysing erythrocytes using lysing 
buffer (Sigma, containing 8.3g/L ammonium chloride) for 10-15 minutes at room 
temperature until the sample was clear. The sample was then washed in PBS and 
fixed in 1% PFA/PBS-0.5% BSA. Soft organs such as spleen, thymus, kidney and 
liver were homogenised and passed through a 70pM cell strainer to generate single
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cell suspensions. Organs which were more fibrous, such as brain, heart, lung and 
muscle were incubated with lg/L dispase (Invitrogen) prior to passing through a cell 
strainer. Briefly, the organ was cut into small pieces and digested by incubation in 
media containing dispase (RPMI 1640, 10% FCS, 1% dispase - Gibco). The organ 
pieces were incubated at 37°C for 30 minutes in a shaking incubator. The cells were 
homogenised and passed through a cell strainer, and any remaining pieces were 
further incubated in dispase medium. Once a single cell suspension was generated, 
with or without the aid of dispase, the cells were centrifuged at 300xg for 5 minutes. 
The supernatant was removed, and red blood cells were lysed by the addition of 
ammonium chloride for 7-10 minutes at room temperature. The samples were 
washed twice with PBS and then resuspended in an appropriate volume using 1% 
PFA/PBS-0.5% BSA and analysed by flow cytometry for eGFP.
For real time PCR analysis, a section of tissue less than 25mg was utilised for DNA 
extraction by the DNeasy kit (Qiagen). Genomic DNA was extracted from the cells 
as per manufacturer’s instructions. Briefly, the tissue was digested by incubation 
with proteinase K. The lysates were loaded onto DNeasy spin columns containing 
silica gel membranes. The DNA binds selectively, and contaminants pass through. 
Residual contaminants were removed by two further washes, and the DNA was 
eluted in a low salt buffer. The samples were then analysed for the presence of the 
human p-actin gene using real time PCR analysis as described in section 2.6.7.
2.4 Virus Production
2.4.1 Gammaretrovirus Production
Gammaretroviral particles were generated by transiently transfecting phoenix cells 
with the vector DNA in the presence of lipofectamine (Invitrogen) to aid uptake of 
DNA. Ecotropic Phoenix cells were plated at a density of 3xl05 cells per well in a 
12-well plate. The following day the cells were transfected using the SFada/W 
plasmid. The diluted vector DNA at lpg was combined with lOpg diluted 
lipofectamine 2000 (Invitrogen) and incubated for 20 minutes at room temperature. 
The DNA-lipofectamine was added to the cells in Optimem and incubated for 4
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hours at 37°C after which the media was replaced with complete DMEM. Following 
48 hours of incubation, the media was replaced.
The virus produced from the Phoenix cells was then used to stably transduce PG13 
cells. The PG13 cells were plated at a density of lx l0 5 cells per well in a 12 well 
plate the day before transduction. The supernatant from the Phoenix cells was 
collected and filtered through a 0.45pm filter. lmL supernatant was added to lmL 
complete DMEM and 8 pg/mL polybrene (Sigma). The cells were transduced twice at 
24-hour time intervals.
To generate gammaretrovirus for transductions of a range of cell types, the 
polyclonal PG13-ADA cells were seeded the day before harvesting. 5xl0 6 PG13- 
ADA cells were plated in a T75, and the cells were incubated at 37°C for 
approximately 8  hours. Once adhered, the media was removed from the cells and 
replaced with the minimal volume 7mL complete DMEM, and the cells were 
incubated overnight at 33°C, which is thought to improve gammaretrovirus stability. 
The gammaretroviral supernatant was collected and filtered through a 0.45pm filter 
prior to use in transductions.
2.4.2 Single Cell Fluorescence Activated Cell Sorting
3xl0 6 cells of the polyclonal PG13 cell population transduced with SFada/W were 
sorted from a viable population using a Becton Coulter ALTRA fluorescent activated 
cell sorter (FACS) and the Expo 2 software. 150pL of a 1:1 ratio of filtered 
conditioned media: fresh media was added to each well in the 96 well plate into 
which each cell was sorted. Following the sort, the plates were spun at 500xg for 1 
minute to pellet the cells. The sorted cells were then incubated at 37°C, and the 
viable cells were expanded in culture. Expression and activity of ADA were then 
evaluated for each single cell clone.
2.4.3 Lentivirus Production
Transfection of the lentiviral DNA was carried out on 293T cells, which were seeded 
in a 150 cm flask one day prior to transfection to be approximately 80% confluent on 
the day of transfection. The DNA was complexed to ImM polyethylenimine (PEI)
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(Sigma) by incubating 40pg of the transgene construct, lOjig of pMDG2 (vesicular 
stomatitis virus envelope glycoprotein (VSV-G)) expression vector and 30pg of 
p8.91 (HIV-1 gag-pol expression vector) with PEI for 20 minutes, before addition to 
the cells. The viral supernatant was harvested 48 and 72 hours after the transfection, 
filtered through a 0.45 pm filter and then concentrated by centrifuging at 91,000xg 
for 2.5 hours. The virus was then resuspended in approximately 300pL X-Vivo 10.
2.4.4 Viral Titration Assay
The gammaretro- and lentivirus were titred on HeLa cells, which were seeded at a 
density of lx l0 5 cells per well in a 6 -well plate one day prior to transduction. The 
gammaretrovirus was used in 5 different concentrations, neat, 1:5, 1:25, 1:125, 
1:625. The lentivirus was diluted 1:100, 1:1000, 1:10,000 and 1:100,000. The virus 
was added to the HeLa cells in the presence of 8 pg/mL polybrene. The cells were 
incubated for 48 hours prior to analysis of transgene expression by flow cytometry. 
The titre of the virus was determined as below:
(% positive cells) x (number of cells infected) = vlrus partlcies/mL
Volume Supernatant (mL) x 100
2.5 Transductions
2.5.1 Gammaretroviral Transduction of ADA' Skin Fibroblasts
Viral supernatant was added to the fibroblasts at a 1:1 dilution with fresh media, 
supplemented with 8 pg/mL polybrene, to enhance cell-virus contact and aid viral 
uptake. Three rounds of transductions were performed at 24-hour intervals. The 
fibroblasts were analysed for transgene expression by Western blotting (see section
2.6.2) and flow cytometry (see section 2.6.1) and for ADA activity (see section
2.6.3).
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2.5.2 Gammaretroviral Transduction of ADA' B-Lymphoblastoid 
Cell Line
As for the skin fibroblasts, the patient LCLs were transduced with ADA 
gammaretrovirus to attempt reconstitution of ADA expression and activity in vitro. 
For virus production, the polyclonal PG13-ADA were grown in complete RPMI. The 
wells of a 24-well plate were coated with 1 Opg/mL fibronectin (Sigma) for 2 hours at 
37°C, and were then washed with complete RPMI-1640. The fibronectin co-localises 
the cells and the virus and thus aids viral uptake. The wells were preloaded with 
virus, and the plate was centrifuged at 200xg for 10 minutes. 50,000-100,000 cells 
were added, followed by neat viral supernatant and 8 pg/mL polybrene, after which 
the samples were centrifuged at 200xg for 10 minutes to pellet the cells. The cells 
were transduced a further two times with neat viral supernatant at 1 2 -hour intervals, 
after which half the media was replaced with fresh complete RPMI.
2.5.3 Gammaretro viral Transduction of Haematopoietic Stem cells
Mobilised peripheral blood derived CD34+ cells, obtained from the Department of 
Haematology, UCL, were transduced with a Good Manufacturing Practice (GMP) 
grade ADA-gammaretrovirus (produced by EUFETS, Germany) during a 5 day 
procedure. On day 1, the cells were activated using a cytokine mix to induce cell 
division upon which gammaretroviruses rely for nuclear entry. The cells were 
counted and resuspended in activation media (Refer to Table 2.2 for media 
composition) to give a cell density of 0.5x106 cells/mL. Retronectin coated plates or 
X-fold cell-culture containers (Nexell, Irvine, CA, USA) were prepared on day two 
by adding 8 pg/mL Retronectin (gift from Takara Bio Inc.) in PBS to the plates, 
which were left to incubate at room temperature for 2 hours. This was followed by a 
wash in PBS-1% HSA, after which the plates were maintained over-night in PBS at 
4°C. On days 3, 4 and 5 the CD34+ cells were transduced with the ADA 
gammaretrovirus and eGFP gammaretrovirus as a control. On day 3, the plate was 
washed with PBS-1%HSA, after which the Retronectin coated plate was pre-loaded 
with gammaretrovirus (enough to cover the surface of the plate or bag) for 30 
minutes on a rocker. The cells were pelleted by centrifugation and then counted, after 
which they were resuspended in half volume transduction media (containing 2 x the 
amount of cytokines and HSA present in the activation media), half volume of viral
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supernatant to achieve a cell density of approximately 0.5x106 cells/mL. The cells 
were then incubated at 37°C for approximately 20 hours. On day 5, the cells were 
transduced for five hours, after which the cells were analysed immediately, or the 
virus was removed and the cells resuspended in fresh media to maintain in culture.
2.5.4 Lentiviral Transduction of ADA' Skin Fibroblasts, 
Mesenchymal Stem Cells and B-Lymphoblastoid Cell Line
200.000 fibroblasts or MSCs were plated in a 6 -well plate in 2mL complete DMEM, 
and 400,000 LCLs were likewise plated in complete RPMI. ADA or eGFP lentivirus 
were added at the appropriate MOI. The cells were then incubated at 37°C until 
analysed for transgene expression one week following the transduction (ADA 
staining protocol described in section 2.6.1). The cells were analysed for activity by 
Dr Lynette Fairbanks, Purine Research Laboratory, Guy’s Hospital, London.
2.5.5 Lentiviral Transduction of Haematopoietic Stem cells
Mobilised peripheral blood derived CD34+ cells were obtained from the Department 
of Haematology, UCL. The cells were counted and resuspended in transduction 
media to give a cell density of lx l0 6 cells/mL (Refer to Table 2.2 for media 
composition). Lentivirus was added immediately at the required MOI and incubated 
with the cells for 24 hours. Following the transduction period, the cells were washed 
and resuspended in fresh transduction medium at a cell density of lx l0 6 cells/mL. 
The cells were maintained in culture for 2-3 days, prior to being analysed for 
transgene expression by flow cytometry to determine the transduction efficiency 
(ADA staining protocol described in section 2.6.1).
2.6 Functional Assays 
2.6.1 Intracellular Flow Cytometry Assay
The primary anti-AD A monoclonal IgGl antibody (IC5) was a generous gift from 
Prof. M.S. Hershfield (Department of Medicine, Duke University Medical Centre, 
North Carolina, USA). To carry out the intracellular staining for the ADA protein, 
the cells were fixed and permeabilised using the Intrastain Fixation and 
Permeabilisation Kit (DAKO, Glostrup, Denmark) using a three step staining
86
C h a p t e r  2
protocol. The cell samples (approximately lx l0 6 cells for cell lines) were collected 
and washed in PBS before resuspending in 50pL PBS. lOOpL Intrastain Reagent A 
(<6 % formaldehyde -DAKO) was added to each sample to fix the cells, and was 
incubated for 15 minutes at room temperature. The cells were then washed with PBS 
and pelleted. The cell pellet was resuspended in lOOpL Intrastain Reagent B 
(DAKO), containing saponin to permeabilise the cells. The appropriate volume of the 
appropriate antibody was then added and left to incubate for 2 0  minutes at room 
temperature. 5pL of lmg/mL mouse anti-AD A or lOpL isotype control 
(PharMingen) were incubated with the cells. lpL of the biotinylated anti-IgGl 
(PharMingen) and streptavidin-phycoerythrin (SA-PE) (PharMingen) were then 
used. Following the final incubation with the SA-PE, the samples were washed and 
resuspended in PBS to be analysed in the flow cytometer. 10,000 cells were analysed 
based on forward scatter and side scatter values to exclude non-viable cells.
2.6.2 Western Blot
Approximately lxlO6 cells to be analysed were collected and lysed using lysis buffer 
(20mM Tris, pH8 , 1% v/v Nonidet P-40, 0.13M NaCl, lOmM NaF, lmM PMSF, 
Na3VC>4 , lx leupeptin, lx pepstatin, lmM DTT). The samples were left on ice for 10 
minutes and were then centrifuged at 1 2 , 0 0 0  x g for 1 minute at room temperature. 
The supernatant was added to an equal volume of loading buffer (0.125M TRIS, 
14pM bromophenol blue, 2% SDS, 2% (3-mercaptoethanol). The proteins were 
separated on a 1 0 % sodium dodecyl sulfate-polyacrylamide gel, and transferred onto 
a nitrocellulose membrane using a semi-dry transfer method at 12V for 20 minutes. 
The nitrocellulose membrane was incubated in 2.5% milk-PBS/0.1%Tween blocking 
solution for 30 minutes. The anti-ADA antibody (0.2pg/pl, Santa Cruz) was then 
added to the blocking buffer at a 1 : 1 0 0  dilution and was allowed to bind for 2  hours 
at room temperature. The blot was washed five times with PBS/0. l%Tween prior to 
the addition of the secondary antibody (Donkey anti-goat-HRP, Serotec) at a 1:1000 
dilution. The HRP (horseradish peroxidase) labelled secondary antibody was 
detected by enhanced chemiluminescence (ECL - Amersham Pharmacia Biotech), 
and the protein was then visualised using Kodak BioMax film.
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2.6.3 ADA Activity Assay
The enzymatic assay was carried out at the Purine Research Unit, Guy’s Hospital, 
London, by Dr Lynette Fairbanks. ADA enzyme activity was established by the 
measurement of the concentration of inosine and hypoxanthine produced from 
adenosine (refer to Figure 1.2). The cells of interest were pelleted and washed twice 
in PBS. Cell lysates were then obtained by two rapid ffeeze-thaw cycles, and the 
cellular debris was removed by centrifugation. 25 pL of the 500pL supernatant was 
added to lOOpL lOOmM phosphate buffer, pH 7.4 and 75pL lOmM adenosine. For 
the control sample, the reaction was immediately stopped by the addition of 50pL 
40% trichloroacetic acid (TCA) to precipitate the protein. The other samples were 
incubated at 37°C for 30 minutes, after which the reaction was stopped by the 
addition of TCA. The samples were centrifuged at 10,000xg for 2 minutes. Water 
saturated ether was then added to the supernatant. The samples were vortexed and 
the ether layer was removed. This washing step was repeated 4 times. The samples 
were then loaded onto a hydrophobic/ionic high pressure liquid chromatography 
(HPLC), and eluted using tetrabutylammonium hydrogen sulphate (TBA) acetate (an 
ion pair agent). The reaction reagents and products were separated by HPLC and the 
values obtained were expressed as nmoles of inosine and hypoxanthine produced per 
hour per gram of total protein.
2.6.4 Protein Estimation by the Lowry Method
The samples used for the activity assay were analysed for total protein concentration 
using the Lowry method (Lowry et al., 1951). The sample (25pL) was added to lmL 
solution containing 2% Na2CC>3 in 0.1 M NaOH, 1% CUSO4 .5 H2O, 2% Na/K tartrate 
and lmg/mL BSA. The samples were allowed to incubate for 10 minutes at room 
temperature. lOOpL Folin & Ciocalteau’s reagent was then added and was left for 30 
minutes. The absorbance was read at 740 nm, and the values obtained were 
extrapolated from a BSA standard curve to obtain the concentrations of the products.
2.6.5 Haematopoietic Colony Assay
Haematopoietic colony formation was analysed following the transduction of CD34+ 
cells. 1000 cells were added to 500pL media, which was then mixed with 2.5 mL of 
methylcellulose (composed of 1% methylcellulose in Iscove’s MDM, 30% foetal
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bovine serum, 1% bovine serum albumin, 3U/mL recombinant human erythropoietin, 
10-4 M 2-mercaptoethanol, 2mM L-glutamine, 50ng/mL recombinant human stem 
cell factor, 20ng/mL recombinant human GM-CSF, 20ng/mL recombinant human 
IL-3, 20ng/mL recombinant human IL-6, 20ng/mL recombinant human G-CSF -  
from Stem Cell Technologies). Approximately 1.5mL of the cells in methylcellulose 
was added carefully to a 35mm plate. The cells were incubated at 37°C, and were 
analysed for colony formation between days 10-14. Colony type was identified by 
morphology, and the number of colonies recorded using an inverted light 
microscope. Individual colonies were picked using a P20 Gilson pipette set on 4pL 
and added to 50pL lysis buffer (lxPCR buffer, 0.5% NP40, 0.5% Tween-20, 
0.9mg/mL Proteinase K). The DNA was isolated from the colonies by incubation in 
lysis buffer at 60°C for 1 hour followed by 95°C for 5 minutes. 12.5pL was then 
used as a template for the PCR as described in the following section.
2.6.6 PCR Analysis
Genomic DNA was extracted from the cells using the Qiagen DNeasy kit according 
to manufacturers’ instructions. Briefly, cell samples were lysed using Proteinase K, 
and the DNA was bound to the silica gel column. The column was washed to remove 
contaminants prior to DNA elution. PCR was performed using primers specific for 
the gammaretroviral backbone and the ADA transgene, amplifying a 310 base pair 
product. Each primer (Invitrogen) was 20 base pairs long, where the sequence of the 
forward primer was CAC CTT TAA CCG AG A CCT CA, and the reverse primer 
CTA CTT TGG GCT TGT CGA AG. The primers were used at 50pmoles per 50pL 
reaction, the magnesium chloride at lmM concentration, with annealing temperature 
of 55°C, and 35 repeat cycles.
2.6.7 Real Time PCR Analysis
Genomic DNA was extracted from the cells using the Qiagen DNeasy kit as 
previously described. Primers and probe sequences for ADA cDNA were designed 
by Dr Klaus Kuehlcke (EUFETS, Germany) and amplified a product within the ADA 
gene. The primer (Invitrogen) and probe (MWG Biotech, Ebersberg, Germany) 
sequences were as follows:
ADA Forward: CCTGGCCAAGTTTGACTACTACATG
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ADA Reverse: TCTCTACAAACTCATAGGCGATCCT 
ADA Probe: FAM-CTATCGCGGGCTGCCGGGA-TAMRA.
p-actin was used as an internal control to determine the number o f cells in each 
reaction, based on each cell having two copies of P-actin. Primers and probe 
sequences for human P-actin were designed by Steve Howe and Doug King (ICH, 
London) and were as follows:
P-actin forward: TCACCCACACTGTGCCCATCTACGA 
P-actin reverse: CAGCGGAACCGCTCATTGCCAATGG 
p-actin probe: VIC-ATGCCCTCCCCCATGCCA-TAMRA
Reaction conditions were as follows: 95°C for 10 minutes, then 40 repeat cycles of 
95°C for 15 seconds and 60°C for 1 minute. The universal master mix was obtained 
from Applied Biosystems (CA, USA). The primers were used at a final concentration 
of 900nM and the probes at 5 pM. The PCR reactions were performed on an ABI 
Prism 7000 SDS (Applied Biosystems) real time thermocycler. The values obtained 
were compared to the ADA plasmid standard curve which ranged from 1 to 10,000 
copies of the ADA gammaretroviral plasmid (Figure 2.1) to calculate absolute 
numbers of viral copies. These values were then compared with the p-actin DNA 
standard curve (Figure 2.2) generated by Steve Howe and Doug King (ICH, London) 
to estimate number of copies per cell.
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2.6.8 Analysis of Patient Mononuclear Cells by Flow Cytometry
A three-colour flow cytometry analysis was performed on patient whole blood using 
antibodies to the following surface markers: CD3, CD4, CD8, CD16+CD56, CD19, 
CD27, CD45, and CD45RO (all from BD Biosciences listed in Table 2.3). This 
phenotype panel was performed at regular intervals to assess the response to PEG- 
ADA or gene therapy on patient leukocyte populations. 5 pL of the relevant 
antibodies were incubated with lOOpL whole blood for 30 minutes at 4°C. The red 
blood cells were lysed by incubation with lx lysis buffer (BD Biosciences, 
containing less than 5% diethylene glycol, and 1.5% paraformaldehyde (PFA)) made 
up in water for 15 minutes at room temperature. The samples were washed twice 
with PBS and fixed using 1% PFA in PBS for 15 minutes. The cells were then 
washed in PBS and resuspended in an appropriate volume of PBS/1% BSA to be 
analysed.
The same flow cytometry analysis was performed by the Clinical Immunology lab at 
Great Ormond Street Hospital to estimate lymphocyte counts. The percentage of the 
particular cell type was multiplied by an absolute lymphocyte count of CD45 cells to 
estimate the numbers of the different types of lymphocytes.
2.6.9 Spectratyping and TREC Analysis
The majority of the T cell receptor excision circles (TREC) analysis was performed 
by Doug King (ICH, London) and the spectratype analysis by Stuart Adams (GOSH, 
London). TRECs are episomal DNA by-products formed during the T cell receptor 
gene rearrangements that occur during T cell differentiation in the thymus and are 
considered markers of thymic activity. Spectratyping is an analysis of the 
distributions of CDR3 lengths to reveal whether there is a normal usage of T cell 
receptors. Briefly, blood samples were obtained from ADA deficient patients at 
regular intervals. The peripheral blood mononuclear cells (PBMCs) were isolated by 
density gradient (1.077g/mL Ficoll-Paque from Pharmacia), by centrifugation at 
l,000xg for 20 minutes, and the cells were resuspended in a small volume of MACS 
buffer (Miltenyi Biotec, Cologne, Germany) to achieve approximately 5xl04 
cells/pL. A proportion of the cells was pelleted and kept at -80°C for later TREC 
analysis. The remaining cells were selected for CD4 and CD8 expression using
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Miltenyi magnetic cell sorting (Miltenyi Biotec). A proportion of the CD4+ and 
CD8+ cells were kept for TREC analysis. The remaining CD4+ and CD8+ cells were 
pelleted and resuspended in Tri Reagent for RNA extraction. Chloroform was added 
to the sample and mixed, and the samples were centrifuged at 10,000xg in the 
microcentrifuge. Isopropanol was added to the top aqueous phase and the samples 
were stored at -20°C to enhance the precipitation of RNA. The samples were 
centrifuged at 10,000xg in the microcentrifuge and the media was carefully removed. 
An ethanol wash was performed, 20pL water was added and the samples were 
incubated at 60°C to facilitate the sample resuspension. dNTPs, oligo d(T)i6 (Roche) 
and RNase inhibitor was added to each tube of RNA. The samples were incubated at 
70°C for 15 minutes, after which MgCh PCR buffer (Promega) and reverse 
transcriptase was added to each sample and incubated at 42°C for 1 hour. PCRs were 
performed on the samples using 24 different Vp primers and one constant primer. 
Following the first PCR reaction, a run-off PCR was performed and the lengths of 
the CDR3 regions were determined using a MegaBase sequencer machine.
For the samples analysed for TREC activity, the cell pellets were resuspended in 
buffer containing Tween-20, proteinase K and NP40 and incubated at 56°C for 2 
hours. The samples were centrifuged at 10,000xg in the microcentrifuge, and the 
proteinase K was inactivated by incubating the samples at 95°C for 15 minutes. A 
small sample of the extracted DNA was then used for real time PCR analysis. The 
primers and probes were as follows:
Forward CACATCCCTTTCAACCATGCT 
Reverse GCC AGCTGC AGGGTTT AGG
Probe FAM-ACACCTCTGGTTTTTGTAAAGGTGCCCACT-TAMRA 
Reaction conditions were as previously described in section 2.6.7. The primers were 
used at a final concentration of 300nM and the probe at 100 nM. For each run, a 
standard curve was generated from triplicate samples of 5-fold serially diluted known 
copies of plasmid DNA containing a TREC fragment. These values were then 
compared with the P-actin DNA standard curve as previously described to estimate 
number of copies per cell.
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3.1 Introduction
Treatment options for patients with ADA-SCID are limited. The therapy o f choice is 
bone marrow transplantation if a fully matched donor is available. The ideal donor is 
a fully matched sibling, however a matched unrelated donor (MUD) is also 
commonly used. In the presence of a matched donor, the prognosis is good, as this 
type of transplant usually leads to complete immune reconstitution. However, this is 
usually only available for approximately a third of the patients, as many do not find a 
fully matched related or unrelated donor. Hence, if transplant is not an option, the 
patient can be treated with PEG-ADA enzyme replacement therapy. The treatment 
involves weekly or bi-weekly intramuscular injections of bovine ADA which has 
been conjugated to PEG in order to increase the half-life of the enzyme. For many 
patients, PEG-ADA therapy is often successful. However, although patients usually 
initially respond well to PEG-ADA, for some patients this response can deteriorate as 
they are maintained on this treatment for a long period of time and may also mount 
an immune response against the bovine ADA (reviewed by Hershfield, 1995 and by 
Hershfield & Mitchell, 2001). No formal data has been previously available on the 
immune recovery of patients during PEG-ADA therapy.
We looked in detail at the immune recovery during PEG-ADA therapy in three 
ADA-SCID patients. A number of assays were performed to analyse the patients’ 
progress: measurements of lymphocyte counts (performed by the Clinical Laboratory 
at Great Ormond Street Hospital) and dATP concentrations (performed by Lynette 
Fairbanks at the Purine Research Laboratory, Guys’ Hospital), analysis of the 
production of nai've immune cells by flow cytometry, spectratyping (performed with 
the help of Stuart Adams, ICH) and TREC analyses (performed with the help of 
Doug King, ICH).
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3.2  R e s u l t s
3.2.1 Analysis of Lymphocyte Counts
Patient 1 is a boy of 3 years old who has been treated with PEG-ADA for nearly 3 
years. Patient 2, a one-year old girl, was diagnosed with ADA-SCID at 2 months of 
age following recurrent infections and commenced PEG-ADA at 3 months of age. 
Patient 3, a boy of 4 years old, was treated with PEG-ADA for more than 3 years 
prior to being treated with gene therapy. Blood samples were taken from each patient 
at regular intervals to assess lymphocyte reconstitution. Prior to PEG-ADA all three 
patients had nearly undetectable lymphocyte counts as expected for ADA deficient 
patients. Patients 1 and 2 responded well to PEG-ADA therapy, with their 
lymphocyte counts increasing following initiation of the treatment and remaining at 
adequate levels (approximately 1,200 and 1,900 cells/pL respectively) for over 2 
years and up to 1 year of treatment respectively (Figures 3.1 A and B). Their 
lymphocyte counts are now at levels just below that of normal age matched controls 
(see Appendix 1). However, although the absolute lymphocyte counts were near 
normal, it was apparent that the number of CD4+ cells was unusually low and a 
reverse CD4/CD8 ratio was observed. Therefore, although the two patients displayed 
good immune recovery, it was not entirely normal. Measurements of dATP levels 
have revealed that patients 1 and 2 both remain detoxified (data not shown), and both 
are clinically free of infection and thriving. Patient 3 did not respond as well as 
patients 1 and 2 to the PEG-ADA treatment as demonstrated by his low lymphocyte 
counts (Figure 3.1C). Following the start of PEG-ADA his absolute lymphocyte 
counts increased, however this was not sustained but decreased rapidly to 
approximately 600 cells/pL. This was in spite of achieving good detoxification as 
demonstrated by the low levels of dATP (see Figure 5.5). It was therefore clear that 
his lymphocyte counts, in particular the T cell counts, were well below normal and 
the patient showed a poor response to PEG-ADA treatment.
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Figure 3.1. Lymphocyte counts during PEG-ADA treatment. Blood samples were 
taken at regular intervals and flow cytometry analysis was performed to estimate the 
number of cells per p.L of the lymphocyte subsets.
A, Patient 1; B, Patient 2; C, Patient 3. 98
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3.2.2 Analysis of Naive Lymphocyte Production
Flow cytometry analysis was performed to assess the levels of CD45RO'CD27+ 
cells. The CD45RO~CD27+ proportion of cells are naive lymphocytes being 
generated (Hamann et al., 1997), an increase of which indicates thymic 
reconstitution. CD27hlgh cells were also examined, which are thought to represent a 
truly naive population of cells. Following initiation of PEG-ADA therapy, both 
patients 1 and 2 showed a significant increase in the proportion of naive cells 
(Figures 3.2 B and C), and a clear population of CD27hlgh cells also developed. For 
patient 2, approximately 10% of the CD45 population were naive cells. Patient 1 
showed a particularly high proportion of naive cells (more than 30%), and compared 
favourably to a normal control (36% naive cells) (Figure 3.2A). Hence, patients 1 
and 2 responded well to the PEG-ADA treatment, as they were generating naive 
lymphocytes and had lymphocyte counts just below normal. In contrast to patients 1 
and 2 however, the proportion of naive cells started to decline for patient 3 after a 
period of time of being treated with PEG-ADA and reached low levels of only 4% 
(Figure 3.2D). Hence, patient 3 was not responding well to PEG-ADA therapy as the 
lymphocyte counts were very low and naive cells were not being generated.
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separate gate has been drawn for cells expressing high levels of CD27 (percentage of 
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3.2.3 Analysis of Thymic Function
Thymic function was evaluated by assessing the production of T cell receptor 
excision circles (TRECs) in the CD4+ and CD8+ subsets of T cells. TRECs are 
episomal DNA by-products formed during the T cell receptor gene rearrangements 
that occur during T cell differentiation in the thymus. As the TRECs are episomal, 
they do not replicate during mitosis and are therefore diluted as a result of cell 
proliferation. Hence, the detection of TRECs in peripheral blood is considered a 
marker of thymic activity. Prior to PEG-ADA, no or only very low TREC activity 
was detectable in the three ADA deficient patients. As a result of PEG-ADA therapy, 
TREC activity increased dramatically in patients 1 and 2 in both the CD4+ and CD8+ 
T cell populations (Figure 3.3). Talvensaari et al. (2002) reported TREC values of 
approximately 4000 TRECs per pg CD3+ DNA from healthy young donors. Patient 1 
was found to have approximately 21,000 TRECs per 106 CD3+ cells (CD4+ and 
CD8+ cells combined) and patient 2 had approximately 19,000 TRECs per 106 CD3+ 
cells. Based on the estimate of 6pg DNA per diploid cell (Jeffreys et al., 1988), 106 
cells (which our TREC values are expressed as a function of) would contain 
approximately 6pg of DNA. Hence, the TREC values obtained equate to 
approximately 3,400 and 3,100 TRECs per pg CD3+ DNA for patients 1 and 2 
respectively. Therefore, these values were comparable to the TREC values observed 
in healthy young donors (Talvensaari et al., 2002). This increase in TREC activity 
indicated that the thymic function of patients 1 and 2 had improved greatly as a result 
of the PEG-ADA treatment. Patient 3, however, showed no TREC activity during his 
PEG-ADA therapy (data not shown), confirming that immune reconstitution for 
patient 3 was poor.
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Figure 3.3. TREC values for patients 1 and 2 during PEG-ADA treatment. Patient 
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separated using magnetic beads column. Real-time PCR analysis was performed on the 
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3.2.4 Analysis of T Cell Receptor (TCR) Diversity
The TCR p-chain repertoire was analysed in CD8+ cells for patient 1 and in CD4+ 
and CD8+ cells for patient 2 (spectratype analysis could not be performed in CD4+ 
cells for patient 1 due to small sample size). The cells were selected for CD4 or CD8 
expression using magnetic beads column. For patient 1, the length pattern analysis of 
the complementary determining regions 3 (CDR3) revealed the expected Gaussian 
curve with more than 6 peaks for some of the p-chain repertoires (e.g. Vp5, Vp9, 
V pi6 and Vp21), whereas some p-chain repertoires were more oligoclonal (Vpl, 
VP2, Vpi2 and Vpl3A) after 27 months of treatment with PEG-ADA (Figure 3.4). 
For patient 2, the spectratyping of the complementary determining regions 3 (CDR3) 
revealed the expected Gaussian curve with more than 6 peaks for some of the p- 
chain repertoires in the CD4+ cells (e.g. Vp2, Vp3, Vp4, Vp5, VP21, VP22), 
however some p-chain repertoires in the CD8+ cells were more clonal (V p il, 
VP13B, V pi6 and Vp24) after 11 months of treatment with PEG-ADA (Figure 3.5), 
perhaps indicating prior antigen stimulation. Therefore, both patients 1 and 2 display 
near normal distributions of CDR3 lengths. Spectratype analysis was not performed 
for patient 3 during the PEG-ADA treatment.
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Figure 3.5B. CD8 spectratypes for patient 2 after 11 months of treatment with PEG-ADA. Patient blood samples were collected at regular intervals and 
CD8+ cells were separated using magnetic beads columns. The RNA was extracted and reverse transcribed. PCRs were performed on the samples using 24 
different Vp primers and one constant primer. A run-off PCR was then performed and the CDR3 lengths were determined using a MegaBase sequencer 
machine.
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3.3  D is c u s s io n
The response of three ADA-SCID patients to PEG-ADA therapy was analysed by 
several different methods to investigate their levels of immune reconstitution. Patient 
1 has been treated with PEG-ADA for over 2 years, and patient 2 for nearly 1 year, 
both with some success. However, following three years of PEG-ADA treatment, the 
immune recovery of patient 3 was deteriorating.
Prior to PEG-ADA, all three patients had an almost undetectable lymphocyte count 
as is to be expected in ADA deficient patients who display a selective toxicity to B, T 
and NK cells. As a result of the detoxification incurred by the PEG-ADA treatment, 
the lymphocyte counts of patients 1 and 2 increased and stabilised at levels slightly 
below normal, suggesting a good immune recovery in these patients. Of the three 
patients analysed in this study, patient 2 appeared to do particularly well as her ALC 
was the highest. However, although patients 1 and 2 had reasonable lymphocyte 
counts, immune recovery was clearly not normal as indicated by the low CD4 counts 
and reverse CD4/CD8 ratios. Patient 3 had very low lymphocyte counts on diagnosis, 
which increased as a result of the enzyme replacement therapy. However, after 3 
years of PEG-ADA therapy his ALC was very low, about half that of patient 1 and a 
third of the ALC of patient 2, suggesting that he had a poor immune recovery.
Analysis of expression of the markers CD45RO and CD27 can reveal the generation 
of new lymphocytes, as CD45RO'CD27+ cells represent a nai've cell population 
(Hamann et al., 1997). Patients 1 and 2 showed a significant increase in the 
proportion of CD45RO’CD27+ cells as a result of PEG-ADA therapy, suggesting the 
production of naive lymphocytes. This was further confirmed by the analysis of 
TRECs, which estimates the level of thymic function. Patients 1 and 2 showed no or 
very low thymic activity prior to PEG-ADA. However, following initiation of PEG- 
ADA treatment, the values of TRECs increased dramatically in both CD4+ and CD8+ 
cells. Thus naive cells were being generated due to the detoxification by PEG-ADA. 
There is generally expected to be a clear correlation between the increase in naive T 
cells according to the flow cytometry analysis and TREC analysis. Thus patient 1 
would be expected to have higher TREC values than patient 2 as he had a higher 
proportion of CD45RO'CD27+ cells. However, this apparent discrepancy could be
107
C h a p t e r  3
due to a number of reasons, as TREC values are affected by the age of the individual, 
peripheral T lymphocyte replication leading to a dilution of TRECs, and the 
longetivity of T cells which can survive in the peripheral blood for between over 7 
years (Talvensaari et al., 2002). However, unlike patients 1 and 2, Patient 3 showed a 
decrease in the proportion of CD45RO’CD27+ cells following 3 years of PEG-ADA 
therapy. Moreover, throughout the PEG-ADA treatment no TREC activity could be 
detected in his CD4+ or CD8+ cells. Thus, he was not generating naive lymphocytes 
in spite of the PEG-ADA treatment.
Spectratype analysis for patient 1 in CD8+ cells and for patient 2 in CD4+ and CD8+ 
cells, revealed near normal Gaussian distributions for some P-chain repertoires. 
However, certain repertoires in the CD8+ cells of patient 2 were more clonal, perhaps 
indicating an as yet incompletely formed repertoire (Talvensaari et al., 2002) or prior 
antigen stimulation. The TCR polyclonality in most p-chain repertoires for patients 1 
and 2 correlated with the high proportion of naive cells and high TREC values.
Hence, patients 1 and 2 have responded well to the PEG-ADA therapy. They are 
both currently at home and are clinically well, and remain on prophylactic 
medication including immunoglobulin replacement. Both patients have showed an 
increase in their lymphocyte counts and thymic function is improving in both 
patients as evidenced by the increase in naive T cells and the increased TREC 
activity. Moreover, both patients display a near normal repertoire of Vp subfamilies. 
However, patient 3 has not responded as well to PEG-ADA therapy as evidenced by 
his low lymphocyte counts and decrease in the production of naive lymphocytes. To 
our knowledge, this is the first time that the effects of PEG-ADA have been analysed 
in relation to thymic activity.
Previous studies of PEG-ADA therapy have reported good survival rates of nearly 
80% (reviewed by Hershfield, 1995). Upon initiation of PEG-ADA treatment, a rapid 
decrease in toxic metabolites is usually observed to levels only slightly above normal 
(Hirschhom et al., 1980 & 1981; Hershfield, 1995). As a result of this detoxification, 
B cell numbers increase during the first month, followed by an increase in T cells at 
about 6-12 weeks of treatment. Approximately half of the patients who receive PEG-
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ADA discontinue intravenous immunoglobulin (IVIG), and the level of immune 
function achieved has been sufficient to protect against opportunistic infections in 
most patients (Hershfield, 1995). The proliferative response of lymphocytes to 
mitogens also usually increases during the first two months and a thymic shadow 
may reappear (Hershfield et al., 1993). However, as was observed with the patients 
in the current study, lymphocyte counts do not commonly reach normal levels of 
age-matched controls, and the degree of immune reconstitution can be varied. Of the 
patients treated previously with PEG-ADA, 50% have developed antibodies against 
the bovine ADA. This could potentially reduce the effectiveness of the treatment, 
however this has only been reported in a few patients. Although unusual, immune 
dysregulation may also occur as a result of PEG-ADA, including refractory immune 
haemolytic anaemia as was observed in two patients (Hershfield et al., 1993). 
Nevertheless, PEG-ADA has been found to be a successful treatment for most ADA 
deficient children, and patients 1 and 2 have shown a similar immune recovery to 
what has been previously reported (Hershfield et al., 1987; 1993 and 1995).
Hence it has been demonstrated that in the absence of a matched bone marrow 
transplant, PEG-ADA therapy can be a successful treatment for some patients, such 
as for patients 1 and 2. However, for some patients, like patient 3, PEG-ADA is 
ineffective and alternative treatments should be considered. Therefore, gene therapy 
was investigated as a potential treatment for patient 3, and experiments were 
performed in order to develop an effective gammaretroviral vector and gene therapy 
protocol.
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4.1 In t r o d u c t io n
Gene therapy is a possible curative treatment for ADA deficiency. For gene therapy 
to be successful, it is thought that a high expression of ADA in the patient target cells 
is required to detoxify the system. Haematopoietic stem cells are used as cell 
delivery vehicles because they are able to repopulate the entire haematopoietic 
system (Hay, 1966) and should therefore deliver ADA expression to different 
haematopoietic cells. Viral vectors and the transduction protocol utilised therefore 
need to be optimised for efficient gene transfer to HSCs which should allow for a 
high expression of ADA.
Gammaretroviruses are the vectors of choice in current gene therapy trials for 
immunodeficiency as they efficiently integrate their genetic material into the host 
cell’s genomic DNA, resulting in the long-term expression of the transgene. 
However, the requirement for efficient integration of the transgene to achieve good 
transgene expression needs to be balanced against the fact that high levels of 
integration can also lead to insertional mutagenesis, which will be discussed further 
in Chapter 8. Retroviral vectors have several other advantages as gene delivery 
vehicles, including a large packaging capacity of up to 10 kilobases, and the absence 
of vector-induced cellular immune responses as they do not encode viral proteins.
The gammaretrovirus used in our study is based on a vector constructed by Baum et 
al. in 1995, and includes the 3’ LTR from the Spleen Focus Forming Virus (SFFV) 
and the 5’LTR derived from MESV (Murine Embryonic Stem Cell Virus). SFFV is a 
replication-defective form of the erythroblastic Friend Murine Leukaemia Virus, and 
has a U3 region encoding strong regulatory influences on cells of the myeloid 
lineage. MESV was generated by combining the LTR from PCMV (PCC4-cell- 
passaged Murine Sarcoma Virus) with a mutated primer binding site from an 
endogenous murine retrovirus and is known to resist silencing (Grez et al, 1990). A 
major concern associated with viral vectors is the phenomenon of silencing of LTR 
directed transcription with time. Silencing, a form of host defence mechanism, can be 
due to methylation dependent or independent molecular modifications, that result in 
promoter shut-off (Challita & Kohn, 1994; Bestor, 2000; Pannell et al., 2000, Pannell 
& Ellis, 2001). It is therefore important to find a promoter for use in gene therapy
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vectors which can resist this silencing process. Modification of the U3 region of the 
LTR and the primer binding sites, important regions for determining transcriptional 
activity, has been used to reduce the risk of silencing and to direct tissue tropism 
(Grez et al, 1990). The transgene expression in our viral vector is therefore regulated 
by the SFFV promoter, which has been shown to result in high transgene expression 
levels in all haematopoietic lineages (Baum et al., 1995, 1997; Flasshove et al., 
2000).
The viral glycolipid membrane envelope determines the cell tropism of the vector. 
The viral vector can be encapsidated either by the envelope protein of that virus or 
that of a different virus (pseudotyping). The gammaretroviral vector used in this 
study was pseudotyped with the Gibbon Ape Leukaemia Virus (GaLV) envelope, 
provided by the PG13 packaging cell line, which has previously been reported to 
result in high gene transfer efficiencies into haematopoietic stem cells (Kiem et al., 
1997) and T cells (Lam et al., 1996). The receptor for the GaLV envelope, glvr-1 
(Pit-1), is a phosphate transport protein (Johann et al., 1992) expressed on several 
different cell types. The GaLV envelope confers the ability to infect human, rat, cat, 
dog and monkey cells, but importantly not murine cells. Thus, it alters the tropism of 
the murine gammaretrovirus to allow the infection of human cells. At the same time, 
pseudotyping with the GaLV envelope reduces the risk of re-infection of the PG13s, 
leading to decreased possibilities of recombination events and the production of 
replication competent retroviruses.
The Woodchuck Post-transcriptional Regulatory Element (WPRE) was included in 
the ADA-gammaretrovirus as it has been shown to enhance the expression levels of 
the transgene eight-fold post-transcriptionally (Zufferey et al., 1999). It is an element 
derived from the Woodchuck hepatitis virus (Donello et al., 1998) and is thought to 
function by affecting polyadenylation and promoting the nuclear export of vector 
RNA (Huang, J. & Liang, 1993; Huang, Z.M. & Yen, 1994; Zufferey et al., 1999). 
Zufferey et al. importantly showed that the WPRE is not reliant on the type of vector, 
transgene, or promoter. Nor is it dependant on the cycling status of the cell, the cell 
type or species. Increased ADA expression is sought-after as high levels of ADA 
may be required to remove the toxic metabolites in the cells of ADA deficient 
patients. Importantly, high levels of ADA expression are thought not to be toxic as
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PEG-ADA therapy results in very high extracellular ADA activity, and individuals 
with ADA over-expression intracellularly have been found to be healthy. Recent 
concerns regarding the safety of WPRE are discussed in chapter 8.
The following experiments were therefore carried out to generate an efficient 
gammaretroviral vector to be used in gene therapy. This vector was tested on 
different patient cells to evaluate its transduction efficiency and to determine whether 
it had any toxic effects on the cells. Once this had been verified, a protocol for the 
efficient transduction of CD34+ cells was established.
4.2  R e s u l t s
4.2.1 Construction of the ADA Gammaretroviral Vector
The ADA cDNA was generated by PCR from the pOTB7 vector carrying the ADA 
(kind gift from Prof D. Valerio, Department of Gene Therapy, University of Leiden, 
Netherlands), using primers specifically designed to amplify the ADA cDNA and 
include Xbal linkers (Figure 4.1 A). These restriction sites were then utilised to insert 
the ADA into the intermediate cloning vector pBlueScript (pBS) (Figure 4 .IB). This 
step facilitated the cloning procedure as the vector has several restriction sites.
The gammaretroviral vector (SFada/W) was constructed by removing the ADA- 
WPRE fragment by an Xbal/Xhol digest from the pBS, and ligating it into the 
gammaretroviral vector already containing the SFFV promoter. Therefore, the 
gammaretroviral vector carried the SFFV promoter, the ADA transgene and the 
WPRE element (Figure 4.1C). The correct design of the constructed vector was 
confirmed by restriction digest patterns (Figure 4 .ID), and sequencing between the 
two LTRs (data not shown).
The gammaretroviral eGFP vector (from the Institute of Child Health Molecular 
Immunology plasmid library) was utilized in some experiments as a control vector 
(Figure 4.IE). Although this vector did not incorporate the WPRE element, a high 
level of eGFP expression was observed.
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Figure 4.1. Generation of gammaretroviral vectors.
A, Map of the human ADA cDNA. The ADA transgene was generated by PCR to 
incorporate Xbal linkers, which were then used to incorporate the transgene into the 
gammaretroviral and lentiviral vectors. B, Vector map of pBlueScript SFFV-ADA-WPRE 
(SAW). This vector was used as an intermediate cloning vector to facilitate the introduction 
of the ADA-WPRE fragment into the gammaretroviral vector, and the SAW fragment into 
the lentiviral vector as described in chapter 6. C, Vector map of the ADA-gammaretroviral 
construct (SFada/W). The ADA-WPRE fragment was digested from the pBS-SAW by an 
XbaHXhoI digest and was then ligated into the gammaretroviral vector. D, Restriction 
digest gel to confirm correct design of SFada/W. M, marker; 1, Xbal digest (Xbal does not 
cut at position 2627 probably because of methylation); 2, BamHI/XhoI digest; 3, 
EcoRI/XhoI digest. E, Vector map of the gammaretroviral GFP vector. The vector encodes 
eGFP, also under the control of the SFFV. 1 1 4
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4.2.2 Generation of Gammaretroviral Packaging Cell Lines
A stable gammaretroviral packaging cell line was generated as this is a simple and 
reliable method of generating gammaretrovirus of reproducible titres for use in 
transduction experiments. To generate gammaretrovirus expressing ADA, the 
SFada/W plasmid DNA was transfected into Phoenix helper free retrovirus producer 
cells. This is a transient packaging cell line providing the ecotropic env gene separate 
from the gag and pol genes. The viral supernatant from these cells was then used to 
stably transduce the murine PG13 cells, derived from the NIH/3T3s. The PG13 cells 
contain genes for Gag and Pol from murine leukaemia virus (MLV) and in trans the 
envelope from GaLV (Miller et al., 1991). Thus, the gammaretrovirus generated 
from these cells are pseudotyped with the GaLV envelope (refer to Figure 1.6).
Flow cytometric analysis demonstrated that nearly 40% of the PG13 cells were 
transduced (Figure 4.2E). Flow cytometric single cell sorting was performed on the 
polyclonal PG13 populations to obtain clonal populations of transduced cells. As 
ADA is expressed intracellularly, this marker could not be used for flow cytometric 
sorting. Hence, the cells were sorted on the basis of cell viability, as determined by 
the forward scatter/side scatter characteristics (Figure 4.2A), into 96 well plates. Of 
the clones that were expanded, 24 were analysed for hADA expression by Western 
blot and flow cytometry to determine which single cell clones had been transduced. 
Of the single cell clones analysed, 10 were found to be positive for human ADA 
expression by both Western blot (Figure 4.2B) and flow cytometry (representative 
plot in Figure 4.2F), and were therefore considered to be transduced. Flow cytometry 
confirmed that the cells expanded were probably single cell clones, as they expressed 
a homogenous amount of ADA. Neither Western Blotting nor intracellular staining 
for flow cytometry detected murine ADA (data not shown).
The virus produced by the polyclonal PG13 population and the single cell clones was 
titred to determine which was the better viral producer. To quantify the titres, viral 
supernatant at different dilutions was used to transduce HeLa cells in one round of 
transduction, and the level of ADA expression in the HeLa cells was measured three 
days post-transduction using flow cytometry to determine the proportion of 
transduced cells (Figure 4.3A-G). The titres of the virus produced from polyclonal
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and single cell clone producer cells ranged from approximately lxlO4 to 4xl04 
transducing units/mL as shown in Figure 4.3H. Two of the single cell clones were 
found not to produce any functional virus although the ADA protein was shown to be 
expressed as determined by Western blotting (SCCs 6 and 8). The titring on HeLa 
cells was performed twice to confirm the values. The polyclonal cell population was 
utilised in some early transduction experiments prior to the generation of single cell 
clones. As its titre was found to be similar to the best viral producers of the single 
cell clones, this cell line was continued to be used for some experiments.
As the SFada/W was to be used in a clinical setting to treat ADA deficient patients, 
virus was produced at a large scale in a good manufacturing practice (GMP) facility 
in Eufets, Germany. The titre of the clinical grade gammaretrovirus was found to be 
8.5x104 transducing units/mL (Figure 4.3H). Several transductions described in this 
project were performed as indicated using test aliquots of the clinical grade virus.
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Figure 4.2. Generation of PG13 single cell clones transduced with the ADA 
gammaretrovirus. PG13 cells were transduced with SFada/W gammaretrovirus. Single 
cells were sorted into 96-well plates by FACS, expanded and analysed for ADA 
expression.
A, FACS plot of selected viable PG13 cells. B, Representative Western blot of 5 single 
cell clones. The hADA protein is a monomer of approximately 40kDa. SCC, single cell 
clone. Representative flow cytometry plots of C, secondary antibody only control; D, 
untransduced cells; E, the polyclonal population prior to sorting and F, single cell clone 5 
(C-F: The values in the flow cytometry plots refer to the ADA+ cells).
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Figure 4.3. Titration of the gammaretrovirus generated by the PG13 packaging cell 
lines. Each gammaretrovirus produced by the different gammaretroviral producer clones 
was titrated on HeLa cells to identify the best viral producer.
A, Forward scatter/side scatter plot; B, secondary antibody only control. C-G, 
Representative flow cytometry plots of single cell clone 5 titred on HeLa cells. The 
gammaretroviral supernatant from the PG13 single cell clones was used neat (C), 1:5 
diluted (D), 1:25 diluted (E), 1:125 diluted (F) and 1:625 diluted (G) (B-G: The values in 
the flow cytometry plots refer to the ADA+ cells). H, Titres of gammaretrovirus produced 
from different gammaretroviral packaging cell lines. The titres were estimated from the 
transduction efficiency of HeLa cells transduced using serial dilutions of gammaretroviral 
supernatants. Average values from two separate experiments. Poly, polyclonal PG13 cell 
population, clin, clinical grade SFada/W gammaretrovirus.
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4.2.3 Transduction of Patient Fibroblasts
The gammaretrovirus generated from the polyclonal PG13 cells was tested by 
transduction of a variety of cell types. It was important to assess the gene transfer 
efficiency of the gammaretrovirus and to analyse the cells for possible toxicity 
caused by the virus. Transductions of patient primary skin fibroblasts were 
performed to achieve reconstitution of ADA expression and activity. Freshly 
produced virus was used to transduce patient fibroblasts in three rounds of 
transduction at an MOI of 1. Transduced cells were analysed for ADA protein 
expression by Western blot and flow cytometry and for functionality by the ADA 
activity assay.
The Western blot demonstrated that the patient fibroblasts did not express any ADA 
protein. The assay also revealed that high levels of ADA were expressed by 
gammaretroviral transduced fibroblasts. Normal fibroblast ADA expression was 
probably below the level of sensitivity of the test (Figure 4.4A).
Gammaretroviral transduction of fibroblasts resulted in over 20% of cells being 
transduced (Figure 4.4E) as determined by flow cytometry. Flow cytometry also 
revealed that no ADA protein was expressed by patient fibroblasts (Figure 4.4D) and 
only very low levels (0.2%) were expressed by normal fibroblasts (Figure 4.4C), 
corroborating the Western blot findings.
The gammaretroviral copy number, as determined by real time PCR analysis, was 
found to be 0.162 (Figure 4.4F). In other words, on average 1 cell in 6 carried a copy 
of the ADA transgene, reflecting the percentage transduction as determined by flow 
cytometry.
The gammaretroviral transduced fibroblasts were found to have an activity of 30,743 
nmoles/hr/mg total protein. In comparison, untransduced patient fibroblasts had an 
activity of 14.3 nmoles/hr/mg total protein and normal fibroblasts 1,756 
nmoles/hr/mg total protein (Figure 4.4 F & G). Hence, gammaretroviral transduction 
resulted in the fibroblasts having an activity 17-fold greater than that of normal. 
Therefore, although the copy number was quite low, the transductions still resulted in
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very high activity levels. The relatively low activity value of the normal fibroblasts 
suggests that ADA expression in fibroblasts is low and may explain why the ADA 
protein cannot be detected by Western blot or by flow cytometry analysis. The 
activity per transgene copy in the transduced patient fibroblasts was found to be 
189,772 nmoles/hr/mg total protein.
From these data one can ascertain that the gammaretrovirus is capable of efficiently 
transducing patient fibroblasts, resulting in high expression of the ADA protein and 
very high levels of ADA activity.
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1BR3 1,756 N/A N/A N/A
PF 14.3 N/A N/A N/A
PF+R 30,743 21.4 0.162 189,772
Patient F
Figure 4.4. Gammaretroviral transduction of patient fibroblasts (PF). The fibroblasts 
were transduced with gammaretrovirus in three rounds of transduction at an MOI of 1.
A, Western blot of untransduced (PF), gammaretroviral transduced patient fibroblasts 
(PF+R), and normal fibroblasts (1BR3). The hADA protein has a molecular weight of 
approximately 40kDa, and p-actin of approximately 42kDa. Flow cytometry plots of B, 
secondary antibody only control; C, normal fibroblasts; D, untransduced patient fibroblasts; 
E, transduced patient fibroblasts (The values in the flow cytometry plots refer to the ADA+ 
cells). F, Table depicting the activity of fibroblasts and activity per copy of 
gammaretroviral transduced fibroblasts. G, Chart displaying the activity values of the 
fibroblasts.
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4.2.4 Transduction of Patient B-LCLs
Patient LCLs were transduced with eGFP and ADA-gammaretrovirus using a similar 
protocol to that used for the fibroblasts. The aim was again to assess transduction 
efficiency by flow cytometry and ADA activity assays. Transductions of LCLs were 
assessed as ADA expression in lymphoid cells will be crucial to the success of the 
gene therapy.
LCLs were generated from patient blood by EBV immortalisation of mononuclear 
cells using standard techniques. Briefly, peripheral blood mononuclear cells were 
isolated by a ficoll density gradient from patient blood samples. The cells were then 
mixed with concentrated Epstein Barr Virus. Following immortalisation, the cells 
grew rapidly in RPMI medium in suspension, and were found to express CD 19 and 
CD45, but not CD3 as expected. Optimisation of gammaretroviral transduction of the 
LCLs was attempted by variation of several parameters, including LCL cell density, 
type of media used for transduction and viral concentration. It was determined that 
the optimal conditions were to use fibronectin coated plates, and three rounds of 
transduction with neat gammaretrovirus in X-vivo 10 and the addition of polybrene. 
The gammaretrovirus was harvested in X-vivo 10 medium to allow for the growth of 
the LCLs during the transduction, and was used at an MOI of 1 in three rounds of 
transduction every 12 hours. The cells and virus were co-localised using fibronectin, 
and viral entry into the host cell was enhanced by the use of polybrene.
Nevertheless, gammaretroviral transductions only resulted in gene transfer 
efficiencies of 6% or less using either the ADA- and eGFP-gammaretrovirus on both 
patient and normal LCLs as determined by flow cytometry (Figures 4.5A-H and data 
not shown). The inefficiency of the gammaretrovirus was confirmed by Western blot 
analysis, which did not reveal any ADA expression (data not shown). Clinical grade 
virus generated similar transduction efficiencies. The use of control eGFP 
gammaretrovirus suggested that the low efficiency of transduction was not due to a 
problem of the SFada/W virus, but a more general problem in gammaretroviral 
transduction of B-LCLs.
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Real time PCR analysis of transduced LCLs revealed that on average 1 in 10 cells 
were transduced with the ADA gammaretrovirus (Figure 4.51), although less than 5% 
were expressing high levels of ADA as determined by flow cytometry.
The gammaretroviral transduced LCLs were found to have an ADA activity of 3,594 
nmoles/hr/mg total protein. This compares with 374 nmoles/hr/mg total protein for 
patient LCLs and 6,641-8,799 nmoles/hr/mg total protein for normal LCLs (Figure 
4.51). Thus, the gammaretroviral transduced patient LCLs displayed an ADA activity 
approximately half that of normal. This is consistent with the low transduction 
efficiency obtained as determined by flow cytometry and real time PCR. The 
calculated activity value per transgene copy was 37,891 nmoles/hr/mg total protein 
per copy, five times less than the transduced patient fibroblasts.
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Cells
ADA activity 
(nmoles/hr/mg protein) % Transduction
Transgene 
Copy Number
Activity (nmoles/hr/mg 
protein) /Copy
Norm LCLs KG 6,641 N/A N/A N/A
Norm LCLs EB 8,799 N/A N/A N/A
P3 LCLs 374 N/A N/A N/A
P3 LCLs + R 3,594 3.5 0.09475 37,891
Figure 4.5. Gammaretroviral transductions of B-LCLs. The LCLs were transduced at 
an MOI of 1 in three rounds with clinical ADA or eGFP gammaretrovirus.
A-E, Gammaretroviral-ADA transductions. A, Patient 3 B-LCLs forward scatter, side 
scatter; B, secondary antibody only control. ADA expression of C, normal LCLs; D, 
untransduced patient 3 B-LCLs; E, transduced patient 3 B-LCLs.
F-H, Gammaretroviral-eGFP transductions. F, Forward scatter-side scatter plot of patient 3 
B-LCLs; G, untransduced patient 3 B-LCLs; H, transduced patient 3 B-LCLs. (B-H: The 
values in the flow cytometry plots refer to the ADA+ cells).
I, Activity of B-LCLs and activity per copy of the gammaretroviral (R) transduced patient 
3 (P3) B-LCLs. 124
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4.2.5 Optimisation of Protocol for the Transduction of CD34+ Cells
Transductions of CD34+ cells were carried out to analyse the efficiency o f the 
gammaretrovirus on these cells and to optimise the protocol for gene therapy clinical 
trials to treat ADA deficient patients. As the gammaretrovirus was inefficient at 
transducing the lymphoid population of B-LCLs, it was especially important to 
determine the transduction efficiency of the gammaretrovirus on CD34+ cells. Bone 
marrow derived or mobilised peripheral blood CD34+ cells, derived from patient or a 
healthy individual, were transduced with clinical grade ADA-gammaretrovirus. The 
five day transduction protocol was based on the procedure used in the X-SCID trial 
carried out by Gaspar et al. (2004), and included two days of pre-stimulation of the 
CD34+ cells with a cytokine cocktail to encourage the cells to divide and therefore 
improve gene transfer efficiency. This was followed by three rounds of 
gammaretroviral transductions at an MOI of 0.5 or 1 on Retronectin coated bags 
(Figure 4.6). Following transduction, cells were cultured in methylcellulose media 
for haematopoietic colony assays and a proportion of cells were kept in culture for an 
additional three days to allow expression of the ADA protein prior to analysis by 
flow cytometry (day 8 data).
The transduction of CD34+ cells was repeated four times to determine the optimal 
protocol for good gene transfer efficiency. CD34+ cell transduction protocols 
typically involve using 50:50 gammaretroviral supernatant: fresh activation media. 
However, using the ADA gammaretrovirus, this would result in an MOI of only 0.5. 
Hence, experiments were performed using 90:10 gammaretroviral supernatant: fresh 
activation media (MOI 1) to determine whether cell viability could be maintained 
using this high volume of viral supernatant. Flow cytometry analysis demonstrated 
that using the higher MOI resulted in improved transduction efficiency (Figure 
4.7A), which increased from 29.3% to 36.7% as analysed on day 8. Trypan blue 
analysis also showed that cell viability remained high at around 90% (data not 
shown).
Similar numbers of the different types of methylcellulose colonies were observed for 
both untransduced and transduced CD34+ cells (Figure 4.7B). Thus, the phenotypes 
of the progenitor cells were not altered by viral transduction and their differentiation
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capacity remained the same after transduction. These data also importantly 
demonstrate that there is no toxicity related to the transduction. PCR on the 
methylcellulose colonies revealed that approximately 50% of the colonies were 
transduced (Figure 4.7C), slightly higher than the transduction efficiency estimated 
by flow cytometry. No preferential transduction into a particular lineage was 
detected by the PCR, although this should be confirmed by repeating this experiment 
which was only performed once.
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Day 1 Day 2 Day 3 Day 4 Day 5
3. Activation of CD34+ cells 
using a cytokine cocktail 
(1% HSA, 300ng/mL hSCF, 
20ng/mL hIL-3, 300ng/mL 
hFlt-3, lOOng/mL hTPO)
Activation of CD34+ cells 
using a cytokine cocktail 
(1% HSA, 300ng/mL hSCF, 
20ng/mL hIL-3, 300ng/mL 
hFlt-3, lOOng/mL hTPO)
2. Isolation of CD34+ cells 
using anti CD34-antibody 
and the CliniMacs CD34+ 
selection procedure
1. Harvest autologous bone 
marrow from patient or 
mobilised peripheral blood 
from normal control
5. Add cells to pre­
coated bag/flask and 
add gammaretrovirus 
at an MOI of 0.5 or 
1. (Cells cultured in 
X-vivo 10 with 1% 
HSA, 300ng/mL 
hSCF, 20ng/mL hlL- 
3, 300ng/mL hFlt-3, 
lOOng/mL hTPO)
6. Second round of 
transduction at 
MOI 0.5 or 1. 
(Cells cultured in 
X-vivo 10 with 1% 
HSA, 300ng/mL 
hSCF, 20ng/mL 
hIL-3, 300ng/mL 
hFlt-3, lOOng/mL 
hTPO)
8. Cells washed thoroughly 
and returned to patient or 
analysed for ADA expression
7. Third round of 
transduction at 
MOI 0.5 or 1 for 
five hours. (Cells 
cultured in X-vivo 
10 with 1% HSA, 
300ng/mL hSCF, 
20ng/mL hIL-3, 
300ng/mL hFlt-3, 
lOOng/mL hTPO)
Figure 4.6. Protocol for transduction of CD34+ cells using a gammaretroviral vector. Based on X-SCID clinical trial reported by Gaspar et al., 2004.
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Figure 4.7. Gammaretroviral transduction of normal CD34+ cells. Activated 
peripheral blood derived CD34+ cells were transduced with clinical grade ADA 
gammaretrovirus at an MOI of 0.5 or 1 following the protocol depicted in the previous 
figure. A, Gammaretroviral transduction efficiency of normal CD34+ cells at two different 
MOIs. Day 5 is following two rounds of transduction and day 8 is following 3 rounds of 
transduction and allowing time for expression of the transgene. (The values in the bottom 
4 flow cytometry plots of days 5 and 8 refer to the ADA+ cells). B, Numbers of different 
haematopoietic colony types grown from 1,000 untransduced or transduced CD34+ cells 
(at MOI 0.5 or 1) in methylcellulose media. C, Representative PCR of methylcellulose 
colonies. M, lkb ladder. The colonies that were found to be positive were 1, 2, 5 and 6. 
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4.3 Discussion
The aim was to design a vector which efficiently transduces haematopoietic stem 
cells resulting in high expression levels of ADA, for use in gene therapy trials for 
ADA deficiency.
The gammaretroviral vector was tested on different cell types for efficiency and 
toxicity prior to transduction of the ultimate target, CD34+ cells. The vector was 
initially used to transduce patient primary skin fibroblasts. Gammaretroviral 
transduction of fibroblasts resulted in a transduction efficiency of 21.4%, increasing 
the ADA activity to 30,743 nmoles/hr/mg protein, 17-fold higher than that of normal 
fibroblasts. These high ADA activity levels were significant as this demonstrated that 
the ADA produced from the integrated gammaretrovirus was a functional enzyme. 
Real time PCR analysis revealed a transgene copy number of 0.162, equivalent to an 
average of 16.2% transduced cells. This is slightly lower than expected as real time 
PCR analysis usually gives higher estimates of transduction efficiency as a result of 
greater sensitivity of the assay system and due to some viral integrants not expressing 
the transgene. Southern blot analysis could therefore have been performed to ensure 
that there are intact viral integrations and therefore confirm the results of this and 
other real time PCR analysis in this project.
The fibroblasts were found to be stably transduced with the gammaretrovirus, as cells 
grown for more than 6 months still showed high ADA expression levels (data not 
shown). This is significant as a constant source of ADA will be required from the 
transduced cells in the gene therapy trial.
Gammaretroviral transduction of LCLs was found to be inefficient as a maximum of 
6% transduction was achieved using either the ADA or eGFP vector. However, the 
gammaretroviral transduced LCLs were found to have an ADA activity of 3,594 
nmoles/hr/mg total protein, approximately half that of normal LCLs. It is not clear as 
to why greater transduction efficiencies were not achieved as the cells were rapidly 
dividing and would be expected to be susceptible to gammaretroviral transduction, 
but it is possible that the LCLs do not express high levels of the GaLV receptor (Pit- 
1) on the cell surface for the virus to bind to. The efficiency of gene transfer seen in
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our experiments cannot be compared with several published values as many groups 
tend to use vectors expressing the Neomycin resistance gene and expand the cells in 
G418 selection media following transductions (Thrasher et al., 1992; Taylor et al., 
1996; Akatsuka et al., 2002).
The gammaretroviral vector used in our study was therefore found to efficiently 
transduce patient fibroblasts resulting in high levels of ADA expression and activity, 
but was less efficient at transducing patient haematopoietic B-LCLs. Hence, the viral 
vector was tested extensively on normal and patient CD34+ cells prior to initiation of 
gene therapy trials. The cells were pre-activated using a cytokine cocktail to induce 
cell division necessary for gammaretroviral transduction. In each experiment, the 
gammaretrovirus was found to be efficient at transducing the haematopoietic cells. It 
was found that using an MOI of 1, which involved using 90% viral supernatant, 
resulted in a transduction efficiency of 36.7% and good cell viability. It was therefore 
decided to use this MOI for the gene therapy trial. PCR of the methylcellulose 
colonies revealed transgene expressing cells in all haematopoietic subsets, 
importantly suggesting that the gammaretrovirus does not show preferential 
integration into a particular cell type. Approximately 50% of the colonies were found 
to be transduced by this method, a transduction efficiency estimate slightly higher 
than the flow cytometry results. Therefore, it is likely that the transduction efficiency 
with the gammaretrovirus is slightly higher than the 36.7% observed at an MOI of 1 
by flow cytometry.
Although slightly different transduction efficiencies have been calculated by the 
different analysis methods, it has been demonstrated that the HSCs have been 
efficiently transduced. The transduction efficiency using gammaretrovirus at an MOI 
of 1 is in the region of 35-50%. These values are in line with published figures of 
CD34+ transduction which are also in the region of 30-50% (Schilz et al., 2000; 
Pollok et al., 2001). Interestingly, the successful gene therapy trial for ADA 
deficiency by Aiuti et al., 2002a, reported that 25 and 21% transduced cells were 
reinfused into the two patients. Hence the transduction efficiencies achieved in our 
trial runs should be sufficient for therapeutic effects in ADA deficient patients.
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In conclusion, an ADA gammaretroviral vector has been generated which adequately 
transduces different cell types without causing toxicity. The clinical gammaretroviral 
vector was utilised to optimise the protocol for transduction of CD34+ cells, and was 
found to transduce these cells with good transduction efficiency and without cellular 
toxicity caused by gammaretroviral mediated expression of the ADA transgene. This 
gammaretroviral vector will therefore be used in clinical gene therapy trials for ADA 
deficiency. Hence, based on the initial results obtained for the ADA- 
gammaretrovirus, it is expected that this vector will not result in cell toxicity but will 
be efficient at transducing the CD34+ cells and generate therapeutic levels of ADA.
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5.1 Introduction
Patient 3 was enrolled in the phase I gene therapy trial, as in spite of the PEG-ADA 
treatment, his lymphocyte counts were low and his naive population of cells was 
diminishing. The gene therapy protocol was approved by the UK Gene Therapy 
Advisory Committee, the Medicines Control Agency (now Medicine and Healthcare 
products Regulatory Agency) and by the local Institutional Research Ethics 
Committee. Entry criteria were confirmation of diagnosis of ADA deficiency by 
mutation analysis or increased levels of dATP, absence of a matched related or 
unrelated donor, and lack of response to PEG-ADA treatment. Prior to initiation of 
gene therapy, written informed consent was obtained from parents following 
discussion of alternative treatment options.
A number of gene therapy trials for ADA-SCED have been performed. These studies 
have involved the ex vivo transduction of target cells, which were either autologous T 
cells, bone marrow derived CD34+ cells or umbilical cord blood CD34+ cells, with a 
gammaretroviral vector encoding the ADA transgene. If CD34+ stem cells have been 
successfully targeted, these should be capable of reconstituting the immune system 
and in so doing will allow haematopoietic detoxification. This would encourage 
production of new immune cells to protect the patient from infections without the 
need for further medication. As the gammaretrovirus integrates the ADA transgene 
into the genome of the host cell, the expression of ADA should persist long term. 
This would result in a life-long treatment for ADA deficient patients and therefore 
obviate the need for further medications or gene therapy procedures.
Aiuti et al., (2002b) demonstrated that the gradual withdrawal of PEG-ADA in a 
patient who did not show immune recovery prior to or following gene therapy, can 
result in improved immune function. Following discontinuation of PEG-ADA, the 
proportion of transduced T-lymphocytes and the absolute T cell counts increased. 
Along with an increase in PBL ADA activity, this allowed for the complete 
restoration of T cell functions. Eventually, metabolite correction was observed in 
erythrocytes, suggesting that a critical number of transduced lymphocytes may be 
required for systemic detoxification. Following these results, a successful gene 
therapy trial for ADA deficiency was performed by Aiuti et al. (2002a). Their
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protocol was carried out as described above, however, there were some significant 
differences from previous gene therapy trials for ADA-SCED. Firstly, the patients did 
not receive PEG-ADA prior to or following gene therapy, thereby creating an 
environment where the transduced cells have a selective advantage. The patients also 
received a low dose of conditioning in order to make more space for the transduced 
cells. The two patients treated with this protocol are currently doing well, showing 
immune reconstitution. Following the successful treatment of these two patients, 3 
further patients have been treated with similarly encouraging results (Aiuti et al., 
2005).
Hence, after three years of PEG-ADA therapy patient 3 was treated with gene 
therapy using the protocol developed in the previous chapter. The gene therapy 
procedure mimics that of Aiuti et al., as patients treated using this protocol have 
shown good immune recovery. We analysed in detail the immune recovery following 
gene therapy in patient 3. This patient was the first in which PEG-ADA was 
electively stopped prior to gene therapy, whereas in the study by Aiuti et al. the 
patients did not commence PEG-ADA. A number of assays were performed to assess 
the progress of patient 3: measurements of lymphocyte counts (performed by the 
Clinical Laboratory at Great Ormond Street Hospital) and dATP concentrations 
(performed by Lynette Fairbanks at the Purine Research Laboratory, Guys’ 
Hospital), immunophenotype panels by flow cytometry to analyse the production of 
naive immune cells, spectratyping (performed with the help of Stuart Adams, ICH) 
and TREC analyses (performed with the help of Doug King, ICH). The five-day gene 
therapy procedure was also assessed by flow cytometry and real-time PCR analysis 
to verify that an adequate number of cells were transduced.
5.2 Results
5.2.1 Gene Therapy Procedure for Patient 3
In order to maximise the selective advantage of transduced cells, PEG-ADA therapy 
was discontinued one month prior to gene therapy. Bone marrow was harvested on 
day -4 and the patient was then conditioned with one dose of melphalan on day -2 
(140mg/m ) to allow for maximum engraftment of the transduced cells (Appendix 2).
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CD34+ cells were isolated from patient bone marrow, activated for two days to 
induce cell division and exposed to the SFada/W virus in three rounds of 
transduction, and 13xl06 autologous cells/kg (247x106 cells in total) were then 
returned to the patient on day 5 of the procedure (refer to Figure 4.6). Throughout the 
transduction procedure, samples of cells were analysed by flow cytometry for ADA 
and CD34 expression. An aliquot of cells was also kept in culture for a further 3 days 
after the end of the transduction procedure, to allow time for expression of the 
transgene for analysis.
On day one of the transduction procedure a large proportion of the cells, 78.3%, were 
CD34 positive. This proportion of cells decreased during the procedure as the cells 
were continually activated, causing them to differentiate. On day 5, the day of the 
reinfusion of transduced cells, the proportion of CD34+ cells had decreased to 37.1%. 
A small aliquot of cells maintained in culture after the infusion of the transduced 
cells revealed that the percentage of ADA positive cells was 25.2%. Therefore, 
25.2% (3.3x106 cells/kg) of the infused cells were transduced and the percentage of 
CD34+ cells upon reinfusion was 37.1% (4.8xl06 cells/kg) (Figure 5.1). However, 
one cannot estimate the percentage of transduced CD34+ cells on the day the cells are 
returned to the patient, as the cells would not have had enough time to express the 
transgene. Hence, ADA expression is analysed on day 8, however by that time the 
CD34 expression has significantly decreased from the time the cells were reinfused. 
Thus, the percentage transduced CD34+ cells is difficult to estimate, as it is clear that 
the maintenance of CD34+ cells in activation media for an extended period of time 
decreases the expression of CD34.
Methylcellulose cultures were set up using the aliquot of cells that was kept in 
culture, and the numbers of the different colonies obtained from 1,000 plated cells 
are displayed in Figure 5.2A. The proportions of the different types of colonies are 
almost identical to both the untransduced and transduced cells in the previous 
gammaretroviral-CD34 experiment shown in Figure 4.7B. Therefore, importantly the 
phenotype of the progenitor cells does not appear to have been altered by the 
transduction procedure.
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PCR was performed on the 20 colonies that were picked (Figure 5.2B). O f these 
colonies, 7 were found to be positive resulting in a calculated transduction efficiency 
of 35%. This corroborated the transduction efficiency estimate obtained by flow 
cytometry, considering that PCR analysis would be expected to give a slightly higher 
estimate as some integrated viruses do not result in expression of the transgene. 
Therefore, the transduction efficiency was in the region of 25-35%. The colonies 
found to be positive by PCR were further analysed by real time PCR analysis, using 
p-actin as the control. This revealed that the average copy number of the transduced 
cells was 2.33 and that the copy number ranged from 1 to 4 (Figure 5.2C).
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Figure 5.1. Expression of ADA and CD34 of patient 3 haematopoietic cells during the 
gene therapy transduction procedure. Cells were maintained in activation media for two 
days prior to gammaretroviral transduction. The cells were infused into the patient on day 
5. Following the 5 day transduction procedure a small aliquot of cells were kept in culture 
for a further 3 days to allow expression of the transgene for analysis (day 8 results).
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Colony type Plate 1 Plate 2 Average
CFU-G 66 67 66.5
CFU-M 35 37 36
CFU-GM 17 19 18
CFU-E 136 166 151
BFU-E 10 9 9.5
B M 1 2 3 4 5 6 7 8 9 10 11 12 13 14
1000-
300-
% of cell population positive by FACS 25.2
% of methylcellulose colonies positive 35
Average copy number of positive colonies 2.33
Range of copy numbers 1-4
Figure 5.2. Analysis of transduced patient 3 CD34+ cells.
A, Numbers of different methylcellulose colonies. Average number of colonies observed 
from a total of 1000 plated CD34+ cells. B, PCR of methylcellulose colonies. M, lkb 
ladder, 1, CFU-E; 2, BFU-E; 3, BFU-E; 4, CFU-G; 5, CFU-G; 6, CFU-M; 7, CFU-M; 8, 
CFU-GM; 9, CFU-GM; 10, CFU-E; 11, CFU-E; 12, BFU-E; 13, BFU-E; 14, negative 
control. The colonies which were found to be positive on this gel were 2 CFU-E’s, 3 BFU- 
E’s, and 1 CFU-G (nos. 1, 2, 3, 4, 11, 12). Product size is 310 base pairs. C, Transduction 
efficiency of patient 3 CD34+ cells. Transduction efficiency was estimated by flow 
cytometry and PCR of methylcellulose colonies. Copy numbers were estimated by real­
time quantitative PCR analysis.
310 bp product
137
C h a p t e r  5
5.2.2 Analysis of Transgene Presence in Lymphocytes
Following gene therapy, it was important to determine whether the transgene was 
present in the haematopoietic lineages and whether it persisted. Patient blood 
samples regularly obtained following gene therapy were sorted by FACS into 
different cell lineages. Each cell type of interest was then analysed for the presence 
of the ADA transgene using real time PCR analysis, and an estimated copy number 
was calculated (Figure 5.3A). A graph was plotted to display the estimated copy 
number in each cell type over time (Figure 5.3B). The ADA transgene was detected 
in all cell types analysed, which were T cells, B cells, NK cells and granulocytes up 
to 16 months post gene therapy. The highest transgene copy number was found to be 
in the T cells and NK cells, which at 16 months post gene therapy was 0.528 and 
0.394 respectively. No analysis was done for B cells during 6 months when these 
cells could not be detected as a result of a treatment for an EBV infection as 
discussed in section 5.3.
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A
Cell Types 1 month 2 months 4 months 6 months 9 months 11 months 13 months 16 months
CD3 0.009 0.014 0.429 0.319 0.212 0.095 0.437 0.528
CD19 0.051 0.076 ND ND 0.038 0.047 0.019 0.077
NK ND 0.131 0.663 0.587 0.210 ND ND 0.394
Gran 0.025 0.015 0.002 0.002 0.009 0.001 0.001 ND
B
Figure 5.3. Average copy number of ADA transgene in patient 3 haematopoietic cells.
A, Copy numbers for the different cell types in the months following gene therapy as 
determined by real time PCR (each value is an average of triplicate readings). ND, not 
determined. B, Copy numbers over time (Gran, granulocytes).
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5.2.3 Analysis of Lymphocyte Counts and Metabolite Levels
Patient 3 was not responding well to PEG-ADA therapy, evident from his low 
lymphocyte counts. Following gene therapy, patient 3 had an EBV infection, 
resulting in a substantial increase in his ALC and in particular his CD8+ T cells, an 
indicator of viral infection. Analysis of the CD8+ T cells demonstrated expansion of 
a single clone (data not shown). Once the infection had cleared, his absolute 
lymphocyte count increased and has now reached a level of approximately 800 
cells/pL, slightly higher than prior to gene therapy (average normal levels are 3,300 
cells/pL for age-matched control -  see Appendix 1). Approximately 14 months post 
gene therapy, his B cells were at a level of 100 cells/pL (average normal levels are 
800 cells/pL for age-matched control -  see Appendix 1) and his CD3+ T cells at 
approximately 500 cells/pL (average normal levels are 2,300 cells/pL for age- 
matched control -  see Appendix 1) of which 150 cells/pL were CD4+ and 350 
cells/pL were CD8+ (average normal levels are 1,300 cells/pL and 800 cells/pL 
respectively for age-matched control -  see Appendix 1), and his NK cells had a value 
of 40 cells/pL (average normal levels are 400 cells/pL for age-matched control -  see 
Appendix 1) (Figure 5.4). These values have therefore significantly improved 
following gene therapy although a complete immune reconstitution has not yet been 
observed.
Prior to PEG-ADA therapy, patient 3 showed very high toxic levels of the metabolite 
dATP. However, the PEG-ADA treatment resulted in efficient removal of dATP, and 
levels which had been at 1,500 pmol/L were rapidly reduced to nearly undetectable 
levels within a few months. Throughout the PEG-ADA treatment, dATP was kept at 
a very low level. As the PEG-ADA was withdrawn prior to gene therapy, these levels 
increased slightly to approximately 100 pmol/L. However, this dATP level was not a 
true reading as the patient had been given a blood transfusion prior to this 
measurement, lowering the metabolite levels. The level of dATP would therefore 
usually be higher as a result of the withdrawal of PEG-ADA. Following gene 
therapy, the levels of dATP were slightly higher than during the PEG-ADA 
treatment. However, the dATP has been maintained at levels similar to those 
observed following bone marrow transplantations (Figure 5.5).
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Figure 5.4. Lymphocyte counts for patient 3 following gene therapy. Blood samples 
were taken at regular intervals and analysed by flow cytometry to estimate the number of 
cells per p.L of the lymphocyte subsets. The period of EBV infection and subsequent 
increased numbers of T cells were omitted from this graph to improve the clarity of the 
figure to demonstrate the trends of the lymphocyte counts.
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Figure 5.5. Patient 3 dATP levels (pmol/L) following PEG-ADA and gene therapy.
During PEG-ADA treatment, the dATP levels decreased to almost undetectable levels. 
Following gene therapy the patient has low levels of dATP, similar to what is seen post 
bone marrow transplantations.
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5.2.4 Analysis of Naive Lymphocyte Production
Following gene therapy, blood samples were obtained at regular intervals for flow 
cytometric analysis to assess the levels of naive CD45RO*CD27+ cells. Prior to gene 
therapy, this proportion of cells was declining indicating a decreased capacity to 
generate naive lymphoid cells even with the PEG-ADA treatment. At the time of 
gene therapy, this proportion of cells had decreased progressively from 17.5% to less 
than 5%. However, approximately 2 months following gene therapy, this proportion 
of cells was found to be increasing. At 9 months following gene therapy the 
CD45RO*CD27+ cells have increased to a level of 31.2% (Figure 5.6). Hence these 
data suggest that patient 3 is capable of producing naive immune cells at a level 
similar to the normal control, as a result of detoxification and recovery of thymic 
function.
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Figure 5.6. Determination of the proportion of patient 3 naive lymphocytes during 
PEG-ADA (second row of plots) and following gene therapy (third and fourth rows 
of plots). The CD45ROCD27+ population of cells represents naive lymphocytes being 
produced. PEG-ADA is discontinued at 38 months in preparation for gene therapy. The 
gene therapy procedure is carried out 1 month following the discontinuation of PEG- 
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5.2.5 Analysis of Thymic Function
Thymic activity was not detected for patient 3 during PEG-ADA treatment or indeed 
for 9 months post gene therapy, as determined by real time PCR analysis for TRECs 
in separated CD4+ and CD8+ T cells. However, 14 months following gene therapy 
TREC activity could be detected at values of 951 TRECs per one million CD8+ cells 
and 1,859 TRECs per one million CD4+ cells (Figure 5.7). Using the calculations 
described in section 3.2.3, these values equate to 468 TRECs per pg CD3+ DNA. 
Although this value is lower than TREC values observed in healthy young donors 
(approximately 4000 TRECs per pg CD3+ DNA from healthy young donors as 
reported by Talvensaari et al., 2002), thymic activity has clearly begun to recover as 
a result of gene therapy, as indicated by both the detection of TRECs and the 
increased proportion of naive lymphocytes.
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Figure 5.7. TREC values for patient 3 pre and post gene therapy. Patient blood 
samples were collected at regular intervals and CD4+ and CD8+ cells were separated using 
magnetic beads column. Real-time PCR analysis was performed on the genomic DNA to 
estimate the numbers of TRECs in the samples.
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5.2.6 Analysis of TCR Diversity
The TCR Vp-chain repertoire was analysed in CD4+ and CD8+ cells (separated using 
magnetic beads column) 5 months and 15 months post gene therapy. At 5 months 
post gene therapy the length pattern analysis of the complementary determining 
regions 3 (CDR3) in CD4+ cells revealed some oligoclonal T cell populations, 
indicating emerging diversifications of Vp-chain repertoires. At 15 months post gene 
therapy Gaussian distributions for many Vp-chain repertoires had developed. In the 
CD8+ T cells, mainly oligoclonal or polyclonal populations were present at 5 months 
post gene therapy, perhaps indicating prior antigen stimulation. However, at 15 
months post gene therapy several Vp families displayed normal patterns. Hence, at 
15 months there was a broadly diversified T cell repertoire in both CD4+ and CD8+ 
cells (Figure 5.8).
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Figure 5.8A. CD4 spectratypes for Patient 3. Patient blood samples were collected at regular intervals and CD4+ cells were separated using magnetic beads 
columns. The RNA was extracted and reverse transcribed. PCRs were performed on the samples using 24 different V(3 primers and one constant primer. A run­
off PCR was then performed and the CDR3 lengths were determined using a MegaBase sequencer machine.
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Figure 5.8B. CD8 spectratypes for Patient 3. Patient blood samples were collected at regular intervals and CD8+ cells were separated using magnetic beads 
columns. The RNA was extracted and reverse transcribed. PCRs were performed on the samples using 24 different V]3 primers and one constant primer. A run­
off PCR was then performed and the CDR3 lengths were determined using a MegaBase sequencer machine.
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5.3 Discussion
Patient 3 was treated with PEG-ADA therapy for three years, as no matched bone 
marrow donor was found. However, the immune function of patient 3 was clearly 
deteriorating, as indicated by his low lymphocyte counts and lack of thymic function. 
As his prognosis was poor, this patient was enrolled in the gene therapy study, and 
his immune recovery was examined.
Following gene therapy, patient 3 had a reactivation of a previous EBV infection. It 
is likely that with the removal of PEG-ADA and with the conditioning in preparation 
for gene therapy, the EBV infection was allowed to propagate. As it was persistent 
and difficult to clear, the patient was treated with Rituximab, an anti CD20 antibody 
that depletes the B cell population where EBV resides, which resulted in a controlled 
infection. Thus, in several methods of analyses shown the B cells were absent 
approximately 3 months to 6 months post gene therapy.
A similar gene therapy protocol to the one described by Auiti et al. (2002a) was used 
to treat patient 3. PEG-AD A was discontinued four weeks prior to gene therapy, and 
the patient received a mild non-myeloablative conditioning 2 days prior to the 
reinfusion of the cells. The removal of PEG-ADA was important as it should create a 
selective advantage to the transduced cells, and the space generated by the 
conditioning should allow for the engraftment of an increased number of gene 
modified cells. The bone marrow cells were selected for CD34+ cells which were 
transduced in a five day procedure in the presence of Retronectin. Patient 3 received 
13xl06 cells/kg, of which 25-35% were transduced. The ADA+ cells had an average 
copy number of 2.33., which corresponds well to previously published results by 
Kustikova et al. (2003). They found an average of 1.6 vector insertions per 
transduced cell for a gene transfer efficiency of less than 31.6%, 2 for 42.5% and 3 
for 52.8% in CD34+. It is important to note that the copy numbers of the transduced 
cells were low as they were in the range of 1-4 copies per cell. Low copy numbers in 
the transduced cells reduce the risk of insertional mutagenesis, which is especially 
significant in the light of the recent leukaemia cases in the Paris X-SCID trial 
(Hacein-Bey-Abina et al., 2003) (further discussed in Chapter 8).
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Following gene therapy, the transgene copy number in B cells, T cells, NK cells, 
mononuclear cells, granulocytes and CD34+ cells was estimated using real time 
quantitative PCR. The transgene was present in all cell types analysed up to 16 
months post gene therapy and the highest level of transgene copy was found to be in 
T cells and NK cells with an average level of 0.5 and 0.4 copies per cell respectively, 
16 months post gene therapy. A copy number of less than one implies that not all of 
the cells are transduced. Thus there must be a general detoxification in the 
haematopoietic system to allow for the survival of ADA' cells. Aiuti et al. (2002a) 
found slightly higher levels of transduced cells in their two patients, but similarly to 
patient 3, it was the T cells and NK cells which showed the highest level of 
transduction as they were all transduced.
Most of the lymphocyte counts, apart from CD 19 cells, have recovered following the 
withdrawal of PEG-ADA and stabilised at levels which are slightly higher to pre 
gene therapy. However, they have clearly not improved to the same extent as the 
lymphocyte counts for patients 1 and 2 who are receiving PEG-ADA. However, the 
concentration of the metabolite dATP reveals that although the lymphocyte counts 
are not normal for patient 3, there are enough ADA positive cells post gene therapy 
to maintain the dATP concentration at a level similar to post-bone marrow 
transplantations. Thus, the level of transduced cells and the level of ADA transgene 
expression can keep the haematopoietic system detoxified, which is corroborated by 
the results obtained for transgene copy numbers.
Encouraging results regarding generation of naive cells also ensued following gene 
therapy. It was shown that the low proportion of CD45RO'CD27+ cells increased 2 
months following gene therapy and has risen from 4.4% to 31.2% of CD45+ cells in 
9 months. A distinct population of CD27hlgh cells has also developed, a good 
indication of truly naive cells being produced. This suggests that some thymic 
function is recovering, supported by the detection of TREC activity for the first time 
14 months post gene therapy (However, TRECs might have been expected to be 
detected earlier as shown by Talvensaari et al., 2002.). An improvement in T cell 
diversity was also apparent at 15 months post gene therapy, as the spectratyping of 
the CDR3 revealed expected Gaussian distributions for many of the p-chain 
repertoires in both CD4+ and CD8+ cells.
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Today, patient 3 is clinically well, free of infection and thriving. Significant immune 
reconstitution has occurred 15 months following gene therapy as indicated by the 
improvement of lymphocyte counts. The dATP concentration is also maintained at a 
low level, suggesting effective detoxification from gene therapy. The increase in 
CD45RO*CD27+ cells and detection of TREC activity also indicate that thymic 
function is improving. However, his immune reconstitution has clearly not been as 
good with neither PEG-ADA nor gene therapy, as that of patients 1 and 2 with PEG- 
ADA treatment. The reasons as to why patient 3 has not showed as good an immune 
recovery are not immediately clear. Based on the number of transduced cells 
returned, patient 3 was expected to show a similar immune reconstitution to patient 1 
in the Aiuti study (2002a). Patient 1 in the Aiuti study received 8.6x106 cells/kg, of 
which 25% were transduced, and patient 2 received only 1.08xl06 cells/kg of which 
21% were transduced. Patient 1 in the Aiuti study has showed a good immune 
reconstitution, with the ALC reaching 3,500 cells/pL 20 months post gene therapy, 
however patient 2 did not reconstitute as well and has an ALC of only 400 cells/pL. 
Patient 3 in our study received 13xl06 cells/kg, of which 25% were transduced. 
However, at 14 months post gene therapy he has an ALC of only 800 cells/pL.
Therefore, although the immune function of patient 3 has clearly improved following 
gene therapy he has only showed a partial immune reconstitution, similar to that of 
patient 2 in the Italian study. Perhaps thymic recovery is compromised in older 
patients such as patient 3. It has been observed in mice that developmental arrest at 
early stages of T cell development results in severe thymic hyperplasia and thymic 
epithelial cell disorganisation (Hollander et al., 1995; Van Ewijk et al., 2000; Klug et 
al., 2002). Similarly, ADA deficient mice show severe depletion of T lymphocytes 
and defects in T cell development as a result of metabolic abnormalities affecting 
various signalling pathways that regulate T cell survival and function. Therefore, 
there may be a time dependent limit on the successful re-initiation of thymopoiesis 
(Hollander et al., 1995; Thrasher et al., 2005) and the age of the patient may be an 
important factor in the success of gene therapy. Moreover, less damage may have 
been done at a younger age as a result of a lack of immune system and possibly as a 
result of infections.
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Stem cells are the ultimate target cells of haematopoietic gene therapy as they have 
the ability to self-renew and can give rise to all cells of the immune system, therefore 
maintaining the expression of ADA in all haematopoietic cell types. However, a 
major disadvantage in using a gammaretrovirus is that it cannot infect quiescent stem 
cells. It is therefore necessary to activate the stem cells to divide, which usually 
results in differentiation. It has been previously demonstrated that extended culture 
of CD34+ cells results in lower engraftment levels in mice (Bhatia et al., 1997; 
Gothot et al., 1998; Rebel et al., 1999; Demaison et al., 2000). During the gene 
therapy transduction procedure for patient 3 the percentage of CD34+ cells was found 
to decrease, reducing the possibilities of transducing stem cells. In order to determine 
whether stem cells have been transduced integration site analysis can be performed. 
If several different cell types are found to have identical integration sites, then it is 
highly likely that they have originated from one transduced stem cell. Another assay 
that could be used is the traditional NOD-SCID mouse model, as engraftment of 
transduced cells in a secondary transplant would reveal the existence of transduced 
stem cells.
Hence it has been demonstrated that gene therapy is a good option when there is no 
matched bone marrow donor and when PEG-ADA is ineffective. The gene therapy 
trial of patient 3 can be considered a success as it was shown to be a well tolerated 
procedure, and patient 3 is now clinically well at home and thriving. He has been off 
PEG-ADA for more than one year and remains detoxified. As a result there has been 
an improvement in the immune function, although he still receives prophylactic 
immunoglubulins. A significant presence of gene modified cells has been detected in 
all cell types analysed 16 months following gene therapy. Continued follow-up of 
patient 3 will show whether he achieves complete functional recovery.
Based on the data obtained from the gene therapy trial, it will important to develop 
improved gene therapy protocols to treat ADA deficient patients. Reasons need to be 
identified as to why some previous ADA gene therapy trials have not been 
successful, such as perhaps the age of the patient at treatment and administration of 
PEG-ADA. It will also be essential to improve the transduction protocol to avoid the 
reduction in CD34 expression as seen during gammaretroviral transduction of CD34+
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cells. This could be done by identifying factors which maintain the progenitor cells 
and by decreasing the length of ex vivo culture of the CD34+ cells.
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6.1 Introduction
Using a more efficient virus such as the lentivirus as the gene delivery vehicle in 
gene therapy trials would improve the transduction efficiency of stem cells and 
shorten the time of cell culture as the lentivirus has the ability of transducing non­
dividing cells. Whereas gammaretroviruses rely on the breakdown of the nuclear 
membrane during mitosis, lentiviruses have developed a not yet fully elucidated 
mechanism of crossing the nuclear membrane to gain access to the host cell’s 
genomic DNA into which the provirus integrates. This property of the lentivirus is 
particularly useful for the transduction of quiescent haematopoietic stem cells and 
slow dividing mesenchymal stem cells. The use of lentiviral vectors to transduce 
CD34+ cells would reduce the time required for activation and the amount of 
cytokine dependence compared to gammaretroviral transductions, as lentiviruses 
only require minimal activation of stem cell division (Uchida et al., 1998; Case et al., 
1999; Miyoshi et al., 1999; Chang et al., 1999). The reduced need for activation 
allows the CD34+ cells to maintain their differentiation and engraftment potentials, 
thus maximising the possibility of haematopoietic repopulation in the patient. Hence, 
the use of lentiviruses may represent an improvement to the gene therapy protocol as 
it should result in high transduction efficiencies of both haematopoietic CD34+ cells 
and mesenchymal stem cells.
The lentiviral vector used in our study is a second generation vector, whose env gene 
has been replaced by the surface glycoprotein of the vesicular stomatitis virus (VSV- 
G) (refer to figure 1.7 -  backbone generated by Christophe Demaison). This 
envelope binds a receptor in the phospholipid bilayer of the cytoplasmic membrane 
of both vertebrates and invertebrates, and therefore confers a broad host range 
(Schlegel et al., 1983; Marsh & Helenius, 1989). The pseudotyping of a lentiviral 
vector with VSV-G therefore alters its tropism from CD4+ T cells and macrophages, 
to a broader host range. Importantly, pseudotyping with VSV-G also increases the 
stability of the viral particle, enabling ultracentrifugation and repeated ffeeze-thaw 
cycles without the loss of viral titre (Bums et al., 1993; Ory et al., 1996). A clear 
advantage of the ability to concentrate the vims pseudotyped with VSV-G is that one 
can use a high MOI for transduction. However, VSV-G has been associated with 
some cytotoxicity due to its fusogenic properties, limiting the concentration of vector
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that can be used. This toxicity has also hindered the development o f lentiviral 
packaging cell lines that pseudotype the vector with VSV-G.
The lentivirus used in this study has the safety feature of being a self-inactivating 
(SIN) vector where a 400 base pair deletion has been introduced in the U3 region of 
the 3’ LTR used to produce the vector RNA (Zufferey et al., 1998). During reverse 
transcription this deletion is transferred to the 5’ LTR, resulting in the creation of an 
inactive 5’ LTR which prevents the synthesis of full-length vector RNA in 
transduced cells, and the expression of the transgene is instead driven by the internal 
promoter. This reduces the number of active promoters from two (the 5’ and 3’ 
LTRs) to one (the internal promoter). The introduction of this mutation also 
eliminates the LTR promoter activity without affecting the viral transduction 
efficiency or transgene expression in vitro. SIN vectors with internal promoters, 
instead of LTR driven vectors, are thought to reduce the risk of activating 
neighbouring genes, thus minimising the risk of insertional mutagenesis. It is also 
thought that the risk of producing replication competent lentivirus will be reduced. 
Hence this modification is thought to be another step to achieve greater biosafety of 
the lentiviral vector.
The lentivirus used contained the cPPT element, important in the process of crossing 
the nuclear membrane, thus increasing the transduction efficiency of the virus by its 
ability to transduce quiescent cells (Zennou et al., 2000; Sirven et al., 2000; 
Demaison et al., 2002; Manganini et al., 2002). Similarly to the gammaretroviral 
vector, the lentivirus also carried the SFFV promoter and the WPRE.
Therefore, the principal aim was to construct an ADA lentiviral vector, to test its 
efficiency in different cell types and to ensure that the lentiviral mediated expression 
of ADA transgene does not have a toxic effect on the cells. Once this had been 
confirmed, the lentiviral vector was used to transduce CD34+ cells and in the 
following chapter to transduce mesenchymal stem cells as possible target cells for 
gene therapy of ADA deficiency.
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6.2 Results
6.2.1 Generation of Lentiviral Vectors
The lentiviral construct, pHR.sin.cPPT.SAW, was generated, incorporating the SFFV 
promoter, human ADA cDNA and the WPRE (Figure 6.1 A). The pBS-SAW vector 
was digested with EcoRl and Kpnl to release the SAW fragment, which was inserted 
into the lentiviral backbone.
The eGFP-lentiviral DNA construct (pHR.sin.cPPT.SEW) was kindly provided by 
Dr Kate Parsley, ICH. It consisted of the same backbone and elements as the ADA- 
lentivirus, but rather than encoding ADA, it encoded the eGFP transgene (Figure 
6.1B).
Lentivirus was generated by the transient transfection of 293T cells. The viral 
supernatant was harvested 48 and 72 hours following the transfection, and was then 
titred on HeLa cells in a similar manner to how the gammaretrovirus was titred. The 
viral titre for ADA-lentivirus was approximately 2xl08 transducing units/ mL, and 
for eGFP lxlO9 transducing units/mL.
157
C h a p t e r  6
WPRE LTR-HIVdelU3
ADA
ampiciliin resistance gene
3' LTR SFFV 
cPPT 
3-splice site
pHR’SINcPPT-SAW
10146 bp
rep on
SV40 promoter-enhancerRRE-Rev responsive element
gag (ORF-disrupted)
5-splice site gpt (OFR-frame shift)
LTR HIV-1
B
WPRE LTR-HIVdelU3
eGFP
3' LTR SFFV ampiciliin resistance gene
cPPT 
3'-splice site
pHR'SINcPPT-SEW
9789 bp
RRE-Rev responsive element rep ori
SV40 promoter-enhancer 
gpt (OFR-frame shift)
gag (ORF-disrupted) 
5’-splice site
LTR HIV-1
Figure 6.1. Lentiviral constructs.
A, Vector map of the lentiviral ADA construct. The lentiviral vector incorporates the SFFV 
promoter driving the transcription of ADA, whose expression levels are enhanced by the 
WPRE; B, Vector map of the lentiviral eGFP construct. This vector, similarly to the ADA 
lentiviral vector, carries the SFFV promoter and the WPRE element.
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6.2.2 Lentiviral Transduction of Patient Fibroblasts
To test the efficiency of the lentiviral vector, patient primary skin fibroblasts were 
transduced with ADA-lentivirus in one round of transduction, using an MOI ranging 
from 0.1 to 30. The cells were then analysed for protein expression by Western blot, 
for transduction efficiency by flow cytometry, for ADA enzyme functionality by the 
activity assay and copy number by real time quantitative PCR analysis.
The patient fibroblasts were efficiently transduced with the lentiviral vector, resulting 
in high levels of ADA expression as seen in the Western blot analysis (Figure 6.2A). 
The lentiviral transduced fibroblasts resulted in a strong band in the Western blot in 
comparison to equivalent numbers of gammaretroviral transduced fibroblasts as 
determined by the P-actin expression levels.
Flow cytometry results clearly displayed the transduction efficiencies obtained by the 
lentiviral transductions at different MOIs. In comparison to normal fibroblasts, of 
which 1% express some levels of ADA (Figure 6.2C), a large proportion of the 
lentiviral transduced cells expressed high levels of ADA. The patient fibroblasts did 
not express any ADA (Figure 6.2D), but once transduced the percentage of cells 
expressing ADA increased to 3.1% at an MOI of 0.1, 8.3% - MOI 0.5, 42.1% - MOI 
1, 50.6% - MOI 10 and 95.2% at an MOI of 30 (Figures 6.2E-I). As a result o f these 
transductions, the mean fluorescence intensity shifted from 130 at an MOI of 1 to 
310 at an MOI of 10 and to 3300 at an MOI of 30.
The lentiviral transductions gave rise to large increases in ADA activity of the 
fibroblasts. The patient fibroblasts displayed minimal ADA activity -  14.3 
nmoles/hr/mg protein. This activity level increased greatly to 6,017 at the low MOI 
of 0.1, 17,701 at an MOI of 0.5 and to 3,824,521 nmoles/hr/mg total protein at an 
MOI of 30 (Figures 6.3A and B). These values are very high in comparison to 
normal fibroblast activity of 1,756 nmoles/hr/mg total protein. Lentiviral 
transduction therefore resulted in activity levels several folds higher than that found 
in normal fibroblasts. At an MOI of 0.1, the activity levels were 3.4 times the amount 
of normal activity levels of fibroblasts, at an MOI of 0.5, 10 times the normal activity
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levels and at an MOI of 30, more than 2000 times greater than normal activity levels 
of fibroblast.
As expected, the copy numbers (average number of ADA transgene copies per cell) 
observed in the transduced fibroblasts increased with the increase in MOI. 
Transductions at an MOI of 0.1 resulted in a copy number of 0.0258, transductions at 
an MOI of 0.5 resulted in a copy number of 0.0968, and transductions at an MOI of 
30 resulted in a copy number of 8.49 (Figure 6.3A). From these values one can 
determine the average level of enzyme activity produced per transgene copy. This 
was found to be approximately 200,000 nmoles/hr/mg protein per copy for the MOIs 
of 0.1 and 0.5, but as much as 450,000 nmoles/hr/mg protein per copy for the MOI of 
30 (Figure 6.3A).
Therefore, the lentiviral construct generated in this study efficiently transduced 
fibroblasts and reconstituted ADA expression and activity.
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A PF PF+R PF+L IBR3
p-Actin
ADA
Figure 6.2. Lentiviral transductions of fibroblasts. The patient fibroblasts were 
transduced with the ADA lentivirus at MOIs ranging from 0.1 to 30.
A, Western blot depicting untransduced fibroblasts (PF), gammaretroviral transduced 
patient fibroblasts (PF+R), lentivirally transduced patient fibroblasts MOI 30 (PF+L) and 
normal fibroblasts (1BR3). B-H, Flow cytometry plots depicting the transduction efficiency 
of the lentiviral vector at MOIs ranging from 0.1 to 30. B, Secondary antibody only control; 
C, normal fibroblasts; D, patient fibroblasts; E, MOI 0.1; F, MOI 0.5; G, MOI 1; H, MOI 
10; I, MOI 30. (The values in the flow cytometry plots refer to the ADA+ cells).
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A
Cells
ADA activity 
(nmoles/hr/mg protein)
%
Transduction
Copy
Number
Activity
(nmoles/hr/mg
protein)/Copy
Norm F 1,756 N/A N/A N/A
Patient F 14.3 N/A N/A N/A
PF  +lenti ADA MOI 0.1 6,017 3.1 0.0258 233,232
P F + lenti ADA MOI 0.5 17,701 8.3 0.0968 182,865
P F + lenti ADA MOI 30 3,824,521 97.2 8.49 450,633
B
4,000,000
20,000
10,000 H 6,017
1756 14.3 r------- ,
17,701
3,824,521
Norm F Patient F P F  + lentiADA P F + lenti ADA P F  + lentiADA
MOI 0.1 MOI 0.5 MOI 30
Figure 6.3. ADA activity values and copy numbers in fibroblasts following 
transductions with ADA-lentivirus. Fibroblasts transduced with the ADA-lentivirus at 
MOIs 0.1,0.5 and 30 were analysed for activity and copy number.
A, ADA activity per copy of the lentivirally transduced fibroblasts. (N/A -  not applicable)
B, Activity values of fibroblasts.
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6.2.3 Lentiviral Transductions of Patient B-LCLs
LCLs were generated from blood samples of patients 1 and 3. The cells were 
transduced with the lentiviral vector, using an MOI of 15 in one round of 
transduction, without the use of fibronectin or polybrene. The transduced cells were 
then analysed for protein expression, copy number and activity levels.
The Western blot analysis revealed a large increase in ADA expression of lentiviral 
transduced patient 1 LCLs. In comparison, two normal LCLs showed only low levels 
of ADA expression from an equivalent amount of cells as determined by the p-actin 
expression (Figure 6.4A).
Transductions of patient LCLs demonstrated that the lentivirus was very effective, 
resulting in transduction efficiencies of between 55 and 70% (Figures 6.4E and F).
Activity results were consistent with the flow cytometry results obtained. The 
lentiviral transduced patient LCLs displayed activity levels of 64,017 and 155,430 
nmoles/hr/mg protein (Figure 6.4G & H). This is equivalent to an ADA activity 7-20 
fold greater than that of normal LCLs. The activity levels per copy of transgene were 
in the region of 16-30,000 nmoles/hr/mg protein per copy (Figure 6.4G), much lower 
than the values seen for the transduced fibroblasts (6-27 fold lower). Therefore, the 
lentivirus efficiently transduced patient LCLs, increasing the ADA expression and 
activity.
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p-actin
Cells
ADA activity 
(nmoles/hr/mg protein) % Transduction Copy Number
Activity (nmoles/hr/mg 
protein)/Copy
Normal LCLs KG 6,641 N/A N/A N/A
Normal LCLs EB 8,799 N/A N/A N/A
Patient 3 LCL 374 N/A N/A N/A
Patient 3 LCL + retro ADA 3,594 3.5 0.09475 37,891
Patient 3 LCL + lenti ADA 64,017 55.5 3.870 16,542
Patient 1 LCL 313 N/A N/A N/A
Patient 1 LCL + lenti ADA 155,430 70 5.09 30,536
H _  180,000 
I  160,000
i .  140,000
I* 120,000
1 100,000
i  80,000
1  60,000
I '  40,000
Z 20,000 
< 0
Normal Normal P3 P3+ P3 + P1 P1 + 
KG EB retro lenti lenti
Figure 6.4. Lentiviral transduction of patients’ B-LCLs. LCLs were transduced with 
the ADA lentivirus at an MOI of 15.
A, Western blot depicting ADA expression in LCLs. PI and P3, patient LCLs; Pl+1, 
lentiviral transduced patient LCLs; N1 and N2, normal LCLs.
B-F, Flow cytometry plots displaying the transduction efficiency of lentiviral transduction 
of patient LCLs. B, Secondary antibody only control; C, Normal LCLs; D, untransduced 
patient 3 LCLs; E, lentiviral transduced patient 3 LCLs; F, lentiviral transduced patient 1 
LCLs. (The values in the flow cytometry plots refer to the ADA+ cells).
G, Activity values and copy numbers for the two patient LCLs. (N/A -  not applicable)
H, ADA activity values of the transduced patient LCLs in comparison with normal LCLs.
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6.2.4 Lentiviral Transductions of CD34+ cells
CD34+ cells were cultured in activation medium and transduced with the lentivirus at 
MOIs 1, 10 or 30 without pre-activation. Unlike transductions with gamma- 
retroviruses, no fibronectin or Retronectin was used. The medium was changed 24 
hours following the transduction, and the cells were incubated for a further 2 days to 
allow expression of the transgene prior to analysis. Following the medium change, 
1000 cells were cultured in methylcellulose medium to allow the growth of 
haematopoietic colonies.
eGFP lentivirus was used as a control vector to assess gene transfer efficiency of 
CD34+ cells. Flow cytometry analysis revealed that the cells were 49.3% transduced 
using an MOI of 30 (Figure 6.5G) and no toxicity was observed as determined by 
trypan blue analysis (data not shown). The lentiviral-eGFP transduced CD34+ cells 
were cultured in methylcellulose medium, and the percentages of eGFP positive 
colonies observed were as follows:
Erythroid cells: 53% transduced 
Myeloid cells: 26% transduced
ADA lentivirus was then used to transduce CD34+ cells. Flow cytometric analysis 
showed that 9.8% of the cells were transduced at an MOI of 1, 41.7% of the cells 
were transduced at an MOI of 10, and 53.4% of the cells were transduced at an MOI 
of 30 (Figures 6.5D-F). Untransduced cells and cells transduced at the varying MOIs 
proliferated well, and the cell numbers at all conditions doubled or tripled in four 
days. No toxicity of the transduced cells was observed, as determined by trypan blue 
analysis (data not shown).
Analysis of the methylcellulose colonies revealed that similar proportions of each 
colony type were observed for cells of each transduction condition and untransduced 
cells (Figure 6.5H). However this experiment, which was only performed once, 
should be repeated to confirm that the progenitor cell phenotype has not been altered 
by the transduction procedure. It was found by PCR that at an MOI of 1, 1 CFU-E 
colony was positive for the ADA transgene. An MOI of 10 gave rise to 2 CFU-G, 3 
CFU-M, 1 CFU-GM, 2 CFU-E and 3 BFU-E transduced colonies. An MOI of 30
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gave rise to 3 CFU-G, 4 CFU-M, 4 CFU-GM, 4 CFU-E and 2 BFU-E transduced 
colonies (Figure 6.51).
Real-time PCR analysis was performed on colonies grown from ADA-lentiviral 
transduced CD34+ cells (Figures 6.6A and B). Average copy number per cell was 
calculated using P-actin as a standard. The range of copy numbers and the average 
copy number of the transduced colonies increased with increasing MOIs. The 
following copy numbers were observed: cells transduced at an MOI of 1 had an 
average copy number of 1.5, cells transduced at an MOI of 10 had a range of copy 
numbers of 1-10, and an average copy number of 3.77, and cells transduced at an 
MOI of 30 had a range of copy numbers of 1-18, and an average copy number of 
5.89 (Figure 6.5J).
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0%
0
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41.7%
FL1
■  Un transduced
■  MOI 1
□  MOI 10
□  MOI 30
■  GFP MOI 20
CFU-M CFU-CH4M
ft! = 49.3%
eGFP
Colony type MOI 1 MOI 10 MOI 30 Retro
CFU-G 2 3 1
CFU-M 3 4
CFU-GM 1 4
CFU-E 1 2 4 2
BFU-E 3 2 3
Transduction efficiencies MOI 1 MOI 10 MOI 30 Retro
Average copy number o f positives 1.52 3.77 5.89 2.33
Range o f copy numbers 1.52 1-10 1-18 1-4
% positive by FACS 9.8 41.7 53.4 25.2
% positive by PCR o f me 5 55 85 30
Figure 6.5. Lentiviral transductions of CD34+ cells. CD34+ cells were activated by a 
cytokine mix and transduced with ADA or eGFP lentivirus at MOIs ranging from 1 to 30.
A-G, Flow cytometry plots displaying the transduction efficiency of the lentiviral vector at 
different MOIs. A-F, ADA-lentiviral transduced cells. A, forward scatter side scatter plot 
reveals the viable population of cells which is gated; B, secondary antibody only control; 
C, untransduced CD34s; lentiviral transduced CD34s at an MOI of D, 1; E, 10; and F, 30. 
(A-F: The values in the flow cytometry plots refer to the ADA+ cells). G, Lenti-eGFP 
transduced cells, MOI 30 (The values in the flow cytometry plot refers to eGFP+ cells)..
H, Numbers of colony types for the different transduction conditions. For each condition, 
1000 cells were cultured in methylcellulose.
I, Types of colonies transduced by the lentivirus.
J, Copy numbers of the transduced colonies, assessed by real time quantitative PCR; me, 
methylcellulose colonies. 167
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Figure 6.6. Real time PCR analysis of lentiviral transduced CD34+ cells. Transduced 
CD34+ cells were analysed for (A) the ADA transgene and (B) for p-actin.
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6.3  D is c u s s io n
A lentiviral vector expressing the ADA transgene was generated and tested on 
different target cells, as a possible improved gene transfer vehicle. As with the 
gammaretrovirus, elements included in the lentivirus were selected on the basis of 
optimising transduction efficiency and achieving high levels of ADA transgene 
expression. The ADA-lentivirus generated was a SIN vector, thought to represent a 
safer vector system as there are reduced numbers of functional promoters. However, 
it has recently been shown that the lentiviral SIN vectors display as much 
transcriptional read-through as gammaretroviral vectors (Zaiss et al., 2002), thus 
increasing the risk of activating oncogenes. This will clearly need to be further 
investigated prior to the use of SIN vectors in the clinic as the risk of insertional 
mutagenesis needs to be minimised.
The transduction efficiency of the ADA-lentiviral vector generated was assessed on a 
variety of cells and the transduced cells were analysed for toxicity related to the viral 
transduction. The ultimate target cells were CD34+ haematopoietic stem cells and 
mesenchymal stem cells (discussed in Chapter 7) to assess the possibility of their use 
in gene therapy trials for ADA deficiency.
The efficiency of the ADA-lentiviral vector was initially tested on patient fibroblast 
cells, as the reconstitution of ADA expression and activity should be apparent in 
these ADA null cells. Gammaretro- and lentiviruses transduced fibroblasts at a 
similar efficiency when using the same MOI. The fibroblasts were transduced three 
times at an MOI o f 1 with the gammaretrovirus, resulting in a transduction efficiency 
of 21.4%. At similar MOIs of 1 and 10, the lentivirus achieved transduction 
efficiencies of 42.1% and 50.6% respectively. However, a high concentration of the 
gammaretrovirus could not be obtained as the GALV envelope does not allow 
ultracentrifugation, thought to be due to structural characteristics of the envelope 
protein. In contrast, the VSV-G envelope confers stability to the viral particle, 
allowing the lentivirus to be concentrated by this method so that high MOIs can be 
achieved. Hence using the lentivirus at an MOI of 30, 95.2% of the cells were 
transduced. The MFI also increased significantly with transductions at high MOIs.
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It is important for the treatment of ADA deficient patients that the expression of 
ADA is maintained as it is an enzyme which is ubiquitously expressed throughout 
life. ADA expression was therefore measured by flow cytometry in both the 
gammaretroviral and lentiviral transduced patient fibroblasts shortly after 
transduction and after a period of time. Both gammaretroviral and lentiviral 
transgene expressions were found to be stable as the percentage of ADA expressing 
cells remained the same following 6 months of culture (data not shown).
The activity values of the transduced fibroblasts were found to be very high. Normal 
fibroblasts had an activity of 1,765 nmoles/hr/mg protein. Gammaretroviral 
transductions resulted in an activity value of 30,743 nmoles/hr/mg protein, 17-fold 
that of normal fibroblasts. Lentiviral transductions at MOIs 0.1 (3.1% transduced), 
0.5 (8.3% transduced) and 30 (95.2% transduced) resulted in activities of 6,017 
nmoles/hr/mg protein, 17,701 nmoles/hr/mg protein, and 3,824,521 nmoles/hr/mg 
protein respectively. These activity values are equivalent to 3-fold, 10-fold and over 
2000-fold the activity levels of normal fibroblasts. Although fibroblasts are not the 
ultimate target cells in gene therapy, these results suggest that low MOIs with 
lentiviral vectors should be sufficient to restore ADA expression and activity in 
patient cells. The activity in lentiviral transduced cells per transgene copy was found 
to be in the region of 200-400,000 nmoles/hr/mg protein per copy, similar to that of 
the gammaretroviral transduced fibroblasts which had a value of nearly 200,000 
nmoles/hr/mg protein per copy. Thus, each copy of gammaretroviral and lentiviral 
vector results in similar amounts of ADA activity.
The greater gene transfer efficiency of the lentiviruses compared with 
gammaretroviruses was made apparent by the transductions of patient LCLs. 
Gammaretroviral transductions of LCLs resulted in very low transduction 
efficiencies in the region of 5%, using an MOI of 1 for each of the three rounds of 
transductions and the assistance of both fibronectin and polybrene. However, 
lentiviral transductions of the same cells gave rise to 60-70% transduced cells using 
an MOI of 15 in one round of transduction and no fibronectin or polybrene. These 
transduction efficiencies appear to be higher than published figures of 17-31% using 
an MOI of 5-10 (Bovia et al., 2003).
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The expression of ADA in lentiviral transduced LCLs was again importantly found 
to be stable as LCLs grown for more than three months showed the same percentage 
transduction as determined by flow cytometry.
Lentiviral transductions resulted in vast increases of ADA activity of patient B-LCLs 
from approximately 300 to 64,017-155,430 nmoles/hr/mg protein. This corresponded 
to activity levels 7-20 fold greater than the levels observed in normal LCLs. Hence, 
lentiviral transductions reconstituted ADA expression and activity in patient B cells 
which should be sufficient to eliminate the toxic ADA substrates of these cells.
The ADA activity per copy of transgene in the lentiviral transduced LCLs was found 
to be in the region of 15,000-30,000 nmoles/hr/mg protein per copy. These values are 
similar to those of the gammaretroviral transduced LCLs which had an activity of 
nearly 40,000 nmoles/hr/mg protein per copy. However, the activities per copy in the 
LCLs are significantly lower (6-27 fold lower) than those observed in the transduced 
fibroblasts, which were found to be 200,000-450,000 nmoles/hr/mg protein per copy. 
Thus, although the gammaretroviral and lentiviral-ADA have integrated into the 
genome of the LCLs they may not be expressing the ADA protein, or the ADA 
enzyme expressed does not exhibit any activity. Low levels of protein expression 
could be due to promoter shut-off in the LCLs. However, if it is the case that the 
enzyme is expressed but not functional, this could be as a result of different post- 
translational modifications in the different cell types.
Although lentiviral vectors can transduce quiescent haematopoietic progenitors 
(Miyoshi et al., 1999; Woods et al., 2000; Sirven et al., 2001), they have been found 
to be more efficient at transducing CD34+ cells which are in Gi or actively cycling in 
G2/S/M (Sutton et al., 1999). Therefore, a cytokine mix is added to the cultured cells 
in order to induce proliferation and improve gene transfer efficiency. However, the 
concentrations of cytokines used are lower than those for the gammaretrovirus, and 
no pre-activation of the cells is required. The lentiviral vector efficiently transduced 
CD34+ cells at MOIs lower than 30. An MOI of 1 resulted in 9.8% transduced cells, 
MOI of 10, 41.7% transduced cells and an MOI of 30 resulted in 53.4% transduced 
cells. These are similar to the transduction efficiencies observed with the LCL, and to 
the gammaretroviral transductions of CD34+ cells, where three rounds of
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transductions at an MOI of 1 resulted in a transduction efficiency of approximately 
25%. It is therefore advantageous to use lentiviral vectors to transduce CD34+ cells 
mainly for the reason that limited activation is needed so that the cells do not need to 
be cultured ex-vivo for long periods of time, and the CD34 expression should 
therefore remain high. Hence, this experiment needs to be repeated to assess the 
CD34 expression levels following lentiviral transductions, and NOD/SCID 
engraftment studies of gammaretroviral and lentiviral transduced CD34+ cells would 
need to be carried out to confirm this hypothesis. Previous studies have demonstrated 
that the culture of CD34+ cells with cytokines results in reduced repopulation ability 
of these cells (Bhatia et al., 1997; Gothot et al., 1998; Rebel et al., 1999; Demaison 
et al., 2000 & 2002). Thus, engraftment studies are necessary to confirm whether a 
shorter transduction procedure using the ADA lentiviral vector would be beneficial.
Methylcellulose haematopoietic colony assays of ADA-lentiviral transduced CD34+ 
cells revealed that the transduction procedure did not affect the proportions of 
different progenitors as untransduced and transduced CD34+ cells gave rise to similar 
numbers of each colony type. It was found by PCR for the ADA transgene that all 
cell types have been transduced, and thus the lentivirus shows no preferential 
transduction of a particular cell type. This lack of preferential transduction is 
advantageous as the ideal target cell is an earlier progenitor cell, capable of self- 
renewal and differentiation into all haematopoietic lineages.
Real time PCR analysis of methylcellulose colonies also gave rise to some very 
interesting results. As each colony is derived from a single cell, this type of analysis 
can estimate the actual number of transgene copies in one transduced cell. This 
analysis showed that with increasing MOI, not only did the percentage of transduced 
cells increase, but the average copy number per cell increased as well. This is likely 
to be due to the fact that the cells which are easily transduced have already been 
infected, and increasing the amount of virus simply results in the extra virus infecting 
the same easily transducible cells rather than infecting other cells which are perhaps 
not dividing. Therefore, increasing the MOI from 1 to 10 increased the average copy 
number from 1.52 to 3.77, and increasing the MOI to 30 further increased the 
average copy number to 5.89. Gammaretroviral transduction resulted in a similar 
copy number (2.33), using an MOI of 1 in three rounds of transduction. Therefore, a
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maximum MOI of less than 10 should probably be used in gene therapy trials with 
lentiviral vectors, as many integrated copies in each cell is not desired as it may 
increase the chance of insertional mutagenesis.
It has therefore been demonstrated that the constructed ADA lentiviral vector 
efficiently transduces several different cell types resulting in high levels of ADA 
expression and activity likely to be sufficient for detoxification, in the absence of 
cytotoxicity caused by lentiviral mediated expression of ADA transgene.
Gammaretro- and lentiviral vectors both have several advantages as gene transfer 
vehicles for ADA gene therapy. They both have a packaging capacity large enough 
for the ADA transgene, they do not exhibit vector induced immune responses, and 
crucially are integrating vectors resulting in long-term expression of the transgene. 
Gammaretroviral vectors are not naturally human pathogens like the HIV-1 
lentivirus, and did therefore not have as many problems to reach clinical trials. In 
fact, gammaretroviral vectors have been used extensively in many gene therapy 
trials, and as a result there is plenty of experience with the use of this vector. 
Packaging cell lines have been generated for gammaretroviral vectors, advantageous 
due to their ease of use and the consistent titre achieved, as well as the reduced risk 
of recombination to generate replication competent retrovirus. Packaging cell lines 
are currently also being developed for lentiviral vectors, however, this has been 
hindered by the toxicity of the VSV-G envelope to the producer cells. Inducible 
promoters were investigated so that the VSV-G would not be constitutively 
expressed in the cell line (Kafri et al., 1999; Klages et al., 2000; Ni et al., 2005), 
however viral production could still only be maintained for a few days due to 
cytotoxicity. Alternative envelopes may therefore need to be studied, such as RD114, 
a feline endogenous retrovirus envelope. Similarly to VSV-G, pseudotyping with 
RD114 allows ultracentrifugation of the virus and in addition is stable in human 
serum. However, virus pseudotyped with RD114 cannot transduce murine cells and 
therefore limits its use in the laboratory for pre-clinical testing. Hence, one 
disadvantage with the use of lentivirus pseudotyped with VSV-G is that a packaging 
cell line has not been generated.
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Therefore, both gammaretroviral and lentiviral vectors have several advantages for 
use in gene therapy. However, the efficiency of transduction of lentiviral vectors 
makes it particularly well suited for the transduction of several cell types, including 
the quiescent CD34+ stem cells and mesenchymal stem cells which will be 
investigated in the following chapter.
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7.1 In t r o d u c t io n
ADA-SCED is a multi-organ disease, resulting in immunodeficiency as well as non- 
immunological abnormalities. Non-immunological symptoms include skeletal 
abnormalities (Cederbaum et al., 1976) and liver problems (Bollinger et al., 1996) as 
well as neurological abnormalities (Hirschhom et al., 1980; Tanaka et al., 1996; 
Rogers et al., 2001; Albuquerque & Gaspar, 2004). Bone marrow transplantations 
and gene therapy using CD34+ haematopoietic stem cells or peripheral blood T cells 
may result in improved immunological function without necessarily correcting the 
non-immunological symptoms. Hence, gene therapy using HSCs in combination with 
MSCs may be an alternative to the use of HSCs alone and could offer a more 
systemic treatment for ADA deficiency.
MSCs were isolated, and their multipotential nature was analysed prior to and 
subsequent to viral transductions, exploring the possibility of their use as therapeutic 
targets in clinical gene therapy trials. MSCs form part of the non-haematopoietic 
environment in the bone marrow, and are readily isolated by ficoll gradient 
centrifugation followed by plastic adherence. They display a fibroblast-like 
morphology, but have a different expression pattern to fibroblasts, which are mature 
mesenchymal cells not capable of differentiation. MSCs have been reported to 
differentiate into several different cell types of the mesenchymal and non- 
mesenchymal lineage, including adipocytes, osteocytes, chondrocytes, myocytes and 
neuronal cells (Piersma et al., 1983 & 1985; Howlett et al., 1986; Friedenstein et al., 
1987; Mardon et al., 1987; Owen & Friedenstein, 1988; Keating et al., 1990; 
reviewed by Caplan, 1991; Haynesworth et al., 1992; Beresford et al., 1992; Cheng 
et al., 1994.; Rickard et al., 1994; reviewed by Clark & Keating, 1995; reviewed by 
Prockop, 1997; Pittenger et al., 1999). Therefore, as gene delivery vehicles, MSCs 
should be very useful in the treatment of ADA deficiency by offering a systemic 
delivery of ADA. Hence, it is hoped that the homing of the ADA+ MSCs to the areas 
of need in the body, and the differentiation of the ADA+ HSCs into all cells of the 
haematopoietic system, could lead to a more complete treatment for ADA deficiency 
than previous gene therapy trials using T cells or CD34+ cells alone. Moreover, 
MSCs have been reported to provide support for the haematopoietic stem cells upon 
transplantation (Dexter & Testa, 1976; Dexter et al., 1977; Gartner & Kaplan, 1980;
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Eaves et al., 1991; Otsuka et al., 1991; Kittler et al., 1992; Quesenberry & Lowry, 
1992; reviewed by Sutherland et al., 1993; reviewed by Deryugina & Muller- 
Sieburg, 1993; Gordon et al., 1996), which would be ideal in the case of gene 
therapy using both HSCs and MSCs. Majumdar et al., 1998, observed that MSCs 
expressed cytokines that act on haematopoietic cells, maintaining and supporting 
differentiation of purified CD34+ cells. Reports have also been published which 
show that co-transplantation of MSCs and HSCs improve haematopoietic 
engraftment following BMT in animal models (Nolta et al., 1994 & 2002: Brouard et 
al., 1998; Noort et al., 2002; Bensidhoum et al., 2004) and in humans (Koc et al., 
1999, 2000; reviewed by Koc & Lazarus, 2001). However, the exact identity o f the 
cells capable of supporting HSCs is still being debated (reviewed by Minguell et al., 
2001). Therefore, as MSCs are thought to be a heterogeneous population of cells, 
more studies are required to assess the effect of isolation procedure and culture 
conditions on the growth of specific cell types, and to determine which cell type is 
best suited for engraftment and haematopoiesis support.
Therefore, the aim was to generate human MSCs and to confirm the multipotential 
nature of the cells. It is vital that the MSCs have a broad differentiation potential and 
that this remains following transduction. Therefore, the differentiation potential will 
be assessed prior to and following transduction with lentiviral vectors. It will be 
particularly important to establish whether the MSCs can differentiate into neurons, 
as it is hoped that neurological symptoms observed in ADA deficient patients can be 
improved by administering ADA-lentiviral transduced autologous MSCs. It will also 
be important to investigate the ability of MSCs to home to different organs in a 
xenotransplant animal model as this may predict how the MSCs will home in the 
patient. There are certain organs which are particularly important to target, including 
the liver and the brain which have displayed abnormalities in ADA deficient patients. 
Thus, the homing abilities of MSCs will be assessed in a NOD/SCID mouse model. 
This mouse was first used to assay human cell reconstitution by Lapidot et al. in 
1992. In this model, the SCID mutation has been transferred onto a diabetes- 
susceptible Non-Obese Diabetic background. Animals homozygous for the SCID 
mutations experience a block in T and B-cell lymphocyte development (Schuler et 
al., 1986) and they also have impaired NK cell and macrophage cell function, and 
lack complement activity (Schultz et al., 1995). The multiple defects in immunity
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unique to this model provide an excellent system for reconstitution with human 
haematopoietic and other cells.
7.2 . R e s u l t s
7.2.1 Generation of Mesenchymal Stem Cells
MSCs were generated from bone marrow taken from the iliac crest of consenting 
patients or donors of less than 10 years of age. Bone marrow mononuclear cells 
(PBMCs) were isolated by density gradient (1.077g/mL Ficoll-Paque from 
Pharmacia), by centrifugation at l,000xg for 20 minutes. These cells were then 
plated into a tissue culture flask, and MSCs were isolated by the plastic adherence 
method. Prior to passaging, it was possible to observe a large number of non­
adherent cells (7.1 A). Following three passages, the cells appeared homogeneous and 
displayed a fibroblastic morphology (Figure 7.1C). Cells used in any experiments 
would be of at least passage 3. The MSCs could usually be grown until passage 17, 
when senescence appeared to set in.
Once the MSCs had been generated, immunophenotyping was performed to confirm 
that they expressed markers previously reported for MSCs. Fibroblasts, a mature type 
of mesenchymal cells, were used as control cells and should have a slightly different 
phenotype compared to MSCs. Both MSCs and fibroblasts were of passage 5. The 
following markers were not detected on MSCs by flow cytometry: CD 14, CD33, 
CD34 and CD45. Hence, they have a different expression pattern from HSCs also 
found in the BM, which express CD34 and CD45 (Table 7.1). They did express the 
following markers: CD13, CD29, CD44, CD73 (SH4), CD90, CD105 (SH2) and 
CD 106 (Figure 7.2). Expression levels of certain markers were noticeably different 
from the fibroblasts. The MSCs expressed lower levels of CD44 compared to 
fibroblasts, and MSCs expressed CD 106, which fibroblasts did not do (Table 7.1).
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Figure 7.1. Phase contrast microscopy images of MSCs at passages 0, 2 and 3.
Mesenchymal stem cells were isolated from bone marrow by ficoll density gradient 
centrifugation followed by plastic adherence. Cells were visualised using the Olympus 
EX70 inverted fluorescence microscope.
A, Day 6  prior to passage; B, Passage 2; C, Passage 3.
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CD13Isotype control
CD33CD29 CD34
CD44 CD45 CD73 (SH4)
CD90 CD 105 (SH2) CD 106
Figure 7.2. Normal MSC phenotype panel. Mesenchymal stem cells and primary normal 
fibroblasts both of passage 5 were stained with antibodies for different markers. The red 
graph depicts MSCs, the blue graph depicts fibroblast.
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Marker MSC P5 MSCP12 MSC SCCP12 Fibroblasts HSC
CD13 + + + + -
CD14 - - - - -
CD29 + + + + -
CD33 - - - - -
CD34 - - - - +
CD44 + + + ++ -
CD45 - - - - +
CD73 (SH4) + +/- + + -
CD90 + +/- +/- + -
CD 105 (SH2) + + + + -
CD 106 + -/+ -/+ - -
Table 7.1. Expression of markers in MSCs and fibroblasts compared with previously 
published data for HSCs (Sutherland et al., 1989; Civin et al., 1996). SCC, single cell 
clone; P, passage number.
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7.2.2 Differentiations of MSCs
To verify the multipotential characteristics of the mesenchymal stem cells isolated, 
they were analysed for adipogenic, osteogenic, chondrogenic and neuronal 
differentiation potential. Normal or patient MSCs of between passage 5-12 were 
grown in the appropriate differentiation medium for up to three weeks. The 
differentiated cells were then analysed using specific assays to confirm that 
differentiation had occurred.
7.2.2.1 Adipocyte Differentiation
Normal and patient MSCs were grown in adipocyte induction media for up to three 
weeks. The MSCs displayed in Figure 7.3 are from a normal individual, and the 
ADA patient MSCs differentiated in the same manner (data not shown). After 
approximately one week, a change toward adipocyte morphology was observed. The 
differentiated MSCs displayed a typical flattened adipocyte-like morphology and had 
clear lipid vacuoles that could be stained with Oil Red O (Figure 7.3B; Refer to 
Table 2.4). Fibroblasts were similarly induced in adipocyte medium as a control. The 
morphology of the fibroblasts remained spindle-shaped following growth in 
adipocyte differentiation medium and no lipid vacuoles could be visualised using the 
Oil Red O stain (Figure 7.3D). Prior to induction, no lipid vacuoles were observed in 
either the MSCs (Figure 7.3A) or the fibroblasts (Figure 7.3C), and both cell types 
had a spindle-shaped morphology. The ADA patient mesenchymal stem cells 
differentiated in the same manner as the normal MSCs (data not shown).
1.2.2.2 Osteocyte Differentiation
Normal and patient MSCs were induced to differentiate into osteocytes for up to 
three weeks. The MSCs displayed in Figure 7.4 are from a normal individual, and the 
ADA patient MSCs differentiated in the same manner (data not shown). The non­
induced and induced cells were stained with Alizarin Red S, which revealed the 
mineralisation of the extracellular matrix (Refer to Table 2.4). The induced MSCs 
stained red (Figure 7.4C), whereas the non-induced MSCs, non-induced fibroblasts 
and induced fibroblasts did not display any mineralisation (Figures 7.4B, D and E 
respectively). The non-differentiated cells retained their spindle shaped morphology 
(Figures 7.4B, D and E), whereas the differentiated osteocytes clearly changed
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morphology and black areas of mineralisation were observed (Figures 7.4A). 
Osteogenesis was confirmed by measurement of calcium content in the cells. The 
non-induced cells and induced fibroblasts did not produce any calcium, whereas the 
induced MSCs produced 2mg/100mL of calcium.
7.2.2.3 Chondrocyte Differentiation
Normal and patient MSCs were induced to differentiate into chondrocytes for three 
weeks. Sections of 5 pM thickness were produced from the stable cartilage-like 
pellets of the induced cells, whereas the non-induced cells were non-viable. Murine 
neuroblastoma tumour sections (generous gift from Dr Susie Barker) were therefore 
utilised as a negative control for the chondrocyte specific staining.
To confirm differentiation, immunohistochemistry was performed on the 
chondrocyte and tumour sections using a chondrocyte specific antibody and stains 
specific for chondrocytes (Refer to Table 2.4). Chondrocyte sections from normal 
MSCs can be seen in Figure 7.5. Patient MSCs differentiated in a similar manner 
(data not shown). The sections were stained for collagen II, which is typical in 
articular cartilage (Figures 7.5A and B). An HRP conjugated secondary antibody 
revealed the presence of collagen II in the chondrocyte sections by generating a 
brown coloured precipitate when incubated with DAB and substrate-chromogen, not 
visualised in the tumour section. The chondrocyte and tumour sections were also 
stained with toluidine blue, which is specific for the proteoglycans within the 
extracellular matrix. It appears that the chondrocyte sections stain more brightly with 
this stain than the tumour sections, suggesting that the MSCs have differentiated into 
chondrocytes (Figures 7.5C and D). The sections were similarly stained using a 
Safranin O stain, which is specific for sulfated proteoglycans. As can be seen in 
Figures 7.5E and F, the chondrocytes stained more brightly red, and more of the cells 
stained with Safranin O than with the tumour section, suggesting chondrocyte 
differentiation of the MSCs. Therefore, the induced MSCs produced a stable pellet 
and deposited significant proteoglycan.
7.2.2.4 Neuronal Differentiation
Normal and patient MSCs were induced to differentiate into neurons for up to three 
weeks in the appropriate induction medium, and differences in morphology were
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observed after approximately one week. The MSCs changed from a mesenchymal 
(7.6A) to a more typical neuronal morphology, with the cells bearing multiple 
processes, as can be seen in Figures 7.6B-D for normal MSCs.
Neuronal differentiated MSCs were stained with fluorescently labelled neuron 
specific antibodies to confirm that differentiation into neurons had taken place (Refer 
to Table 2.4). Although not quantified, a similar number of induced and non-induced 
cells were observed in the photographic frames displayed (Figure 7.7), and whereas 
none of the non-induced cells expressed any of the four neuronal markers tested, 
increased expression was observed in nearly all induced cells for three neuronal 
markers. Upregulation in expression was therefore observed for neuron specific 
enolase NSE (Figures 7.7B and C), NeuN (Figures 7.7D and E) and Tau-2 (Figures 
7.7F and G). NSE is a cytoplasmic glycolytic enzyme specific to nervous tissue, 
NeuN stains neuronal nuclei specifically, and Tau-2 is a microtubule associated 
protein resulting in staining of the cell body and processes. However, no 
upregulation was observed with the astrocyte marker GFAP (data not shown). It 
therefore appears that the MSCs have differentiated into neurons.
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Figure 7.3. Adipocyte differentiation. Normal MSCs and fibroblasts were cultured in 
adipocyte inducing media and stained with Oil Red O, specific for lipid vacuoles, and 
haematoxylin to visualise the nucleus. Cells were visualised using the Olympus 1X70 
inverted fluorescence microscope.
A, Non-induced MSCs; B, MSCs cultured in adipocyte inducing media; C, Non-induced 
fibroblasts; D, Fibroblasts cultured in adipocyte inducing media. Representative 
photographs.
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Calcium deposition assay to show osteogenesis: 
Non-induced MSCs -  Omg/lOOmL 
Osteogenic induced M SC s- 2mg/100mL 
Non-induced fibroblasts -  Omg/lOOmL 
Osteogenic induced fibroblasts -  Omg/lOOmL
Figure 7.4. Osteocyte differentiation. Normal MSCs and fibroblasts were cultured in 
osteocyte inducing media and stained with Alizarin Red S to visualise mineralisation of 
extracellular matrix. Cells were visualised using the Olympus 1X70 inverted fluorescence 
microscope.
A, Unstained MSCs cultured in osteocyte inducing media; B, Non-induced MSCs stained 
with Alizarin Red S; C, MSCs cultured in osteocyte inducing media, stained with Alizarin 
Red S; D, Non-induced fibroblasts stained with Alizarin Red S; E, Fibroblasts cultured in 
osteocyte inducing media stained with Alizarin Red S. Representative photographs.
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Figure 7.5. Chondrocyte differentiation. Normal mesenchymal stem cells were 
cultured in chondrocyte inducing medium for 3 weeks. 5 jiM sections were generated 
and tumour sections were used as controls for the chondrocyte specific stains. Cells were 
visualised using the Olympus EX70 inverted fluorescence microscope.
A, Tumour section stained for collagen II, typical in articular cartilage, and 
counterstained with methyl green. B, Chondrocyte section stained for collagen II and 
counterstained with methyl green. C, Tumour section stained with toluidine blue, 
specific for proteoglycans within the extracellular matrix. D, Chondrocyte section 
stained with toluidine blue. E, Tumour section stained with Safranin O, specific for 
sulfated proteoglycans, and counterstained with methyl green. F, Chondrocyte section 
stained with Safranin O, and counterstained with methyl green.
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Figure 7.6. Neuronal differentiation. Normal MSCs were cultured in neural induction 
medium for 3 weeks. Cells were visualised using the Olympus 1X70 inverted fluorescence 
microscope.
A, Non-differentiated MSCs. B-D, MSCs cultured in neural induction media. 
Representative photographs.
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Figure 7.7. Fluorescence staining following neuronal differentiation. Patient 3 MSCs 
were grown in neuronal induction medium for three weeks. Confocal microscopy 
photographs were taken on 10-12 sections using a laser-scanning microscope (Leica, St 
Gallen, Switzerland). Maximal projection pictures are displayed: red -  phalloidin staining 
for actin filaments, green -  neuron specific marker as specified below. Some areas of 
increased fluorescence of neuronal markers have been indicated with a white arrow.
A, Secondary antibody only control; B, Undifferentiated MSCs stained with the neuron 
specific enolase (NSE); C, Neuronal differentiated MSCs stained with NSE; D, 
Undifferentiated MSCs stained with NeuN; E, Neuronal differentiated MSCs stained with 
NeuN; F, Undifferentiated MSCs stained with Tau-2; G, Neuronal differentiated MSCs 
stained with Tau-2. \ § 9
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7.2.3. Transductions of Mesenchymal Stem Cells
Normal or patient MSCs were transduced with clinical grade SFada/W 
gammaretrovirus or with ADA-lentivirus. Three rounds of transductions were 
performed with the gammaretrovirus at an MOI of 2. Lentiviral transductions were 
performed at MOIs ranging from 1-30 using only one round of transduction.
Gammaretroviral transduction of patient MSCs was found to be inefficient; resulting 
in only 5.7% transduced cells at an MOI of 2 with 3 rounds of transduction (Figure 
7.8C). However, flow cytometry analysis revealed that the lentivirus was more 
effective at gene transfer. At an MOI of 1, 12% were transduced (Figure 7.8D), MOI 
of 10, 55.4% were transduced (Figure 7.8E) and at an MOI of 30, 81.1% of the 
MSCs were transduced (Figure 7.8F). Similarly eGFP-lentivirus transduction of 
MSCs at an MOI of 30 resulted in 79% transduction (data not shown).
Transductions of patient MSCs resulted in large increases in ADA activity values for 
both gammaretroviral and lentiviral transduced cells. Normal MSCs displayed 
activity levels of 615.8 nmoles/hr/mg protein. Gammaretroviral transductions 
resulted in an increase from nearly non-existent activity levels of 20 to 6,456 
nmoles/hr/mg protein, 10-fold the activity of normal MSCs. Lentiviral transductions 
at different MOIs gave rise to very high ADA activity values between approximately 
2,000 and 200,000 nmoles/hr/mg protein, 3-fold to 300-fold higher than that of 
normal MSCs. Transduction with lentivirus at MOI of 1 resulted in activity levels of 
2,046 nmoles/hr/mg protein; MOI of 10 resulted in activity levels of 56,880 
nmoles/hr/mg protein; and MOI of 30 resulted in activity levels of 207,203 
nmoles/hr/mg protein (Figures 7.8G and H).
The calculated activity levels per copy were high for all transduction conditions. The 
gammaretroviral transductions resulted in a slightly lower value of 165,538 
nmoles/hr/mg protein per copy compared with the lentiviral transductions which 
ranged from 400,000 to 500,000 nmoles/hr/mg protein per copy for the different 
MOIs (Figure 7.8G).
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Figure 7.8. Transductions of patient mesenchymal stem cells with vectors encoding 
the ADA transgene. MSCs were transduced with the SFada/W gammaretroviral vector at 
an MOI of 2 using three rounds of transductions. MSCs were also transduced with ADA- 
lentivirus at MOIs ranging from 1 to 30.
Flow cytometry plots of A, Secondary antibody only control; B, Untransduced patient 
MSCs; C, Gammaretroviral transduced MSCs; D, Lentiviral transduced MSCs, MOI of 1; 
E, Lentiviral transduced MSCs, MOI of 10; F, Lentiviral transduced MSCs, MOI of 30. 
(The values in the flow cytometry plots refer to the ADA+ cells). G, Activity values and 
copy numbers for untransduced and transduced MSCs. H, Activity values for untransduced 
and transduced MSCs.  ^^  1
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7.2.4. Differentiation of Normal MSCs Following Transduction with 
eGFP-lenti virus
Gene therapy would utilise lentiviral transduced mesenchymal stem cells in an 
undifferentiated state to allow engraftment of immature cells which could then 
differentiate into several different cell types. It would therefore be vital that the 
MSCs were capable of differentiation following the transduction procedure. It would 
also be essential that the transgene expression remained following differentiation, 
therefore enabling the MSCs to deliver the ADA transgene to different sites. Hence, 
it was demonstrated in vitro that the MSCs were capable of differentiation following 
transduction and that transgene expression was maintained following differentiation. 
This was initially done by transducing normal MSCs with eGFP-lentivirus so that 
one could visualise the transduced, differentiated cells. Hence, MSCs were 
transduced with eGFP-lentivirus at an MOI of 10, which resulted in approximately 
30% transduction. The flow cytometry plots displayed in Figure 7.9 confirm that 
even after differentiation into adipocytes, osteocytes and neurons, the eGFP 
expression remained in around 30-40% of the cells.
Differentiation into the different cell types was confirmed by the change in cell 
morphology and by specific staining procedures. Transduced MSCs expressing eGFP 
were capable of differentiating into adipocytes which stained for Oil Red O (Figures 
7.10A-F) and into osteocytes which stained for Alizarin Red S (Figures 7.10G-L). 
They were also capable of differentiating into neurons as shown by upregulation of 
expression of neuronal markers NSE (Figure 7.1 IB), NeuN (Figure 7.1 ID) and Tau- 
2 (Figure 7.1 IF). From these photographs it was apparent that the transduced MSCs 
retained the expression of the eGFP transgene following differentiation.
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Figure 7.9. Expression of the eGFP transgene following differentiation of normal
MSCs. eGFP transgene expression remains at the same level in the three differentiated cell 
types adipocytes, osteocytes and neurons. (The values in the flow cytometry plots refer to 
the GFP+ cells).
193
C h a p t e r  7
50.00|im
Figure 7.10. Differentiation of normal MSCs to adipocytes and osteocytes following 
transduction with lentivirus. The three photographs in each row displays the same cell or 
group of cells. Cells were visualised using the Olympus 1X70 inverted fluorescence 
microscope.
A-F, Adipocytes expressing eGFP, showing the characteristic lipid vacuoles which stain 
with Oil Red O. A-C: same cell; A, unstained; B, stained with Oil Red O and C, showing 
eGFP expression. D-F: same cell; D, unstained; E, stained with Oil Red O and F, showing 
eGFP expression.
G-L, Osteocytes expressing eGFP, showing black areas of mineralisation which stain with 
Alizarin Red S. G-I: same group of cells; G, unstained; H, stained with Alizarin Red S and 
I, showing eGFP expression. J-L: same group of cells; J, unstained; K, stained with 
Alizarin Red S and L, showing eGFP expression.
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Figure 7.11. Differentiation of normal MSCs to neuronal cells following transduction 
with lentivirus. Confocal microscopy, maximal projection, overlay photographs taken 
using a laser-scanning microscope (Leica, St Gallen, Switzerland). Red -  phalloidin, green 
-  eGFP, blue -  neuron specific markers as specified below. Some areas of increased 
fluorescence of neuronal markers have been indicated with a white arrow.
A, MSCs stained for NSE; B, Neuronal differentiated MSCs stained for NSE; C, MSCs 
stained for NeuN; D, Neuronal differentiated MSCs stained for NeuN; E, MSCs stained for 
Tau-2; F, Neuronal differentiated MSCs stained for Tau-2.
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7.2.5. Differentiation of Patient MSCs Following Transduction with 
ADA-lentivirus
An alternative way of demonstrating that transduced MSCs were capable of 
differentiation and that differentiated cells retained the transgene expression was to 
generate transduced single cell clones of MSCs expressing ADA. Following 
transduction, the cells were sorted into single cells and expanded, after which the 
MSCs were of a relatively high passage of 12. These cells were then used for 
differentiation experiments.
A phenotype panel, similar to the one shown in Figure 7.2, was performed for two 
single cell clones and one untransduced patient MSC population of the same passage 
(Figure 7.12) to show that transduction and cell sorting does not affect the MSC 
phenotype. The expression pattern of the markers was mainly as expected. The 
MSCs were importantly negative for CD34 and CD45 and positive for SH2 (CD 105) 
and SH4 (CD73). There are some slight differences in marker expression compared 
to the lower passage MSCs shown in Figure 7.2. This is likely to be due to the 
increase in passage rather than the transduction and sorting procedure as the high 
passage untransduced MSCs displayed the same markers as the high passage SCCs. 
The differences were as follows: a small proportion of the high passage cells 
expressed low levels of CD90 and a large proportion of the high passage cells have 
lost some of the CD 106 expression. Therefore, the high passage untransduced and 
transduced MSCs were negative for the following markers: CD14, CD33, CD34, 
CD45, and CD 106 (although a small proportion was still positive). They were 
positive for the following markers: CD13hig\  CD29high, CD44hig\  CD73 (SH4), 
CD90 (although a proportion of the cells were negative) and CD 105 (SH2) (Refer to 
Table 7.1).
Following confirmation of the expression of ADA in the transduced single cell 
clones, the cells were tested for their differentiation potential. The single cell clones 
were differentiated into adipocytes, osteocytes and neurons. Following adipogenic 
induction, the cells had a more flattened appearance and displayed the lipid vacuoles 
typical for adipocytes, which stained with Oil Red O (Figure 7.13B). Following 
osteogenic induction, the cells displayed a mineralisation of the ECM which stained
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with Alizarin Red S (Figure 7.13D). The cells also differentiated into neurons. 
Following neuronal induction, the cells were stained for the three different neuronal 
markers NSE, NeuN and Tau-2. In comparison to the untransduced, undifferentiated 
MSCs there appears to be an upregulation in all three markers (Figures 7.13F, H and 
J). Although not quantified, a similar number of induced and non-induced cells were 
observed in the photographic frames displayed (Figure 7.13), and whereas none of 
the non-induced cells expressed any neuronal markers, increased expression was 
observed in nearly all induced cells for these three neuronal markers. These cells 
were also stained for the astrocyte marker GFAP, which showed no upregulation in 
expression (data not shown). It therefore appears that the MSCs, following 
transduction, are capable of differentiating into neurons. Hence, in comparison to 
untransduced MSCs (Figures 13-1.1) the transduced cells differentiate in a similar 
manner, as assessed by morphology and by specific staining procedures.
Real-time PCR analysis was performed on the MSC single cells clones (SCCs) to 
determine the copy number of the ADA transgene. It was found that both of the 
SCCs had a calculated copy number of approximately 0.3-0.5 (Figure 7.14A), which 
is likely to mean that the cells carry one copy of the ADA transgene.
Flow cytometry analysis of the different MSC populations revealed that ADA 
transgene expression persisted following differentiation into adipocytes, osteocytes 
and neurons (Figure 7.14B). Hence, differentiation does not affect transgene 
expression levels.
Therefore, although the transduced MSCs have a slightly changed marker phenotype, 
probably due to the high passage of the cells, they are still capable of differentiation 
into three different lineages. Importantly, following these differentiations, the cells 
retained their ADA expression.
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Figure 7.12. Patient MSC single cell clone phenotype panel. Flow cytometry plots 
displaying the phenotype panel of two transduced single cell clones in comparison to 
untransduced MSCs. Red -  untransduced MSCs, pink -  SCC1, green -SCC2.
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Figure 7.13. Differentiation of transduced patient MSC SCCs. Following ADA-lentiviral 
transduction, the MSCs were differentiated into adipocytes, osteocytes and neurons. Some areas of 
increased fluorescence of neuronal markers have been indicated with a white arrow.
A-D, Cells were visualised using the Olympus 1X70 inverted fluorescence microscope. A, MSCs 
stained with Oil Red O; B, Adipocyte differentiated MSCs stained with Oil Red O; C, MSCs stained 
with Alizarin Red S; D, Osteocyte differentiated MSCs stained with Alizarin Red S; E-J Confocal 
microscopy maximal projection overlay photographs taken using a laser-scanning microscope (Leica, 
St Gallen, Switzerland) , red -  phalloidin, green -  neuron specific marker. Undifferentiated cells are 
untransduced. E, MSCs stained for NSE; F, Neuronal differentiated MSCs stained for NSE; G, MSCs 
stained for NeuN; H, Neuronal differentiated MSCs stained for NeuN; I, MSCs stained for Tau-2; J, 
Neuronal differentiated MSCs stained for Tau-2. Mag, magnification. -i go
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Figure 7.14. Retention of ADA transgene presence and expression following 
differentiation of patient MSCs.
A, Copy numbers of ADA transgene in the two single cell clones prior to and following 
differentiation. B, Flow cytometry plots displaying the expression of ADA in untransduced 
and 2 single cell clones prior to and following differentiation into 3 different cell types.
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7.2.6. Homing and Engraftment of MSCs in NOD-SCID Mice
It was important to assess the homing and engraftment abilities of MSCs, as ADA 
needs to be delivered to several different organs in ADA deficient patients. Prior to 
initiation of gene therapy trials it will be necessary to demonstrate in an animal 
model that MSCs are capable of homing to the organs of interest, including the liver 
and the brain, and engrafting in those organs. Hence, in order to evaluate the homing 
abilities of MSCs, the xenotransplant model the NOD-SCED mouse was utilised. 13 
sublethally irradiated mice were injected intravenously with 0.5x106 untransduced or 
transduced non-differentiated mesenchymal stem cells. There were four different 
groups; 2 mice were injected with untransduced patient MSCs, 6 mice were injected 
with patient MSCs transduced with eGFP-lentivirus at M O I10, 1 mouse was injected 
with untransduced normal MSCs and 4 mice were injected with normal MSCs 
transduced with eGFP-lentivirus at MOI 10. All mesenchymal stem cells were of 
passage 9. Patient MSC input cells were 57.6% transduced, and the normal MSCs 
input cells were 67.7% transduced (Figure 7.15A). The mice were analysed 6 weeks 
after injection of the cells. Of the 6 mice injected with patient MSCs transduced with 
eGFP-lentivirus, 3 died before the 6 weeks.
For each mouse, ten different organs were analysed for the presence of eGFP by flow 
cytometry and for the presence of human genomic DNA by real-time PCR analysis. 
The organs analysed were: blood, bone marrow, spleen, thyroid gland, liver, kidney, 
brain, heart, lung and muscle. For flow cytometry analysis, single cell suspensions 
were generated and the cells were fixed in PFA. The organs of the mice which 
received untransduced cells were utilised as negative controls. No eGFP expression 
was detected in any of the organs of the mice that received transduced cells. 
Representative plots from 2 mice which received untransduced or transduced MSCs 
are displayed in Figure 7.15B.
A small section of tissue from each organ was used to isolate genomic DNA. Real­
time PCR analysis was performed on the DNA generated, using primers for human 
P-actin. This is a very sensitive assay, detecting as few as 10 cells in a sample, which 
should reveal the presence of human cells within the mouse organs, irrespective of 
the presence of eGFP. Each of the ten organs of the ten mice were analysed for the
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presence of P-actin, however no human DNA was detectable (Figure 7.16A). A 
positive control of human fibroblasts was run in parallel to ensure that the assay was 
functioning, and this gave a clear positive signal (Figure 7.16A). To verify that there 
was human or mouse genomic DNA present of good amplifiable quality, a standard 
PCR was performed using primers for HPRT specific for either human or mouse 
DNA (representative samples are shown in Figure 7.16B). This revealed that there 
was good quality DNA present and hence confirmed that the result obtained for p- 
actin was negative.
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Figure 7.15. Analysis of eGFP expression in cells of different mouse organs.
Lentivirus-eGFP transduced MSCs were injected into NOD-SCID mice. 6  weeks following 
injection, 10 different organs from each mouse were analysed for the presence of the eGFP 
transgene by flow cytometry. Samples have been gated on the forward scatter/side scatter 
characteristics to select cells of each organ type and to exclude dead cells and debris.
A, eGFP expression of MSC input cells (left-hand side plots are untransduced cells and 
right-hand side plots are transduced cells).
B, Flow cytometry plots displaying eGFP expression of cells of different organs. For each 
organ, the left hand side plots depicts the organ from a mouse which received untransduced 
normal MSCs and the right hand side plot depicts the organ from a mouse which received 
transduced normal MSCs. (The values in the flow cytometry plots refer to eGFP+ cells)203
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Figure 7.16. Analysis of the presence of human DNA in mouse organs. Genomic DNA 
was extracted from a tissue section of each of the ten organs analysed for each mouse. 
Real-time PCR analysis of the genomic DNA was performed to test for the presence of 
human (3-actin.
A, Real time PCR amplification plot. No human genomic DNA was detected in 40 cycles. 
The positive control is genomic DNA from human fibroblasts.
B, PCR using HPRT primers, generating a product of 220bp, to confirm presence of human 
or mouse genomic DNA. The gel was loaded in the following order: M, lkb ladder; a, 
Blood 1; b, bone marrow 1; c, spleen 2; d, thyroid gland 2; e, liver 3; f, kidney 3; g, brain 
4; h, heart 4; i, lung 5; j, muscle 5; k, blood 6 ; 1, bone marrow 6 ; M, lkb ladder; m, spleen 
7; n, thyroid gland 7; o, liver 8 ; p, kidney 8 ; q, brain 9; r, heart 9; s, lung 10; t, muscle 10; 
N, negative control (numbers refer to different mice).
204
C h a p t e r  7
7.3. D is c u s s io n
Haematopoietic stem cell transplantation to treat ADA deficiency results in the 
correction of immune function (Hirschhom et al., 1981). Neurological and other 
organ system problems appear to remain, and it is also likely that gene therapy using 
T cells or haematopoietic stem cells will fail to treat the non-immunological 
symptoms of this systemic disease. Therefore, the aim was to investigate the 
possibility of utilising MSCs to offer a more systemic treatment for ADA-SCID.
Homogeneous populations of mesenchymal stem cells were readily generated by the 
isolation of mononuclear cells from bone marrow, followed by plastic adherence of 
MSCs. To verify the homogeneity of the population and the identity as MSCs, 
immunophenotyping was performed. The MSCs were found to have the same 
expression pattern of surface markers as has been previously reported (Zhang, W., et 
al., 2004; Lee, R.H., et al., 2004; Xu et al., 2004). Importantly, they were found not 
to express haematopoietic markers, and were clearly a different cell population from 
the HSCs which are also found in the bone marrow. Hence, the MSCs appeared to 
have the expected phenotype, however to confirm that they were indeed MSCs their 
differentiation potential was assessed. Importantly, the MSCs did not spontaneously 
differentiate during culture unless grown in differentiation medium. However, when 
cultured in the appropriate induction medium, the MSCs differentiated into four 
different cell types (adipocytes, osteocytes, chondrocytes and neuronal cells) 
assessed by their change in morphology and by specific staining assays. Increased 
expression was seen for the three neuronal markers NSE, NeuN and Tau-2, whereas 
no upregulation was observed with the astrocyte marker GFAP, suggesting that the 
MSCs have differentiated into neurons and not astrocytes by this differentiation 
method using hEGF and hbFGF. The expression pattern for each of the three markers 
appears to be nuclear or peri-nuclear. Some faint cytoplasmic staining can also be 
observed for NeuN and Tau-2. NSE is a cytoplasmic glycolytic enzyme specific to 
nervous tissue, NeuN is a neuronal nuclei protein and Tau-2 is a microtubule 
associated protein. Therefore, NSE and Tau-2 staining would be expected to be 
mainly cytoplasmic and NeuN staining should be mainly nuclear in brain derived 
neurons. However, recent reports (Lu et al., 2004) have revealed that visualisation of 
neuronal markers, as performed in this study, may not be adequate to confirm the
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identity of the cells. They showed that the “induction of neuronal differentiation” by 
addition of specific chemicals resulted in cellular shrinkage and thus increased the 
concentration or apparent upregulation of neuronal markers, although not 
differentiation. Moreover, it has been shown that mesenchymal derived neurons may 
have different distributions of these neuronal markers (Jin et al., 2003) compared 
with brain derived neurons, which may explain the slight difference in cellular 
distribution observed for these markers in the present study. This may indicate that 
the mesenchymal derived neurons do not have the functional characteristics of 
neurons. Therefore, in order to conclusively prove that the MSCs have differentiated 
into neuronal cells, one would not only need to demonstrate the expression of 
neuronal markers but also that the cells have acquired the electrophysiological 
properties of neurons. Hence, measurement of the action potential and voltage gated 
Na+ and K+ currents would be required as has been previously demonstrated (Li et 
al., 2005; Cho et al., 2005).
Once the MSCs had been shown to express the characteristic markers and to 
differentiate into four different cell types, viral transductions were performed. 
Gammaretroviral transductions were found to be greatly inefficient, which may be 
due to a lack of Pit-1 GaLV receptors on the surface of the MSCs or due to their low 
rate of cell division. In a homogeneous population of MSCs it has been found that 
most of the cells are standing at the Go/Gi phase of the cell cycle (Conget & 
Minguell, 1999), which could explain the difficulties in transducing MSCs using a 
gammaretrovirus that can only transduce dividing cells. However, other groups have 
obtained transduction efficiencies of approximately 80% using different protocols 
such as high titre gammaretroviruses pseudotyped with VSV-G or amphotropic 
envelope (Marx et al., 1999; Baxter et al., 2002; Mangi et al., 2003) or centrifugation 
of cells together with the gammaretrovirus (Lee, K., et al., 2001). These high 
transduction efficiencies could not be obtained in the present study, and the 
differences in transduction procedure, the centrifugation step, the high titre and 
different envelopes of the gammaretroviruses, may explain the differences in 
transduction efficiencies obtained. Perhaps the MSCs express higher levels of Pit-2 
(amphotropic receptor) or VSV-G receptors than Pit-1, which the viral GaLV 
envelope targets. The expression of these receptors on MSCs should be further 
investigated if the gammaretrovirus was the vector of choice. However, whereas
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consistently low transduction efficiencies were observed with gammaretroviral 
vectors, lentiviral transductions were extremely efficient. Reasons as to why 
lentiviral transductions were much more efficient than gammaretroviral transductions 
may be due to the cPPT element that permits the lentivirus to transduce these 
quiescent cells which are mainly in the Go/Gi stage of the cell cycle, or due to the 
different viral envelopes. Previous studies using lentiviral vectors have obtained 
slightly higher gene transfer efficiencies than observed here, with transductions at an 
MOI of 1 resulting in approximately 50% transduced cells (Zhang et al., 2002; 
Totsugawa et al., 2002). Similarly to the fibroblasts and LCLs, the transduced MSCs 
in our study were found to maintain the expression of the transgene for a long period 
of over 14 passages (more than 4 months). This is important as sustained expression 
of the ADA transgene would be essential for the treatment of ADA deficiency.
Interestingly, the copy numbers and activity values obtained for the lentiviral 
transductions of the MSCs are quite different from the fibroblasts although the 
percentage gene transfer was similar at an MOI of 30. Lentiviral transductions of 
fibroblasts resulted in a high average copy number of 8, whereas the same 
transductions only resulted in an average copy number of 0.4 in the MSCs. This may 
suggest that all of the transduced MSCs have only one copy of the transgene, 
whereas each transduced fibroblast has several copies. This may be related to the fact 
that fibroblasts were more easily transduced. The activity values of transduced MSCs 
are nearly twenty times lower than the transduced fibroblasts. However, this is likely 
to be as a result of the difference in copy number, as the calculated values of activity 
per copy are nearly identical for the two cell types at around 500,000 nmoles/hr/mg 
protein per copy. Therefore, as expected, each copy of the lentiviral transgene gives 
rise to a similar activity value.
Nevertheless, the activity values observed for the transduced MSCs should be more 
than adequate for gene therapy. Values ranging from 2,000 to 200,000 nmoles/hr/mg 
protein were obtained for the different MOIs, which is 3-300 times higher than the 
ADA activity in normal MSCs. These activity values should clearly be sufficient to 
detoxify the MSCs as even the cells transduced at a low MOI display an ADA 
activity higher than normal.
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It was important to demonstrate that the MSCs were capable of differentiation 
following transduction. The maintenance of MSC phenotype and function as well as 
transgene expression following differentiation was demonstrated by generating 
single cell clones which expressed ADA. The phenotype of transduced single cell 
clones was shown to be similar to untransduced low passage MSCs apart from the 
down-regulation of the marker CD 106, and some loss in the expression of CD90. 
However, this was probably due to the high passage of the cells rather than the 
transduction procedure as high passage untransduced cells showed the same 
phenotype. Similar down-regulations in marker expressions have also been observed 
in other studies. Conget and Minguell (1999) found that MSCs of high passage lost 
expression of SH3, ICAM and integrin p i. The transduced single cell clones were 
importantly negative for haematopoietic markers and positive for SH2 and SH3, 
hence the transduction procedure did not affect the MSC phenotype.
It was also vital to demonstrate that transduced cells were capable of differentiation, 
and that differentiation did not affect transgene expression. Transduced MSCs were 
found to differentiate into the three different lineages tested: adipocytes, osteocytes 
and neurons. The expression of the ADA or eGFP transgene remained following 
differentiation. Hence, transduced MSCs remained multipotential and transgene 
expression was not affected by differentiation. Similar studies have demonstrated the 
maintained differentiation potential following gammaretroviral transduction (Lee, K., 
et al., 2001; Baxter et al., 2002) and lentiviral transductions (Quintavalla et al., 2002; 
Zhang, X.Y., et al., 2002), and the sustained transgene expression following 
differentiation.
Following the generation of multipotential MSCs, we investigated the homing 
abilities of these cells to observe into which organs they engraft. MSCs were tagged 
with an eGFP marker using the lentiviral vector and were then injected into NOD- 
SCID mice. Of a group of 6 mice injected with transduced patient MSCs, 3 mice 
died. As they were all from the same group, there may have been an infection in the 
cell culture that the immunodeficient mice could not fight. Because the NOD-SCID 
mice do not have a completely functional immune system, the human MSCs should 
not be rejected. However, no eGFP positive cells and no human cells could be 
detected in any of the ten different organs of the ten mice analysed. The absence of
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eGFP expression in the organs analysed is unlikely to be due to gene silencing, as 
real-time PCR analysis did not detect the presence of human cells using p-actin 
markers. It therefore appears that the MSCs did not engraft in the mice, contrary to 
findings of some previous reports. A successful engraftment study was carried out by 
Pereira and colleagues (Pereira et al., 1995; reviewed by Prockop, 1997) who infused 
marked MSCs into X-ray irradiated mice, and analysed several tissues at different 
time points. After 1 week, no MSCs could be detected in any tissues. However, at 1 
and 5 months the MSCs accounted for 1 to 12% of the cells in a number of tissues 
including bone, cartilage, lung, marrow and spleen. Other groups have similarly 
reported engraftments in mice (Dao et al., 1997; Allay et al., 1997; Chuah et al., 
2000) and different animal models (Devine et al., 2001; Saito et al., 2002; reviewed 
by Krause, 2002). However, our negative results could be due to a number of 
reasons. It is possible that too few cells were injected as 5xl05 cells may not be 
enough to be able to detect after 6 weeks, considering that only a small percentage of 
cells usually engraft. It is also conceivable that the cells were of too high a passage, 
and perhaps cells of a passage lower than 9 would have engrafted. This is supported 
by studies carried out by Baxter et al. (2004) who reported that even minimal 
expansions of MSCs induce rapid aging of the cells, thus probably reducing their 
long-term engraftment potential in vivo. Rombouts & Ploemacher (Rombouts & 
Ploemacher, 2003) also found that culturing of MSC significantly reduced their 
homing abilities. It that study it was observed that in contrast to transplantations of 
primary uncultured MSC which gave rise to 55-65% recovered cells in BM (24 hours 
post-transplant), following 24 hours in culture the recovery was dramatically 
decreased and following only 48 hours in culture, no MSCs could be detected in the 
lymphohaematopoietic organs. Protocols for engraftment of MSCs may therefore 
need to be optimised, as other groups have similarly found MSC engraftment 
difficult to achieve (Friedenstein et al., 1978; Laver et al., 1987; Simmons et al., 
1987; Athanasou et al., 1990; Santucci et al., 1992; Tanaka et al., 1994). Hence, to 
assess the homing abilities of MSCs, the experiment should be repeated using a 
higher number of lower passage MSCs, perhaps injected with irradiated carrier cells 
to encourage engraftment of the MSCs.
Therefore, MSCs were readily generated by the plastic adherence method and were 
multipotential as demonstrated by their ability to differentiate into adipocytes,
209
C h a p t e r  7
osteocytes, chondrocytes and neurons. Although the homing abilities of the MSCs 
could not be demonstrated, it was shown that the MSCs were capable of 
differentiation prior to and following transduction and that the expression of the 
transgene remained following expansion and differentiation. As ADA deficient 
patients have good numbers of both HSCs and MSCs in the bone marrow, gene 
therapy using lentiviral vectors to transduce these cells would be feasible. If 
engraftment is obtained with the MSCs, the levels of ADA activity observed with the 
lentiviral transductions should be sufficient to reduce toxicity of the ADA substrates. 
Moreover, engraftment of HSCs in combination with MSCs may improve the 
engraftment levels of HSCs as MSCs have been found to provide support for 
haematopoiesis. Therefore gene therapy using lentiviral vectors to transduce HSCs 
and MSCs could constitute a successful systemic treatment for ADA deficiency.
2 1 0
G e n e r a l  D isc u ssio n
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8.1 Pa t ie n t  Im m u n e  F u n c t io n  F o l l o w in g  PEG-ADA o r  
G e n e  T h e r a p y
Three ADA deficient patients who did not have bone marrow donors available were 
treated with PEG-ADA enzyme replacement therapy. Patients 1 and 2, who remain 
on PEG-ADA, have responded well to this treatment displaying a good proportion of 
naive cells and thymic activity, and lymphocyte counts just below normal. The 
immune function of patient 3 did not improve to the same extent as those for patients 
1 and 2 as a result of PEG-ADA. Therefore, patient 3 was enrolled in a Phase I gene 
therapy trial using the previously tested SFada/W vector to transduce autologous 
CD34+ cells.
Based on the recent successful treatment of ADA deficient patients (Aiuti et al., 
2002a), a protocol was designed for the ADA gene therapy trial. This involved the 
withdrawal of PEG-ADA prior to gene therapy in order to maximise the selective 
growth advantage of transduced cells, and a mild conditioning treatment to generate 
space for reinfused cells. Patient 3 was therefore treated using a similar protocol to 
previously published gene therapy trials. Following the infusion of transduced cells, 
the transgene could be detected in the patient’s mononuclear cells up to sixteen 
months post gene therapy. The patient now appears to be generating a larger 
proportion of naive cells compared to prior to gene therapy and lymphocyte counts 
are higher than when he was treated with PEG-ADA.
When patient 3 received PEG-ADA, he did not respond as well to this treatment as 
patients 1 and 2 as determined by lower lymphocyte counts and a smaller proportion 
of naive cells. Following gene therapy the immune function of patient 3 improved 
significantly, however, his immune recovery was still not as good as for patients 1 
and 2 being treated with PEG-ADA. It would therefore be interesting to follow this 
further to determine why patients 1 and 2 responded better to treatment than patient 
3. It could for instance be due to the mutation carried by the patient, as Hirschhom et 
al. (1993) suggested that genotype is related to phenotype and response to treatment. 
It was hypothesised that patients with mutations allowing for some ADA expression 
might respond better to PEG-ADA therapy. There are clearly several other factors
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which could also contribute to the response to treatment, such as age at treatment and 
previous infections. It has been proposed that treatment of X-SCID patients at an 
older age results in limited initiation of thymopoiesis and T cell recovery (Thrasher 
et al., 2005), and this is likely to hold true for ADA-deficient patients. Furthermore, 
the lack of ADA during foetal development may result in different extent of damage 
to the foetus. It may therefore be difficult to determine the reasons for different 
treatment responses in patients. Mutational analysis and evaluation of T cell 
functions and thymic function at an early age might clarify the differences in 
treatment response.
Further similar studies should therefore be carried out on ADA deficient patients 
treated with either bone marrow transplantation, PEG-ADA or gene therapy. It 
would be interesting to compare immunological recovery and improvements of non- 
immunological functions as a result of the different treatments. Although no study 
with direct comparisons of the different treatments have been done to date, there 
have already been some suggestions regarding the efficacies of the different 
treatments. The conventional treatments of bone marrow transplantations and PEG- 
ADA are both thought to have certain limitations. Bone marrow transplantations, for 
instance, are known to improve immune function, however the metabolic 
abnormalities have been found to remain quite high in other organs (Hirschhom et 
al., 1981). Therefore, improvements of non-immunological defects may be poor. 
Although not yet proven, it is thought that PEG-ADA, being a more systemic 
treatment than BMT, may be a better treatment for neurological symptoms and other 
non-immunological defects (Rogers et al., 2001; Albuquerque et al., 2004). 
However, the efficacy of this treatment may diminish with time, particularly if 
antibodies are generated against the bovine ADA. Hence, gene therapy may be an 
improved treatment for ADA deficient patients as it results in a long-lived effect due 
to integration into stem cells, and if MSCs are utilised it might offer a systemic 
treatment as discussed below. However, data is not yet available to support these 
hypotheses. It is therefore vital to perform more thorough and direct comparative 
studies on the different treatments options, so that patients can be better informed on 
the efficacy and safety of the treatments available.
213
C h a p t e r  8
8.2 S id e  E f f e c t s  o f  G e n e  T h e r a p y
8.2.1 Insertional Mutagenesis
Gene therapy has suffered a recent setback with reports of leukaemia incidents in 
three of the ten children successfully treated for X-SCID (Hacein-Bey-Abina et al., 
2003; Check et al., 2005; Kaiser et al., 2005). The leukaemia, which is thought to be 
specific for gene therapy for X-SCED, has been found to be a direct result of the 
gammaretroviral integration near to and subsequent activation of the oncogene 
LM02. Up till that date, this risk was recognized but was considered to be minimal 
as the previous 40 clinical trials involving gammaretroviral transfer to HSCs in more 
than 250 patients and thousands of preclinical studies in animal models had not 
reported the occurrence of this event (Kohn et al., 2003) (although just prior to the 
discovery of leukaemia in the SCID patients, Li et al. (2002) observed one mouse 
with acute myeloid leukaemias from five mice that received BM transduced ex vivo 
with a gammaretrovirus).
The first case showed a monoclonal y8 T cell lymphoproliferative disorder and the 
gammaretrovirus was found to have integrated in reverse orientation within an intron 
of LM02. The second case revealed an ap  T cell proliferation of three cell types and 
the gammaretrovirus had integrated 5kb upstream of LM02. The third case involved 
multiple insertions affecting four different oncogenes, including LM02, and was 
discovered approximately 2 years after gene therapy. LM02 is a proto-oncogene 
which encodes Lim domain protein, that binds certain transcription factors required 
for normal haematopoiesis. LM02 transcription is activated in childhood acute 
lymphoblastic leukaemia as a result of a chromosomal translocation. Transgenic 
mice which express Lmo2/rhombotin-2 under the transcriptional control of the CD2 
enhancer/promoter have been found to develop T cell tumours as early as at 5 
months of age (Larson et al., 1995). In transgenic mice generated using the 
metallothionein promoter to direct the expression of LM02, the number of 
thymocytes at the most primitive stage of differentiation increased 10-fold with 
thymic tumours developing in 15% of the mice suggesting that Lmo2 is specifically a 
T cell oncogene (Neale et al., 1995). Therefore, Lmo2 is a leukaemogenic 
oncoprotein, however it does not cause rapid onset of leukaemia in
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immunocompetent mice. LM02 is also not one of the most commonly activated 
oncogenes found in spontaneous human T cell leukaemias. It is therefore possible 
that either LM02 is a common retroviral integration site in CD34+ cells, or random 
integrations activating LM02 results in a growth advantage of those cells. The long 
latency (two to three years) observed in the X-SCID patients indicates that LM02 
transactivation is not sufficient to cause leukaemia and additional factors may be 
required. The initial mutation in progenitor cells might increase cell proliferation and 
therefore also the risk of accumulating second mutations.
Gamma chain cytokine signalling has been shown to enhance leukaemogenesis. IL-7 
and IL-15 receptors, which contain the common gamma chain, have been implicated 
in T cell survival (Puel et al., 1998; Schluns et al., 2000; Schluns et al., 2003). 
Transgenic mice which over express IL-7 are more susceptible to pro-B and pre-B 
cell tumours (Valenzona et al., 1996). Those that over express IL-15 frequently 
develop T-NK lymphocytic leukaemias (Fehniger et al., 2001). IL-7, required for 
thymocytes development, is of particular interest because its levels are elevated in 
SCUD patients (Bolotin et al., 1999). Therefore, increased signalling through the IL-7 
receptor could have primed haematopoietic cells of SCID patients for transformation. 
The additional upregulation of LM02 could multiply this effect, therefore increasing 
the likelihood of transforming the cells.
Hence, the activation of LM02, which encodes a transcription factor required for 
haematopoiesis, in combination with the gamma chain expression, a subunit of 
several receptors acting as T cell growth factors, are thought to be the cause of 
leukaemia (Hacein-Bey-Abina et al., 2003). Dave et al. (2004) similarly discovered 
murine leukaemia as a result of gammaretroviral insertions in both LM02 and 
gamma c, suggesting that the two genes are cooperating to cause cancer. For this 
reason, the leukaemia observed should be specific to the X-SCID. Furthermore, it 
may be the case that a secondary event is required to activate the leukaemia, implied 
by the long latency of the onset of disease. In the case of the first two patients who 
developed leukaemia, these events could be a partial trisomy with a chromosome 
translocation or a varicella-zoster infection in the first patient (Hacein-Bey-Abina et 
al., 2003; reviewed by McCormack & Rabbitts, 2004), and two chromosomal 
aberrations in the second patient (Hacein-Bey-Abina et al., 2003). Replication
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competent retrovirus was not detected in any of the three patients. The X-SCID trials 
which have been carried out in Great Ormond Street Hospital, London, where 8 
patients have been treated, have not observed any adverse events. This could be due 
to a shorter follow up period than the Paris study or simply due to the fact that fewer 
patients have been treated. Differences in the procedure include that no FCS was 
used for cell culture in the London study and the gammaretrovirus was pseudotyped 
with the GALV envelope rather than the amphotropic envelope but it is not known 
whether these differences are significant. Clearly, there are other possible reasons as 
to why adverse events have only been observed in the Paris study and these should 
be further investigated to determine the risk of the gene therapy procedure.
Therefore, the leukaemia cases may be specific for X-SCID, and the risk of 
leukaemia as a result of ADA gene therapy is minimal. This is supported by the fact 
that previous gene therapy trials carried out more than a decade ago for ADA 
deficiency, in which patients still have significant numbers of transduced cells, and 
the successful ADA gene therapy trial carried out by Aiuti et al., 2002a, have not 
observed any adverse events (5 patients have been treated in this study to date).
It is therefore important to find a balance between a high transduction efficiency, and 
therefore probably a high transgene expression, and achieving a copy number that 
reduces the risk of insertional mutagenesis. As a result of the leukaemia cases, there 
are extensive studies on preferential integration of gammaretroviruses and 
lentiviruses. Although some studies had suggested that retroviruses tend to integrate 
into regions of open chromatin (Vijaya et al., 1986; Rohdewohld et al., 1987) viral 
integration had previously been considered to be essentially random. It has now been 
demonstrated that both gammaretroviruses and lentiviruses preferentially integrate in 
the vicinity of transcriptionally active genes (Shroder et al., 2002; Wu et al., 2003). 
More specifically, gammaretroviral vectors were found to integrate in and around 
promoters of active genes, and lentiviral vectors in the transcriptional units of active 
genes (Bushman et al., 2003; reviewed by Wu & Burgess, 2004; De Palma et al., 
2005).
Due to safety concerns, viral vectors are therefore constantly being developed to 
minimise the risk of generation of replication competent viruses, such as the
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generation of split genome vectors and packaging cell lines. In any viral vector, RNA 
readthrough of the 3’ polyadenylation signal could lead to transcription of down­
stream cellular genes, including oncogenes. Hence, it will be important to develop 
vectors which carry an efficient polyadenylation signal to prevent these readthrough 
effects. Enhancers contained in viral promoters can also lead to the activation of gene 
transcription over large distances. The mechanism for this is not clear, but three 
common models have been put forward: the scanning, linking and looping models. 
Of these, the most accepted model is the looping model, which proposes that the 
contacts between enhancer bound activating proteins and promoter bound 
transcription factors bring together the enhancer and promoter elements, resulting in 
the looping out of the intervening DNA (Ptashne, 1986; Petraschek et al., 2005). 
Insulators have therefore been used in viral vectors to prevent the unintentional 
activation of genes nearby to the viral integration site (Emery et al., 2000; Ramezani 
et al., 2003; Li et al., 2005).
SIN-gammaretroviral vectors are currently being developed for use in gene therapy. 
The integrated copies of these vectors do not have functional retroviral promoters 
and therefore lack the enhancer activities which can lead to the activation of nearby 
genes. These vectors may therefore still insert in the vicinity of oncogenes, but 
should not lead to their activation.
More research is also currently being performed to attempt to direct the insertion of 
the proviral DNA into “safe” regions of the genome, including the use of the site 
specific integration system of bacteriophage <|>C31 (Groth et al., 2000; Olivares et al., 
2002, Ortiz-Urda et al., 2002). Umov et al. (2005) recently reported the successful 
direct targeting and replacement of a faulty gamma chain using a different approach. 
The targeting was performed using zinc finger proteins to which an endonuclease 
was fused. The endonuclease generated a cut in the DNA, thus stimulating 
homologous recombination with the extrachromosomal DNA carrying the correct 
sequence, resulting in nearly 20% corrected cells. This technique would therefore 
avoid the risk of insertional mutagenesis as only the sequence of interest is targeted. 
Therefore, all basic research on developing vector systems is vital to avoid further 
adverse events such as the leukaemia cases observed in the X-SCID trial.
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8.2.2 WPRE Cancer Risk
The safety of the WPRE, utilised in several vectors to enhance the transgene 
expression has been brought into question. A short communication regarding 
concerns about WPRE was recently published (Kingsman et al., 2005), following 
reports suggesting that the WPRE may have caused liver cancer in a mouse study 
(Themis et al., 2005a, b & c). These mice had been inoculated in utero using an 
equine infectious anaemia virus (EIAV) lentiviral vector, but the mechanism of 
tumour formation has still not been clarified. WPRE is considered a possible cause of 
the cancers because previous reports have suggested that truncated hepadna virus X 
proteins (the gene of which is found within the open reading frame of the WPRE) 
may have oncogenic properties (Sirma et al., 1999; Tu et al., 2001). Kingsman et al. 
(2005) reported that the EIAV vector contained an open reading frame in the WPRE 
which could express the truncated form of the oncogenic X protein and act as a weak 
oncogene. However, any link between liver cancer and the WPRE will need to be 
confirmed as it could in fact also have been caused by insertional mutagenesis or by 
other elements within the vector. In fact, of the 20 integration sites identified, half 
were in the vicinity of genes encoding proteins with kinase activity or nucleic acid 
binding functions, or proteins involved in signal transduction, transcription, cell 
proliferation or DNA repair, which are all important in oncogenesis. Hence, further 
analysis is being performed on these integration sites to elucidate the mechanism of 
oncogenesis.
The WPRE that may have caused liver cancer in the murine study was wild type, 
whereas the WPRE used in our study had been mutated in the ATG start codon of the 
X protein and also in the X protein promoter. These deletions are believed to 
minimise the risk of causing cancer, and the WPRE is therefore very unlikely to 
cause problems in our gene therapy trial. Importantly, lentiviral vectors containing 
these exact mutations were found not to result in liver cancer in this study (Themis et 
al., 2005a, b & c). Sequencing performed on sorted T cells by Dr Zhang confirmed 
that the WPRE sequence in the transduced cells of patient 3 remained mutated and 
had not reverted back to wild type (data not shown). Therefore, the risk of liver 
cancer caused by the WPRE remains very unlikely.
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Whilst there are possible side-effects associated with gene therapy, it is important to 
remember that gene therapy is still a treatment at an early stage of development, and 
it is crucial that clinical trials are continued so that this potentially life-saving 
treatment can be further developed. It is also important to realise that the patients 
treated with gene therapy have a life-threatening condition with limited treatment 
options available, which also have their own associated risks. Furthermore, at this 
point in time gene therapy is only a treatment choice for ADA deficiency when no 
bone marrow match can be found, and when PEG-ADA is not successful. Hence it 
offers a solution to several patients for whom other treatments are not possible or are 
not successful. Moreover, the overall possible risks will only become apparent after 
treatment of greater numbers of patients.
8.3 D e v e lo p m e n t  o f  G e n e  T h e r a p y  t o  A c h ie v e  a  
S y s t e m ic  T r e a t m e n t  f o r  A D A  D e f i c i e n c y
8.3.1 Lentiviral Vector as an Improved Gene Delivery System
Gene therapy currently represents a good alternative treatment for ADA deficient 
patients. However, improvements need to be made not only regarding the safety of 
the vector utilised, but protocols also need to be modified in order to achieve 
systemic delivery of ADA. We demonstrated that the five day activation and 
transduction protocol of HSCs using SFada/W gammaretrovirus decreased the 
expression of CD34, a marker thought to be present on most haematopoietic stem 
cells. Thus, if  the number of stem cells were reduced during the transduction 
procedure, the likelihood of transducing a multipotential stem cell would clearly be 
reduced. It has previously been reported that the activation of CD34+ cells to enter 
the cell cycle, necessary for the gammaretroviral vector to gain entry into the 
nucleus, also results in the differentiation of the CD34+ cells thus reducing their 
multipotential nature and engraftment capacity (Bhatia et al., 1997; Gothot et 
a/., 1998, Rebel et al., 1999). The broad differentiation potential displayed by HSCs 
is essential for the successful treatment of ADA deficiency, as the transduced stem 
cells are required to repopulate the entire haematopoietic system for effective 
treatment and to achieve maximal detoxification. Lentiviral vectors were therefore
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considered as an alternative to the gammaretroviral vector as they are able to 
transduce non-dividing cells (Lewis et al., 1992; Bukrinsky et al., 1993; Lewis & 
Emerman, 1994; Naldini et al., 1996a), useful for the transduction of largely 
quiescent cells such as HSCs and slow dividing cells such as MSCs. Lentiviral 
transductions of CD34+ cells have been reported to require no or less activation of 
the cells (Uchida et al., 1998; Case et al., 1999; Miyoshi et al., 1999; Chang et al., 
1999). Therefore the CD34+ cells should maintain their multipotential nature and 
higher levels of engraftment would be expected, essential for the ADA gene therapy 
trial.
The ADA lentiviral vector constructed in this study was found to be more efficient 
than the gammaretrovirus at transducing a variety of cells, including primary skin 
fibroblasts, patient B-LCLs and MSCs. The lentiviral vector also efficiently 
transduced CD34+ cells, crucially requiring less cytokines and a shorter period of 
activation than the gammaretrovirus. However, the multipotential nature of CD34+ 
cells can only be demonstrated if NOD/SCID repopulating experiments are 
performed. The lentiviral transduced cells displayed reconstituted ADA expression 
and activity at levels greater than that observed in normal cells. Hence, the ADA- 
lentiviral vector could offer an alternative and improved vector system for use in 
clinical gene therapy trials.
8.3.2 Mesenchymal Stem Cells
8.3.2.1 MSC Differentiation
In the case of ADA deficiency it is likely to be important to achieve systemic 
delivery of ADA as it is a multi-organ disease. HSCs are one of the target cells for 
the improved gene therapy protocol as they are capable of differentiating into all the 
cells of the haematopoietic system (Hay, 1966). The additional use of mesenchymal 
stem cells may provide the systemic delivery method as they can differentiate into 
several different cell types of both mesenchymal and non-mesenchymal origin. 
Hence, a combination of HSCs and MSCs could be used for the gene therapy 
treatment of ADA deficiency to achieve haematopoietic and non-haematopoietic 
ADA reconstitution. MSCs have been reported to differentiate into several different
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cell types, including adipocytes, osteocytes and chondrocytes (Piersma et al., 1983 & 
1985; Howlett et al., 1986; Friedenstein et al., 1987; Mardon et al., 1987; Owen & 
Friedenstein, 1988; Keating et al., 1990; Caplan, 1991; Haynesworth et al., 1992; 
Beresford et al., 1992; Cheng et al., 1994.; Rickard et al., 1994; reviewed by Clark & 
Keating, 1995; reviewed by Prockop, 1997; Pittenger et al., 1999). They have 
furthermore been reported to differentiate into cardiomyocytes (Mangi et al., 2003; 
Makino et al., 1999; Toma et al., 2002), and neuronal cells (Sanchez-Ramos et al., 
2000; Kohyama et al., 2001; Kim et al., 2002; Jiang et al., 2003). The ability of 
MSCs to differentiate into neuronal cells was considered particularly interesting as 
ADA deficient children have been reported to suffer from neurological problems 
(Hirschhom et al., 1980; Tanaka et al., 1996; Rogers et al., 2001; Albuquerque et al., 
2004). Preliminary experiments were therefore carried out on MSCs as a potential 
gene delivery vehicle, as it was thought they may be able to home to areas of damage 
in the brain and differentiate into neuronal cells, supplying the brain with the ADA 
enzyme and ameliorating neurological abnormalities.
The identity of the MSCs isolated from bone marrow was verified by analysis of 
antigenic expression and by their in vitro differentiation potential. The MSCs 
displayed the same phenotypic characteristics as previously reported (Haynesworth 
et al., 1992; Pittenger et al., 1999; Colter et al., 2000; Guo et al., 2001; Suva et al., 
2004), including the lack of expression of the common haematopoietic markers 
CD34 and CD45. The ability of the MSCs to differentiate into adipocytes that 
accumulate lipid vacuoles, osteocytes that produce mineralized extracellular 
matrices, chondrocytes that produce type II collagen, and neurons that express 
common neuronal markers was also demonstrated under in vitro conditions. In fact, 
they retained this multipotential nature until at least passage 12. This is a significant 
finding as some groups have previously reported the loss of differentiation potential 
after extended subculture (Muraglia et al., 2000; Quirici et al., 2002).
The neuronal differentiation was particularly important as it demonstrated the ability 
of patient mesenchymal stem cells to differentiate into cells of non-mesenchymal 
origin, termed transdifferentiation. The expression of Tau-2, NeuN and NSE and the 
lack of expression of GFAP suggested that the mesenchymal stem cells had 
differentiated into neurons rather than astrocytes. However, to confirm the
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differentiation into neuronal cells, functional and electrophysiological characteristics 
of the neurons would need to be demonstrated by measurement of the action 
potential of these cells, to ensure that the mesenchymal derived neurons have the 
same functional characteristics as brain derived neurons.
The multipotential MSCs were efficiently transduced by the lentiviral vector, and the 
ADA expression was maintained for more than four months. Transduced MSC 
maintained their ability to undergo adipogenic, osteogenic, and neuronal 
differentiation when exposed to the appropriate stimuli. Moreover, transgene 
expression was not affected by the differentiation into three different cell types, 
crucial for the application of MSC gene therapy. This has been similarly 
demonstrated in previous studies (Quintavalla et al., 2002; Zhang, X.Y., et al., 2002).
8.3.2.2 Transdifferentiation vs Fusion
Transdifferentiation, such as the differentiation of MSCs into neurons, could occur 
by two possible mechanisms. Transdifferentiation may be indirect, involving 
dedifferentiation to a more immature cell type followed by maturation down an 
alternative pathway, or it could be direct, in which there is a direct transition in the 
gene expression pattern of the cell. However, rather than differentiation, an 
alternative mechanism could be fusion, where the gene expression pattern of the 
original bone marrow stem cell is converted to that of the fusion partner. Certain 
scientists believe that in vivo experiments which have showed MSCs to be able to 
differentiate into neuronal cells or other cells have not observed transdifferentiation 
but cell fusion. Weimann et al. (2003a), for instance, observed that following BMT 
in mice, the “differentiated” cells in the brain always had 2 nuclei, one of which had 
originated from the bone marrow cell. They also demonstrated that the donor cells 
acquired the characteristics of the host cell after fusion, which would be important in 
the repair of neurological damage by gene or cell therapy. Previously, Prockop and 
colleagues (reviewed by Prockop et al., 2003) also examined the possibilities of 
fusion and differentiation. They cultured MSCs together with heat-shocked small 
airway epithelial cells. The damaged epithelial cells induced the majority of the 
MSCs to differentiate into epithelial cells. Up to 25% of the MSCs underwent cell 
fusion with the epithelial cells, a few of which also underwent nuclear fusion. Hence,
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as previously discussed, several groups believe to have observed MSC differentiation 
in vivo (Prockop et al., 1997; Azizi et al., 1998; Kopen et al., 1999), however other 
groups report on cell fusion occurring (Wang et al., 2003; Vassilopoulos et al., 2003; 
Weimann et al., 2003a and b). Therefore, there is clearly still a debate regarding the 
issue of differentiation versus fusion. However, it is quite likely that there is a 
combination of both events occurring. Ultimately, in the case of gene therapy for 
ADA deficiency it may not be crucial whether differentiation or fusion is occurring 
as the main objective is to deliver ADA expression to the brain and other organs. 
Hence differentiation of MSCs may not be required, and engraftment of the 
transduced MSCs could be sufficient. MSCs could therefore repair tissues by three 
different mechanisms: creating an environment that enhances regeneration of 
endogenous cells, transdifferentiation, or cell fusion, and either of these mechanisms 
would provide ADA expression to the areas of need.
8.3.2.3 Homing of MSCs
Prior to the use of MSCs in a clinical trial, the ability of MSCs to home to different 
tissues should be demonstrated. Therefore, the murine study in Chapter 7 was 
performed where MSCs were injected intravenously into sublethally irradiated NOD- 
SCID mice. However, no human MSCs were detected in any of the ten different 
organs analysed. This study would therefore need to be repeated to confirm the 
engraftment potential of MSCs. Reasons as to why no engraftment was observed 
could be due to, as previously discussed, that too few cells were injected or that the 
passage of the cells was too high. However, it has also been suggested that 
intravenous injections of MSCs may not be the ideal route of delivery as MSC do not 
commonly circulate in the blood stream, hence this would be an unnatural 
environment for the cells and they may be unable to cross the endothelial wall (Daga 
et al., 2002). Some engraftment has been observed in a number of previous studies 
following intravenous injections of MSCs of conditioned mice (Dao et al., 1997; 
Allay et al., 1997; Chuah et al., 2000). However this was usually detected by PCR 
and the percentage viability of the MSCs was not known. Thus it has been suggested 
that MSCs should be injected subcutaneously rather than intravenously as local 
delivery to the target organ may be required. Engraftment levels should therefore be 
assessed for the two different routes of administration in a mouse model, to
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determine whether viability of the MSCs may be reduced as a result o f circulation in 
the blood. This clearly has important implications for the use of MSCs in a human 
gene therapy trial.
Some observations suggest that mononuclear cells can cross the blood-brain barrier 
and contribute to normal turnover of microglia (Lawson et al., 1992). However, bone 
marrow transplantations have been only partially effective in treating CNS defects 
(reviewed by Neufield, 1995; Peters et al., 1996). Therefore, it may prove difficult to 
treat brain lesions effectively with either BMT or systemic administration of gene 
modified MSCs. This will be important to consider for future gene therapy trials 
using MSCs with the aim of correcting neurological abnormalities. It is vital to treat 
the neurological symptoms in ADA deficient children, and other symptoms such as 
gastrointestinal problems and immunodeficiency also need to be targeted. The route 
of administration is likely to be crucial to the success of systemic gene therapy, and 
perhaps local delivery of MSCs as well as co-injections of MSCs and HSCs 
intravenously may be required. However, this would be extremely difficult to 
perform as ADA needs to be delivered to several different organs including the brain. 
Intracerebral injections of MSCs have been successfully carried out in rats and mice 
(Schwartz et al., 2001; Jin et al., 2002) and MSCs injected following traumatic brain 
injury were found to migrate towards the site of injury (Mahmood et al., 2002 &
2004). Intracerebral transplantations of foetal nerve tissue have also been carried out 
in human trials for Parkinson’s disease although the effectiveness for this treatment 
has not yet been established (Widner et al., 1992; Peschanski et al., 1994; Levivier et 
al., 1997; Hagell et al., 1999; reviewed by Lindvall & Bjorklund, 2004). Therefore, 
although intracerebral injections may be difficult to perform it is clearly achievable. 
However, some studies (Mahmood et al., 2004) suggest that MSCs injected 
intravenously promote cellular proliferation following traumatic brain injury in rats. 
Brain injury is often seen in ADA deficient patients and may therefore enhance MSC 
engraftment. It will therefore need to be clarified whether systemically infused MSCs 
can improve brain abnormalities. However, at this stage it has only been proven that 
ADA transduced MSCs can trans-differentiate and the next step would be to 
investigate models of engraftment and in vivo activity. Therefore, it may take some 
time before clinical trials using MSCs could be performed.
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As well as examining engraftment levels in NOD/SCID mice, it would also be 
interesting to observe where the MSCs would home in an ADA deficient mouse 
model. It has been previously reported that MSCs preferentially home to areas of 
damage in animal models (Devine et al., 2001; reviewed by Labat, 2001; Mahmood 
et al., 2002 & 2004; Saito et al., 2002; Shake et al., 2002; Deng et al., 2004). It 
might therefore be expected that MSCs would home to organs damaged by ADA 
deficiency, including the brain and the haematopoietic system which have shown 
abnormalities in ADA deficient children, and the GI tract which has been found to be 
particularly damaged in the ADA deficient mouse. This would clearly be 
advantageous as the MSCs would then be ideal delivery vehicles of ADA to the areas 
of particular need. Therefore, as well as repeating the engraftment studies in the 
NOD/SCID mouse model, it would be necessary to perform this study in the more 
relevant ADA deficient mouse model to predict where MSCs would home in an 
ADA deficient patient.
The study of MSC engraftment in ADA deficient mice would also need to assess 
whether ADA-lentiviral transduced MSCs are capable of detoxifying an entire solid 
organ. In current gene therapy trials for ADA deficiency, a general detoxification of 
the entire haematopoietic system is expected. This is because the ADA substrates are 
able to enter and leave the cells from the blood, hence the ADA enzyme present in 
the transduced cells can convert these substrates and thus reduce the levels of toxic 
metabolites in the entire haematopoietic system. However, in the case of a solid 
organ such as the liver or the brain, diffusion of toxic substrates into and out of cells 
may not occur. Hence, to achieve a general detoxification of the organ by a small 
proportion of transduced cells, metabolites would need to be carried by the organ 
blood vessel system between untransduced and transduced cells. However, if 
detoxification via the organ blood vessel system does not occur, high levels of 
engraftment of transduced MSCs would probably be required. The transport of 
metabolites in the solid organs of the ADA deficient mouse should thus be examined, 
and levels of metabolites should be measured in the organs following engraftment of 
MSCs to determine whether a general detoxification of the entire organ would be 
possible.
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8.3.2.4 Protocol for the Use of MSCs in Gene Therapy
Engraftment studies are the starting point for important in vivo work that needs to be 
carried out prior to clinical trials using MSCs. Once the engraftment abilities of 
MSCs have been demonstrated, a protocol for gene therapy will need to be devised. 
Important points to consider are the type of conditioning required and the route of 
administration of the two cell types. Currently, MSCs are cultured in FCS in vitro as 
the growth of MSC has been found to be dependent on this. However, FCS should 
not be used in clinical trial as it carries the risks of possible infections and prions and 
may result in antibody formation to bovine proteins and rejection of the transplanted 
cells. Therefore, for clinical trials, the use of HSA or autologous serum should be 
further investigated as MSCs have been reported to grow well in the presence of 
autologous serum and retain their multipotential nature (Stute et al., 2004).
The issue of PEG-ADA therapy also needs to be addressed. It is now believed that if 
the patient is being treated with PEG-AD A, this needs to be withdrawn prior to gene 
therapy in order to introduce a selective advantage to the transduced cells and 
maximise the chances of immune recovery. Aiuti et al., (2002a) recently 
demonstrated that gene therapy without the use of PEG-ADA can constitute a 
successful treatment for ADA deficiency. In one study they successfully withdrew 
PEG-ADA in one patient who had previously undergone gene therapy (Aiuti et al., 
2002b) and in a second study PEG-ADA therapy was never initiated prior to gene 
therapy (Aitui et al., 2002a). The successful treatment of ADA deficiency by gene 
therapy without the use of PEG-ADA has now been reported in five patients (Aiuti et 
al., 2005). Therefore, our clinical gene therapy trial using gammaretroviral 
transduced CD34+ cells included the withdrawal of PEG-ADA to maximise the 
selective growth advantage of transduced cells. Similarly, gene therapy using 
lentiviral transduced CD34+ cells and MSCs would include the withdrawal of PEG- 
ADA. A mild conditioning was performed in the gene therapy treatment for patient 
3, similar to that described in the Milan study (Aiuti et al., 2002a), to create space for 
the transduced CD34+ cells, and this would be similarly repeated for the CD34+ 
cell/MSC gene therapy in order to encourage CD34+ cell and MSC engraftment.
It has been reported that MSCs can serve as a feeder layer for HSCs in vitro (Dexter 
& Testa, 1976; Gartner & Kaplan, 1980; Quesenberry & Lowry, 1992; Sutherland et
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al., 1993; reviewed by Deryugina & Muller-Sieburg, 1993; Majumdar et al., 1998; 
Haynesworth et al., 1996; Gordon et al., 1996; Dormady et al., 2001) and support the 
engraftment of HSCs in vivo in animal models (Nolta et al., 1994 & 2002: Brouard et 
al., 1998; Noort et al., 2002: Bensidhoum et al., 2004) and in humans (Koc et al., 
1999, 2000, 2001). Hence, to maximise the engraftment of HSCs and MSCs, co­
injections of MSCs and HSCs would be necessary. Therefore, if clinical trials are to 
be carried out using MSCs and HSCs, several issues such as these will need to be 
examined whilst devising the gene therapy protocol.
8.3.2.5 Identification of Primitive MSCs
Further studies should be performed to identify the most primitive and multipotential 
MSC which could be of even more use in gene therapy for ADA deficiency than the 
MSCs currently being studied. It has been suggested that multipotent adult 
progenitor cells (MAPCs) are more immature and demonstrate greater plasticity than 
the MSCs (Jiang et al., 2002). MAPCs do not only differentiate into MSCs but also 
into cells with visceral mesoderm, neuroectoderm and endoderm characteristics in 
vitro. When transplanted, they also differentiated into HSCs as well as epithelium of 
the liver, lung and gut. If it is confirmed that this cell type is capable of 
differentiating into HSCs then MAPCs may be the only cells required for the 
systemic gene therapy treatment of ADA deficiency. It will therefore be important to 
definitively identify the most multipotential mesenchymal stem cell. The engraftment 
potential of these cells should also be assessed following different routes of 
administration, as the identification of a multipotential cell capable of engrafting into 
several tissues following intravenous administration is pivotal to the success of a 
systemic treatment for ADA deficiency.
8.3.2.6 Umbilical Cord Blood MSCs
Several studies have been carried out on MSCs isolated from umbilical cord blood 
(UCB). Their existence in UCB is still being debated (Wexler et al., 2002), however, 
several groups have reported the successful isolation of multipotential MSCs from 
UCB (Erices et al., 2000; Romanov et al., 2003; Lee O.K. et al., 2004; Lee, M.W. et 
al., 2004). MSC from UCB are believed to have a wider differentiation potential as
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they are more immature cells. Hence, the use of these cells could prove to be 
valuable if the ADA deficient child is diagnosed prenatally. The advantage of using 
UCB MSCs is that the child could be treated at a young age which may improve the 
chances of ameliorating neurological and other abnormalities before irreversible 
damage occurs due to continual ADA deficiency, and furthermore the risk of 
developing infections would be much reduced. Moreover, PEG-ADA may not need 
to be administered if the child is treated immediately with gene therapy, hence 
maximising the selective growth advantage of the transduced cells. In the case of 
patient 3 who was treated with gene therapy in this study, the persistent EBV 
infection may have been avoided had he received gene therapy earlier. Moreover, as 
a result of the poor response to PEG-ADA for a period of time prior to gene therapy, 
thymic function may have diminished and compromised immune recovery. The 
gene therapy treatment may therefore have been more effective if the patient was 
treated at a younger age, and if the disease was diagnosed prenatally UCB MSCs 
could have potentially been used.
8.4 I n  U t e r o  C e l l  a n d  G e n e  T h e r a p y
If ADA deficiency was diagnosed pre-natally, treating ADA deficient patients prior 
to disease onset could be done by in utero cell or gene therapy. Although not proven, 
it is very likely that the lack of ADA during development results in considerable 
damage to different organs of the foetus. With conventional gene therapy, usually 
performed when the child is a few months old, damage to tissues might already have 
occurred due to the lack of ADA during gestation and the immediate post-natal 
period. However, with in utero cell or gene therapy, the foetus would develop with 
ADA expression is some cells during the latter part of gestation and the post-natal 
period. This may therefore avoid damage to the child as a result of lack of ADA 
during gestation and the early part of its life that might occur with conventional gene 
therapy. Advantages of in utero cell or gene therapy therefore include the possible 
prevention of early disease related tissue damage, the possibility of postnatal 
tolerance to the vector and transgene due to the underdeveloped immune system in 
the early stages of development (although one would have to ensure that vector 
tolerance does not compromise the immune defence against the wild type virus), and 
the possibility of targeting early stem cells believed to be highly plastic. However, 
with in utero gene therapy there is a major concern about the possibility of
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inadvertent germ line modification (reviewed by Coutelle et al., 2003; by Jones, 
2004; and by Chauhan et al., 2004). Vector DNA has been detected by PCR in the 
gonads of foetal sheep treated with in utero gene therapy, however, no germ line 
transmission could be found by PCR analysis of sperm derived from three rams bom 
after breeding of in utero treated animals (Porada et al., 2004). Due to the concerns 
of germ line modifications, direct injection of the transgene carrying vector is 
currently not permitted and is unlikely to be so for some period of time according to 
the Gene Therapy Advisory Committee (GTAC), although injection of non­
transduced or transduced cells could be possible.
The administration of MSCs and HSCs to the foetus should be relatively straight­
forward as the foetal circulation can be accessed trans-abdominally under ultrasound 
from 17 weeks gestation. The risk of germ-line transmission at this stage would be 
similar to conventional gene therapy as compartmentalisation of primordial germ 
cells occurs at week 7. In utero gene therapy has been performed in mice and sheep 
(Porada et al., 2004 & 2005; Dejneka et al., 2004; Gregory et al., 2004; Shen et al.,
2005), and with some success in a small number of trials during human pregnancies 
including for X-SCID and Osteogenesis Imperfecta (Wengler et al., 1996; Le Blanc 
et al., 2005). In utero gene therapy using MSCs in a sheep model resulted in low 
level multiorgan engraftment (Schoeberlein et al., 2005). The ex vivo gene therapy 
protocol currently utilised for post-natal gene therapy might be difficult to use for in 
utero gene therapy as autologous cells could be difficult to obtain. However, the 
reported existence of MSCs in first trimester foetal blood may make in utero gene 
therapy with MSCs possible (Campagnoli et al., 2001 & 2002). If autologous cells 
are difficult to obtain, another option is to perform in utero cell therapy, which would 
not carry the risks of germ-line transmission (reviewed by Flake, 2004). This would 
involve the administration of MSCs from a normal donor which would provide the 
foetus with ADA positive cells thus avoiding the need for transducing the cells with 
an ADA vector. However, this would clearly then rely on finding a matched donor, 
which is usually only available for one third of the patients.
In utero cell or gene therapy for ADA deficiency should be tested extensively in 
animal models prior to the initiation of clinical trials. It would be interesting to 
perform studies in ADA deficient mice, comparing immunological and non-
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immunological symptoms in groups of mice that received either in utero cell or gene 
therapy or post-natal cell or gene therapy. It would be expected that the mice 
receiving in utero therapy would sustain less damage to different organs and show a 
better immune recovery. However, the significance of the results of these studies 
would be limited by the fact that mice display an even stronger requirement for ADA 
during gestation than humans, as ADA deficient mice have been found to die peri- 
natally. Differences in response might therefore be observed in ADA deficient mice 
and humans treated with in utero therapy. Nevertheless, it would still be necessary to 
perform these murine studies and more pre-clinical experiments to determine 
whether there is a risk of germ line transmission prior to performing in utero gene 
therapy in humans. Therefore, this could be another step forward in the treatment of 
ADA deficiency as it may be crucial to deliver ADA at the earliest stage possible to 
minimise the damage to different organs as a result of an absence of ADA.
8.5 C o n c lu d in g  R e m a r k s
This study has highlighted that PEG-ADA therapy can be a successful treatment for 
some ADA deficient patients. For others, however, gene therapy is a good alternative 
treatment when a fully matched bone marrow donor is not available and when PEG- 
ADA therapy is ineffective. Current gene therapy trials involve the use of transduced 
CD34+ stem cells, which have proven to successfully treat the immunological 
symptoms of ADA deficiency. However, lentiviral transduced MSCs together with 
CD34+ cells could constitute a more systemic treatment for ADA deficiency than 
gene therapy using CD34+ cells alone. The main findings of this study were:
• PEG-ADA therapy is a successful treatment for some ADA deficient 
patients.
• The SFada/W gammaretroviral vector efficiently transduced a number of cell 
types, including patient primary skin fibroblasts and haematopoietic stem 
cells, resulting in enhanced ADA expression and activity.
• Gene therapy using CD34+ cells improved the immunological function of 
one ADA deficient patient for whom PEG-ADA therapy was not successful.
• The ADA lentiviral vector was more efficient than the gammaretroviral 
vector at transducing several cell types, including patient primary skin
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fibroblasts and in particular B-lymphoblastoid cells and mesenchymal stem 
cells.
• Lentiviral transductions resulted in enhanced ADA expression in 
haematopoietic stem cells, and enhanced ADA expression and activity in 
fibroblasts, B-LCLs and MSCs.
• Mesenchymal stem cells were readily isolated from bone marrow and their
multipotential nature was demonstrated in vitro by differentiation into four
different cell lineages.
• The multilineage potential of MSCs was maintained following lentiviral 
transductions and transgene expression was retained following 
differentiation.
8.6  F u t u r e  W o r k  R e l a t e d  t o  t h is  St u d y
Further work in relation to this study is listed below:
• Evaluate the WPRE to confirm that the WPRE does indeed increase
transgene expression and does not constitute a cancer risk.
• Identify the most multipotential stem cell, possibly MAPCs or UCB MSCs.
• Perform functional studies on differentiated MSCs including measurement of 
action potential of MSC derived neurons to confirm that MSC derived 
neurons are functional.
• Confirm the homing abilities of MSCs in the NOD/SCID mouse model.
• Perform engraftments of transduced MSCs and CD34+ cells to study MSC 
support of HSC engraftment and to ultimately rescue the ADA deficient 
mouse.
• Perform further assessments of ADA deficient patients treated with PEG- 
ADA, BMT and gene therapy to identify which treatment results in better 
immune reconstitution, improvement in non-immunological abnormalities 
and overall systemic detoxification.
231
C h a p t e r  8
8.7 P u b l ic a t io n s  R e l a t e d  t o  t h is  St u d y
Bjorkegren, E.K.M., Parsley, K.L., Fairbanks, L.D., Gilmour, K.C., Kuehlcke, K., 
Kinnon, C., Thrasher, A.J., Gaspar, H.B (2003). Development of Gene Therapy 
Vectors for the Treatment of Adenosine Deaminase (ADA)-Deficient Severe 
Combined Immunodeficiency (SCID). Poster presentated at the European Society o f  
Gene Therapy Annual Meeting, Edinburgh.
Gaspar H.B, Bjorkegren E, Parsley K, Gilmour K.G, Fairbanks L, King D et al., 
(2004). Somatic gene therapy for ADA SCID following cessation of PEG-ADA and
t huse of a mild conditioning regime. Presented at 11 meeting o f the European Society 
o f Immunodeficiencies, Versailles, France.
Hubert B. Gaspar, Emma Bjorkegren, Katherine Parsley, Kimberly C. Gilmour, Jo 
Sinclair, Fang Zhang, Lynette D. Fairbanks, Doug King, Graham Davies, Paul A. 
Veys Christine Kinnon, Adrian J. Thrasher (2005). Somatic Gene Therapy for ADA- 
SCID Following Cessation of PEG-ADA and Use of a Mild Conditioning Regime. 
Presented at the British Society o f Gene Therapy Annual Meeting, Manchester, UK.
Hubert B. Gaspar, Emma Bjorkegren, Katherine Parsley, Kimberly C. Gilmour, Jo 
Sinclair, Fang Zhang, Lynette D. Fairbanks, Doug King, Graham Davies, Paul A. 
Veys Christine Kinnon, Adrian J. Thrasher (2005). Somatic Gene Therapy for ADA- 
SCID Following Cessation of PEG-ADA and Use of a Mild Conditioning Regime. 
Presented at the American Society o f Gene Therapy Annual Meeting, St Louis, 
Missouri, USA.
Gaspar, H.B., Bjorkegren, E., Parsley, K., Gilmour, K., King, D., Sinclair, J., Adams 
S., Fairbanks, L.D., Gaspar, J., Henderson, L, Davies, E.G., Veys, P.A., Kinnon, C. 
and Thrasher, A.J. (2005). Successful reconstitution of immune function in ADA- 
SCJD by stem cell gene therapy following cessation of PEG-ADA and use of mild 
pre-conditioning. Submitted fo r  review.
232
R e f e r e n c e s
R e f e r e n c e s
(1999), Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International 
Union of Immunological Societies, Clin.Exp.Immunol. 118 Suppl 1: 1-28
Abeles RH, Fish S, Lapinskas B (1982), S-Adenosylhomocysteinase: mechanism of inactivation by 2'- 
deoxyadenosine and interaction with other nucleosides, Biochemistry 21: 5557-5562
Adams A, Harkness RA (1976), Adenosine deaminase activity in thymus and other human tissues, 
Clin.Exp.Immunol. 26: 647-649
Aggarwal S, Pittenger MF (2005), Human mesenchymal stem cells modulate allogeneic immune cell 
responses, Blood 105: 1815-1822
Aitken DA, Kleijer WJ, Niermeijer MF, Herbschleb-Voogt E, Galjaard H (1980), Prenatal detection 
of a probable heterozygote for ADA deficiency and severe combined immunodeficiency disease using 
a microradioassay, Clin.Genet. 17: 293-298
Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, 
Carlucci F, Marinello E, Cattaneo F, Vai S, Servida P, Miniero R, Roncarolo MG, Bordignon C 
(2002a), Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative 
conditioning, Science 296: 2410-2413
Aiuti A, Vai S, Mortellaro A, Casorati G, Ficara F, Andolfi G, Ferrari G, Tabucchi A, Carlucci F, 
Ochs HD, Notarangelo LD, Roncarolo MG, Bordignon C (2002b), Immune reconstitution in ADA- 
SCID after PBL gene therapy and discontinuation of enzyme replacement, Nat.Med. 8 : 423-425
Aiuti A, Benninghoff A, Cassani B, Cattaneo F, Andolfi G, Mirolo M, Caputo A, Callegaro L, 
Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Miniero R, Roncarolo MG, Bordignon C. 
Hematopoietic Stem Cell Gene Therapy for ADA-Deficient SCID. 2005. Presentation in the 11th 
Meeting of the European Society for Immunodeficiencies.
Akatsuka Y, Goldberg TA, Kondo E, Martin EG, Obata Y, Morishima Y, Takahashi T, Hansen JA 
(2002), Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines, 
Tissue Antigens 59: 502-511
Albert D, Bluestein HG, Thompson L, Seegmiller JE (1984), The mechanism of inhibition and 
"reversal" of mitogen-induced lymphocyte activation in a model of adenosine deaminase deficiency, 
Cell Immunol. 8 6 : 510-517
Albuquerque W, Gaspar HB (2004), Bilateral sensorineural deafness in adenosine deaminase-deficient 
severe combined immunodeficiency, J.Pediatr. 144: 278-280
Aldrich MB, Chen W, Blackburn MR, Martinez-Valdez H, Datta SK, Kellems RE (2003), Impaired 
germinal center maturation in adenosine deaminase deficiency, J.Immunol. 171: 5562-5570
Allay JA, Dennis JE, Haynesworth SE, Majumdar MK, Clapp DW, Shultz LD, Caplan Al, Gerson SL 
(1997), LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived 
human osteogenic mesenchymal progenitors, Hum.Gene Ther. 8 : 1417-1427
Apasov SG, Koshiba M, Chused TM, Sitkovsky MV (1997), Effects of extracellular ATP and 
adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled 
purinergic receptor, J.Immunol. 158: 5095-5105
Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV (2001), Adenosine deaminase 
deficiency increases thymic apoptosis and causes defective T cell receptor signalling, J  Clin Invest. 
108: 131-41
233
R e f e r e n c e s
Armentano D, Yu SF, KantofFPW, von Ruden T, Anderson WF, Gilboa E (1987), Effect of internal 
viral sequences on the utility of retroviral vectors, J. Virol. 61: 1647-1650
Arredondo-Vega FX, Santisteban I, Daniels S, Toutain S, Hershfield MS (1998), Adenosine 
deaminase deficiency: genotype-phenotype correlations based on expressed activity of 29 mutant 
alleles, AmJ.Hum.Genet. 63: 1049-1059
Arredondo-Vega FX, Santisteban I, Richard E, Bali P, Koleilat M, Loubser M, Al Ghonaium A, Al 
Helali M, Hershfield MS (2002), Adenosine deaminase deficiency with mosaicism for a "second-site 
suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement 
therapy, Blood 99: 1005-1013
Athanasou NA, Quinn J, Brenner MK, Prentice HG, Graham A, Taylor S, Flannery D, McGee JO 
(1990), Origin of marrow stromal cells and haemopoietic chimaerism following bone marrow 
transplantation determined by in situ hybridisation, Br.J. Cancer 61: 385-389
Azizi SA, Stokes D, Augelli BJ, DiGirolamo C, Prockop DJ (1998), Engraftment and migration of 
human bone marrow stromal cells implanted in the brains of albino rats—similarities to astrocyte 
grafts, Proc.Natl.Acad.Sci.U.S.A 95: 3908-3913
Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC (2004), 
Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium, Nature 428: 
668-673
Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker 
D, Deans R, Moseley A, Hofftnan R (2002), Mesenchymal stem cells suppress lymphocyte 
proliferation in vitro and prolong skin graft survival in vivo, Exp.Hematol. 30: 42-48
Baum C, Hegewisch-Becker S, Eckert HG, Stocking C, Ostertag W (1995), Novel retroviral vectors 
for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells, J. Virol. 
69: 7541-7547
Baum C, Itoh K, Meyer J, Laker C, Ito Y, Ostertag W (1997), The potent enhancer activity of the 
polycythemic strain of spleen focus-forming virus in haematopoietic cells is governed by a binding 
site for Spl in the upstream control region and by a unique enhancer core motif, creating an exclusive 
target for PEBP/CBF, J  Virol. 71, 6323-6331
Baum C, Peinert S, Carpinteiro A, Eckert HG, Fairbaim LJ (2000), Genetic modification of 
haematopoietic cells for combined resistance to podophyllotoxins, other agents covered by MDR1- 
mediated efflux activity and nitrosoureas, Bone Marrow Transplant. 25 Suppl 2: S71-S74
Baxter MA, Wynn RF, Deakin JA, Bellantuono I, Edington KG, Cooper A, Besley GT, Church HJ, 
Wraith JE, Carr TF, Fairbaim LJ (2002), Retrovirally mediated correction of bone marrow-derived 
mesenchymal stem cells from patients with mucopolysaccharidosis type I, Blood 99: 1857-1859
Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbaim LJ, Bellantuono I (2004), Study of telomere 
length reveals rapid aging of human marrow stromal cells following in vitro expansion, Stem Cells 22: 
675-682
Bensidhoum M, Chapel A, Francois S, Demarquay C, Mazurier C, Fouillard L, Bouchet S, Bertho JM, 
Gourmelon P, Aigueperse J, Charbord P, Gorin NC, Thierry D, Lopez M (2004), Homing of in vitro 
expanded Stro-1- or Stro-l+ human mesenchymal stem cells into the NOD/SCID mouse and their role 
in supporting human CD34 cell engraftment, Blood 103: 3313-3319
Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME (1992), Evidence for an inverse 
relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell 
cultures, J.Cell Sci. 102 ( Pt 2): 341-351
Bestor T (2000), Gene silencing as a threat to the success of gene therapy, J  Clin Invest. 105:409-411
234
R e f e r e n c e s
Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J (2005), 
Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell 
unresponsiveness, Blood 105: 2214-2219
Bhatia M, Bonnet D, Kapp U, Wang JC, Murdoch B, Dick JE (1997), Quantitative analysis reveals 
expansion of human hematopoietic repopulating cells after short-term ex vivo culture, J. Exp. Med. 
186: 619-624
Bhatia M, Bonnet D, Murdoch B, Gan 01, Dick JE (1998), A newly discovered class of human 
hematopoietic cells with SCID-repopulating activity, Nat. Med. 4: 1038-1045
Blackburn MR, Datta SK, Kellems RE (1998), Adenosine deaminase-deficient mice generated using a 
two-stage genetic engineering strategy exhibit a combined immunodeficiency, J.Biol.Chem. 273: 
5093-5100
Blackburn MR, Aldrich M, Volmer JB, Chen W, Zhong H, Kelly S, Hershfield MS, Datta SK, 
Kellems RE (2000a), The use of enzyme therapy to regulate the metabolic and phenotypic 
consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and 
immunologic abnormalities, J.Biol.Chem. 275: 32114-32121
Blackburn MR, Volmer JB, Thrasher JL, Zhong H, Crosby JR, Lee JJ, Kellems RE (2000b), 
Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in 
alveogenesis, pulmonary inflammation, and airway obstruction, J.Exp.Med. 192: 159-170
Blease R (1992), Development of gene therapy for immunodeficiency: adenosine deaminase 
deficiency, Pediatric Research 3: 49-55
Blease R, Culver K, Miller A, Carter C, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, 
Tolstoshev P, Greenblatt J, Rosenberg S, Klein H, Berger M, Mullen C, Ramsey W, Muul L, Morgan 
R, Anderson W (1995), T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 
years, Science 270: 475-480
Bodine DM, Karlsson S, Nienhuis AW (1989), Combination of interleukins 3 and 6 preserves stem 
cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells, 
Proc.Natl.Acad.Sci. U.S.A 8 6 : 8897-8901
Bodine PV, Trailsmith M, Komm BS (1996), Development and characterization of a conditionally 
transformed adult human osteoblastic cell line, J.Bone Miner.Res. 11: 806-819
Bollinger ME, Arredondo-Vega FX, Santisteban I, Schwarz K, Hershfield MS, Lederman HM (1996), 
Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency, N.Engl.J.Med. 
334: 1367-1371
Bolotin E, Annett G, Parkman R, Weinberg K (1999), Serum levels of IL-7 in bone marrow transplant 
recipients: relationship to clinical characteristics and lymphocyte count, Bone Marrow Transplant. 23: 
783-788
Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E, Maggioni D, 
Rossi C, Servida P, . (1995), Gene therapy in peripheral blood lymphocytes and bone marrow for 
ADA- immunodeficient patients, Science 270: 470-475
Borkowsky W, Gershon AA, Shenkman L, Hirschhom R (1980), Adenosine deaminase deficiency 
without immunodeficiency: clinical and metabolic studies, Pediatr.Res. 14: 885-889
Borzy MS, Schulte-Wissermann H, Gilbert E, Horowitz SD, Pellett J, Hong R (1979), Thymic 
morphology in immunodeficiency diseases: results of thymic biopsies, Clin.Immunol.Immunopathol. 
12: 31-51
235
R e f e r e n c e s
Bosch A, Perret E, Desmans N, Trono D, Heard JM (2000), Reversal of pathology in the entire brain 
of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer, Hum. Gene Ther. 11: 
1139-1150
Bovia F, Salmon P, Matthes T, Kvell K, Nguyen TH, Wemer-Favre C, Barnet M, Nagy M, Leuba F, 
Arrighi JF, Piguet V, Trono D, Zubler RH (2003), Efficient transduction of primary human B 
lymphocytes and nondividing myeloma B cells with HIV-1-derived lentiviral vectors, Blood  101: 
1727-1733
Brady TG, O’Donovan Cl (1965), A study of the tissue distribution of adenosine deaminase in six 
mammal species, Comp Biochem.Physiol 14: 101-120
Brouard N, Chapel A, Neildez-Nguyen TM, Granotier C, Khazaal I, Peault B, Thierry D (1998), 
Transplantation of stromal cells transduced with the human IL3 gene to stimulate hematopoiesis in 
human fetal bone grafts in non-obese, diabetic-severe combined immunodeficiency mice, Leukemia 
12: 1128-1135
Brox L, Ng A, Pollock E, Belch A (1984), DNA strand breaks induced in human T-lymphocytes by 
the combination of deoxyadenosine and deoxycoformycin, Cancer Res. 44: 934-937
Bmder SP, Fink DJ, Caplan Al (1994), Mesenchymal stem cells in bone development, bone repair, 
and skeletal regeneration therapy, J.Cell Biochem. 56: 283-294
Bruder SP, Jaiswal N, Haynesworth SE (1997), Growth kinetics, self-renewal, and the osteogenic 
potential of purified human mesenchymal stem cells during extensive subcultivation and following 
cryopreservation, J.Cell Biochem. 64: 278-294
Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, Roberts JL, Puck JM 
(1997), Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in 
one hundred eight infants, J.Pediatr. 130: 378-387
Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, Myers LA, Ward FE (1999), 
Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency, 
N.Engl.J.Med. 340:508-516
Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, 
Emerman M, Stevenson M (1993), A nuclear localization signal within HIV-1 matrix protein that 
governs infection of non-dividing cells, Nature 365: 666-669
Bums JC, Friedmann T, Driever W, Burrascano M, Yee JK (1993), Vesicular stomatitis vims G 
glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer 
into mammalian and nonmammalian cells, Proc.Natl.Acad.Sci. U.S.A 90: 8033-8037
Bushman F, et al. Where do lentiviral and oncoretroviral vectors integrate in the human genome. 
2003. ESGT Conference, Edinburgh.
Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM (2001), Identification of 
mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow, 
Blood 98: 2396-2402
Campagnoli C, Bellantuono I, Kumar S, Fairbaim LJ, Roberts I, Fisk NM (2002), High transduction 
efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex 
vivo gene therapy, BJOG. 109: 952-954
Cannon PM, Kim N, Kingsman SM, Kingsman AJ (1996), Murine leukemia virus-based Tat- 
inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency 
vims gene therapy, J. Virol. 70: 8234-8240
Caparrelli DJ, Shake JG, Baumgartner WA, Conte JV (2001), Heterotopic abdominal heart 
transplantation: the answer to the donor shortage?, J.Heart Lung Transplant. 20: 187-188
236
R e f e r e n c e s
Caplan Al (1990), Stem cell delivery vehicle, Biomaterials 11: 44-46 
Caplan Al (1991), Mesenchymal stem cells, J.Orthop.Res. 9: 641-650
Carpenter MK, Cui X, Hu ZY, Jackson J, Sherman S, Seiger A, Wahlberg LU (1999), In vitro 
expansion of a multipotent population of human neural progenitor cells, Exp.Neurol. 158: 265-278
Carson DA, Kaye J, Seegmiller JE (1977), Lymphospecific toxicity in adenosine deaminase 
deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s), 
Proc.Natl.Acad.Sci. U.S.A 74: 5677-5681
Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, 
Kohn DB, Crooks GM (1999), Stable transduction of quiescent CD34(+)CD38(-) human 
hematopoietic cells by HIV-1-based lentiviral vectors, Proc.Natl.Acad.Sci.U.S.A 96: 2988-2993
Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, 
Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000), Gene therapy of human severe 
combined immunodeficiency (SCID)-Xl disease, Science 288: 669-672
Cederbaum SD, Kaitila I, Rimoin DL, Stiehm ER (1976), The chondro-osseous dysplasia of 
adenosine deaminase deficiency with severe combined immunodeficiency, J.Pediatr. 89: 737-742
Certo JL, Shook BF, Yin PD, Snider JT, Hu WS (1998), Nonreciprocal pseudotyping: murine 
leukemia virus proteins cannot efficiently package spleen necrosis virus-based vector RNA, J. Virol. 
72: 5408-5413
Challita PM, Kohn DB (1994), Lack of expression from a retroviral vector after transduction of 
murine hematopoietic stem cells is associated with methylation in vivo, Proc.Natl.Acad.Sci.U.S.A 91: 
2567-2571
Chang LJ, Urlacher V, Iwakuma T, Cui Y, Zucali J (1999), Efficacy and safety analyses of a 
recombinant human immunodeficiency vims type 1 derived vector system, Gene Ther. 6 : 715-728
Chauhan DP, Srivastava AS, Moustafa ME, Shenouda S, Carrier E (2004), In utero gene therapy: 
prospect and future, Curr.Pharm.Des 10: 3663-3672
Chechik BE, Schrader WP, Minowada J (1981), An immunomorphologic study of adenosine 
deaminase distribution in human thymus tissue, normal lymphocytes, and hematopoietic cell lines, 
J.Immunol. 126: 1003-1007
Chechik BE, Schrader WP, Perets A, Fernandes B (1984), Immunohistochemical localization of 
adenosine deaminase in human benign extrathymic lymphoid tissues and B-cell lymphomas, Cancer 
53: 70-78
Check E (2005), Gene therapy put on hold as third child develops cancer, Nature 433: 561
Chen SH, Ochs HD, Scott CR, Giblett ER, Tingle AJ (1978), Adenosine deaminase deficiency: 
disappearance of adenine deoxynucleotides from a patient's erythrocytes after successful marrow 
transplantation, J. Clin.Invest 62: 1386-1389
Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP 
(2004), Effect on left ventricular function of intracoronary transplantation of autologous bone marrow 
mesenchymal stem cell in patients with acute myocardial infarction, Am.J.Cardiol. 94: 92-95
Cheng SL, Yang JW, Rifas L, Zhang SF, Avioli LV (1994), Differentiation of human bone marrow 
osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone, 
Endocrinology 134: 277-286
237
R e f e r e n c e s
Cho KJ, Trzaska KA, Greco SJ, McArdle J, Wang FS, Ye JH, Rameshwar P (2005), Neurons Derived 
From Human Mesenchymal Stem Cells Show Synaptic Transmission and Can Be Induced to Produce 
the Neurotransmitter Substance P by Interleukin-1 {alpha}, Stem Cells 23: 383-391
Chuah MK, Van Damme A, Zwinnen H, Goovaerts I, Vanslembrouck V, Collen D, VandenDriessche 
T (2000), Long-term persistence of human bone marrow stromal cells transduced with factor VIII- 
retroviral vectors and transient production of therapeutic levels of human factor VIII in 
nonmyeloablated immunodeficient mice, Hum.Gene Ther. 11: 729-738
Clark BR, Keating A (1995), Biology of bone marrow stroma, Ann.N. Y.Acad.Sci. 770: 70-78
Coffin JM (1996), Retroviridae: the viruses and their replication, in Fundamental Virology, ed. Fields 
BN, Knipe DM, and Howley PM, Lippincott-Raven Publishers, Philadelphia p 637-844
Cohen A, Hirschhom R, Horowitz SD, Rubinstein A, Polmar SH, Hong R, Martin DW, Jr. (1978), 
Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency, 
Proc.Natl.Acad.Sci.U.S.A 75: 472-476
Cohen F, Cejka J, Chang CH, Brough AJ, Rowe BJ, Gaines PJ (1979), Adenosine deaminase 
deficiency and immunodeficiency, in Inborn Errors o f  Specific Immunity, ed. Pollara B, Pickering RJ, 
Meuwissen HJ, and Porter IH, Academic, New York p 401
Cole BO, Welbury RR, Bond E, Abinun M (2000), Dental manifestations in severe combined 
immunodeficiency following bone marrow transplantation, Bone Marrow Transplant. 25: 1007-1009
Colter DC, Class R, DiGirolamo CM, Prockop DJ (2000), Rapid expansion of recycling stem cells in 
cultures of plastic-adherent cells from human bone marrow, Proc.Natl.Acad.Sci.U.S.A 97: 3213-3218
Comans-Bitter WM, de Groot R, van den BR, Neijens HJ, Hop WC, Groeneveld K, Hooijkaas H, van 
Dongen JJ (1997), Immunophenotyping of blood lymphocytes in childhood. Reference values for 
lymphocyte subpopulations, J.Pediatr. 130: 388-393
Conget PA, Minguell JJ (1999), Phenotypical and functional properties of human bone marrow 
mesenchymal progenitor cells, J.Cell Physiol 181: 67-73
Consiglio A, Quattrini A, Martino S, Bensadoun JC, Dolcetta D, Trojani A, Benaglia G, Marchesini S, 
Cestari V, Oliverio A, Bordignon C, Naldini L (2001), In vivo gene therapy of metachromatic 
leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning 
impairments in affected mice, Nat.Med. 7: 310-316
Coutelle C, Themis M, Waddington S, Gregory L, Nivsarkar M, Buckley S, Cook T, Rodeck C, 
Peebles D, David A (2003), The hopes and fears of in utero gene therapy for genetic disease—a 
review, Placenta 24 Suppl B: SI 14-S121
Daddona PE, Kelley WN (1977), Human adenosine deaminase. Purification and subunit structure, 
J.Biol.Chem. 252: 110-115
Daddona PE, Kelley WN (1978), Human adenosine deaminase binding protein. Assay, purification, 
and properties, J.Biol.Chem. 253: 4617-4623
Daddona PE, Kelley WN (1980), Analysis of normal and mutant forms of human adenosine 
deaminase - a review, Mol. Cell Biochem. 29: 91 -101
Daddona PE, Mitchell BS, Meuwissen HJ, Davidson BL, Wilson JM, Koller CA (1983), Adenosine 
deaminase deficiency with normal immune function. An acidic enzyme mutation, J.Clin.Invest 72: 
483-492
Daga A, Muraglia A, Quarto R, Cancedda R, Corte G (2002), Enhanced engraftment of EPO- 
transduced human bone marrow stromal cells transplanted in a 3D matrix in non-conditioned 
NOD/SCID mice, Gene Ther. 9: 915-921
238
R e f e r e n c e s
Dao MA, Pepper KA, Nolta JA (1997), Long-term cytokine production from engineered primary 
human stromal cells influences human hematopoiesis in an in vivo xenograft model, Stem Cells 15: 
443-454
Dave UP, Jenkins NA, Copeland NG (2004), Gene therapy insertional mutagenesis insights, Science 
303: 333
Davies EG, Levinsky RJ, Webster DR, Simmonds HA, Perrett D (1982), Effect of red cell 
transfusions, thymic hormone and deoxycytidine in severe combined immunodeficiency due to 
adenosine deaminase deficiency, Clin.Exp.Immunol. 50: 303-310
De Palma M, Montini E, de Sio FR, Benedicenti F, Gentile A, Medico E, Naldini L (2005), Promoter 
trapping reveals significant differences in integration site selection between MLV and HIV vectors in 
primary hematopoietic cells, Blood 105: 2307-2315
Deans RJ, Moseley AB (2000), Mesenchymal stem cells: biology and potential clinical uses, 
Exp.Hematol. 28: 875-884
Dejneka NS, Surace EM, Aleman TS, Cideciyan AV, Lyubarsky A, Savchenko A, Redmond TM, 
Tang W, Wei Z, Rex TS, Glover E, Maguire AM, Pugh EN, Jr., Jacobson SG, Bennett J (2004), In 
utero gene therapy rescues vision in a murine model of congenital blindness, Mol. Ther. 9: 182-188
Demaison C, Brouns G, Blundell MP, Goldman JP, Levinsky RJ, Grez M, Kinnon C, Thrasher AJ 
(2000), A defined window for efficient gene marking of severe combined immunodeficient- 
repopulating cells using a gibbon ape leukemia virus-pseudotyped retroviral vector, Hum. Gene Ther. 
11:91-100
Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, Grez M, Thrasher AJ (2002), 
High-level transduction and gene expression in hematopoietic repopulating cells using a human 
immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an 
internal spleen focus forming virus promoter, Hum.Gene Ther. 13: 803-813
Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z, You S, Deng H, Zhao RC (2004), Allogeneic bone 
marrow-derived flk-l+Sca-1- mesenchymal stem cells leads to stable mixed chimerism and donor- 
specific tolerance, Exp.Hematol. 32: 861-867
Deryugina El, Muller-Sieburg CE (1993), Stromal cells in long-term cultures: keys to the elucidation 
of hematopoietic development?, Crit Rev. Immunol. 13: 115-150
Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, 
Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman R (2001), 
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following 
systemic infusion, Exp.Hematol. 29: 244-255
Dexter TM, Testa GM (1976), Differentiation and proliferation of haemaopoietic cells in culture, in 
Methods in Cell Biology, ed. Prescott DM, Academic Press, New York p 387-405
Dexter TM, Allen TD, Lajtha LG (1977), Conditions controlling the proliferation of haemopoietic 
stem cells in vitro, J.Cell Physiol 91: 335-344
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM 
(2002), Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or 
nonspecific mitogenic stimuli, Blood 99: 3838-3843
Donahue RE, Kessler SW, Bodine D, McDonagh K, Dunbar C, Goodman S, Agricola B, Byrne E, 
Raffeld M, Moen R, . (1992), Helper virus induced T cell lymphoma in nonhuman primates after 
retroviral mediated gene transfer, J.Exp.Med. 176: 1125-1135
Donello JE, Loeb JE, Hope TJ (1998), Woodchuck hepatitis virus contains a tripartite 
posttranscriptional regulatory element, J. Virol. 72: 5085-5092
239
R e f e r e n c e s
Dooley T, Fairbanks LD, Simmonds HA, Rodeck CH, Nicolaides KH, Soothill PW, Stewart P, 
Morgan G, Levinsky RJ (1987), First trimester diagnosis of adenosine deaminase deficiency, 
Prenat.Diagn. 7: 561-565
Dormady SP, Bashayan O, Dougherty R, Zhang XM, Basch RS (2001), Immortalized multipotential 
mesenchymal cells and the hematopoietic microenvironment, J.Hematother.Stem Cell Res. 10: 125- 
MO
Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L (1998), A third-generation 
lentivirus vector with a conditional packaging system, J. Virol. 72: 8463-8471
Dvorin JD, Bell P, Maul GG, Yamashita M, Emerman M, Malim MH (2002), Reassessment of the 
roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import, 
J.Virol. 76: 12087-12096
Dyminski JW, Daoud A, Lampkin BC, Limouze S, Donofrio J, Coleman MS, Hutton JJ (1979), 
Immunological and biochemical profiles in response to transfusion therapy in an adenosine 
deaminase-deficient patient with severe combined immunodeficiency disease, 
Clin.Immunol.Immunopathol. 14: 307-326
Eaves CJ, Cashman JD, Kay RJ, Dougherty GJ, Otsuka T, Gaboury LA, Hogge DE, Lansdorp PM, 
Eaves AC, Humphries RK (1991), Mechanisms that regulate the cell cycle status of very primitive 
hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative 
regulators produced by stromal cells within the adherent layer, Blood 78: 110-117
Edwards YH, Hopkinson DA, Harris H (1971), Adenosine deaminase isozymes in human tissues, 
Ann.Hum. Genet. 35: 207-219
Emery DE, Yannaki E, Tubb J, Stamatoyannopoulos G (2000), A chromatin insulator protects 
retrovirus vectors from chromosomal position effects, PNAS 97: 9150-9155
Erices A, Conget P, Minguell JJ (2000), Mesenchymal progenitor cells in human umbilical cord 
blood, Br.J.Haematol. 109: 235-242
Fehniger TA, Suzuki K, VanDeusen JB, Cooper MA, Freud AG, Caligiuri MA (2001), Fatal leukemia 
in interleukin-15 transgenic mice, Blood Cells Mol.Dis. 27: 223-230
Fernandez M, Simon V, Herrera G, Cao C, Del Favero H, Minguell JJ (1997), Detection of stromal 
cells in peripheral blood progenitor cell collections from breast cancer patients, Bone Marrow 
Transplant. 20: 265-271
Ferrari G, Rossini S, Giavazzi R, Maggioni D, Nobili N, Soldati M, Ungers G, Mavilio F, Gilboa E, 
Bordignon C (1991), An in vivo model of somatic cell gene therapy for human severe combined 
immunodeficiency, Science 251: 1363-1366
Fischer A, Landais P, Friedrich W, Morgan G, Gerritsen B, Fasth A, Porta F, Griscelli C, Goldman 
SF, Levinsky R, . (1990), European experience of bone-marrow transplantation for severe combined 
immunodeficiency, Lancet 336: 850-854
Flake AW (2004), In utero stem cell transplantation, Best.Pract.Res.Clin.Obstet.Gynaecol. 18: 941- 
958
Flasshove M, Bardenheuer W, Schneider A, Hirsch G, Bach P, Bury C, Moritz T, Seeber S, Opalka B
(2000), Type and position of promoter elements in retroviral vectors have substantial effects on the 
expression level of an enhanced green fluorescent protein reporter gene, J.Cancer Res.Clin.Oncol. 
126: 391-399
Fletcher FA, Moore KA, Ashkenazi M, De Vries P, Overbeek PA, Williams DE, Belmont JW (1991), 
Leukemia inhibitory factor improves survival of retroviral vector-infected hematopoietic stem cells in
240
R e f e r e n c e s
vitro, allowing efficient long-term expression of vector-encoded human adenosine deaminase in vivo, 
J.Exp.Med. 174: 837-845
Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R 
(1996), A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild 
lung disease, Hum. Gene Ther. 7: 1145-1159
Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L (2000), Gene transfer by lentiviral vectors is 
limited by nuclear translocation and rescued by HIV-1 pol sequences, Nat.Genet. 25: 217-222
Frank MH, Sayegh MH (2004), Immunomodulatory functions of mesenchymal stem cells, Lancet 
363: 1411-1412
Frankel AD, Young JA (1998), HIV-1: fifteen proteins and an RNA, Annu.Rev.Biochem. 67: 1-25
Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970), The development of fibroblast colonies in 
monolayer cultures of guinea-pig bone marrow and spleen cells, Cell Tissue Kinet. 3: 393-403
Friedenstein AJ, Gorskaja JF, Kulagina NN (1976), Fibroblast precursors in normal and irradiated 
mouse hematopoietic organs, Exp.Hematol. 4: 267-274
Friedenstein AJ, Chailakhyan RK, Gerasimov UV (1987), Bone marrow osteogenic stem cells: in 
vitro cultivation and transplantation in diffusion chambers, Cell Tissue Kinet. 20: 263-272
Gallay P, Swingler S, Song J, Bushman F, Trono D (1995a), HIV nuclear import is governed by the 
phosphotyrosine-mediated binding of matrix to the core domain of integrase, Cell 83: 569-576
Gallay P, Swingler S, Aiken C, Trono D (1995b), HIV-1 infection of nondividing cells: C-terminal 
tyrosine phosphorylation of the viral matrix protein is a key regulator, Cell 80: 379-388
Gallay P, Stitt V, Mundy C, Oettinger M, Trono D (1996), Role of the karyopherin pathway in human 
immunodeficiency virus type 1 nuclear import, J. Virol. 70: 1027-1032
Gallay P, Hope T, Chin D, Trono D (1997), HIV-1 infection of nondividing cells through the
recognition of integrase by the importin/karyopherin pathway, Proc.Natl.Acad.Sci.U.S.A 94: 9825- 
9830
Gang EJ, Hong SH, Jeong JA, Hwang SH, Kim SW, Yang IH, Ahn C, Han H, Kim H (2004), In vitro 
mesengenic potential of human umbilical cord blood-derived mesenchymal stem cells, 
Biochem.Biophys.Res.Commun. 321: 102-108
Gartner S, Kaplan HS (1980), Long-term culture of human bone marrow cells, 
Proc.Natl.Acad.Sci.U.S.A 77: 4756-4759
Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle 
C, Barington T, Jakobsen MA, Christensen HO, Al Ghonaium A, White HN, Smith JL, Levinsky RJ, 
Ali RR, Kinnon C, Thrasher AJ (2004), Gene therapy of X-linked severe combined 
immunodeficiency by use of a pseudotyped gammaretroviral vector, Lancet 364: 2181-2187
Geffiier ME, Stiehm ER, Stephure D, Cowan MJ (1986), Probable autoimmune thyroid disease and 
combined immunodeficiency disease, Am.J.Dis. Child 140: 1194-1196
Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ (1972), Adenosine-deaminase
deficiency in two patients with severely impaired cellular immunity, Lancet 2: 1067-1069
Gilgenkrantz H, Duboc D, Juillard V, Couton D, Pavirani A, Guillet JG, Briand P, Kahn A (1995), 
Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: 
role of the immune response, Hum. Gene Ther. 6 : 1265-1274
241
R e f e r e n c e s
Glennie S, Soeiro I, Dyson PJ, Lam E, Dazzi F (2005), Bone marrow mesenchymal stem cells induce 
division arrest anergy of activated T cells, Blood 105: 2821-2827
Glimm H, Eaves CJ (1999), Direct evidence for multiple self-renewal divisions of human in vivo 
repopulating hematopoietic cells in short-term culture, Blood 94: 2161-2168
Goldberg VM, Caplan Al (1994), Biological resurfacing: an alternative to total joint arthroplasty, 
Orthopedics 17: 819-821
Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996), Isolation and functional 
properties of murine hematopoietic stem cells that are replicating in vivo, J.Exp.Med. 183: 1797-1806
Gordon MY, Lewis JL, Grand FH, Marley SB, Goldman JM (1996), Phenotype and progeny of 
primitive adherent human hematopoietic progenitors, Leukemia 10: 1347-1353
Gothot A, van der Loo JC, Clapp DW, Srour EF (1998), Cell cycle-related changes in repopulating 
capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined 
immune-deficient mice, Blood  92: 2641-2649
Gregory LG, Waddington SN, Holder MV, Mitrophanous KA, Buckley SM, Mosley KL, Bigger BW, 
Ellard FM, Walmsley LE, Lawrence L, Al Allaf F, Kingsman S, Coutelle C, Themis M (2004), 
Highly efficient ELAV-mediated in utero gene transfer and expression in the major muscle groups 
affected by Duchenne muscular dystrophy, Gene Ther. 11: 1117-1125
Grez M, Akgun E, Hilberg F, Ostertag W (1990), Embryonic stem cell virus, a recombinant murine 
retrovirus with expression in embryonic stem cells, Proc.Natl.Acad.Sci.U.S.A 87: 9202-9206
Gronthos S, Simmons PJ (1996), The biology and application of human bone marrow stromal cell 
precursors, J.Hematother. 5: 15-23
Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, Simmons PJ (2003), Molecular 
and cellular characterisation of highly purified stromal stem cells derived from human bone marrow, 
J.Cell Sci. 116: 1827-1835
Groth AC, Olivares EC, Thyagarajan B, Calos MP (2000), A phage integrase directs efficient site- 
specific integration in human cells, Proc.Natl.Acad.Sci.U.S.A 97: 5995-6000
Guo Z, Yang J, Liu X, Li X, Hou C, Tang PH, Mao N (2001), Biological features of mesenchymal 
stem cells from human bone marrow, Chin Med. J.(Engl.) 114: 950-953
Hacein-Bey-Abina S, le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, 
Wulfffaat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo 
M (2002), Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene 
therapy, N.Engl.J.Med. 346: 1185-1193
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulfffaat N, Leboulch P, Lim A, 
Osbome CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint BG, 
Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, 
Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, 
Rabbitts TH, le Deist F, Fischer A, Cavazzana-Calvo M (2003), LM02-associated clonal T cell 
proliferation in two patients after gene therapy for SCID-X1, Science 302: 415-419
Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell 
JC, Odin P, Wenning GK, Morrish P, Gustavii B, Bjorklund A, Brooks DJ, Marsden CD, Quinn NP, 
Lindvall O (1999), Sequential bilateral transplantation in Parkinson's disease: effects of the second 
graft, Brain 122 ( Pt 6): 1121-1132
Halbert CL, Alexander IE, Wolgamot GM, Miller AD (1995), Adeno-associated virus vectors 
transduce primary cells much less efficiently than immortalized cells, J. Virol. 69: 1473-1479
242
R e f e r e n c e s
Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, Klein MR, van Lier RA (1997), 
Phenotypic and functional separation of memory and effector human CD8+ T cells, J.Exp.Med. 186: 
1407-1418
Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA (1996), Colocalization of 
retrovirus and target cells on specific fibronectin fragments increases genetic transduction of 
mammalian cells, Nat.Med. 2: 876-882
Hanenberg H, Hashino K, Konishi H, Hock RA, Kato I, Williams DA (1997), Optimization of 
fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells, Hum. Gene Ther. 
8: 2193-2206
Hantzopoulos PA, Sullenger BA, Ungers G, Gilboa E (1989), Inproved gene expression upon transfer 
of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector, 
Proc.Natl.Acad.Sci.U.S.A 8 6 : 3519-3523
Hart SL, Lane AB, Jenkins T (1986), Partial adenosine deaminase deficiency: another family from 
southern Africa, Hum. Genet. 74: 307-312
Hay E (1966), Regeneration, Holt; Rinehart; Winston, New York
Haynesworth SE, Baber MA, Caplan Al (1992), Cell surface antigens on human marrow-derived 
mesenchymal cells are detected by monoclonal antibodies, Bone 13: 69-80
Haynesworth SE, Baber MA, Caplan Al (1996), Cytokine expression by human marrow-derived 
mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha, J.Cell Physiol 166: 
585-592
Henderson JF, Scott FW, Lowe JK (1980), Toxicity of naturally occurring purine 
deoxyribonucleosides, Pharmacol. Ther. 8 : 573-604
Hershfield MS, Mitchell BS (2001), Immunodeficiency Diseases Caused by Adenosine Deaminase 
Deficiency and Purine Nucleoside Phosphorylase Deficiency, in The Metabolic and Molecular Bases 
o f  Inherited Disease, ed. Scriver CR, Beaudet AL, Sly WS, and Valle DS, New York p 2585-2625
Hershfield MS (1979a), Apparent suicide inactivation of human lymphoblast S-adenosylhomocysteine 
hydrolase by 2'-deoxyadenosine and adenine arabinoside. A basis for direct toxic effects of analogs of 
adenosine, J.Biol.Chem. 254: 22-25
Hershfield MS, Kredich NM, Ownby DR, Ownby H, Buckley R (1979b), In vivo inactivation of 
erythrocyte S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine in adenosine deaminase- 
deficient patients, J. Clin. Invest 63: 807-811
Hershfield MS, Kurtzberg J, Aiyar VN, Suh EJ, Schiff R (1985), Abnormalities in S- 
adenosylhomocysteine hydrolysis, ATP catabolism, and lymphoid differentiation in adenosine 
deaminase deficiency, Ann.N.Y.Acad.Sci. 451: 78-86
Hershfield MS, Buckley RH, Greenberg ML, Melton AL, Schiff R, Hatem C, Kurtzberg J, Markert 
ML, Kobayashi RH, Kobayashi AL, . (1987), Treatment of adenosine deaminase deficiency with 
polyethylene glycol-modified adenosine deaminase, N.Engl.J.Med. 316: 589-596
Hershfield MS, Chaffee S, Sorensen RU (1993), Enzyme replacement therapy with polyethylene 
glycol-adenosine deaminase in adenosine deaminase deficiency: overview and case reports of three 
patients, including two now receiving gene therapy, Pediatr.Res. 33: S42-S47
Hershfield MS (1995), PEG-ADA: an alternative to haploidentical bone marrow transplantation and 
an adjunct to gene therapy for adenosine deaminase deficiency, Hum.Mutat. 5: 107-112
Hershfield MS (2003), Genotype is an important determinant of phenotype in adenosine deaminase 
deficiency, Curr.Opin.Immunol. 15: 571-577
243
R e f e r e n c e s
Hildinger M, Abel KL, Ostertag W, Baum C (1999), Design of 5' untranslated sequences in retroviral 
vectors developed for medical use, J. Virol. 73: 4083-4089
Hirschhom R, Beratis N, Rosen FS, Parkman R, Stem R, Polmar S (1975), Adenosine-deaminase 
deficiency in a child diagnosed prenatally, Lancet 1: 73-75
Hirschhom R, Martiniuk F, Rosen FS (1978), Adenosine deaminase activity in normal tissues and 
tissues from a child with severe combined immunodeficiency and adenosine deaminase deficiency, 
Clin.lmmunol.lmmunopathol. 9: 287-292
Hirschhom R (1979a), Clinical delineation of adenosine deaminase deficiency, in Enzyme Defects and 
Immune Dysfunction, Ciba Foundation Symposium 68, ed. Elliot K and Whelan J, Excerpta Medica, 
New Yorkp 35
Hirschhom R (1979b), Prenatal diagnosis and heterozygote detection in adenosine deaminase 
deficiency, in Inborn Errors o f  Immunity and Phagocytosis, ed. Guttler F, Seakins JWT, and Harkness 
RA, MTP Press, Lancaster p 121
Hirschhom R, Roegner V, Jenkins T, Seaman C, Piomelli S, Borkowsky W (1979c), Erythrocyte 
adenosine deaminase deficiency without immunodeficiency. Evidence for an unstable mutant enzyme, 
J.Clin.Invest 64: 1130-1139
Hirschhom R, Vawter GF, Kirkpatrick JA, Jr., Rosen FS (1979d), Adenosine deaminase deficiency: 
frequency and comparative pathology in autosomally recessive severe combined immunodeficiency, 
Clin.lmmunol.lmmunopathol. 14: 107-120
Hirschhom R, Paageorgiou PS, Kesarwala HH, Taft LT (1980), Amelioration of neurologic 
abnormalities after "enzyme replacement" in adenosine deaminase deficiency, N.Engl.J.Med. 303: 
377-380
Hirschhom R, Roegner-Maniscalco V, Kuritsky L, Rosen FS (1981), Bone marrow transplantation 
only partially restores purine metabolites to normal in adenosine deaminase-deficient patients, 
J.Clin.Invest 6 8 : 1387-1393
Hirschhom R, Ellenbogen A (1986), Genetic heterogeneity in adenosine deaminase (ADA) 
deficiency: five different mutations in five new patients with partial ADA deficiency, 
Am.J.Hum.Genet. 38: 13-25
Hirschhom R (1990a), Adenosine Deaminase Deficiency, in Immunodeficiency Reviews, ed. Rosen 
FS and Seligman M, Harwood Academic Publications, London p 175-198
Hirschhom R (1990b), Immunodeficiency Disorders, in The Principles and Practice o f  Medical 
Genetics, ed. Emery AEH and Rimoin DL, Edinburgh p 1411-1430
Hirschhom R, Tzall S, Ellenbogen A (1990c), Hot spot mutations in adenosine deaminase deficiency, 
Proc.Natl.Acad.Sci.U.S.A 87: 6171-6175
Hirschhom R, Nicknam MN, Eng F, Yang DR, Borkowsky W (1992), Novel deletion and a new 
missense mutation (Glu 217 Lys) at the catalytic site in two adenosine deaminase alleles of a patient 
with neonatal onset adenosine deaminase- severe combined immunodeficiency, J. Immunol. 149: 
3107-3112
Hirschhom R, Yang DR, Insel RA, Ballow M (1993), Severe combined immunodeficiency of reduced 
severity due to homozygosity for an adenosine deaminase missense mutation (Arg253Pro), Cell 
Immunol. 152: 383-393
Hirschhom R, Yang DR, Israni A, Huie ML, Ownby DR (1994), Somatic mosaicism for a newly 
identified splice-site mutation in a patient with adenosine deaminase-deficient immunodeficiency and 
spontaneous clinical recovery, AmJ.Hum.Genet. 55: 59-68
244
R e f e r e n c e s
Hirschhom R, Yang DR, Puck JM, Huie ML, Jiang CK, Kurlandsky LE (1996), Spontaneous in vivo 
reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency, 
Nat.Genet. 13:290-295
Hirschhom R (1999), Immunodeficiency Disease Due to Deficiency of Adenosine Deaminase, in 
Primary Immunodeficiency Diseases. A Molecular and Genetic Approach, p 121-139
Hock RA, Miller AD, Osborne WR (1989), Expression of human adenosine deaminase from various 
strong promoters after gene transfer into human hematopoietic cell lines, Blood 74: 876-881
Hoeben RC, Valerio D, van der Eb AJ, van Ormondt H (1992), Gene therapy for human inherited 
disorders: techniques and status, Crit Rev.Oncol.Hematol. 13: 33-54
Hollander GA, Wang B, Nichogiannopoulou A, Platenburg PP, van Ewijk W, Burakoff SJ, Gutierrez- 
Ramos JC, Terhorst C (1995), Developmental control point in induction of thymic cortex regulated by 
a subpopulation of prothymocytes, Nature 373: 350-353
Hoogerbmgge PM, Vossen JM, Beusechem VW, Valerio D (1992), Treatment of patients with severe 
combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous 
transplantation of genetically modified bone marrow cells, Hum.Gene Ther. 3: 553-558
Hoogerbmgge PM, van Beusechem VW, Fischer A, Debree M, le Deist F, Perignon JL, Morgan G, 
Gaspar B, Fairbanks LD, Skeoch CH, Moseley A, Harvey M, Levinsky RJ, Valerio D (1996), Bone 
marrow gene transfer in three patients with adenosine deaminase deficiency, Gene Ther. 3: 179-183
Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, 
Marx JC, Pyeritz RE, Brenner MK (1999), Transplantability and therapeutic effects of bone marrow- 
derived mesenchymal cells in children with osteogenesis imperfecta, Nat.Med. 5: 309-313
Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T (2002), 
Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children 
with osteogenesis imperfecta: Implications for cell therapy of bone, Proc.Natl.Acad.Sci.U.S.A 99: 
8932-8937
Howe S, Thrasher AJ (2003), Gene therapy for inherited immunodeficiencies, Curr.Hematol.Rep. 2: 
328-334
Howlett CR, Cave J, Williamson M, Farmer J, Ali SY, Bab I, Owen ME (1986), Mineralization in in 
vitro cultures of rabbit marrow stromal cells, Clin.Orthop. 251-263
Huang J, Liang TJ (1993), A novel hepatitis B virus (HBV) genetic element with Rev response 
element-like properties that is essential for expression of HBV gene products, Mol.Cell Biol. 13: 
7476-7486
Huang ZM, Yen TS (1994), Hepatitis B virus RNA element that facilitates accumulation of surface 
gene transcripts in the cytoplasm, J. Virol. 6 8 : 3193-3199
Hutton JJ, Wiginton DA, Coleman MS, Fuller SA, Limouze S, Lampkin BC (1981), Biochemical and 
functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during 
enzyme replacement therapy, J.Clin.Invest 6 8 : 413-421
Jeffreys AJ, Wilson V, Neumann R, Keyte J (1988), Amplification of human minisatellites by the 
polymerase chain reaction: towards DNA fingerprinting of single cells, Nucleic Acids Res. 16: 10953- 
10971
Jhanwar SC, Berkvens TM, Breukel C, van Ormondt H, van der Eb AJ, Meera KP (1989), 
Localization of human adenosine deaminase (ADA) gene sequences to the ql2— ql3.11 region of 
chromosome 20 by in situ hybridization, Cytogenet.Cell Genet. 50: 168-171
245
R e f e r e n c e s
Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, 
Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie 
CM (2002), Pluripotency of mesenchymal stem cells derived from adult marrow, Nature 418: 41-49
Jiang Y, Henderson D, Blackstad M, Chen A, Miller RF, Verfaillie CM (2003), Neuroectodermal 
differentiation from mouse multipotent adult progenitor cells, Proc.Natl.Acad.Sci.U.S.A 100 Suppl 1: 
11854-11860
Jin HK, Carter JE, Huntley GW, Schuchman EH (2002), Intracerebral transplantation of mesenchymal 
stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities 
and extends their life span, J.Clin.Invest 109: 1183-1191
Jin K, Mao XO, Batteur S, Sun Y, Greenberg DA (2003), Induction of neuronal markers in bone 
marrow cells: differential effects of growth factors and patterns of intracellular expression, 
Exp.Neurol. 184: 78-89
Johann SV, Gibbons JJ, O'Hara B (1992), GLVR1, a receptor for gibbon ape leukemia virus, is 
homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain 
and thymus, J. Virol. 6 6 : 1635-1640
Jones DR (2004), In utero stem cell transplantation: a European overview, Fetal Diagn.Ther. 19: 207- 
211
Jones EA, Kinsey SE, English A, Jones RA, Straszynski L, Meredith DM, Markham AF, Jack A, 
Emery P, McGonagle D (2002), Isolation and characterization of bone marrow multipotential 
mesenchymal progenitor cells, Arthritis Rheum. 46: 3349-3360
Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM (1999), A packaging cell line for lentivirus 
vectors, J. Virol. 73: 576-584
Kaiser J (2005), Gene therapy. Panel urges limits on X-SCID trials, Science 307: 1544-1545
Kantoff PW, Kohn DB, Mitsuya H, Armentano D, Sieberg M, Zwiebel JA, Eglitis MA, McLachlin 
JR, Wiginton DA, Hutton JJ, . (1986), Correction of adenosine deaminase deficiency in cultured 
human T and B cells by retrovirus-mediated gene transfer, Proc.Natl.Acad.Sci.U.S.A 83: 6563-6567
Karlsson S (1991), Treatment of genetic defects in hematopoietic cell fimction by gene transfer, Blood 
78: 2481-2492
Keating A, Horsfall W, Hawley RG, Toneguzzo F (1990), Effect of different promoters on expression 
of genes introduced into hematopoietic and marrow stromal cells by electroporation, Exp.Hematol. 18: 
99-102
Kiem HP, Heyward S, Winkler A, Potter J, Allen JM, Miller AD, Andrews RG (1997), Gene transfer 
into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia vims 
pseudotyped retroviral vectors in a competitive repopulation assay in baboons, Blood  90: 4638-4645
Kim BJ, Seo JH, Bubien JK, Oh YS (2002), Differentiation of adult bone marrow stem cells into 
neuroprogenitor cells in vitro, Neuroreport 13: 1185-1188
Kingsman SM, Mitrophanous K, Olsen JC (2005), Potential oncogene activity of the woodchuck 
hepatitis post-transcriptional regulatory element (WPRE), Gene Ther. 12: 3-4
Kittler EL, McGrath H, Temeles D, Crittenden RB, Kister VK, Quesenberry PJ (1992), Biologic 
significance of constitutive and subliminal growth factor production by bone marrow stroma, Blood 
79:3168-3178
Kizaki H, Shimada H, Ohsaka F, Sakurada T (1988), Adenosine, deoxyadenosine, and 
deoxyguanosine induce DNA cleavage in mouse thymocytes, J.Immunol. 141: 1652-1657
246
R e f e r e n c e s
Kizaki H, Suzuki K, Tadakuma T, Ishimura Y (1990), Adenosine receptor-mediated accumulation of 
cyclic AMP-induced T-lymphocyte death through intemucleosomal DNA cleavage, J.Biol.Chem. 265: 
5280-5284
Klages N, Zufferey R, Trono D (2000), A stable system for the high-titer production of multiply 
attenuated lentiviral vectors, Mol. Ther. 2: 170-176
Klug DB, Carter C, Gimenez-Conti IB, Richie ER (2002), Cutting edge: thymocyte-independent and 
thymocyte-dependent phases of epithelial patterning in the fetal thymus, J.Immunol. 169: 2842-2845
Klug w, cummings m (1999), Concepts o f  Genetics, Prentice Hall, New Jersey p 699-700
Koc ON, Peters C, Aubourg P, Raghavan S, Dyhouse S, DeGasperi R, Kolodny EH, Yoseph YB, 
Gerson SL, Lazarus HM, Caplan Al, Watkins PA, Krivit W (1999), Bone marrow-derived 
mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after 
allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases, Exp.Hematol. 
27: 1675-1681
Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan Al, Lazarus HM (2000), 
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded 
marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose 
chemotherapy, J. Clin. Oncol. 18: 307-316
Koc ON, Lazarus HM (2001), Mesenchymal stem cells: heading into the clinic, Bone Marrow 
Transplant. 27: 235-239
Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W (2002), Allogeneic mesenchymal stem 
cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH), 
Bone Marrow Transplant. 30: 215-222
Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, 
Brooks JS, el Khoureiy A, . (1995), Engraftment of gene-modified umbilical cord blood cells in 
neonates with adenosine deaminase deficiency, Nat. Med. 1: 1017-1023
Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, 
Chan R, Burotto F, Annett G, Nolta JA, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Madsen E, 
Snyder FF, Bastian J, Muul L, Blaese RM, Weinberg K, Parkman R (1998), T lymphocytes with a 
normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood 
CD34+ cells in ADA-deficient SCID neonates, Nat.Med. 4: 775-780
Kohn DB, Sadelain M, Glorioso JC (2003), Occurrence of leukaemia following gene therapy of X- 
linked SCID, Nat.Rev. Cancer 3: 477-488
Kohyama J, Abe H, Shimazaki T, Koizumi A, Nakashima K, Gojo S, Taga T, Okano H, Hata J, 
Umezawa A (2001), Brain from bone: efficient "meta-differentiation" of marrow stroma-derived 
mature osteoblasts to neurons with Noggin or a demethylating agent, Differentiation 6 8 : 235-244
Kopen GC, Prockop DJ, Phinney DG (1999), Marrow stromal cells migrate throughout forebrain and 
cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains, 
Proc.Natl.Acad.Sci.U.S.A 96: 10711-10716
Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, McBride J, Chen EY, Palfi S, 
Roitberg BZ, Brown WD, Holden JE, Pyzalski R, Taylor MD, Carvey P, Ling Z, Trono D, Hantraye 
P, Deglon N, Aebischer P (2000), Neurodegeneration prevented by lentiviral vector delivery of GDNF 
in primate models of Parkinson's disease, Science 290: 767-773
Krause DS (2002), Plasticity of marrow-derived stem cells, Gene Ther. 9: 754-758
Kredich NM, Martin DV, Jr. (1977), Role of S-adenosylhomocysteine in adenosinemediated toxicity 
in cultured mouse T lymphoma cells, Cell 12: 931-938
247
R e f e r e n c e s
Kubota M, Carrera CJ, Wasson DB, Carson DA (1984), Deoxynucleoside overproduction in 
deoxyadenosine-resistant, adenosine deaminase-deficient human histiocytic lymphoma cells, 
Biochim.Biophys.Acta 804: 37-43
Kustikova OS, Wahlers A, Kuhlcke K, Stahle B, Zander AR, Baum C, Fehse B (2003), Dose finding 
with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer 
efficiency in a cell population, Blood 102: 3934-3937
Kuznetsov SA, Krebsbach PH, Satomura K, Kerr J, Riminucci M, Benayahu D, Robey PG (1997), 
Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in 
vivo, 7.Bone Miner.Res. 12: 1335-1347
Labat ML (2001), Stem cells and the promise of eternal youth: embryonic versus adult stem cells, 
Biomed.Pharmacother. 55: 179-185
Lagasse E, Connors H, Al Dhalimy M, Reitsma M, Dohse M, Osbome L, Wang X, Finegold M, 
Weissman IL, Grompe M (2000), Purified hematopoietic stem cells can differentiate into hepatocytes 
in vivo, Nat.Med. 6 : 1229-1234
Lam JS, Reeves ME, Cowherd R, Rosenberg SA, Hwu P (1996), Improved gene transfer into human 
lymphocytes using retroviruses with the gibbon ape leukemia virus envelope, Hum. Gene Ther. 7: 
1415-1422
Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE, Dick JE (1992), Cytokine stimulation of 
multilineage hematopoiesis from immature human cells engrafted in SCID mice, Science 255: 1137- 
1141
Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH (1995), The oncogenic LIM protein Rbtn2 
causes thymic developmental aberrations that precede malignancy in transgenic mice, Oncogene 11: 
853-862
Latchman DS (1994), Herpes simplex virus vectors for gene therapy, Mol.Biotechnol. 2: 179-195
Laver J, Jhanwar SC, O'Reilly RJ, Castro-Malaspina H (1987), Host origin of the human 
hematopoietic microenvironment following allogeneic bone marrow transplantation, Blood  70: 1966- 
1968
Lawson LJ, Perry VH, Gordon S (1992), Turnover of resident microglia in the normal adult mouse 
brain, Neuroscience 48: 405-415
Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan Al (1995), Ex vivo expansion and 
subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal 
progenitor cells): implications for therapeutic use, Bone Marrow Transplant. 16: 557-564
Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O (2003), HLA expression and 
immunologic properties of differentiated and undifferentiated mesenchymal stem cells, Exp.Hematol. 
31: 890-896
Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O (2004), 
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem 
cells, Lancet 363: 1439-1441
Le Blanc K, Gotherstrom C, Ringden O, Hassan M, McMahon R, Horwitz E, Anneren G, Axelsson O, 
Nunn J, Ewald U, Norden-Lindeberg S, Jansson M, Dalton A, Astrom E, Westgren M (2005), Fetal 
mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe 
osteogenesis imperfecta, Transplantation 79: 1607-1614
Lee K, Majumdar MK, Buyaner D, Hendricks JK, Pittenger MF, Mosca JD (2001), Human 
mesenchymal stem cells maintain transgene expression during expansion and differentiation, 
Mol. Ther. 3: 857-866
248
R e f e r e n c e s
Lee MW, Choi J, Yang MS, Moon YJ, Park JS, Kim HC, Kim YJ (2004), Mesenchymal stem cells 
from cryopreserved human umbilical cord blood, Biochem.Biophys.Res.Commun. 320: 273-278
Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH (2004), Isolation of multipotent 
mesenchymal stem cells from umbilical cord blood, Blood 103: 1669-1675
Lee RH, Kim B, Choi I, Kim H, Choi HS, Suh K, Bae YC, Jung JS (2004), Characterization and 
expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue, Cell 
Physiol Biochem. 14: 311-324
Lemischka IR, Raulet DH, Mulligan RC (1986), Developmental potential and dynamic behavior of 
hematopoietic stem cells, Cell 45: 917-927
Levivier M, Dethy S, Rodesch F, Peschanski M, Vandesteene A, David P, Wikler D, Goldman S, 
Claes T, Biver F, Liesnard C, Goldman M, Hildebrand J, Brotchi J (1997), Intracerebral 
transplantation of fetal ventral mesencephalon for patients with advanced Parkinson's disease. 
Methodology and 6-month to 1-year follow-up in 3 patients, Stereotact.Funct.Neurosurg. 69: 99-111
Levy Y, Hershfield MS, Femandez-Mejia C, Polmar SH, Scudiery D, Berger M, Sorensen RU (1988), 
Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with 
polyethylene glycol-modified adenosine deaminase, J.Pediatr. 113: 312-317
Lewis P, Hensel M, Emerman M (1992), Human immunodeficiency virus infection of cells arrested in 
the cell cycle, EMBOJ. 11: 3053-3058
Lewis PF, Emerman M (1994), Passage through mitosis is required for oncoretroviruses but not for 
the human immunodeficiency virus, J. Virol. 6 8 : 510-516
Li C, Emery DW (2005) Flanking a Retrovirus Vector with the cHS4 Chromatin Insulator Reduces 
the Frequency of Vector-Mediated Trans-Activation of Endogenous Genes, American Society of Gene 
Therapy Annual Conference
Li GR, Sun H, Deng X, Lau CP (2005), Characterization of ionic currents in human mesenchymal 
stem cells from bone marrow, Stem Cells 23: 371-382
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997), 
Cytochrome c and dATP-dependent formation of Apaf-l/caspase-9 complex initiates an apoptotic 
protease cascade, Cell 91: 479-489
Li Z, Dullmann J, Schiedlmeier B, Schmidt M, Von Kalle C, Meyer J, Forster M, Stocking C, 
Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, Baum C (2002), Murine leukemia 
induced by retroviral gene marking, Science 296: 497
Lim B, Williams DA, Orkin SH (1987), Retrovirus-mediated gene transfer of human adenosine 
deaminase: expression of functional enzyme in murine hematopoietic stem cells in vivo, Mol.Cell 
Biol 7: 3459-3465
Limon A, Briones J, Puig T, Carmona M, Fomas O, Cancelas JA, Nadal M, Garcia J, Rueda F, 
Barquinero J (1997), High-titer retroviral vectors containing the enhanced green fluorescent protein 
gene for efficient expression in hematopoietic cells, Blood 90: 3316-3321
Limon A, Nakajima N, Lu R, Ghory HZ, Engelman A (2002), Wild-type levels of nuclear localization 
and human immunodeficiency virus type 1 replication in the absence of the central DNA flap, J. Virol. 
76: 12078-12086
Linch DC, Levinsky RJ, Rodeck CH, Maclennan KA, Simmonds HA (1984), Prenatal diagnosis of 
three cases of severe combined immunodeficiency: severe T cell deficiency during the first half of 
gestation in fetuses with adenosine deaminase deficiency, Clin.Exp.Immunol. 56: 223-232
Lindvall O, Bjorklund A (2004), Cell Therapy in Parkinson's Disease, Neurorx. 1: 382-393
249
R e f e r e n c e s
Liu X, Kim CN, Yang J, Jemmerson R, Wang X (1996), Induction of apoptotic program in cell-free 
extracts: requirement for dATP and cytochrome c, Cell 8 6 : 147-157
Loncar D (1992), Ultrastructural analysis of differentiation of rat endoderm in vitro. Adipose 
vascular-stromal cells induce endoderm differentiation, which in turn induces differentiation of the 
vascular-stromal cells into chondrocytes, J.Submicrosc.Cytol.Pathol. 24: 509-519
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951), Protein Measurement with the Folin Phenol 
Reagent,J.Biol.Chem. 193: 265-275
Lu P, Blesch A, Tuszynski MH (2004), Induction of bone marrow stromal cells to neurons: 
differentiation, transdifferentiation, or artifact?, J.Neurosci.Res. 77: 174-191
Luciw PA, Leung NJ (1992), Mechanisms of Retrovirus Replication, in The Retroviridae, ed. Levy 
JA, Plenum Press, New York p 159-298
Luciw PA (1996), Human Immunodeficiency Viruses and Their Replication, Lippincott-Raven, 
Philadelphia
MacGregor RR (2001), Clinical protocol. A phase 1 open-label clinical trial of the safety and 
tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV- 
positive subjects, Hum.Gene Ther. 12: 2028-2029
Mahmood A, Lu D, Wang L, Chopp M (2002), Intracerebral transplantation of marrow stromal cells 
cultured with neurotrophic factors promotes functional recovery in adult rats subjected to traumatic 
brain injury, J.Neurotrauma 19: 1609-1617
Mahmood A, Lu D, Chopp M (2004), Marrow stromal cell transplantation after traumatic brain injury 
promotes cellular proliferation within the brain, Neurosurgery 55: 1185-1193
Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL (1998), Phenotypic and functional 
comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells, J.Cell 
Physiol 176: 57-66
Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, 
Hata J, Umezawa A, Ogawa S (1999), Cardiomyocytes can be generated from marrow stromal cells in 
vitro, J.Clin.Invest 103: 697-705
Manganini M, Serafini M, Bambacioni F, Casati C, Erba E, Follenzi A, Naldini L, Bemasconi S, 
Gaipa G, Rambaldi A, Biondi A, Golay J, Introna M (2002), A human immunodeficiency virus type 1 
pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing 
monocytes and T lymphocytes by lentiviral vectors, Hum.Gene Ther. 13: 1793-1807
Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ (2003), Mesenchymal stem 
cells modified with Akt prevent remodeling and restore performance of infarcted hearts, Nat.Med. 9: 
1195-1201
Mann GJ, Fox RM (1986), Deoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in 
cultured T lymphoblasts, J.Clin.Invest 78: 1261-1269
Mansky LM (1996), The mutation rate of human immunodeficiency virus type 1 is influenced by the 
vprgene, Virology 222: 391-400
Mansky LM, Preveral S, Selig L, Benarous R, Benichou S (2000), The interaction of vpr with uracil 
DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate, J. Virol. 
74: 7039-7047
Mardon HJ, Bee J, von der MK, Owen ME (1987), Development of osteogenic tissue in diffusion 
chambers from early precursor cells in bone marrow of adult rats, Cell Tissue Res. 250: 157-165
250
R e f e r e n c e s
Mareschi K, Biasin E, Piacibello W, Aglietta M, Madon E, Fagioli F (2001), Isolation of human 
mesenchymal stem cells: bone marrow versus umbilical cord blood, Haematologica 8 6 : 1099-1100
Marsh M, Helenius A (1989), Virus entry into animal cells, Adv. Virus Res. 36: 107-151
Marx JC, Allay JA, Persons DA, Nooner SA, Hargrove PW, Kelly PF, Vanin EF, Horwitz EM (1999), 
High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector 
encoding the green fluorescent protein in human marrow stromal cells, Hum.Gene Ther. 10: 1163- 
1173
McCormack MP, Rabbitts TH (2004), Activation of the T-cell oncogene LM02 after gene therapy for 
X-linked severe combined immunodeficiency, N.Engl.J.Med. 350: 913-922
Mets T, Verdonk G (1981), In vitro aging of human bone marrow derived stromal cells, Mech.Ageing 
Dev. 16: 81-89
Migchielsen AA, Breuer ML, van Roon MA, te RH, Zurcher C, Ossendorp F, Toutain S, Hershfield 
MS, Bems A, Valerio D (1995), Adenosine-deaminase-deficient mice die perinatally and exhibit 
liver-cell degeneration, atelectasis and small intestinal cell death, Nat.Genet. 10: 279-287
Migchielsen AA, Breuer ML, Hershfield MS, Valerio D (1996), Full genetic rescue of adenosine 
deaminase-deficient mice through introduction of the human gene, Hum.Mol.Genet. 5: 1523-1532
Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, Eiden MV (1991), Construction and 
properties of retrovirus packaging cells based on gibbon ape leukemia vims, J. Virol. 65: 2220-2224
Miller DG, Adam MA, Miller AD (1990), Gene transfer by retrovirus vectors occurs only in cells that 
are actively replicating at the time of infection, Mol. Cell Biol. 10: 4239-4242
Minguell JJ, Erices A, Conget P (2001), Mesenchymal stem cells, Exp.Biol.Med. (Maywood.) 226: 
507-520
Miwa S, Fujii H, Matsumoto N, Nakatsuji T, Oda S, Asano H, Asano S (1978), A case of red-cell 
adenosine deaminase overproduction associated with hereditary hemolytic anemia found in Japan, 
AmJ.Hematol. 5: 107-115
Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE (1999), Transduction of human CD34+ 
cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors, Science 283: 682-686
Mohandas T, Sparkes RS, Passage MB, Sparkes MC, Miles JH, Kaback MM (1980), Regional 
mapping of ADA and ITP on human chromosome 20: cytogenetic and somatic cell studies in an X/20 
translocation, Cytogenet.Cell Genet. 26: 28-35
Mohandas T, Sparkes RS, Suh EJ, Hershfield MS (1984), Regional localization of the human genes 
for S-adenosylhomocysteine hydrolase (cen— ql31) and adenosine deaminase (ql31— qter) on 
chromosome 20, Hum. Genet. 6 6 : 292-295
Morgan G, Levinsky RJ, Hugh-Jones K, Fairbanks LD, Morris GS, Simmonds HA (1987), 
Heterogeneity of biochemical, clinical and immunological parameters in severe combined 
immunodeficiency due to adenosine deaminase deficiency, Clin.Exp.Immunol. 70: 491-499
Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J (1991), The toxicity of busulphan and 
cyclophosphamide as the preparative regimen for bone marrow transplantation, Br.J.Haematol. 77: 
529-534
Moritz T, Patel VP, Williams DA (1994), Bone marrow extracellular matrix molecules improve gene 
transfer into human hematopoietic cells via retroviral vectors, J.Clin.Invest 93: 1451-1457
251
R e f e r e n c e s
Moritz T, Dutt P, Xiao X, Carstanjen D, Vik T, Hanenberg H, Williams DA (1996), Fibronectin 
improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of 
direct viral binding to chymotryptic carboxy-terminal fragments, Blood 8 8 : 855-862
Muraglia A, Cancedda R, Quarto R (2000), Clonal mesenchymal progenitors from human bone 
marrow differentiate in vitro according to a hierarchical model, J. Cell Sci. 113 ( Pt 7): 1161-1166
Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag 
JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ (2004), Haematopoietic 
stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts, Nature 428: 664-668
Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, 
Alleyne M, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese RM, 
Candotti F (2003), Persistence and expression of the adenosine deaminase gene for 12 years and 
immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial, 
Blood 101: 2563-2569
Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chang 
AE (1996), Immune response in human melanoma after transfer of an allogeneic class I major 
histocompatibility complex gene with DNA-liposome complexes, Proc.Natl.Acad.Sci.U.S.A 93: 
15388-15393
Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996a), In vivo 
gene delivery and stable transduction of nondividing cells by a lentiviral vector, Science 272: 263-267
Naldini L, Blomer U, Gage FH, Trono D, Verma IM (1996b), Efficient transfer, integration, and 
sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector, 
Proc.Natl.Acad.Sci.U.S.A 93: 11382-11388
Neale GA, Rehg JE, Goorha RM (1995), Ectopic expression of rhombotin-2 causes selective 
expansion of CD4-CD8- lymphocytes in the thymus and T-cell tumors in transgenic mice, Blood 8 6 : 
3060-3071
Neufield EF (1995), Metabolic and Molecular Basis o f  Disease, McGraw-Hill, New York p 2483- 
2495
Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R, Binder G, Chang YN, Slepushkin V, 
Dropulic B (2005), Generation of a packaging cell line for prolonged large-scale production of high- 
titer HIV-1-based lentiviral vector, J.Gene Med. 7:818-834
Nishihara H, Ishikawa S, Shinkai K, Akedo H (1973), Multiple forms of human adenosine deaminase. 
II. Isolation and properties of a conversion factor from human lung, Biochim.Biophys.Acta 302: 429- 
442
Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ 
(1993), Interleukin-2 receptor gamma chain mutation results in X-linked severe combined 
immunodeficiency in humans, Cell 73: 147-157
Nolta JA, Hanley MB, Kohn DB (1994), Sustained human hematopoiesis in immunodeficient mice by 
cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of 
long-lived progenitors, Blood 83: 3041-3051
Nolta JA, Thiemann FT, Arakawa-Hoyt J, Dao MA, Barsky LW, Moore KA, Lemischka IR, Crooks 
GM (2002), The AFT024 stromal cell line supports long-term ex vivo maintenance of engrafting 
multipotent human hematopoietic progenitors, Leukemia 16: 352-361
Noort WA, Kruisselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, Heemskerk 
MH, Lowik CW, Falkenburg JH, Willemze R, Fibbe WE (2002), Mesenchymal stem cells promote 
engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice, Exp.Hematol. 
30: 870-878
252
R e f e r e n c e s
Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M (1998), Human trabecular bone cells are 
able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders, 
J.Bone Miner.Res. 13:371-382
O'Reilly RJ, Keever CA, Small TN, Brochstein J (1989), The use of HLA-non-identical T-cell- 
depleted marrow transplants for correction of severe combined immunodeficiency disease, 
Immunodefic.Rev. 1: 273-309
Ochs HD, Buckley RH, Kobayashi RH, Kobayashi AL, Sorensen RU, Douglas SD, Hamilton BL, 
Hershfield MS (1992), Antibody responses to bacteriophage phi XI74 in patients with adenosine 
deaminase deficiency, Blood 80: 1163-1171
Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP (2002), Site-specific genomic 
integration produces therapeutic Factor IX levels in mice, Nat.Biotechnol. 20: 1124-1128
Onodera M, Ariga T, Kawamura N, Kobayashi I, Ohtsu M, Yamada M, Tame A, Furuta H, Okano M, 
Matsumoto S, Kotani H, McGarrity GJ, Blaese RM, Sakiyama Y (1998), Successful peripheral T- 
lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by 
adenosine deaminase deficiency, Blood  91: 30-36
Orkin SH, Daddona PE, Shewach DS, Markham AF, Bruns GA, Goff SC, Kelley WN (1983), 
Molecular cloning of human adenosine deaminase gene sequences, J.Biol.Chem. 258: 12753-12756
Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, 
Bodine DM, Leri A, Anversa P (2001), Bone marrow cells regenerate infarcted myocardium, Nature 
410: 701-705
Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP, Khavari PA (2002), Stable 
nonviral genetic correction of inherited human skin disease, Nat.Med. 8 : 1166-1170
Ory DS, Neugeboren BA, Mulligan RC (1996), A stable human-derived packaging cell line for 
production of high titer retrovirus/vesicular stomatitis vhus G pseudotypes, Proc.Natl.Acad.Sci.U.S.A 
93: 11400-11406
Osterman JV, Waddell A, Aposhian HV (1970), DNA and gene therapy: uncoating of polyoma 
pseudovirus in mouse embryo cells, Proc.Natl.Acad.Sci.U.S.A 67: 37-40
Otsuka T, Humphries RK, Hogge DE, Eaves AC, Eaves CJ (1991), Continuous activation of primitive 
hematopoietic cells in long-term human marrow cultures containing irradiated tumor cells, J.Cell 
Physiol 148: 370-379
Owen M, Friedenstein AJ (1988), Stromal stem cells: marrow-derived osteogenic precursors, Ciba 
Found.Symp. 136:42-60
Ozsahin H, Arredondo-Vega FX, Santisteban I, Fuhrer H, Tuchschmid P, Jochum W, Aguzzi A, 
Lederman HM, Fleischman A, Winkelstein JA, Seger RA, Hershfield MS (1997), Adenosine 
deaminase deficiency in adults, Blood 89: 2849-2855
Pannell D, Osbome CS, Yao S, Sukonnik T, Pasceri P, Karaiskakis A, Okano M, Li E, Lipshitz HD, 
Ellis J (2000), Retrovirus vector silencing is de novo methylase independent and marked by a 
repressive histone code, EMBOJ. 19: 5884-5894
Pannell D, Ellis J (2001), Silencing of gene expression: implications for design of retrovirus vectors, 
Rev.Med. Virol. 11: 205-217
Parkman R, Gelfand EW, Rosen FS, Sanderson A, Hirschhom R (1975), Severe combined 
immunodeficiency and adenosine deaminase deficiency, N.Engl.J.Med. 292: 714-719
Pereira RF, O'Hara MD, Laptev AV, Halford KW, Pollard MD, Class R, Simon D, Livezey K, 
Prockop DJ (1998), Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues
253
R e f e r e n c e s
in transgenic mice with a phenotype of osteogenesis imperfecta, Proc.Natl.Acad.Sci.U.S.A 95: 1142- 
1147
Perignon JL, Hamet M, Broyer M, Griscelli C, Lenoir G, Cartier P (1980), Primary hyperoxaluria and 
adenosine deaminase deficiency without immunodeficiency, Int.J.Pediatr.Nephrol. 1: 26-29
Perignon JL, Hamet M, Buc HA, Cartier PH, Derycke M (1982), Biochemical study of a case of 
hemolytic anemia with increased (85 fold) red cell adenosine deaminase, Clin.Chim.Acta 124: 205- 
212
Peschanski M, Defer G, N'Guyen JP, Ricolfi F, Monfort JC, Remy P, Geny C, Samson Y, Hantraye P, 
Jeny R, . (1994), Bilateral motor improvement and alteration of L-dopa effect in two patients with 
Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon, Brain 117 ( 
Pt 3): 487-499
Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD, Henslee-Downey J, Trigg ME, 
Cowan MJ, Sanders J, Bunin N, Weinstein H, Lenarsky C, Falk P, Harris R, Bowen T, Williams TE, 
Grayson GH, Warkentin P, Sender L, Cool VA, Crittenden M, Packman S, Kaplan P, Lockman LA, . 
(1996), Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler 
syndrome, Blood 87: 4894-4902
Petrascheck M, Escher D, Mahmoudi T, Verrijzer CP, Schaffner W, Barberis A (2005), DNA looping 
induced by a transcriptional enhancer in vivo , Nucl. Acid Res. 33:3743-3750
Phipps S, Brenner M, Heslop H, Krance R, Jayawardene D, Mulhem R (1995), Psychological effects 
of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal 
study, Bone Marrow Transplant. 15: 829-835
Piersma AH, Ploemacher RE, Brockbank KG (1983), Transplantation of bone marrow fibroblastoid 
stromal cells in mice via the intravenous route, Br.J.Haematol. 54: 285-290
Piersma AH, Brockbank KG, Ploemacher RE, van Vliet E, Brakel-van Peer KM, Visser PJ (1985), 
Characterization of fibroblastic stromal cells from murine bone marrow, Exp.Hematol. 13: 237-243
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti 
DW, Craig S, Marshak DR (1999), Multilineage potential of adult human mesenchymal stem cells, 
Science 284: 143-147
Pollok KE, Hanenberg H, Noblitt TW, Schroeder WL, Kato I, Emanuel D, Williams DA (1998), 
High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is 
mediated by transduction on recombinant fibronectin fragments, J. Virol. 72: 4882-4892
Pollok KE, Der Loo JC, Cooper RJ, Hartwell JR, Miles KR, Breese R, Williams EP, Montel A, 
Seshadri R, Hanenberg H, Williams DA (2001), Differential transduction efficiency of SCID- 
repopulating cells derived from umbilical cord blood and granulocyte colony-stimulating factor- 
mobilized peripheral blood, Hum.Gene Ther. 12: 2095-2108
Polmar SH, Stem RC, Schwartz AL, Wetzler EM, Chase PA, Hirschhom R (1976), Enzyme 
replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency, 
N.EnglJ.Med. 295: 1337-1343
Porada CD, Park P, Almeida-Porada G, Zanjani ED (2004), The sheep model of in utero gene therapy, 
FetalDiagn.Ther. 19: 23-30
Porada CD, Park PJ, Almeida-Porada G, Liu W, Ozturk F, Glimp HA, Zanjani ED (2005), Gestational 
age of recipient determines pattern and level of transgene expression following in utero retroviral gene 
transfer, Mol. Ther. 11: 284-293
254
R e f e r e n c e s
Prioleau MN, Nony P, Simpson M, Felsenfel G (1999), An insulator element and condensed 
chromatin region separate the chicken beta-globin locus from an independently regulated erythroid- 
specific folate receptor gene, EMBO J. 18:4035-4948
Prockop DJ (1997), Marrow stromal cells as stem cells for nonhematopoietic tissues, Science 276: 71- 
74
Prockop DJ, Gregory CA, Spees JL (2003), One strategy for cell and gene therapy: harnessing the 
power of adult stem cells to repair tissues, Proc.Natl.Acad.Sci.U.S.A 100 Suppl 1: 11917-11923
Ptashne M (1986), Gene regulation by proteins acting nearby and at a distance, Nature 322:697-701
Puel A, Ziegler SF, Buckley RH, Leonard WJ (1998), Defective IL7R expression in T(-)B(+)NK(+) 
severe combined immunodeficiency, Nat. Genet. 20: 394-397
Purcell DF, Broscius CM, Vanin EF, Buckler CE, Nienhuis AW, Martin MA (1996), An array of 
murine leukemia virus-related elements is transmitted and expressed in a primate recipient of 
retroviral gene transfer, J. Virol. 70: 887-897
Qasim W, Gaspar HB, Thrasher AJ (2004), Gene therapy for severe combined immune deficiency, 
Expert.Rev .Mol.Med. 2004: 1-15
Quesenberry PJ, Lowry PA (1992), The colony-stimulating factors. An overview, Cancer 70: 909-912
Quintavalla J, Uziel-Fusi S, Yin J, Boehnlein E, Pastor G, Blancuzzi V, Singh HN, Kraus KH, 
O'Byme E, Pellas TC (2002), Fluorescently labeled mesenchymal stem cells (MSCs) maintain 
multilineage potential and can be detected following implantation into articular cartilage defects, 
Biomaterials 23: 109-119
Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Deliliers GL (2002), Isolation of bone 
marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies, Exp.Hematol. 30: 
783-791
Ramezani A, Hawley TS, Hawley RG (2003), Performance and safety-enhanced lentiviral vectors 
containing the human interferon-P scaffold attachment region and the chicken P-globin insulator, 
Blood 101:4717-4724
Ratech H, Greco MA, Gallo G, Rimoin DL, Kamino H, Hirschhom R (1985), Pathologic findings in 
adenosine deaminase-deficient severe combined immunodeficiency. I. Kidney, adrenal, and chondro- 
osseous tissue alterations, Am.J.Pathol. 120: 157-169
Ratech H, Hirschhom R, Greco MA (1989), Pathologic findings in adenosine deaminase deficient- 
severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract 
lymphoid tissue alterations, Am.J.Pathol. 135: 1145-1156
Reading L (2000), Bone 26S: 9S
Rebel VI, Tanaka M, Lee JS, Hartnett S, Pulsipher M, Nathan DG, Mulligan RC, Sieff CA (1999), 
One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined 
immune-deficient repopulating cells using high-titer vesicular stomatitis vims G protein pseudotyped 
retrovirus, Blood 93: 2217-2224
Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I (1994), Induction of rapid osteoblast 
differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2, Dev.Biol. 161: 
218-228
Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R, Koc H, Bunjes D, 
Gluckman E, Rocha V, Schattenberg A, Frassoni F (2002), Transplantation of peripheral blood stem 
cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid 
leukemia and acute lymphoblastic leukemia, J.Clin.Oncol. 20: 4655-4664
255
R e f e r e n c e s
Roe T, Reynolds TC, Yu G, Brown PO (1993), Integration of murine leukemia virus DNA depends on 
mitosis, EMBOJ. 12: 2099-2108
Rogers MH, Lwin R, Fairbanks L, Gerritsen B, Gaspar HB (2001), Cognitive and behavioral 
abnormalities in adenosine deaminase deficient severe combined immunodeficiency, J.Pediatr. 139: 
44-50
Rohdewohld H, Weiher H, Reik W, Jaenisch R, Breindl M (1987), Retrovirus integration and 
chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I- 
hypersensitive sites, J. Virol. 61: 336-343
Romanov YA, Svintsitskaya VA, Smirnov VN (2003), Searching for alternative sources of postnatal 
human mesenchymal stem cells: candidate MSC-like cells from umbilical cord, Stem Cells 21: 105- 
110
Rombouts WJ, Ploemacher RE (2003), Primary murine MSC show highly efficient homing to the 
bone marrow but lose homing ability following culture, Leukemia 17: 160-170
Rubinstein A, Hirschhom R, Sicklick M, Murphy RA (1979), In vivo and in vitro effects of thymosin 
and adenosine deaminase on adenosine-deaminase-deficient lymphocytes, N.Engl.J.Med. 300: 387- 
392
Sachs L (1987), The molecular control of blood cell development, Science 238: 1374-1379
Sakiyama Y, Ariga T, Ohtsu M (2005), Gene therapy for adenosine deaminase deficiency, Nippon 
Rinsho 63: 448-452
Saito T, Kuang JQ, Bittira B, A1 Khaldi A, Chiu RC (2002), Xenotransplant cardiac chimera: immune 
tolerance of adult stem cells, Ann.Thorac.Surg. 74: 19-24
Sanchez-Ramos J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, Freeman TB, Saporta 
S, Janssen W, Patel N, Cooper DR, Sanberg PR (2000), Adult bone marrow stromal cells differentiate 
into neural cells in vitro, Exp.Neurol. 164: 247-256
Santisteban I, Arredondo-Vega FX, Kelly S, Mary A, Fischer A, Hummell DS, Lawton A, Sorensen 
RU, Stiehm ER, Uribe L, . (1993), Novel splicing, missense, and deletion mutations in seven 
adenosine deaminase-deficient patients with late/delayed onset of combined immunodeficiency 
disease. Contribution of genotype to phenotype, J.Clin.Invest 92: 2291-2302
Santucci MA, Trabetti E, Martinelli G, Buzzi M, Zaccaria A, Pileri S, Farabegoli P, Sabattini E, Tura 
S, Pignatti PF (1992), Host origin of bone marrow fibroblasts following allogeneic bone marrow 
transplantation for chronic myeloid leukemia, Bone Marrow Transplant. 10: 255-259
Sato T, Laver JH, Ogawa M (1999), Reversible expression of CD34 by murine hematopoietic stem 
cells, Blood 94: 2548-2554
Schilz AJ, Schiedlmeier B, Kuhlcke K, Fruehauf S, Lindemann C, Zeller WJ, Grez M, Fauser AA, 
Baum C, Eckert HG (2000), MDR1 gene expression in NOD/SCID repopulating cells after retroviral 
gene transfer under clinically relevant conditions, Mol.Ther. 2: 609-618
Schlegel R, Tralka TS, Willingham MC, Pastan I (1983), Inhibition of VSV binding and infectivity by 
phosphatidylserine: is phosphatidylserine a VSV-binding site?, Cell 32: 639-646
Schluns KS, Kieper WC, Jameson SC, Leffancois L (2000), Interleukin-7 mediates the homeostasis of 
naive and memory CD8 T cells in vivo, Nat.Immunol. 1: 426-432
Schluns KS, Leffancois L (2003), Cytokine control of memory T-cell development and survival, 
Nat. Rev. Immunol. 3: 269-279
256
R e f e r e n c e s
Schmalstieg FC, Mills GC, Nelson JA, May LT, Goldman AS, Goldblum RM (1978), Limited effect 
of erythrocyte and plasma infusions in adenosine deaminase deficiency, J.Pediatr. 93: 597-603
Schmalstieg FC, Mills GC, Tsuda H, Goldman AS (1983), Severe combined immunodeficiency in a 
child with a healthy adenosine deaminase deficient mother, Pediatr.Res. 17: 935-940
Schoeberlein A, Holzgreve W, Dudler L, Hahn S, Surbek DV (2005), Tissue-specific engraftment 
after in utero transplantation of allogeneic mesenchymal stem cells into sheep fetuses, 
Am. J.Obstet.Gynecol. 192: 1044-1052
Schrader WP, Stacy AR, Pollara B (1976), Purification of human erythrocyte adenosine deaminase by 
affinity column chromatography, J.Biol.Chem. 251: 4026-4032
Schrader WP, Stacy AR (1977), Purification and subunit structure of adenosine deaminase from 
human kidney, J.Biol.Chem. 252: 6409-6415
Schrader WP, Woodward FJ, Pollara B (1979), Purification of an adenosine deaminase complexing 
protein from human plasma, J.Biol.Chem. 254: 11964-11968
Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F (2002), HIV-1 integration in the 
human genome favors active genes and local hotspots, Cell 110: 521-529
Schuler W, Weiler U, Schuler A, Phillips RA, Rosenberg N, Mak TW, Kearney JF, Perry RP, Bosma 
MJ (1986), Rearrangement of antigen receptor genes is defective in mice with severe combined 
immune deficiency, Cell 46: 963-972
Schwarz EJ, Reger RL, Cusick CG, Harlan RE, Prockop DJ. Intracerebral transplantation of 
allogeneic bone marrow stromal cells in adult rats. 2001. Seventh Annual Symposium, ISHAGE, 
Quebec City.
Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, Prockop DJ (2002), Expansion of human 
adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors 
and evaluate their quality, Stem Cells 20: 530-541
Shake JG, Gruber PJ, Baumgartner WA, Senechal G, Meyers J, Redmond JM, Pittenger MF, Martin 
BJ (2002), Mesenchymal stem cell inplantation in a swine myocardial infarct model: engraftment and 
functional effects, Ann.Thorac.Surg. 73: 1919-1925
Sharff AJ, Wilson DK, Chang Z, Quiocho FA (1992), Refined 2.5 A structure of murine adenosine 
deaminase at pH 6.0, J.Mol.Biol. 226: 917-921
Shen JS, Meng XL, Yokoo T, Sakurai K, Watabe K, Ohashi T, Eto Y (2005), Widespread and highly 
persistent gene transfer to the CNS by retrovirus vector in utero: implication for gene therapy to 
Krabbe disease, J.Gene Med. 7:540-551
Shields LE, Andrews RG (1998), Gestational age changes in circulating CD34+ hematopoietic 
stem/progenitor cells in fetal cord blood, Am.J.Obstet.Gynecol. 178: 931-937
Shovlin CL, Hughes JM, Simmonds HA, Fairbanks L, Deacock S, Lechler R, Roberts I, Webster AD 
(1993), Adult presentation of adenosine deaminase deficiency, Lancet 341: 1471
Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, 
Mobraaten L, Rajan TV, Greiner DL, . (1995), Multiple defects in innate and adaptive immunologic 
function in NOD/LtSz-scid mice, J.Immunol. 154: 180-191
Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM (1989), Circulation of CD34+ 
hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: 
enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor, 
Blood 14: 1905-1914
257
R e f e r e n c e s
Simmons PJ, Przepiorka D, Thomas ED, Torok-Storb B (1987), Host origin of marrow stromal cells 
following allogeneic bone marrow transplantation, Nature 328: 429-432
Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brechot C (1999), Hepatitis B virus X 
mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and 
transactivation effects of HBx, Oncogene 18: 4848-4859
Sirven A, Pflumio F, Zennou V, Titeux M, Vainchenker W, Coulombel L, Dubart-Kupperschmitt A, 
Chameau P (2000), The human immunodeficiency virus type-1 central DNA flap is a crucial 
determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem 
cells, Blood 96: 4103-4110
Sirven A, Ravet E, Chameau P, Zennou V, Coulombel L, Guetard D, Pflumio F, Dubart- 
Kupperschmitt A (2001), Enhanced transgene expression in cord blood CD34(+)-derived 
hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following 
transduction with modified trip lentiviral vectors, Mol. Ther. 3: 438-448
Soudais C, Shiho T, Sharara LI, Guy-Grand D, Taniguchi T, Fischer A, Di Santo JP (2000), Stable 
and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by 
retroviral-mediated gene transfer, Blood 95: 3071-3077
Spangrude GJ, Heimfeld S, Weissman IL (1988), Purification and characterization of mouse 
hematopoietic stem cells, Science 241: 58-62
Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M (2002), Bone marrow- 
derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors, Cancer Res. 62: 
3603-3608
Stute N, Holtz K, Bubenheim M, Lange C, Blake F, Zander AR (2004), Autologous serum for 
isolation & expansion of human mesenchymal stem cells for clinical use, Exp.Hematol. 32:1212-1225
Sutherland DR, Stewart AK, Keating A (1993), CD34 antigen: molecular features and potential 
clinical applications, Stem Cells 11 Suppl 3: 50-57
Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM (1989), Characterization and 
partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro, 
Blood  74: 1563-1570
Sutton RE, Reitsma MJ, Uchida N, Brown PO (1999), Transduction of human progenitor 
hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle 
dependent, J. Virol. 73: 3649-3660
Suva D, Garavaglia G, Menetrey J, Chapuis B, Hoffmeyer P, Bemheim L, Kindler V (2004), Non- 
hematopoietic human bone marrow contains long-lasting, pluripotential mesenchymal stem cells, 
J. Cell Physiol 198: 110-118
Talvensaari K, Clave E, Douay C, Rabian C, Garderet L, Busson M, Gamier F, Douek D, Gluckman 
E, Charron D, Toubert A (2002), A broad T-cell repertoire diversity and an efficient thymic function 
indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation, Blood 
99: 1458-1464
Tanaka C, Hara T, Suzaki I, Maegaki Y, Takeshita K (1996), Sensorineural deafness in siblings with 
adenosine deaminase deficiency, Brain Dev. 18: 304-306
Tanaka J, Kasai M, Imamura M, Masauzi N, Ohizumi H, Matsuura A, Morii K, Kiyama Y, Naohara 
T, Saitoh M, . (1994), Evaluation of mixed chimaerism and origin of bone marrow derived 
fibroblastoid cells after allogeneic bone marrow transplantation, Br.J.Haematol. 8 6 : 436-438
Tavassoli M, Minguell JJ (1991), Homing of hemopoietic progenitor cells to the marrow, 
Proc.Soc.Exp.Biol.Med. 196: 367-373
258
R e f e r e n c e s
Taylor N, Uribe L, Smith S, Jahn T, Kohn DB, Weinberg K (1996), Correction of interleukin-2 
receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the gamma-c 
gene, Blood 87: 3103-3107
Themis M, Waddington S, Schmidt M, Von Kalle C, Wang Y, A1 Allaf F, Gregory L, Nivsarkar M, 
Themis M, Holder MV, Buckley S, Dighe N, Ruthe A, Mistry A, Bigger BW, Thrasher A, Coutelle C. 
Oncogenesis Following Delivery of a Non-Primate Lentiviral Gene Therapy Vector to Fetal Mice. 
2005a. The American Society of Gene Therapy Annual Meeting, St Louis, Missouri, USA.
Themis M, Schmidt M, Von Kalle C, Wang Y, A1 Allaf F, Gregory L, Nivsarkar M, Holder MV, 
Ruthe A, Buckley S, Bigger BW, Thrasher A, Waddington S, Coutelle C. A Potential inVivo Model 
to Test for the Safety of Lentivirus Gene Therapy Vectors. 2005b. BSGT Annual Meeting, 
Manchester, UK.
Themis M, Waddington SN, Schmidt M, Von Kalle C, Wang Y, A1 Allaf F, Gregory L, Nivsarkar M, 
Themis M, Holder MV, Buckley S, Dighe N, Ruthe A, Mistry A, Bigger B, Rahim A, Nguyen TH, 
Trono D, Thrasher AJ, Coutelle C (2005c), Oncogenesis Following Delivery of a Nonprimate 
Lentiviral Gene Therapy Vector to Fetal and Neonatal Mice, Mol Ther. 12: 763-771
Thrasher A, Chetty M, Casimir C, Segal AW (1992), Restoration of superoxide generation to a 
chronic granulomatous disease-derived B-cell line by retrovirus mediated gene transfer, Blood 80: 
1125-1129
Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, Blanche S, Davies EG, Parsley K, Gilmour K, King 
D, Howe S, Sinclair J, Hue C, Carlier F, Von Kalle C, de Saint BG, le Deist F, Fischer A, Cavazzana- 
Calvo M (2005), Failure of SCID-X1 gene therapy in older patients, Blood 105: 4255-4257
Tischfield JA, Creagan RP, Nichols EA, Ruddle FH (1974), Assignment of a gene for adenosine 
deaminase to human chromosome 20, Hum.Hered. 24: 1-11
Tjonnfjord GE, Steen R, Veiby OP, Friedrich W, Egeland T (1994), Evidence for engraftment of 
donor-type multipotent CD34+ cells in a patient with selective T-lymphocyte reconstitution after bone 
marrow transplantation for B-SCID, Blood 84: 3584-3589
Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD (2002), Human mesenchymal stem cells 
differentiate to a cardiomyocyte phenotype in the adult murine heart, Circulation 105: 93-98
Totsugawa T, Kobayashi N, Okitsu T, Noguchi H, Watanabe T, Matsumura T, Maruyama M, 
Fujiwara T, Sakaguchi M, Tanaka N (2002), Lentiviral transfer of the LacZ gene into human 
endothelial cells and human bone marrow mesenchymal stem cells, Cell Transplant. 11: 481-488
Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, Paterlini-Brechot P, Brechot C, 
Kremsdorf D (2001), Biological inpact of natural COOH-terminal deletions of hepatitis B virus X 
protein in hepatocellular carcinoma tissues, Cancer Res. 61: 7803-7810
Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM (2002), Immune response to fetal calf 
serum by two adenosine deaminase-deficient patients after T cell gene therapy, Hum.Gene Ther. 13: 
1605-1610
Uchida N, Sutton RE, Friera AM, He D, Reitsma MJ, Chang WC, Veres G, Scollay R, Weissman IL 
(1998), HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly 
isolated G0/G1 human hematopoietic stem cells, Proc.Natl.Acad.Sci. U.S.A 95: 11939-11944
Udvardy A, Maine E, Schedl P (1985), The 87A7 chromomere. Identification of novel chromatin 
structures flanking the heat shock locus that may define the boundaries of higher order domains, J. 
Mol. Biol. 185: 341-358
Ullman B, Clift SM, Gudas LJ, Levinson BB, Wormsted MA, Martin DW, Jr. (1980), Alterations in 
deoxyribonucleotide metabolism in cultured cells with ribonucleotide reductase activities refractory to 
feedback inhibition by 2'-deoxyadenosine triphosphate, J.Biol.Chem. 255: 8308-8314
259
R e f e r e n c e s
Umetsu DT, Schlossman CM, Ochs HD, Hershfield MS (1994), Heterogeneity of phenotype in two 
siblings with adenosine deaminase deficiency, J.Allergy Clin.Immunol. 93: 543-550
Umov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, 
Gregory PD, Holmes MC (2005), Highly efficient endogenous human gene correction using designed 
zinc-finger nucleases, Nature 435: 646-651
Valentine WN, Paglia DE, Tartaglia AP, Gilsanz F (1977), Hereditary hemolytic anemia with 
increased red cell adenosine deaminase (45- to 70-fold) and decreased adenosine triphosphate, Science 
195: 783-785
Valenzona HO, Pointer R, Ceredig R, Osmond DG (1996), Prelymphomatous B cell hyperplasia in 
the bone marrow of interleukin-7 transgenic mice: precursor B cell dynamics, microenvironmental 
organization and osteolysis, Exp.Hematol. 24: 1521-1529
Valerio D, Duyvesteyn MG, Meera KP, Geurts vK, de Waard A, van der Eb AJ (1983), Isolation of 
cDNA clones for human adenosine deaminase, Gene 25: 231-240
Valerio D, Duyvesteyn MG, Dekker BM, Weeda G, Berkvens TM, van d, V, van Ormondt H, van der 
Eb AJ (1985), Adenosine deaminase: characterization and expression of a gene with a remarkable 
promoter, EMBO J. 4:437-443
van Beusechem VW, Kukler A, Einerhand MP, Bakx TA, van der Eb AJ, van Bekkum DW, Valerio 
D (1990), Expression of human adenosine deaminase in mice transplanted with hemopoietic stem 
cells infected with amphotropic retroviruses, J. Exp. Med. 172: 729-736
van Beusechem VW, Kukler A, Heidt PJ, Valerio D (1992), Long-term expression of human 
adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells, 
Proc.Natl.Acad.Sci.U.S.A 89: 7640-7644
Van der Weyden MB, Kelley WN (1976), Human adenosine deaminase. Distribution and properties, 
J.Biol.Chem. 251: 5448-5456
van Ewijk W, Hollander G, Terhorst C, Wang B (2000), Stepwise development of thymic 
microenvironments in vivo is regulated by thymocyte subsets, Development 127: 1583-1591
Vanin EF, Kaloss M, Broscius C, Nienhuis AW (1994), Characterization of replication-competent 
retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations 
regarding the mechanism of oncogenesis, J. Virol. 6 8 : 4241-4250
Vassilopoulos G, Wang PR, Russell DW (2003), Transplanted bone marrow regenerates liver by cell 
fusion, Nature 422: 901-904
Vijaya S, Steffen DL, Robinson HL (1986), Acceptor sites for retroviral integrations map near DNase 
I-hypersensitive sites in chromatin, J. Virol. 60: 683-692
Waddell D, Ullman B (1983), Characterization of a cultured human T-cell line with genetically altered 
ribonucleotide reductase activity. Model for immunodeficiency, J.Biol.Chem. 258: 4226-4231
Wagers AJ, Sherwood RI, Christensen JL, Weissman IL (2002), Little evidence for developmental 
plasticity of adult hematopoietic stem cells, Science 297: 2256-2259
Wakamiya M, Blackburn MR, Jurecic R, McArthur MJ, Geske RS, Cartwright J, Jr., Mitani K, 
Vaishnav S, Belmont JW, Kellems RE, . (1995), Disruption of the adenosine deaminase gene causes 
hepatocellular impairment and perinatal lethality in mice, Proc.Natl.Acad.Sci.U.S.A 92: 3673-3677
Wakitani S, Goto T, Pineda SJ, Young RG, Mansour JM, Caplan AI, Goldberg VM (1994), 
Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage, J.Bone Joint 
Surg.Am. 76: 579-592
260
R e f e r e n c e s
Wakitani S, Saito T, Caplan AI (1995), Myogenic cells derived from rat bone marrow mesenchymal 
stem cells exposed to 5-azacytidine, Muscle Nerve 18: 1417-1426
Wang JC, Doedens M, Dick JE (1997), Primitive human hematopoietic cells are enriched in cord 
blood compared with adult bone marrow or mobilized peripheral blood as measured by the 
quantitative in vivo SCID-repopulating cell assay, Blood 89: 3919-3924
Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al Dhalimy M, Lagasse E, Finegold M, 
Olson S, Grompe M (2003), Cell fusion is the principal source of bone-marrow-derived hepatocytes, 
Nature 422: 897-901
Watt FM, Hogan BL (2000), Out of Eden: stem cells and their niches, Science 287: 1427-1430
Weimann JM, Johansson CB, Trejo A, Blau HM (2003a), Stable reprogrammed heterokaryons form 
spontaneously in Purkinje neurons after bone marrow transplant, Nat.Cell Biol. 5: 959-966
Weimann JM, Charlton CA, Brazelton TR, Hackman RC, Blau HM (2003b), Contribution of 
transplanted bone marrow cells to Purkinje neurons in human adult brains, Proc.Natl.Acad.Sci.U.S.A 
100: 2088-2093
Wengler GS, Lanfranchi A, Frusca T, Verardi R, Neva A, Brugnoni D, Giliani S, Fiorini M, Mella P, 
Guandalini F, Mazzolari E, Pecorelli S, Notarangelo LD, Porta F, Ugazio AG (1996), In-utero 
transplantation of parental CD34 haematopoietic progenitor cells in a patient with X-linked severe 
combined immunodeficiency (SCIDXI), Lancet 348: 1484-1487
Wexler SA, Donaldson C, Denning-Kendall P, Rice C, Bradley B, Hows JM (2003), Adult bone 
marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult 
blood are not, Br.J.Haematol. 121: 368-374
Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, Bjorklund A, Lindvall O, 
Langston JW (1992), Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced 
by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP), N.Engl.J.Med. 327: 1556-1563
Wiginton DA, Coleman MS, Hutton JJ (1981), Purification, characterization and radioimmunoassay 
of adenosine deaminase from human leukaemic granulocytes, BiochemJ. 195: 389-397
Wiginton DA, Adrian GS, Friedman RL, Suttle DP, Hutton JJ (1983), Cloning of cDNA sequences of 
human adenosine deaminase, Proc.Natl.Acad.Sci.U.S.A 80: 7481-7485
Wiginton DA, Kaplan DJ, States JC, Akeson AL, Perme CM, Bilyk IJ, Vaughn AJ, Lattier DL, 
Hutton JJ (1986), Complete sequence and structure of the gene for human adenosine deaminase, 
Biochemistry 25: 8234-8244
Williams JT, Southerland SS, Souza J, Calcutt AF, Cartledge RG (1999), Cells isolated from adult 
human skeletal muscle capable of differentiating into multiple mesodermal phenotypes, Am.Surg. 65: 
22-26
Wilson DK, Rudolph FB, Quiocho FA (1991), Atomic structure of adenosine deaminase complexed 
with a transition-state analog: understanding catalysis and immunodeficiency mutations, Science 252: 
1278-1284
Wilson JM, Grossman M, Raper SE, Baker JR, Jr., Newton RS, Thoene JG (1992), Ex vivo gene 
therapy of familial hypercholesterolemia, Hum.Gene Ther. 3: 179-222
Witte DP, Wiginton DA, Hutton JJ, Aronow BJ (1991), Coordinate developmental regulation of 
purine catabolic enzyme expression in gastrointestinal and postimplantation reproductive tracts, J. Cell 
Biol. 115: 179-190
261
R e f e r e n c e s
Wolfson JJ, Cross VF (1975), The radiographic findings in 49 patients with immunodeficiency, in 
Combined Immunodeficiency and Adenosine Deaminase Deficiency: A Molecular Defect, ed. Pollara 
B, Pickering RJ, Meuwissen HJ, and Porter IH, Academic, New York p 225
Woods NB, Fahlman C, Mikkola H, Hamaguchi I, Olsson K, Zufferey R, Jacobsen SE, Trono D, 
Karlsson S (2000), Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells, 
Blood 96: 3725-3733
Wu X, Li Y, Crise B, Burgess SM (2003), Transcription start regions in the human genome are 
favored targets for MLV integration, Science 300: 1749-1751
Wu X, Burgess SM (2004), Integration target site selection for retroviruses and transposable elements, 
Cell Mol.Life Sci. 61: 2588-2596
Xu W, Zhang X, Qian H, Zhu W, Sun X, Hu J, Zhou H, Chen Y (2004), Mesenchymal stem cells 
from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro, 
Exp.Biol.Med. (Maywood.) 229: 623-631
Yang Y, Wilson JM (1995), Clearance of adenovirus-infected hepatocytes by MHC class I-restricted 
CD4+ CTLs in vivo, J.Immunol. 155: 2564-2570
Yu M, Xiao Z, Shen L, Li L (2004), Mid-trimester fetal blood-derived adherent cells share 
characteristics similar to mesenchymal stem cells but full-term umbilical cord blood does not, 
Br.J.Haematol. 124: 666-675
Zaiss AK, Son S, Chang LJ (2002), RNA 3' readthrough of oncoretrovirus and lentivirus: implications 
for vector safety and efficacy, J. Virol. 76: 7209-7219
Zanjani ED, Almeida-Porada G, Livingston AG, Flake AW, Ogawa M (1998), Human bone marrow, 
Exp.Hematol. 26: 353-360
Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Chameau P (2000), HIV-1 genome nuclear 
import is mediated by a central DNA flap, Cell 101: 173-185
Zhang W, Ge W, Li C, You S, Liao L, Han Q, Deng W, Zhao RC (2004), Effects of Mesenchymal 
Stem Cells on Differentiation, Maturation, and Function of Human Monocyte-Derived Dendritic 
Cells, Stem Cells Dev. 13: 263-271
Zhang XY, La Russa VF, Bao L, Kolls J, Schwarzenberger P, Reiser J (2002), Lentiviral vectors for 
sustained transgene expression in human bone marrow-derived stromal cells, Mol.Ther. 5: 555-565
Ziegler JB, Lee CH, Van der Weyden MB, Bagnara AS, Beveridge J (1980), Severe combined 
immunodeficiency and adenosine deaminase deficiency: failure of enzyme replacement therapy, 
Arch.Dis.Child 55: 452-457
Ziegler JB, Van der Weyden MB, Lee CH, Daniel A (1981), Prenatal diagnosis for adenosine 
deaminase deficiency, J. Med. Genet. 18: 154-156
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997), Multiply attenuated lentiviral vector 
achieves efficient gene delivery in vivo, Nat.Biotechnol. 15: 871-875
Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D (1998), Self-inactivating 
lentivirus vector for safe and efficient in vivo gene delivery, J. Virol. 72: 9873-9880
Zufferey R, Donello JE, Trono D, Hope TJ (1999), Woodchuck hepatitis vims posttranscriptional 
regulatory element enhances expression of transgenes delivered by retroviral vectors, J. Virol. 73: 
2886-2892
262
Lymphocyte subpopulations Neonatal 1 wk-2mo 2-5mo 5-9mo 9-15mo 15-24mo 2-5yr 5-10yr 10-16yr Adults
Lymphocytes 4,800 6,700 5,900 6,000 5,500 5,600 3,300 2,800 2,200 1,800
CD19+B lymphocytes 600 1,000 1,300 1,300 1,400 1,300 800 500 300 200
CD3+ T lymphocytes 2,800 4,600 3,600 3,800 3,400 3,500 2,300 1,900 1,500 1,200
CD3+/CD4+ T lymphocytes 1,900 3,500 2,500 2,800 2,300 2,200 1,300 1,000 800 700
CD3+/CD8+ T lymphocytes 1,100 ' 1,000 1,000 1,100 1,100 1,200 800 800 400 400
CD3+/CD16-56+ NK cells 1,000 500 300 300 400 400 400 300 300 300
Appendix 1. Absolute size of lymphocyte subpopulations8 at different ages. Adapted from Comans-Bitter et al., 1997. 
a Absolute counts (/pL).
GT clinical trial 
inclusion criteria
1. No HLA identical 
donor.
2. Diagnosis of ADA 
deficiency based on 
immunophenotype 
(absent or reduced 
numbers of T and B 
lymphocytes).
3. Diagnosis confirmed 
by sequencing and/or 
metabolite analysis.
Counselling
Consent
1
Withdrawal of PEG- 
ADA one month prior 
to receiving treatment
1
Day -4: Bone marrow harvest
Day -4 to 0: Cell 
processing and CD34H 
cell transduction
Day -2: Conditioning
Day 0: Reinfusion 
of transduced cells
Appendix 2. Gene therapy protocol.
